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Abstract
Schizophrenia is a debilitating condition that affects 1% of the population, causes
significant hardship and though there are treatments available they are characterised
by several limitations. It is a complex mental disorder where some individuals show
mild subclinical cognitive symptoms before psychosis onset in adolescence. The
treatments available only target a portion of the symptoms and although extensive
research has been conducted, a comprehensive understanding of the nature of
schizophrenia remains elusive. Unlike other neurodevelopmental disorders,
schizophrenia symptoms do not typically present themselves until adolescence. This
study aimed to discover gene co-expression networks at multiple developmental
stages to identify candidate therapeutic targets to better treat and manage
schizophrenia.
Recent genome-wide association studies have identified 145 genetic loci associated
with schizophrenia. Allen Brain Atlas’s BrainSpan resource provides brain
development data from neurotypical brains. Using this resource it was possible to
study the gene expression of 316 schizophrenia-associated genes, identified
previously in a large-scale GWAS, across each of the developmental stages available
in the Allen Brain Atlas. K means Clustering and a systems biology approach
(WGCNA) was applied to these schizophrenia-associated genes at each
developmental stage where modules within networks were created by grouping coexpressed genes. To facilitate biological interpretation of these modules co-expressed
genes were visualised using Cytoscape and gene ontology pathway enrichment
analysis was applied.
We identified 21 hub genes using WGCNA. Of the 316 schizophrenia-associated
genes, 27 modules were identified and 3 hub genes GPR52, INA, SATB2 were
common in multiple developmental stages. Our results suggest that GPR52, INA,
SATB2 represent candidate genes for future evaluation of their potential as therapeutic
targets of schizophrenia. Additional hub genes included TRANK1 and ALMS1, genes
which were previously identified as expression quantitative trait loci. Taken together
our results add further evidence that these genes could be good candidates for further
research as they may regulate several schizophrenia-related genes in their respective
modules. Finally, our enrichment analysis implicated a role for positive regulation of
macrophage proliferation and cellular response to catecholamine stimulus, and
cellular response to diacyl bacterial lipopeptide at each developmental stage. The
immune system and catecholamines, including dopamine, have long been associated
with schizophrenia and our results provide further support for these hypotheses.
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Chapter 1 – Introduction to schizophrenia
Schizophrenia is a debilitating psychiatric condition that manifests itself early in
adolescence and can last a lifetime. It has a 1% global prevalence and comes with
significant societal and economic costs as well as substantial mortality and morbidity
(1). Its complex nature is believed to originate from a mixture of genetic and
environmental factors including prenatal exposure to infection and lack of nutrients
which cause disruptions during early brain development in utero (2,3). There are
many hypotheses about the causes of schizophrenia, but the aetiology is unknown.
This lack of understanding of schizophrenia is evident in its treatments which
haven’t significantly advanced since the introduction of the first-generation
antipsychotic medication such as Chlorpromazine in the 1950s (4). This complex
condition presents with three modes of clinical features namely: positive symptoms
(psychoses manifesting as delusions and hallucinations, paranoia, hyperactivity and
agitation), negative symptoms (social withdrawal, lack of motivation, asociality,
avolition, affective flattening, consummatory and anticipatory anhedonia, and
alogia), and cognitive symptoms (trouble with critical thinking, working memory and
difficulty integrating feelings, thoughts and behaviour, attention and vigilance, verbal
learning, reasoning and problem solving, and social cognition) as well as motor
disturbances which regularly results in a poor quality of life (5–7). The presentation
of symptoms is heterogeneous which makes schizophrenia both difficult to diagnose
and treat (8). The negative and cognitive symptoms are chronic and are closely
related to functional outcomes, and contribute greatly to illness burden, (6) the
positive symptoms usually relapse and remit (8). Despite some progress in the
understanding of several of the fundamental mechanisms involved in schizophrenia’s
13

aetiology, the current treatments available come with serious side effects,
inconsistent efficacy, and lack of evidence that they substantially improves the
outcomes (9,10). At present, schizophrenia’s treatments consist of antipsychotic
drugs, social support, rehabilitation, and psychological therapies (8). Current
antipsychotics are associated with serious limitations. Firstly, around 30% of
sufferers are treatment-resistant, secondly, they mainly ameliorate positive symptoms
only leaving cognitive and negative symptoms untreated and lastly, antipsychotics
trigger both neurological and metabolic side effects (11). As a result, there is a clear
need for more efficient and effective treatments as well as uncovering a model for
prediction of efficacy as currently determining the most effective treatment of
schizophrenia is a trial and error method (7,12). It is important to study patients at
several clinical stages to give insight into the effects of schizophrenia itself, its
progression and what alterations are caused by the pharmacological treatments (13).

1.1 Schizophrenia’s aetiology
At present, there are no clinical diagnostic tests available for schizophrenia so
diagnosis relies on clinical observations and self-report (14). Schizophrenia remains
incurable and the best outcome continues to be managing symptoms and preservation
of independence and functionality (9). Until there is a more complete understanding of
schizophrenias aetiology, there is little hope for improving diagnosis, predicting
susceptibility, management, and treatments for those with schizophrenia.

1.2 Understanding of schizophrenia to date
Schizophrenia’s complicated and unknown underlying mechanisms has meant that
there has been no fundamental innovation in schizophrenia treatments since the
14

introduction of first-generation antipsychotics in the 1950s (15). As treatments
mainly target the positive symptoms there is a clear need for a focus on cognitive and
negative symptom domains. These types of studies could lead to new
endophenotypic markers which could promote novel treatment discovery and could
initiate concurrent medication strategies with current antipsychotics (15).

1.2.1 Immune System
Schizophrenias pathogenesis is elusive, and though animal models have been used to
understand elements, the human central nervous system (CNS) and immune system
are much more complex and intricate (16). Both systems share common features in
developmental mechanisms, so therefore CNS and immune system dysregulation
should be studied in humans (16,17). The immune hypothesis of schizophrenia has
been around for a long time and is supported by epidemiological, genetic, imaging
and biomarker studies (17). The accumulating evidence that anti-inflammatory and
immunosuppressive medications are effective treatments and that autoimmune
conditions and immune activation are risk factors for developing schizophrenia
provides perhaps the most convincing evidence of the immunes system involvement
(18,19).
Dysregulation of the innate and adaptive immune system has been identified by
epidemiological, genetic, postmortem and therapeutic studies and are likely to
contribute to some of the symptoms of schizophrenia (20). Though there have been a
large number of studies with significant funding devoted to better understand
schizophrenia outcomes remain poor and hope remains in advances in
psychoneuroimmunology and other advanced technological research areas to provide
more consistent and successful management of schizophrenia (12). Several
15

autoimmune conditions display neuropsychiatric symptoms suspected to be caused
by brain reactive antibodies (21). Schizophrenia and autoimmune diseases are often
comorbid likely because of some genetic overlap, (22) affecting common underlying
pathways which entail inflammatory immune response antibodies which can attack
brain tissue (23)(22). A national cohort found if a patient had a prior autoimmune
disease they are 29% more likely to develop schizophrenia in adolescence (21).
Maternal Immune Activation (MIA) can disrupt normal fetal brain development and
has been linked to schizophrenia for over a century, it is estimated that if MIA could
be avoided that 30% of schizophrenia cases would be averted (20). Lower levels of
acute-phase proteins in neonates which increases the susceptibility of infection have
also been hypothesized to increase the risk of psychosis in adulthood (22). Patients
experiencing acute episodes of schizophrenia often have increased levels of
Interleukin-1- beta (IL-1 β), Interleukin-6 (IL-6), and transforming growth factorbeta (TGF- β) (23). In unmedicated patients, tumour necrosis factor-alpha (TNF α)
protein levels and IL-1β messenger RNA (mRNA) is seen to be elevated (24).

Within the body exists a dynamic population of gut microbes which houses many
bacteria approximately 1014 cells. The biological biodiversity is established in the
first couple of months of existence, and has a continuous role throughout life, and is
very susceptible to environmental factors (25). The gut microbiome can control how
the brain behaves and functions via the microbiota-gut-brain (MGB) and it has been
reported to be related to changes in cognition, anxiety, and memory, as well as
development, maturation of immune, neural and endocrine systems in animal models
(26). These physiological and behavioural processes are often impaired in people
with schizophrenia. A high α-diversity score is usually a sign of good health (27). In
16

a study performed by Zheng et al. medicated and unmedicated patients with
schizophrenia, it has been observed that they have a decreased α-diversity in their
microbiome when compared to healthy controls (HCs) (26). It was also found that
Veillonellaceae and Lachnospiraceae found in the microbiome environment were
associated with symptom severity in schizophrenia (26). β- diversity analysis of
schizophrenia patients and HCs found clear differences in the compositions of each
microbiome by looking at operational taxonomic units (OTU) levels (26). In one
study when the linear discriminating analysis effect size was applied to 77
differential OTUs it was observed that 23 out of the 77 OTUs saw an increase in
patients with schizophrenia patients when compared to controls. The OTUs belonged
to the bacterial families Veillonellaceae, Coriobacteriaceae, Bacterioidaceae, and
Prevotellaceae, the other 54 OTU levels were seen to be decreased in patients with
schizophrenia (Lachnospiraceae, Norank, Ruminococcaceae and Enterobacteriaceae).
(26)

1.2.2 Neurodevelopmental hypothesis
Epidemiological, basic, and clinical neuroscience research has presented evidence
that schizophrenia is of neurodevelopmental origin (28). This hypothesis is now
widely

accepted

but

what

differentiates

schizophrenia

from

other

neurodevelopmental conditions is its time of onset, in adolescence (29). Autism
spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD) and
intellectual disabilities (ID) characteristically present themselves much earlier in
childhood (29). Schizophrenia shares many phenotypic and clinical similarities and is
often comorbid with these neurodevelopmental disorders but because of its delayed
presentation, they were not initially linked (29). Before they were connected it was
17

then hypothesised that schizophrenia may be a neurodegenerative disorder, but when
post-mortem studies failed to identify traumatic, neurotoxic, or neurodegenerative
mechanisms in the brain this theory was disproven, and the neurodevelopmental
hypothesis replaced it (29). In neonatal primates and rodents, prenatal cortical lesions
were shown to lead to the emergence of abnormalities that mimicked schizophrenia
in early adolescence, proving that early developmental abnormalities could have an
impact on cortical function in later life, making the neurodevelopmental hypotheses
for schizophrenia plausible (30). Instead of each neurodevelopmental disorder being
viewed

independently

an

alternative

view

was

proposed,

that

these

neurodevelopmental disorders lie on an etiological continuum with a diverse range of
outcomes that follows from early brain development disturbances because of shared
genetic variants and environmental factors (29). These neurodevelopmental disorders
are diagnosed based on symptoms, the timing of onset, severity/persistence, and
abnormal brain development (29). Before the first psychotic episode, schizophrenia
presents itself very similarly to the other neurodevelopmental disorders, but only the
negative and cognitive symptoms. There are several rare copy number variants
(CNVs), genes affected by loss of function (LoF) mutations, genes enriched with 3
nonsynonymous mutation and alleles that have significant associations with
schizophrenia, ASD, ADHD and ID which represent direct outcomes of the rare
pathogenic mutations that they share (29). This would also suggest that the risk of
developing positive symptoms is not mediated by cognitive impairment.

1.2.3 Dopamine hypothesis
Dopamine is a catecholamine neurotransmitter in the brain which regulates critical
neurological processes such as cognition, motor control, reward and learning (31). In
18

the 1950s Chlorpromazine an antipsychotic drug and affective antagonist for the D2,
D3, and D5 receptors was released and the treatments dopamine receptor antagonists
have remained the most prevalent therapeutic (11). Chlorpromazine controlled the
positive symptoms of schizophrenia patients and the theory that dopamine alterations
in the mesolimbic pathway caused positive symptoms was strengthened and
confirmed (11). Other key evidence supporting the dopamine hypothesis was when
amphetamines were administered which increase the extracellular concentrations of
dopamine and psychotic symptoms like schizophrenias appeared (32). This evidence
was reinforced when treatments that depleted the concentration of dopamine such as
alpha-methyl-para-tyrosine and reserpine were shown to reduce psychotic symptoms
(32).

These

antipsychotics

target

other

dopamine

receptors,

serotonin,

norepinephrine, acetylcholine and histamine as well (32). It is often seen has that in
the associative striatum there is an increased dopamine synthesis capacity for people
who have psychotic disorders including schizophrenia (33). The increased dopamine
synthesis is detectable in ultra-high-risk (UHR) subjects and before early symptoms
of people who eventually develop schizophrenia thus are not a consequence of
antipsychotic exposure or psychotic episodes (33). Rodent models have been able to
replicate this, these models have also shown that increased synthesis and release of
striatal dopamine can be a result of acute stressors and inflammatory challenges in
utero (34). These developmental disruptions cause the dopamine system to become
hyper-responsive later in life, in the rodent equivalent of adolescence (34). Recent
studies have pinned that part of the cause for schizophrenia to be a combination of an
increased spontaneous dopamine release and decreased dopamine release for relevant
stimuli (34). Studies using amphetamines have been important for proving this. At
moderate doses, amphetamines act as a reward predicting cue by increasing the
19

levels of striatal dopamine appropriately while at larger doses, the amphetamines
blunt adaptive responses, which alters the behavioural response and increases the
spontaneous transients (spikes in the levels of dopamine) (35). These spontaneous
transients may explain the inappropriate phasic firing of dopamine neurons known to
be part of schizophrenia (35). All psychostimulants including amphetamines have the
effect of increasing spontaneous transients in the striatum which correlate and could
explain some of the positive symptoms of schizophrenia. Some of the primary
negative symptoms of schizophrenia could be explained by the decreased adaptive
transients in the striatum. (35) It is thought that many antipsychotic drugs perform in
the same manner and affect the adaptive and spontaneous transients similarly, where
one cannot be fixed without aggravating the other (34).

Around 30% of patients with schizophrenia do not respond to antipsychotics with high
D2 occupancy and do not respond to treatments that diminish the levels of presynaptic
dopamine concentrations. (32,36) Demjaha et.al found that people who responded to
typical antipsychotic treatment had higher dopamine synthesis capacity and that
increased synaptic dopamine may be used to predict treatment responsiveness. (36).
Treatment-resistant patients did not have this capacity, this demonstrated that there
may be a subtype of schizophrenia which is non-dopaminergic. Accumulating
evidence has shown that schizophrenia’s core pathophysiology may also involve
dysfunction in glutamatergic, serotonergic and gamma-aminobutyric acid (GABA).
(37)

20

1.2.4 Glutamate hypothesis
The dopamine hypothesis can account for a portion of the psychopathology of
schizophrenia, in particular positive symptoms (38). Atypical antipsychotic drugs
apart from Clozapine have little to no effect on negative and cognitive symptoms
(11). Negative and cognitive symptoms are neglected by antipsychotics and persist
causing chronic disability (4). In patients with chronic schizophrenia cortical atrophy
correlates with the negative and cognitive symptoms but not with the severity of the
psychosis, (39) showing that although some of the cognitive and negative symptoms
may be caused by dysregulation in dopamine pathways, not all are.

Glutamatergic pathways are primarily the excitatory neurotransmitters in the brain
and glutamatergic neurons utilise between 60-80% of the total brain metabolic
activity (32). Glutamate pathways have been linked to the limbic system, cortex,
thalamus and are mediated by N-methyl-D-aspartate receptors (NMDARs) (37).
Glutamate was originally associated with schizophrenia because it was observed that
there were decreased levels of glutamate in cerebrospinal fluid (CSF) of patients with
schizophrenia (32). There is now mounting evidence that glutamatergic
dysregulation in the prefrontal cortex causes dopamine hyperactivity in the ventral
tegmental area (VTA) which causes auditory hallucinations and paranoid delusions
(40). Studies using NMDAR antagonists (Ketamine and phencyclidine (PCP),
dizocilpine (MK-801)) on HCs induce schizophrenia-like symptoms (negative and
cognitive) and increased prefrontal glutamine levels, these can last up to two weeks
(41). PCP and Ketamine are non-competitive antagonists that bind at the NMDA
subtype of glutamate receptor (39,42). From observing the effects of the NMDAR
antagonists on healthy individuals, it has been proposed that certain symptoms of
21

schizophrenia may result from the hypofunction of NMDAR (43). It has also been
observed that patients with schizophrenia undergoing long term treatment have
increased levels of glutamine in the anterior dorsal cingulate cortex which was linked
with the severity of psychotic symptoms (41), suggesting that despite the treatment
with antipsychotic treatments there is a basal increase of presynaptic glutamate
which is consistent with the NMDAR hypofunction pathophysiological model of
schizophrenia (41). It has been seen in patients with schizophrenia that increased
synaptic release of glutamine is associated with psychosis, while glutamate
metabolism is related to cognitive impairments (41). In one metanalysis it was
observed that glutamate in the frontal region was lower but glutamine is higher in
people with schizophrenia when compared with controls, over time the levels of both
reduce which could suggest a progressive load of synaptic activity (44). Patients with
schizophrenia who don’t respond to typical antipsychotic treatment seem to have
more marked glutamatergic abnormalities while treatment responders have
dopaminergic abnormalities (36).

The role of glutamate in the pathophysiology of schizophrenia has been investigated
in Genome-wide association studies (GWAS) they have highlighted several genes
associated with glutamatergic neurotransmission or with downstream mediators
(GRM3, GRIN2A, and GRIA1) (32).

1.2.5 Gamma-aminobutyric Acid (GABA)
GABA is a major inhibitory neurotransmitter located in the CNS (37). Results from
animal models and postmortem studies suggest that part of schizophrenias
pathophysiology is caused by both dysfunctions of GABAergic interneurons and
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NMDARs(45,46). In human postmortem studies in individuals with schizophrenia,
alterations were seen in GABA-related epigenetic, transcript, synaptic, and protein
markers especially evident was the subpopulation of GABA neurons which
encompass calcium-binding protein parvalbumin (PV) (47). GABA interneurons are
an important part of the brains rhythm generating network, they are also important in
controlling neural oscillations which are fundamental mechanisms for memory,
perception and consciousness (5). The third layer of the prefrontal cortex houses a
microcircuit where GABAergic PV cells and glutamatergic cells synchronize neural
oscillations (11). The PFC PV neurons have lower levels of PV and proteins and a
GABA synthesizing enzyme GAD67 (45). These structural and molecular alterations
are hypothesised to alter GABA neurotransmission and weaken the PFC gamma
oscillations in people with schizophrenia (47). GABA antagonists have been shown
to effective in improving some of the core symptoms of schizophrenia in clinical
studies (48). Benzodiazepine which works on the GABA-A receptor allosteric site is
used often with antipsychotic medications to treat schizophrenia (5).

1.2.6 Serotonin Hypothesis (5-hydroxytryptamine, 5-HT)
Although the serotonin hypotheses are one of the oldest in regards to schizophrenias
pathogenesis it remains highly topical because of the lack of reproducible results
(49). Serotonin has been linked to schizophrenia’s pathophysiology since studies
looking at the interaction between 5-HT and the hallucinogenic drug lysergic acid
diethylamide (LSD) which resulted from antagonism of 5-HT in the CNS (37,50).
Psychotic symptoms due to dementia and Parkinson’s are successfully treated with
5HT2A antagonists without D2 antagonism which halts excess serotonin being
released which stops the downstream release of glutamate which can activate the
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mesolimbic dopamine pathway (40). Sizeable evidence from multiple methods
suggests that a subpopulation of patients with schizophrenia display serotonergic
function abnormalities (49). It is believed that 5-HT receptors (5-HT1A, 5-HT2A, 5HT2C) may underlie cognitive symptoms and motivational disabilities and this shown
by atypical antipsychotics which act on 5-HT1A and 5-HT2A receptors and how they
ameliorate negative symptoms and mood disturbances (51). In mutant mice who
display decreased willingness to work for a reward, there were D2 receptors
overexpression and up-regulation of 5-HT2C receptors in the striatum (51). The
extrapyramidal effects of antipsychotics can be ameliorated by serotonin antagonists,
(37) though the pathogenesis of schizophrenia has not been explicitly linked with
serotonergic dysfunction, 5HT-3 and 5HT-6 continue to be looked into as potential
therapeutic targets.

1.3 Environmental risks for schizophrenia
Many epidemiological studies have investigated the impact of the environment on
the development of schizophrenia. Several risk factors have been highlighted, such as
being raised in an urban environment, early life adversities, and the use of cannabis
(especially compounds with high tetrahydrocannabinol levels) early and frequently
which has an impact on the developing social brain (2,3,8). Immigration (first and
second-generation) has also been studied as well as an increase in the rate of
incidence in individuals with young parents or with relatively old parents.
(2,8,52,53). Prenatal exposure to infection, preterm births, social disadvantage, and
lack of nutrients in the womb have all been linked to heightening the risk of
developing schizophrenia (28,54). Prenatal stress increases the basal secretion of
glucocorticoid hormones which can reprogram the hypothalamic-pituitary-adrenal
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axis (3). In rodent models, following prenatal stress malformations in the DNA
methylation in GABAergic neurons were observed and connected to schizophrenialike symptoms (3). Exposure to prenatal infection has been shown to induce
epigenetic modifications which can cause the downregulation of genes essential for
synaptic plasticity, transmission, working memory, and social cognition (55).
Obstetric complications such as bleeding during pregnancy, pre-eclampsia and
traumatic births can also increase the risk of developing schizophrenia (3). Severe
famine at the time of conception or early in the pregnancy increased the risk of
developing schizophrenia two-fold, while mothers with inadequate weight gain
increased the risk of psychosis for their offspring by 9-fold (56). Prenatal immune
system activation can affect brain development negatively and can slow or alter the
neurodevelopmental trajectories which can cause behavioural and cognitive
impairments later in life (3). The brain is especially vulnerable in the first and second
trimester of pregnancy during critical brain development so maternal stress such as
bereavements, unwanted pregnancies and other serious life events are positively
linked with the development of schizophrenia and other serious mental disorders (3).
Particular childhood and adolescent risk factors are capable of predicting the age of
manifestation in patients with and without a relative who has schizophrenia (53).
Studies have shown that some patients who develop schizophrenia during
adolescence experienced delayed developmental milestones in their first year, had
hearing impairments, emotional problems, low IQ in childhood, and interpersonal
difficulties (2).

Some of the positive symptoms of schizophrenia have been linked to developmental
trauma, cannabis use, living in an urbanised area and the minority group position in
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that area, for these studies cultural bias and selective migration were inspected and
found to not impact these association (56). Living in an area densely populated with
the same ethnic group and moving from an urban area to a rural environment
decreases the risk of developing any kind of psychosis (2,56). The accumulating
evidence that environmental exposures occurring preconception through to
adolescence and adulthood play a role in the susceptibility of schizophrenia, as well
as ample evidence that exposures to environmental factors in utero produce brain
anomalies as well as phenotypes similar to schizophrenia (56). Though the
associations with environmental factors are robust the observational epidemiology
cannot distinguish true causation from the association as a result of pleiotropy or
reverse causation (8).

The role of environment in schizophrenia has been hypothesised for decades but the
lack of biological models and methodologic limitations has made it a difficult test to
what extent they are involved (52). In recent years genetics has dominated the
discourse of schizophrenia’s aetiology (9,52). Twin studies have shown a
discordance rate for monozygotic twins who develop schizophrenia of 40-55%.
Monozygotic twins have identical genomes this illustrates that the risk of developing
schizophrenia is not solely genetic but plays an important role (56). The most
plausible explanation for this discordance is exposure to environmental factors which
are likely to occur as early as in utero, or gene-environment interactions during
crucial brain development (2,56).
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1.4 MRI Findings
The first MRI (magnetic resonance imaging) study focused on schizophrenia was
conducted in 1984 and with advancements in technology over recent years many
more followed. These studies have shown that there is not distinct diagnostic
neuropathology for schizophrenia, but any of the subtle changes which are evident is
apparent when a patient first becomes symptomatic (49,57). The lack of evidence of
distinct neuropathology for schizophrenia could be explained by schizophrenias
diverse presentation, range and severity of the symptoms and if the patient has been
treated with antipsychotic medications before the time of MRI scan (48,57). Studies
have found that several of the brain abnormalities which can occur are evident before
any symptoms appear, hinting at schizophrenias neurodevelopmental nature and that
these abnormalities may change over time (21,26). Understanding these changes in
brain structure could prove most valuable in prognosis, treatment, and intervention.
Across studies, reduced volume in the intracranial is seen especially with male
patients and because 90% of the intracranial volume is usually reached at the age of
five this suggests that there is an early developmental cause (59). Reduced total brain
volume has also been observed consistently with a marked reduction in grey matter
volume (GMV), while cerebrospinal fluid, third and lateral ventricles, and the left
side of the planum temporale have increased volumes and are associated with more
severe symptoms (60). The levels of GMV reduction is associated with elevated
doses of antipsychotics and duration of illness (27). In antipsychotic naive patients
(ANPs) most of the brain abnormalities observed are the same as those found in
medicated patients but to a lesser extent, in ANPs GMV and total brain volume, the
effect size was up to 30% less (24). Conversely thalamic and caudate nucleus
volumes are more prominent in ANPs which strengthens the evidence that typical
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antipsychotic medication enlarges the volume of the basal ganglia (61). The levels of
white matter reductions are similar in medicated patients and ANPs which suggests
that the levels of white matter do not considerably change after onset (60). Some
post-mortem studies have also uncovered neuroinflammation in the brains of
schizophrenia patients which are unrelated to treatments (9,20).

1.5 Genetics of Schizophrenia
Schizophrenia is heritable meaning having a family member with the disorder
heightens the odds of developing it during a lifetime (53,62). Offspring with one
parent with schizophrenia have a risk rate of 7% while offspring, where neither parent
has schizophrenia, is 0.86% (63). Twin studies have been pivotal in furthering our
understanding of the role that genetics plays in schizophrenia’s aetiology (62,63). A
study performed using the Danish Wide Twin Register found that the propandwise
concordance for schizophrenia is 7% for dizygotic twins (Fraternal) and 33% for
monozygotic twins (Identical) in terms of disease liability (8). Although previous
studies have found higher rates of concordance, with monozygotic twins achieving 3040% and heritability estimates for schizophrenia >80% (6,21). Longitudinal twin
studies have shown that children of the unaffected monozygotic twin have a similar
risk as to the affected twins’ children of developing schizophrenia or a schizophreniarelated disease in their lifetimes (9). Taken together, these findings highlighted a clear
genetic susceptibility to schizophrenia.

As a result of multiple technological advances and extensive collaboration, there
have been remarkable advances in the genetics of schizophrenia in the past decade
(64). Genome-wide association studies (GWAS) have been valuable in uncovering
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many schizophrenia risk loci, including single nucleotide polymorphisms (SNPs),
copy number variants (CNVs) and insertions or deletions in bases in the genome
(INDELs) (48). These GWA studies aim to identify areas of the genome that increase
an individual’s risk for developing schizophrenia (65). Schizophrenia is a complex
polygenic psychotic disorder meaning it is not caused by one genetic variation with a
large effect but rather by a combination of multiple genetic variants that each subtly
increases the risk of the disease developing (66,67).

Genome-wide association studies (GWAS) are a powerful tool used for studying the
genetic architecture of diseases (68). It is an experimental design used to uncover
associations between traits of interest and genetic variants, with the aim of better
understanding the underlying biology which could lead to better treatments and
prevention strategies (69). GWASs have also been successful in uncovering diseaseassociated biological processes and assisting in risk prediction. (69). GWAS exploits
linkage disequilibrium (LD) to measure an association at one genetic variant as a
proxy for other genetic variants, the statistical power of these studies depends on the
sample size, the distribution of effect size of the casual genetic variants, their
frequency in the general population and the LD between genotyped DNA variants
and unknown causal variants (65,69). In 2009 the first robustly associated loci linked
with schizophrenia were identified using a sample size of 3000, and in 2014 using a
sample size of 35,000 cases the number of genetic variants increased to 128 common
variant associations across 108 genetic loci (1). In 2018 a schizophrenia metaanalysis identified 179 independent significant SNPs which mapped to 145 loci
(1,66).
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The 2018 meta-analysis GWA study for schizophrenia had 11,260 people with
schizophrenia (cases) and 25,542 healthy controls (HCs). Potential schizophrenia risk
genes were generated by taking proximity of a gene to SNPs into account but also the
kind of genetic variant, expression quantitative trait loci (eQTLs), chromosome
conformation data and genomic finemapping (70). Despite the large sample size,
there was not a huge overlap of results from the previous GWAS, which can be
expected from studying a complex, polygenic disorder like schizophrenia. (1,66).
This study found that associations converge in specific cell types like pyramidal
cells, some interneurons and medium spiny neurons (67). It was estimated that from
a third to a half of genetic liability derive from common alleles, and a large portion
of rare variant architecture comes from mutation intolerant genes which have also
consistently been observed in other neurodevelopmental disorder (1,66). It was also
noted that in the case of schizophrenia there was an enrichment of common variants
associated with loss of function (LoF) and mutation intolerant genes and that these
genes accounted for 30% of SNPs based heritability (66). People with schizophrenia
have decreased fecundity and early mortality, but the common risk alleles persist in
the population which could be because of 1) balance selection that schizophreniarelated alleles have reproductive advantages so are preserved because of their
association with positively selected alleles or 2) the effects of gene-environment
interaction on these rare variants (8).

Despite this improved knowledge, the understanding of the underlying biological
mechanism has not progressed far enough to develop new treatments or cultivate
preventative strategies.
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1.6 Aim of the project
Understanding how gene expression and regulation differ between individuals has
advanced the understanding of healthy tissues and the origins of diseases and
complex traits (71). To get a better understanding of the control of gene expression
it’s important to understand the relationship between genotype and phenotype and
RNA sequencing which is a more quantitatively accurate absolute transcript (72).

This study aims to examine gene expression of the schizophrenia-associated genetic
loci, identified by Pardiñas et al., in the developing human brain using the BrainSpan
Atlas of the ABA repository. Of the 145- independent schizophrenia-associated loci
provided by Pardiñas et al. 316 genes were available on ABA’s resource, BrainSpan
for further investigation. The expression profile of the 316 schizophrenia-associated
genes was investigated using 1) K-means to identify underlying patterns in the genetic
data and 2) network analysis using weight-gene co-expression network analysis
(WGCNA) in the developmental stages available in ABA’s Brainspan resource. Both
steps were performed across the five developmental stages of the ABA dataset. Gene
modules identified using WGCNA were further characterized by identifying hub genes
and performing enrichment analysis to identify schizophrenia-related biological
pathways. Identifying relevant biological pathways can further our understanding of
disease aetiology and present new targets for novel therapeutics which could provide
better outcomes for schizophrenia patients.
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Chapter 2 – Methods
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Figure 1.6.1 Diagram of methods performed in this study.
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Chapter 2 - Methods2.1 Collation of Schizophrenia-associated
Genes
Our knowledge of schizophrenia’s genetics has vastly improved in the past decade,
however, identifying gene targets has proven difficult (1). Pardiñas et al. completed a
GWAS meta-analysis in 2018 which had 11,260 cases obtained from a CLOZUK
sample on genetic information from people with schizophrenia in the UK and 24,542
controls (66). The meta-analysis used cases from the CLOZUK GWAS and
combined them with Psychiatric Genetic Consortium (PGC) datasets from the 2014
GWAS excluding any overlapping samples which brought the total number of cases
to 40,657 cases and 64,643 controls, the meta-analysis highlighted 179 independent
genome-wide SNPs which were significant, which mapped to 145 loci (66). 93 of the
145 loci had been previously identified by the PGC GWAS in 2014 and had shown
an increased association in the 2018 meta-analysis (1,66). Summary statistics were
added to the ClOZUK genes so a combined analysis could occur. The PGC data was
re-examined with a fixed-effects procedure derived from standard errors and
polygenic risk scores were calculated for the whole dataset (66). In this study,
schizophrenia-associated genes (n=316) identified by the GWAS meta-analysis
conducted in 2018 by Pardiñas et al. who identified 145 loci total with P < 5 × 108. If
the loci did not overlap with a gene, the closest gene within a 500kb radius was used.
Of the 145 loci, 316 genes were available from ABA’s BrainSpan resource (66).
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2.2 Allen Brain Atlas
The brain is the most complex system in the human body with approximately 86
billion neurons and around a trillion synapses per cubic centimetre of the cortex (73).
Its circuitry, cellular and structural diversity and the regulation of its transcriptome
are far from being completely understood. One billion people are suffering
worldwide with brain diseases and disorders but there is a lack of diseased tissue to
study. There is a need for another approach to uncovering their aetiologies (74). The
challenge of this type of research is the scarcity of high-quality post-mortem human
brains. These brains are normally dissected at brain banks and distributed to various
research groups and thus data derived from these analyses have diversified
hypotheses that are non-parallel as well as different types of research methods, which
has hindered the analysis of brain disorders (73). Although other species model
systems have been useful, analyses of the human brain itself are essential to get a
true understanding (73).

ABA is a public resource that gives access to gene expression, connectivity, and
neuroanatomical data for mouse, primate, adult humans, and developing brains for
humans and mice which integrates MRI, genomic and anatomic information,
histology, diffusion tensor imaging and gene expression data derived from ISH and
microarray methods (75). The original Allen Human Brain Atlas (AHBA) uses highquality post-mortem brains from males and females between the ages of 18-68 with
no known neuropathological or neuropsychiatric history and maps the genes
expression to the stereotaxic space. (76) This valuable tool can help researchers
trying to comprehend how spatial variation on the molecular scale associate with
macroscopic neuroimaging phenotypes (76). While there are other human atlases,
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only Allen Human Brain Atlas (AHBA) possesses high-resolution coverage of the
majority of the brain (76).

The brain tissue underwent several tests including serology, toxicology and tested
the RNA quality to determine if it meets the inclusion factors (74). If the brain tissue
samples passed, they were then sent to tissue repositories for initial tissue processing.
After which the brain tissue was frozen, after and sent to the Allen Institute where
thorough quality control (QC) tests were performed, the brain tissues that passed this
threshold have histological data collected from them and the tissues were subdivided
and categorised based on if they contain cortical or subcortical substructures.
Additional tissue containing subcortical structures were collected and then placed on
membrane slides so laser microdissection (LMD) could occur. Both cortical and
subcortical tissue samples were collected for microarray analysis. The microarray
analysis quantified the expression levels of thousands of genes at once by measuring
the hybridisation of Cy3-labelled RNA (cRNA) to a probe on a microarray chip
(Agilent 8 X 60K custom design arrays) (74). The probes were mapped to a specific
location of DNA that contains single-stranded nucleic acid profiles which recombine
with their complementary targets during hybridisation. The gene expression levels in
the tissue samples were quantified by measuring the fluorescence at the sequencespecific locations which correlate to the levels of mRNA (76).

2.2.1 Brainspan Atlas of the Developing Human Brain
The human brain develops following a complex series of histogenic occurrences that
depend on differential gene expression and its complex development is not fully
understood (77). During the first 6 months of embryonic life, the brains general
36

architecture is formed this is driven by strong genetic influences which are silenced
in the third trimester allowing for environmental factors to influence the last
trimester (78). Mice and non-human primates’ models have been useful in
developing some knowledge of the brain but the differences between species is a
huge limitation. Firstly, because of the difference in size, in addition to this the
evolutionary differences which are seen in the superficial layers of the neocortex and
secondly the developmental differences in the evolution of GABAergic interneurons
(77). The shortage of human prenatal tissue and the use of different species models
which have their restrictions has hindered the development of an anatomically
comprehensive atlas of the prenatal human brain which could be used for studying
the roots of neurodevelopmental and psychiatric disorders (79). The ABA resource
BrainSpan transcriptional atlas of developing human brain is a repository of RNA
sequences expression profiles of 16 brain structures from 8 weeks post-conception
(prenatal) to 40 years of age (80). The stages are outlined in Table 1. The prenatal
stage is made up of four high quality mid gestational brains, two from fifteen to
sixteen post-conceptual weeks, and two twenty-one post-conceptual weeks
specimens. These tissues had no history of maternal drug or alcohol abuse or
potential agents that could disturb their development or relations with HIV 1 or 2 or
HepB or HepC (77). The specimens were donated from the birth defects research lab
at Washington University and the Advanced Biosciences resource in California (77).
The left hemispheres were coronally, serially cytosectioned onto polyethylene
naphthalene (PEN) membrane slides for LMD and histologically stained for detailed
structure identification, and three hundred regions per specimen were isolated (77).
The right hemisphere of two of the specimens was handled similarly and was used
further for In situ hybridisation and Nissl staining for structure identification (81).
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The sample locations were mapped to MRI coordinates and then to the Montreal
Neurological Institute (MNI) coordinate space (81). This data was anatomically
delineated to create a digital reference atlas which allows for the visualisation of
transcriptome data in its exact coordinates. The atlas resources also include MRI,
diffusion-weighted MRI from three brains with the approximate same postconceptual weeks as well as the white matter reconstruction for three additional
brains (77).

Table 2.1: Age categories from the developmental stages for ABA’s resource BrainSpan available
for download in R.

Stage

Age category

1

Prenatal

2

Infant (0-2 years)

3

Child (3-11 years)

4

Adolescent (12-19 years)

5

Adult (>19 years)

2.2.2 ABA and its application in research
The scarcity of suitable brain tissue available for research led scientists to develop
Allen Brains Atlas human brain resource. ABA’s gene expression data being
accessible at high neuroanatomical data makes it possible to identify intricate gene
expression patterns for healthy human brains, these profiles for healthy brains can be
used as a baseline to identify genes involved in neurological conditions by using
machine learning techniques which could be connected with a neurological
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condition. This approach was successfully applied by Negi et al. where they applied
machine learning methods such as hierarchical clustering and weighted coexpression on ABAs gene expression profiles across brain regions (82). From there
they were able to build supervised classification models for Autism and Parkinson’s
with 84% and 81% accuracies respectively (82). Researchers can solely use ABAs
resources alone or can apply external data from GWAS or MRI studies to aid their
analysis. McCarthy et al. applied the latter technique when investigating Bipolar
disorder (BD), they took 58 genes identified to be involved with BD from a
previously published GWAS and looked at their expression pattern across 900 areas
(83). They also compiled a meta-analysis of MRI studies looking for structural
abnormalities across patients diagnosed with BD (83). They aimed to see if they
could link unusual gene expression in the BD genes with the brain structural
differences (83). Using ABA’s Brainspan human brain transcriptome database
Mahfouz et al. hypothesised that understanding the functional relationships between
ASD candidate genes during normal development could provide insight into ASD’s
genetic heterogeneity (80). Over human development, the heterogeneous ASD
candidate genes share transcriptional networks related to protein turnover,
mitochondrial function and synapse elimination and formation (80).

39

Figure 2.2.2.1 Schizophrenia-associated genes identified by Pardiñas et al and their position on
the chromosomes.

2.2.3 Collation of schizophrenia-associated genes from ABA
The ABA data was downloaded into R (version 4.0.0) using the R packages ABAData
and ABAEnrichment (52,74). The complete ABA dataset has 17,245 genes expressed
in 16 distinct areas over five developmental stages from prenatal to adulthood (See
Table 2.1 for more detail). The genes found to be significantly related to
schizophrenia identified by Pardiñas et al. determined by their p-values (66) were
exported by CSV file into R. The 17,245 genes available in ABAData were filtered
into five dataframes for each of the developmental stages for further analysis. The
dataframes were shaped into a wide format using the pivot_wider function in R
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where the brain areas are the column names, and the row names were converted to the
schizophrenia-associated gene names using column_to_rowname function in R
and the gene expression for each gene was scaled. The schizophrenia-associated genes
are available in Table 37 in the Appendix.
Figure 2.2.2.1 shows the schizophrenia-associated genes identified by Pardiñas et al.
which were available on ABA’s resource and where they lie on the chromosome.

2.3 Machine Learning and Clustering
Regression analysis, feature selection methods, and classification are elements of the
term Machine Learning (84). Classification can be subdivided into supervised, semisupervised, and unsupervised. Supervised classification deals with objects that are
labelled beforehand and build a learning algorithm which is then used to predict the
classification of unlabelled data. Semi-supervised uses labelled and unlabelled data to
train an algorithm (85). Unsupervised classification defines classes without help from
previously known labels (84), clustering is a form of unsupervised learning.

In genetics, large datasets of genes and their expression are given to a clustering
algorithm to cluster genes whose expression are similar to each other. These
algorithms can be used for prediction, classification, and identification in DNA
sequences but can also be taught to distinguish between phenotypes and identify
possible biomarkers (85).

2.3.1 Unsupervised Learning and clustering for gene expression data
Unsupervised learning is a machine learning technique that looks for natural structures
in data and groups them without classifying them (85). Gene expression data is
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massively complex. Clustering is an unsupervised learning approach capable of
discovering subgroups within a dataset, each of these subgroups or clusters have
similar observations within them. This type of analysis has been a cornerstone for
interpreting biological information from large gene datasets (86). Clustering can group
genes based on their similar expression across brain areas and discover patterns in the
data. Clustering can suggest regulatory relationships between genes and transcription
factors and can further genome annotation by using the principle of guilt by
association, as well as give a better understanding of how diseases manifest and can
progress over time (87).

2.3.2 K-means clustering and NbClust
One of the most fundamental modes of understanding learning is to organise data into
sensible groupings (88). K-means is a numerical, unsupervised, iterative, nondeterministic method that is classified as a partitional clustering algorithm (89). The kmeans algorithm finds a split so the squared error between the points in a cluster and the
empirical mean is minimized in each of the clusters. To perform k-means the number of
clusters (k), distance metric and cluster initialisation must be pre-specified before the
algorithm can be run (88). The goal of k-means is to produce groupings each with a
high degree of similarity and a low degree of similarity with the other groupings (90).
One of the issues with k-means is deciding the number of clusters (k) that are suitable
for a dataset, there are many different indices to determine this but a package in R called
NbClust integrates thirty different indices in one package to determine the optimal
number of clusters in a dataset (91).
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2.3.3 Kmeans analysis of schizophrenia-associates genes
In this study, unsupervised machine learning techniques were performed on the
schizophrenia-associated gene set to identify underlying patterns. The NbClust package
in R was used to determine the optimal number of clusters for each of the developmental
stages. NbClust uses thirty different methods of determining cluster number and produces
a bar chart to visualise which cluster number fits best (91). The optimal cluster number
was put into the kmeans function in R for the centres. Twenty-five was selected to be the
optimum number for initial configurations (nstart) and Euclidean distance was used. Each
cluster is filled with genes with similar expression patterns. After the K-means analysis
was performed each of the clusters was visualised using the fvis_cluster from the
factoextra package in R (92). A table to show module assignment for each of the genes is
available in table 17 in the appendix.

2.4 Co-expression Network Analysis
The information found in gene expression data can be used to link genes with unknown
function to biological processes, identify candidate genes for disease, determine
transcriptional regulatory systems, and identify novel targets for therapeutics (93). Coexpression network analysis recognises genes that show coordinated expression patterns,
and the networks can be shown as gene-gene similarity matrixes in later analyses. Coexpression looks to identify relationships between pairs of genes by using mutual
background information or correlation (93). These pair-wise correlations between them
are then rolled out to the other genes in the dataset until a network is formed where
multiple modules are fashioned and each node signifies a gene, and the edges represent
the presence and strength of the relationship. Functional enrichment analysis can be
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applied to the modules formed after applying the co-expression network analysis method,
these modules can often represent biological processes (93).

2.5 Weighted correlation network analysis (WGCNA)
Genes do not work alone, and each gene can work with between four to eight genes
which in turn could be involved in up to ten biological processes (94). Any dysfunction in
these pathways can potentially lead to diseases. There are many ways to analyse complex,
multi-dimensional genetic data, and one of the most popular methods are correlation
networks. This technique is a useful way of discovering the underlying intrinsic
organisation of the transcriptome. Constructing gene co-expression networks (GCN) for
complex diseases is an important method of identifying genes involved in disease,
highlighting highly connected genes within the networks and modules that can lead to
novel therapeutics or biomarkers for diagnosis. WGCNA is an unsupervised learning
systems biology network analysis method for associating correlation patterns among
genes across gene expression microarray samples. The WGCNA package which is
available for download in R can construct gene networks, identify modules, and can
detect highly connected genes that are representative of the module using hierarchical
clustering (95). When WGCNA is performed the algorithm evaluates the expression for
each gene, pairing them based on topological overlap (TO) and then considering the
degree of shared neighbours looking for consistent gene expression patterns and placing
them into modules (82). Once the modules are defined the module eigengene (ME) which
is the first principal component of the module is isolated and centralised. Highly
connected nodes which are most like the ME and that are representative of the modules
are specified and these are called hub genes (HG). The module membership (MM)
calculates the degree of correlation between the genes within a module and the ME (96).
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Using module significance (MS) methods can help detect important modules which
contain high average node significance (NS) and the gene significance (GS) which is the
correlation between a node and a phenotype of interest (95). The WGCNA algorithm can
execute network construction, module detection, gene selection, data simulation,
visualisation, and calculate topological properties (95). WGCNA has been applied
successfully with cancers, mice and yeast genetics, and brain imaging data.

2.5.1 Network analysis using WGCNA
After the initial unsupervised learning analysis looking for underlying patterns, network
analysis was performed using WGCNA in R. WGCNA was performed on the
developmental stages because it is an effective way to characterise correlation patterns
within the schizophrenia gene set, genes that correlate sometimes are related biologically.
Networks were constructed using an adjacency matrix which looked at the co-expression
similarity between a pair of genes and constructed a hierarchical graph. Pairwise
correlations were used to identify modules where genes with similar gene expression are
grouped into modules. To construct the weighted gene network, a soft threshold power
analysis was first performed using the pickSoftThreshold function within the
WGCNA package to calculate the adjacency by using gene co-expression, the power in the
pickSoftThreshold function was calculated independently for each developmental
stage and verbose was set at five (94,95). Once the power is chosen to calculate
adjacencies, the adjacency is transformed into Topological Overlap Matrix (TOM) and
used to calculate the dissimilarity. A clustering dendrogram is made from the genes using
TOM-based dissimilarity and subsequently a minimum module size of 10 was chosen the
genes were assigned to modules with genes of similar expression profiles. HG and ME
were identified in each of the modules using the moduleEigengenes function and the
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chooseTopHubInEachModule function in WGCNA. Each gene in the module is
annotated to its distance from the ME this is the MM.

2.5.2 Networks and their applications
Networks are abstract models made up of nodes, vertices, and a set of edges. The nodes are
the entities and the edges are the information that connects them (97). There are different
types of networks for different situations that can yield different outputs, directed networks
are formed when nodes are asymmetrical and mean one can influence the second, but the
second cannot influence the first. Undirected networks are when the relationship between
the nodes is symmetrical and is most useful for exploratory analysis of genes (97).
Understanding the intricate relationship between diseases or disorders and their underlying
mechanism is a subject that continues to challenge the areas of medicine and biology.
There is clear evidence that there are disease-disease associations where two or more
conditions can have similar or identical underlying mechanisms and understanding one can
further the understanding of the other (80). The advancements of high throughput
technologies like DNA microarray and next-generation sequencing have given researchers
large scale genomic datasets (98). Constructing new biological pathways is generally
achieved by using the interactions found from previous studies with gene regulation
information for specific diseases or tissues, using system-level biological data is predicted
to improve current knowledge of underlying mechanisms and lead to improvements in
diagnosis, prognosis and treatments (99).

2.5.3 Cytoscape
Cytoscape is a free software project which combines expression data with biomolecular
networks and aids in visualising, querying, and linking the data to functional annotation
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databases (100). Functional proteomics and genomics techniques allow for measurements
of expression profiles and interactions between cells and tissue to be collected which could
potentially map cellular processes and their dynamics. From these expression profiles
active biological processes can be identified using enriched gene annotation and by
combining expression profiles and cellular network interactions changes in biological
activity could be explained (101). Cytoscape allows for protein or gene properties to be
associated with the nodes and edges by changing their appearances which allows for
numerous types of data to be seen in a network context. It also includes a range of
environments that can model gene transcription kinetics, biochemical reactions, and
metabolic control, which advance biological research (100). To gain insight into the
structure and organisation of a network Cytoscape’s NetworkAnalyzer plugin was
developed for visualisation and analysis (102). NetworkAnalyzer computes a set of
topological parameters, including, the number of nodes, edges, network diameter, radius,
density, centralization, heterogeneity, connected components, clustering coefficient and
shortest path lengths (103).

2.5.4 Visualisation of modules using data from WGCNA in Cytoscape
Gene relationship data, module membership, weight and direction of the edge was saved
to csv files Node files for each module in the developmental stage, this data was generated
using WGCNA analysis in R. These CSV files were exported into Cytoscape (104)
(version 3.7.1) using the exportNetworkToCytoscape function so each of the
modules for the developmental stages could be visualised. Firstly, the edge data was
exported, source and target node columns were selected, and the p-value for SNP inclusion
determined by Pardiñas et al. (66) was marked as the source node attribute and weight
which was filtered to 0.8 and above was selected as the edge attribute. To the node file
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produced by Cytoscape, the node table for each of the modules was loaded in for the
module membership of each node. Cytoscape’s NetworkAnalyser was applied to each of
the modules, each of the modules was treated as undirected. Using the visualise parameters
function in NetworkAnalyzer the size of the Node (which referred to the genes) used the
MM, edge width was mapped to the weight of the schizophrenia genes and the node
colours were charted to the p-value determined by Pardiñas et al. (66).

2.6 Gene Ontologies (GO)
A gene ontology defines a gene's function and how the functions of other genes are related
to each other (105). GO is described with respects to three features: molecular function
(the activities performed at a molecular level by the gene products), cellular components
(where the gene product performs a function relative to a cellular structure), and, biological
processes (the biological programs which are completed by several molecular activities)
(105,106). As the knowledge of gene ontology is expanding so too are the databases that
house them.

anRichment a package available in R is used to calculate ontology enrichment within the
modules provided when compared to known reference gene sets such as KEGG, GO,
Reactome, etc. (107). By using the function enrichmentAnalysis in anRichment and
providing a module in the classes input and a collection reference gene set, GO enrichment
analysis was applied (107). GO enrichment using anRichment was performed on each of
the modules to identify biological processes which are over-represented in each of the
modules (107). To run the analysis using anRichment the enichmentAnalysis
function was run using GOcollection which is built using org.Hs.eg.db R package
(108) and specifying species as human, the threshold was set at 1e-4, the threshold type
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was Bonferroni, getOverlapEntrez = TRUE, getOverlapSymbols = TRUE and ignoring the
grey module.
Formatted: Left, Right: 0 cm, Line spacing: single
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Chapter 3 -Results
3.1 Data Pre-processing
The schizophrenia-associated genes (genes tagged) from the GWAS meta-analysis by
Pardiñas et al. (66) are found in the supplementary materials section NIHMS958804supplement-Supplementary_Table.xlsx on the sheet titled “Supplementary Data Table 4:
Independent genome-wide significant association signals from the CLOZUK + PGC metaanalysis, clumped and amalgamated into loci”. This data was downloaded into R (66). The
dataset_5_stages function available within the ABAData package was loaded into
R, each of the five age categories was separated into their data frame and then filtered so
they only included the schizophrenia-associated genes identified by Pardiñas et al (66).
This gave five dataframes for each developmental Stage with 316 schizophrenia-associated
genes expression over 16 distinct brain regions. Each of the dataframes was placed in a
wide format where the gene names were rows, and the brain regions were columns. This is
illustrated below in Table 3.1.
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Table 3.1: Wide-format of the schizophrenia-associated genes data frame. Brain areas available from ABAs Brainspan are the names of the columns in bold and
the schizophrenia-associated genes are the row names. Each cell contains the scaled gene expression for each brain area

10163

10173

10185

10194

10209

10225

ABCB1

0.645635

0.193074

0.103555

-1.09892

0.05936

-1.24916

ABCB9

-0.62942

0.871415

1.128378

-0.6889

-0.32854

0.351194

ABCD2

1.410626

0.488282

0.541653

0.88314

1.281896

0.40718

ACO2

-0.66424

-0.09813

-0.02023

-0.50082

-0.88345

-1.04544

ACP2

-0.5259

-0.74472

-0.28589

-0.63244

-0.70708

-0.90644

ACTR1A

0.84579

0.475071

0.904972

0.463709

1.186486

0.717958

ACTR5

-0.97613

0.244193

0.215631

-0.26563

-1.25836

-0.95691
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3.2 Unsupervised learning using K-means analysis on the
schizophrenia-associated genes
Unsupervised learning looks for patterns in data. During this project, a large amount of
gene expression data from the ABA was used to associate schizophrenia-associated
genes based on the similarity of their expression profiles across brain areas.
Unsupervised learning allows users to group the schizophrenia-associated genes into
clusters.
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3.3 Determining Optimal cluster Number using NbClust
K-means analysis was used to cluster each developmental stage to show the schizophreniaassociated genes cluster. As K-means requires the number of clusters to be prespecified,
the NbClust function in R was used to determine the optimum number of clusters in each
developmental stage as is illustrated in Figure 3.3.1.
NbClust uses thirty optima (91) ways of determining cluster number and produces a bar
plot to represent how many times each number of clusters appeared. The optimal cluster
numbers for developmental stages 1-5 are as seen in Figure 3.3.1. The kmeans function
available in R was used to run the analysis and the package factoextra was used to
visualise the clusters (109).
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Figure 3.3.1 NbClust analysis performed on the schizophrenia genes identified by Pardiñas et al. to identify the optimal number of clusters (looking between 1-10 clusters)
for K-means clustering on each of the five developmental stages available on ABA’s BrainSpan resource

From the results in Figure 3.3.1, there is a clear indication of the optimal number for all clusters except Stage Four where 2 and 3 are both optimal.
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Figure 3.3.2.-3.3.6 visualise the cluster assignments for each of the schizophreniaassociated genes in each developmental stage. Figure 3.3.7 exhibits the clusters of
each developmental stage side by side for comparison.
The sum of squares of a cluster measures the total variance within a cluster. A smaller
sum of squares means a more compact cluster which means there is internal cohesion
in the cluster. A low total variance tells us that the genes in the Developmental stage
are like each other, in good clustering, a total variance would achieve a high
percentage where the difference between the groups would explain a majority of the
total variance and the within-cluster variance would explain the small fraction left.

Figure 3.3.2: K-means analysis on the Developmental Stage One genes using the kmeans function in R with 2 centres selected as per the
NbClust recommendation and nstart= 25

Table 3.2: Sum of squares for each module in Developmental Stage One determined using the kmeans function in R.

Cluster

1

2

Sum of Squares per cluster

1714.970

2115.253

The total variance in the data (Between SS/ Total SS) = 24%
In Figure 3.3.2 cluster One is the most compact cluster, and this is confirmed by it
having a smaller sum of squares seen in Table 3. Both cluster One and cluster Two
have a very high within-cluster variance. A total variance value of 24% shows that the
gene expression data in all of the genes are similar and most of the variance is
explained by within-cluster variance. A higher total variance is more desirable with
only

a

portion

of

the

variance

being

explained

within

the

clusters.

Figure 3.3.3: K-means analysis on the Developmental Stage Two genes using the kmeans function in R with 3 centres selected as per the
NbClust recommendation and nstart= 25.

Table 3.3: Sum of squares for each module in Developmental Stage Two determined using the
kmeans function in R

Cluster

1

2

3

Sum of squares of
cluster

1339.484

1128.824

1247.380

Total variance in the data = 26.3%
In the clusters in Figure 3.3.3 each of the sum of squares is high, this tells us that there
is a lot of in-cluster variation, the total variance of the data is also low at 26.3%. The
high sum of squares within the clusters explains a lot of the total variance in the
dataset.

Figure 3.3.4: K-means analysis on the Developmental Stage Three genes using the kmeans function in R with 3 centres selected as per the
NbClust recommendation and nstart= 25

Table 3.4: Sum of squares for each module in Developmental Stage Three determined using the
kmeans function in R

Cluster

1

2

3

Sum of
squares of
cluster

925.8711

1544.4462

1389.3763

The total variance of data in module = 23.4%

The sum of squares of both clusters in Figure 3.3.4 tells us that again there is some
variance in the clusters. The low total variance in the data also tells us that the clusters
are similar. Ideally, the properties of good clustering would have clusters that are
alike, and the other clusters would be very different giving a total variance of the data
a percentage closer to 1.

Figure 3.3.5: K-means analysis on the Developmental Stage Four genes using the kmeans function in R with 3 centres selected as per the
NbClust recommendation and nstart= 25.

Table 3.5: Sum of squares for each module in Developmental Stage Four determined using the
kmeans function in R

Cluster

1

2

3

Sum of
squares of
cluster

1430.5423

1308.7500

993.0729

The total variance of data in module = 25.9%

The in-cluster variation in Figure 3.3.5 is especially high for cluster One whereas
cluster Two and Three there has a similar cluster sum of squares. A large portion of
the total variance in the module would be explained by cluster One.

Figure 3.3.6 K-means analysis on the developmental stage Five genes using the kmeans function in R with 3 centres selected as per the
NbClust recommendation and nstart= 25.

Table 3.6: Sum of squares for each module in developmental stage Five determined using the
kmeans function in R

Cluster

1

2

3

Sum of squares
of cluster

1268.6299

952.0207

1120.2446

The total variance of data in module = 33.7 %
In Figure 3.3.6 all of the clusters have high in-cluster variation and a cluster that is not
compact, and it can be seen the total variance in the data is low at 33.7% meaning
both clusters are similar so a large portion of the 33.7% variation will be explained by
the within-cluster variance.

Figure 3.3.7: Kmeans analysis run on schizophrenia genes identified by Pardiñas et al. to determine intrinsic patterns within the genes at each of the developmental stages
from ABAs Brainspan resource

3.4 WGCNA on schizophrenia-associated genes and Network
Visualisation using Cytoscape
We next employed WGCNA to undertake a system-level approach to identify networks
of co-expressed modules of schizophrenia-associated genes. WGCNA is performed to
organise highly correlated genes into gene modules.

First, an analysis of the topology of the networks at various soft thresholding powers
was performed separately for developmental stages (results are illustrated in Figure
3.4.1). The soft threshold is calculated to identify the power of the gene correlation
should be raised. By raising the correlation to this power, it will reduce the noise of
any correlations in the adjacency matrix.
Table 3.7: The Soft Thresholding power of each developmental stage calculated using WGCNA
and shown in Figure 3.4.1
Developmental Stage

Soft Thresholding power

Stage One

7

Stage Two

6

Stage Three

7

Stage Four

9

Stage Five

9

WGCNA is used to organise highly correlated genes into modules. Below a gene coexpression network is constructed which is represented by an adjacency matrix which
signifies similar co-expression between a gene pair. Hierarchical clustering is used to
identify modules and uses topological overlap to measure dissimilarity. Once the
schizophrenia-associated genes are separated into modules these modules were
summarised by calculating a module eigengene and defining an intramodular hub

gene. Then the modules were and visualised using Cytoscape’s NetworkAnalyzer.
Next, GO enrichment was performed on each of the modules using anRichment an
R package (107).
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After the differential topological matrix is calculated, a gene clustering dendrogram is
plotted using the hclust function in R. Each leaf of the dendrogram is a gene and
after the minimum module is set, the genes may remerge. The dendrogram clusters the
branches into coloured modules but some of the modules may need to merge because
their genes are highly co-expressed. This is done by calculating eigengenes of each
module and re-clustering based on the module eigengene dissimilarity correlations
using the mergeCloseModules function in WGCNA. Once the modules have
merged the module eigengene is re-calculated. WGCNA identified 7 modules in Stage
One, 3 modules in Stage Two, 5 modules in Stage Three, 6 modules in Stage Four and
9 modules in Stage Five.

The merged modules and initial modules are illustrated in Figure 3.4.2. After the
modules are merged the eigengene is recalculated and in Figure 3.4.3 the adjacency of
the eigengene compared to the other eigengenes in the developmental stage is shown.

Network heatmap plot for the developmental stages one through five, using the
function TOMplot in WGCNA, were created to visualise the topological overlap
matrix (illustrated in Figure 3.4.4). This TOM matrix uses the adjacency matrix to
build another adjacency matrix which takes topological overlap (the number of shared
neighbours of the nodes).
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3.5 Intramodular Hub Genes and Network Analysis
Hub genes (absolute module membership ⩾ 0.8) for each module within each stage
were identified using the function chooseTopHubInEachModule in the
WGCNA package. Identified HGs for each module, the function of each gene, as
defined by NCBI and their association with disease phenotypes are outlined in
Table 9.
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Table 3.8: Gene Functions and the phenotypes they are involved in for each hub genes identified by the WGCNA function in R when performed on the
schizophrenia-associated genes identified by Pardiñas et al. for the five developmental stages available on ABA’s Brainspan.
Module
Colour

Black

Blue

Brown

Pink

Hub Gene

Gene Name

Genomic
Location

Function (NCBI gene and Gene ontology)

Association with other
Conditions

Reference
s (PMID
ID)

SOX5

SRY-Box
Transcription
Factor 5

NC_000012.
12

FHIT

Fragile
Histidine Triad
Diadenosine
Triphosphatase

NC_000003.
12

Stage One
This gene encodes a member of the SOX (SRY-related HMG-box)
family of transcription factors involved in the regulation of
embryonic development and the determination of cell fate. The
encoded protein may act as a transcriptional regulator after forming
a protein complex with other proteins. The encoded protein may
play a role in chondrogenesis
The protein encoded by this gene is a P1-P3-bis(5'-adenosyl)
triphosphate hydrolase involved in purine metabolism. This gene
encompasses the common fragile site FRA3B on chromosome 3,
where carcinogen-induced damage can lead to translocations and
aberrant transcripts. Aberrant transcripts from this gene have been
found in about half of all oesophageal, stomach, and colon
carcinomas. The encoded protein is also a tumour suppressor, as
loss of its activity results in replication stress and DNA damage.

SLC12A4

Solute Carrier
Family 12
Member 4

NC_000016.
10

The encoded protein controls the movement of potassium and
chloride ions across the plasma membrane.

Sickle Cell and Fisheye
disease

31792382

NC_000003.
12

Secreted glycoprotein with a C-terminal complement Cq1-like
globular domain that belongs to the C1q/tumour necrosis factorrelated protein (CTRP) family. The encoded protein is expressed in
the inner ear and forms a multimeric complex called the otoconia,
together with cerebellin-1 and otoconin-90, as part of the otoconial
membrane. It contains extensive posttranslational modifications
including hydroxylated prolines and glycosylated lysine’s

Benign Paroxysmal
Positional
Nystagmus and
Vestibular Disease

29533337,
31120422

OTOL1

Otolin 1

Lamb-Shaffer
Syndrome and Optic
Nerve Hypoplasia,
Bilateral.

31578471

Renal Cell Carcinoma,
Nonpapillary and Sporad
ic Breast Cancer.

28404875
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Module
Colour

Hub Gene

Gene Name

Genomic Location

Function (NCBI gene and Gene
ontology)

Association
with other
Conditions

Stage Two

Blue

KCNV1Potassium
Voltage-Gated
Channel
Modifier
Subfamily V
Member 1

Brown

NDRG4-NDRG
Family Member
4

Green

GPR52- G
Protein-Coupled
Receptor 52

Turquoise

STAG1-Stromal
Antigen 1

NC_000008.11

NC_000016.10

NC_000001.11

NC_000003.12

Potassium channel subunit that does not form functional channels
by itself. Modulates KCNB1 and KCNB2 channel activity by
shifting the threshold for inactivation to more negative values and
by slowing the rate of inactivation. Can down-regulate the channel
activity of KCNB1, KCNB2, KCNC4 and KCND1, possibly by
trapping them in intracellular membranes.
This gene is a member of the N-myc downregulated gene family
which belongs to the alpha/beta hydrolase superfamily. The protein
encoded by this gene is a cytoplasmic protein that is required for
cell cycle progression and survival in primary astrocytes and may
be involved in the regulation of mitogenic signalling in vascular
smooth muscles cells

Members of the G protein-coupled receptor (GPR) family play
important roles in signal transduction from the external
environment to the inside of the cell
SCC3 family and is expressed in the nucleus. It encodes a
component of cohesin, a multi-subunit protein complex that
provides sister chromatid cohesion along the length of a
chromosome from DNA replication through prophase and
prometaphase, after which it is dissociated in preparation for
segregation during anaphase.

Atrial Septal Defect
5 and Familial Adult Myoclonic
Epilepsy

25969726

Infantile
Myofibromatosis and Pulmonary
Atresia With Ventricular Septal
Defect.

31832525,
19711485

Huntington’s disease

33796846,
24587241

Mental Retardation, Autosomal
Dominant 47 and Cornelia De
Lange Syndrome.

2467316,
28430577,
28119487,
32778134
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Module
Colour

Blue

Brown

Turquoise

Yellow

Hub Gene

Gene Name

Genomic
Location

NC_000002.1
2
(199269500.1
99471266,
complement)

SATB2

SATB homeobox 2

INA

Internexin Neuronal
Intermediate Filament
Protein Alpha

TRANK1

Tetratricopeptide
repeat and ankyrin
repeat-containing 1

NC_000010.1
1
NC_000003.1
2
(36826817.36
945662,
complement)

Ankyrin repeat domain
63

NC_000015.1
0
(40278372.40
282586,
complement)

ANKRD63

Function (NCBI gene and Gene ontology)

Stage Three
SATB2 encodes for a DNA binding protein that
binds specifically at nuclear matrix attachment
regions. These regions are involved in
chromatin remodelling and transcription
regulation.
Neurofilaments are type IV intermediate
filament heteropolymers composed of light,
medium, and heavy chains. Neurofilaments
comprise the axoskeleton and they functionally
maintain the neuronal calibre. They may also
play a role in intracellular transport to axons and
dendrites. This gene is a member of the
intermediate filament family and is involved in
the morphogenesis of neurons

Association with other
Conditions

References
(PMID ID)

Glass syndrome (with
intellectual disability)

24301056

Gastroenteropancreatic
Neuroendocrine Neoplasm
and Medulloepithelioma.

29339073

Associated with BPD

24309898
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Module
Colour

Hub Gene

Gene
Name

Genomic
Location

Function (NCBI gene and Gene ontology)

Association with other
Conditions

References
(PMID ID)

NC_00000
5.10

Encodes a member of the MADS-box transcription enhancer factor 2
(MEF2) family of proteins, which play a role in myogenesis. The
encoded protein, MEF2 polypeptide C, has both trans-activating and
DNA binding activities. This protein may play a role in maintaining the
differentiated state of muscle cells. Mutations and deletions at this locus
have been associated with severe cognitive disability, stereotypic
movements, epilepsy, and cerebral malformation

Mental Retardation,
Autosomal Dominant
20 and autism spectrum
disorder.

32418612,
27779093

NC_00001
7.11

This gene encodes a component of the telomerase ribonucleoprotein
complex responsible for the replication and maintenance of chromosome
ends. The encoded protein also plays a role in the nonsense-mediated
mRNA decay (NMD) pathway, providing the endonuclease activity near
the premature translation termination codon that is needed to initiate
NMD

Pancreatic Adenosquamous
Carcinoma and Lissencephaly.

25770585

Involved in many different processes, including, cell signalling,
microtubule organization and stability, and apoptosis.

Wilson-Turner X-Linked
Mental Retardation
Syndrome and Syndromic XLinked Intellectual Disability

29467497

NC_00001
1.10

Bind’s opioids in the presence of acidic lipids; probably involved in cell
contact.

Ovarian
Cancer and Hypogonadotropic
Hypogonadism 14 With Or
Without Anosmia.

29907679,
33777925,
31577955

NC_00000
1.11

Members of the G protein-coupled receptor (GPR) family play important
roles in signal transduction from the external environment to the inside
of the cell

Psychiatric disorders

33796846,
24587241

Stage Four

Blue

Brown

Green

Magenta

Purple

MEF2C

Myocyte
Enhancer
Factor 2C

SMG6

SMG6 No
nsense
Mediated
mRNA
Decay
Factor

TAOK2

OPCML

GPR52

TAO
Kinase 2
Opioid
Binding
Protein/Cel
l Adhesion
Molecule
Like
G ProteinCoupled
Receptor
52

NC_00001
6.10
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Red

Turquoise

Yellow

Nuclear
Receptor
Binding
SET
Domain
Protein 3

NC_00000
8.11

CA8

Carbonic
anhydrase
8

NC_00000
8.11
(60185412.
60281400,
compleme
nt)

In the carbonic anhydrase family but carbonic anhydrase activity (i.e.,
the reversible hydration of carbon dioxide) The absence of CA8 gene
transcription in the cerebellum of the lurcher mutant in mice with a
neurologic defect suggests an important role for this acatalytic form.

Wolf-Hirschhorn
Syndrome and Nut Midline
Carcinoma
Mutations in this gene are
associated with cerebellar
ataxia, mental retardation, and
disequilibrium syndrome 3
(CMARQ3). Polymorphisms
in this gene are associated
with osteoporosis, and
overexpression of this gene in
osteosarcoma cells suggests an
oncogenic role.

ALMS1

ALMS1 C
entrosome
and Basal
Body
Associated
Protein

NC_00000
2.12

Involved in PCM1-dependent intracellular transport. Required, directly
or indirectly, for the localization of NCAPD2 to the proximal ends of
centrioles. Required for proper formation and/or maintenance of primary
cilia (PC), microtubule-based structures that protrude from the surface of
epithelial cells.

Alstrom
Syndrome and Premature
Ovarian Failure 1.

WHSC1L1/NSD
3

Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys27' of histone H3 forming H3K2me2 and H3K27me2. H3 'Lys-4'
methylation represents a specific tag for epigenetic transcriptional
activation, while 'Lys-27' is a mark for transcriptional repression

31190890,
27285764,
25942451

19461874

30421101,
32808654
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Developmental
Stage

Hub
Gene

Gene Name

Genomic
Location

Function (NCBI gene and Gene ontology)

Association with other
Conditions

References
(PMID ID)

Stage Five

Black

C16orf86

Chromosome 16
Open Reading Frame
86

Brown

RFTN2

Raftlin Family
Member 2

NC_000016.10

NC_000002.12

Nuclear Factor of
Activated T Cells 3

Green

Greenyellow

NC_000016.10
NFATC3

SATB2

SATB homeobox 2

NC_000002.12
(199269500.199
471266,
complement)

Cholinergic Receptor
Nicotinic Alpha 5
Subunit
Pink

NC_000015.10

CHRNA5
Internexin Neuronal
Intermediate
Filament Protein
Alpha

Red
INA

NC_000010.11

Protein Coding Gene
Upon bacterial lipopolysaccharide stimulation, mediates
clathrin-dependent internalization of TLR4 in dendritic cells,
resulting in activation of TICAM1-mediated signalling and
subsequent IFNB1 production. May regulate B-cell antigen
receptor-mediated signalling.

Glass Syndrome.

Acts as a regulator of transcriptional activation. Plays a role in
the inducible expression of cytokine genes in T-cells, especially
in the induction of the IL-2 (PubMed:18815128). Along with
NFATC4, involved in embryonic heart development

Crouzon Syndrome with
Acanthosis
Nigricans and Leukostasis

SATB2 encodes for a DNA binding protein that binds
specifically at nuclear matrix attachment regions. These regions
are involved in chromatin remodelling and transcription
regulation.

Glass syndrome (with
intellectual disability)

The protein encoded by this gene is a nicotinic acetylcholine
receptor subunit and a member of a superfamily of ligand-gated
ion channels that mediate fast signal transmission at synapses.
Neurofilaments are type IV intermediate filament
heteropolymers composed of light, medium, and heavy chains.
Neurofilaments comprise the axoskeleton and they functionally
maintain the neuronal calibre. They may also play a role in
intracellular transport to axons and dendrites. This gene is a
member of the intermediate filament family and is involved in
the morphogenesis of neurons

33639916

31249342,
33520407

24301056
33752734,
30366711,
32817066,
33511332

Smoking as a Quantitative
Trait Locus 3and Tobacco
Addiction

Gastroenteropancreatic
Neuroendocrine Neoplasm
and Medulloepithelioma.

29339073
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3.6 Cytoscape and Network Visualisation
NetworkAnalyzer, a Cytoscape plugin, aids in visualisation but can also
calculate a network’s topological properties (103). Using data loaded into
Cytoscape including source nodes, target nodes, the p-value for SNP inclusion
identified by Pardiñas et al, weights and node attributes, the network could be
visualised using NetworkAnalyzer. NetworkAnalyzer also calculates
the properties of a network as shown in Figure 3.6.1, treating the network as
undirected. The clustering coefficient is a ratio of closed triangles over the total
open and closed triangles (110). Connected components measure the number
of separated fragments in the overall network. Network diameter is the largest
number of edges to transverse the network. Network centralization measures
the centrality of each node in the network, a network that is highly centralized
(= 1) contains a few nodes that dominate the network and without these nodes,
the network would become fragmented and leave unconnected sub-networks
(111). Network density is a measure of how densely a network is filled with
edges, where 0 means there are no edged and 1 means the network is highly
populated with edges. Network heterogeneity is a measure of the diversity of
the number of connections a node has shown by the node degrees where a
homogenous network is equal to 0 and 1 is heterogeneous (112). Networks
containing biological data are usually very heterogeneous where most nodes
have very few edges apart from HGs which are highly connected (113). The
network visualisations for the modules can be seen in the appendix and the
network topological parameters are below in Table 3.9 -3.13.
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Table 3.9 Network topology parameters calculated by NetworkAnalyzer in Cytoscape for
Developmental Stage One.
Module
Colour
Black
Blue
Brown
Pink
Turquoise

Cluster
Coefficient
0.61
0.55
0.634
0.72
0.477

Diameter
5
6
5
4
7

Network
Centralization
0.414
0.271
0.378
0.421
0.258

Number of Nodes
47
74
32
20
101

Network
Density
0.299
0.161
0.323
0.411
0.127

Network
Heterogeneity
0.63
0.777
0.66
0.551
0.805

Table 3.10 Network topology parameters calculated by NetworkAnalyzer in Cytoscape for
Developmental Stage Two.

Module Colour
Blue
Brown
Turquoise
Yellow

Cluster
Coefficient
0.595
0.585
0.57
0.365

Diameter
5
4
11
6

Network
Centralization
0.356
0.308
0.281
0.21

Number of Nodes
33
14
144
16

Network
Density
0.197
0.429
0.177
0.217

Network
Heterogeneity
0.654
0.554
0.922
0.62

Table 3.11 Network topology parameters calculated by NetworkAnalyzer in Cytoscape for
Developmental Stage Three

Module Colour

Blue
Brown
Turquoise
Yellow

Cluster
Coefficient

Diameter

0.595
0.585
0.57
0.365

5
4
11
6

Network
Centralization

0.356
0.308
0.281
0.21

Number of Nodes

33
14
144
16

Network
Density

Network
Heterogeneity

0.197
0.429
0.177
0.217

0.654
0.554
0.922
0.62

Table 3.12 Network topology parameters calculated by NetworkAnalyzer in Cytoscape for
Developmental Stage Four.

Module Colour
Blue
Brown
Green
Magenta
Purple
Red
Turquoise
Yellow

Cluster
Coefficient
0.636
0.578
0.373
0.397
0.582
0.37
0.708
0.648

Diameter
4
5
4
4
4
4
4
5

Network
Centralization
0.348
0.274
0.2125
0.327
0.338
0.359
0.316
0.379

Number of Nodes
38
25
17
12
32
14
58
21

Network
Density
0.265
0.29
0.25
0.273
0.264
0.308
0.379
0.357

Network
Heterogeneity
0.558
0.417
0.522
0.593
0.553
0.598
0.537
0.512
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Formatted: Table

Table 3.13 Network topology parameters calculated by NetworkAnalyzer in Cytoscape for
Developmental Stage Five.
Module
Colour
Black

Cluster
Coefficient
0.643

Diameter
5

Network
Centralization
0.289

Number of Nodes
104

Network
Density
0.202

Network
Heterogeneity
0.781

Brown
Green
Greenyellow
Pink
Red

0.642
0.614
0.544
0.538
0.44

5
4
6
4
4

0.244
0.379
0.262
0.309
0.288

36
19
77
12
19

0.256
0.327
0.179
0.379
0.298

0.522
0.634
0.678
0.425
0.51

T

3.7 Gene Ontologies
Gene ontologies that are enriched for each module within each stage were
identified using the function enrichmentAnalysis which uses the GO
collection database in the anRichment Bioconductor package in R. Finding GOs
which are enriched in each of the modules can deepen the understanding of
schizophrenia and lead to the discovery of novel therapeutic targets.
Table 10 – Table 14 displays the most enriched gene ontologies per module per
stage. In the appendix Tables 10 – 27 illustrate the full gene ontologies
identified by anRichment. It is clear from the ontology results that positive
regulation of macrophage proliferation is very important as it appears in the top
3 ontologies in a significant number of the modules per Developmental Stage.
Cellular response to catecholamine stimulus and cellular response to diacyl
bacterial lipopeptide appear in the top three ontologies at least once per stage
also.

These enriched ontologies are candidates for future investigation.

83

Table 3.9: Gene Ontologies of the top enriched gene ontologies in Stage One using anRichment
GOID
GO:0120041
GO:0005488

GO:0043231
GO:0120041
GO:0070013

GO:0071870
GO:0120041
GO:0005488
GO:0070013

GO:0005515
GO:0120041

GO:0008152
GO:0120041

GO:0071726
GO:0070016

DEFINITION
Any process that activates or increases the frequency, rate, or extent of
macrophage proliferation.
The selective, non-covalent, often stoichiometric, interaction of a molecule
with one or more specific sites on another molecule.
The organised structure of distinctive morphology and function, bounded by
a single or double lipid bilayer membrane and occurring within the cell.
Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes
the plasma membrane.
Any process that activates or increases the frequency, rate, or extent of
macrophage proliferation.
An organelle lumen is part of an intracellular organelle.
Any process that results in a change in state or activity of a cell (in terms of
movement, secretion, enzyme production, gene expression, etc.) as a result of
a catecholamine stimulus. A catecholamine is any of a group of biogenic
amines that includes 4-(2-aminoethyl) pyrocatechol [4-(2-aminoethyl)
benzene-1,2-diol] and derivatives formed by substitution.
Any process that activates or increases the frequency, rate, or extent of
macrophage proliferation.
The selective, non-covalent, often stoichiometric, interaction of a molecule
with one or more specific sites on another molecule.
An organelle lumen is part of an intracellular organelle.
Interacting selectively and non-covalently with any protein or protein
complex (a complex of two or more proteins that may include other
nonprotein molecules).
Any process that activates or increases the frequency, rate, or extent of
macrophage proliferation.
The chemical reactions and pathways, including anabolism and catabolism,
by which living organisms transform chemical substances. Metabolic
processes typically transform small molecules, but also include
macromolecular processes such as DNA repair and replication, and protein
synthesis and degradation.
Any process that activates or increases the frequency, rate or extent of
macrophage proliferation.
Any process that results in a change in state or activity of a cell (in terms of
movement, secretion, enzyme production, gene expression, etc.) as a result of
a diacylated bacterial lipopeptide stimulus.
Interacting selectively and non-covalently with the armadillo repeat domain

ONTOLOGY

Module

GO Process/ Term

FDR

BP

Black

positive regulation of macrophage proliferation

2.92E-15

MF

Black

binding

1.88E-10

CC

Black

intracellular membrane-bounded organelle

6.74E-10

BP
CC

Blue
Blue

positive regulation of macrophage proliferation
intracellular organelle lumen

1.75E-29
2.74E-14

BP

Blue

cellular response to catecholamine stimulus

4.03E-13

BP

Brown

positive regulation of macrophage proliferation

2.10E-15

MF
CC

Brown
Brown

binding
intracellular organelle lumen

3.36E-10
4.32E-09

MF

Pink

protein binding

1.61E-08

BP

Pink

positive regulation of macrophage proliferation

2.30E-07

BP

Pink

metabolic process

6.41E-07

BP

Turquoise

positive regulation of macrophage proliferation

9.49E-49

BP
MF

Turquoise
Turquoise

cellular response to diacyl bacterial lipopeptide
armadillo repeat domain binding

1.07E-17
4.10E-17
84

of a protein, an approximately 40 amino acid long tandemly repeated
sequence motif first identified in the Drosophila segment polarity protein
armadillo. Arm-repeat proteins are involved in various processes, including
intracellular signalling and cytoskeletal regulation.
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Table 3.10: Gene Ontologies for the most enriched ontologies in Stage Two using anRichment
GOID
GO:0120041

GO:0043231
GO:0005737
GO:0120041
GO:0070013
GO:0005737

GO:0003674
GO:0120041
GO:1902644
GO:0120041

GO:0070016

GO:0071726

DEFINITION
Any process that activates or increases the frequency, rate or extent
of macrophage proliferation.
Organized structure of distinctive morphology and function, bounded
by a single or double lipid bilayer membrane and occurring within
the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and
vesicles. Excludes the plasma membrane.
All of the contents of a cell excluding the plasma membrane and
nucleus but including other subcellular structures.
Any process that activates or increases the frequency, rate or extent
of macrophage proliferation.
An organelle lumen is part of an intracellular organelle.
All of the contents of a cell excluding the plasma membrane and
nucleus but including other subcellular structures.
A molecular process that can be carried out by the action of a single
macromolecular machine, usually via direct physical interactions
with other molecular entities. Function in this sense denotes an
action, or activity, that a gene product (or a complex) performs.
These actions are described from two distinct but related
perspectives: (1) biochemical activity, and (2) role as a component in
a larger system/process.
Any process that activates or increases the frequency, rate, or extent
of macrophage proliferation.
The chemical reactions and pathways involving tertiary alcohol
Any process that activates or increases the frequency, rate, or extent
of macrophage proliferation.
Interacting selectively and non-covalently with the armadillo repeat
domain of a protein, an approximately 40 amino acid long tandemly
repeated sequence motif first identified in the Drosophila segment
polarity protein armadillo. Arm-repeat proteins are involved in
various processes, including intracellular signalling and cytoskeletal
regulation.
Any process that results in a change in state or activity of a cell (in
terms of movement, secretion, enzyme production, gene expression,
etc.) as a result of a diacylated bacterial lipopeptide stimulus.

ONTOLOGY

Module
Blue

GO Process/ Term
positive regulation of macrophage
proliferation

BP

FDR
9.38E-19

CC

Blue

intracellular membrane-bounded organelle

2.90E-12

CC

Blue

1.74E-10

BP
CC

Brown
Brown

cytoplasm
positive regulation of macrophage
proliferation
intracellular organelle lumen

CC

Brown

cytoplasm

9.37E-09

MF

Green

2.31E-12

BP
BP

Green
Green

BP

Turquoise

molecular function
positive regulation of macrophage
proliferation
tertiary alcohol metabolic process
positive regulation of macrophage
proliferation

MF

Turquoise

armadillo repeat domain binding

3.94E-28

BP

Turquoise

cellular response to diacyl bacterial
lipopeptide

4.57E-25

7.94E-15
2.07E-09

7.16E-10
2.55E-09
1.10E-69
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Table 3.11: Gene Ontologies for the most enriched ontologies in Stage Three using anRichment
GOID

DEFINITION

ONTOLOGY

Module

GO:0120041

BP

GO:0044238

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
Organized structure of distinctive morphology and function, bounded by a single or double lipid
bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids,
vacuoles, and vesicles. Excludes the plasma membrane.
The chemical reactions and pathways involving those compounds are formed as a part of the
normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the
organism.

GO:0120041
GO:0070013

GO:0099582

GO:0043231

GO:0120041

Blue

GO Process/ Term
positive regulation of
macrophage proliferation

2.37E-12

CC

Blue

intracellular membranebounded organelle

1.70E-10

BP

Blue

Any process that activates or increases the frequency, rate or extent of macrophage proliferation.
An organelle lumen is part of an intracellular organelle.

BP
CC

Brown
Brown

Any neurotransmitter receptor activity that is involved in regulating the concentration of calcium
in the presynaptic cytosol.

MF

Brown

BP

Turquoise

primary metabolic process
positive regulation of
macrophage proliferation
intracellular organelle lumen
neurotransmitter receptor
activity involved in the
regulation of presynaptic
cytosolic calcium ion
concentration
positive regulation of
macrophage proliferation

BP

Turquoise

cellular response to
catecholamine stimulus

4.05E-29

cellular response to diacyl
bacterial lipopeptide

1.01E-23

BP

Turquoise

GO:0005488

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion,
enzyme production, gene expression, etc.) as a result of a catecholamine stimulus. A
catecholamine is any of a group of biogenic amines that includes 4-(2-aminoethyl) pyrocatechol
[4-(2-aminoethyl) benzene-1,2-diol] and derivatives formed by substitution.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion,
enzyme production, gene expression, etc.) as a result of a diacylated bacterial lipopeptide
stimulus.
The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more
specific sites on another molecule.

MF

Yellow

GO:0120041
GO:0044237

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
The chemical reactions and pathways by which individual cells transform chemical substances.

BP
BP

Yellow
Yellow

GO:0071870

GO:0071726

binding
positive regulation of
macrophage proliferation
cellular metabolic process

FDR

1.03E-09
4.06E-08
8.00E-06

1.25E-05
5.64E-77

3.20E-07
3.44E-07
1.60E-06

87

Table 3.12: Gene Ontologies for the most enriched ontologies in Stage Four using anRichment
GOID

DEFINITION

ONTOLOGY

Module

GO:0120041

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
All of the contents of a cell excluding the plasma membrane and nucleus but including other
subcellular structures.
The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more
specific sites on another molecule.

BP

GO:0005737
GO:0005488
GO:0120041

Blue

GO Process/ Term
positive regulation of
macrophage proliferation

FDR
1.70E-10

CC

Blue

cytoplasm

4.22E-09

MF

Blue

binding
positive regulation of
macrophage proliferation

4.46E-08

4.85E-07

0.000174

BP

Brown

GO:0005488

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more
specific sites on another molecule.

MF

Brown

GO:0070013

An organelle lumen is part of an intracellular organelle.

CC

Brown

GO:0120041

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.

BP

Green

GO:0070013

CC

Green

MF

Green

CC

Magenta

cytoplasm

7.51E-05

MF

Magenta

BP

Magenta

GO:0120041

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.

BP

Purple

GO:0070013

An organelle lumen is part of an intracellular organelle.

CC

Purple

GO:1901666

Any process that activates or increases the frequency, rate, or extent of NAD+ ADPribosyltransferase activity

BP

Purple

BP

Red

molecular function
regulation of metabolic
process
positive regulation of
macrophage proliferation
intracellular organelle
lumen
positive regulation of
NAD+ ADPribosyltransferase activity
positive regulation of
macrophage proliferation

0.000264

GO:0019222

An organelle lumen is part of an intracellular organelle.
Interacting selectively and non-covalently with a chondroitin sulphate proteoglycan, any
proteoglycan containing chondroitin sulphate as the glycosaminoglycan carbohydrate unit.
All of the contents of a cell excluding the plasma membrane and nucleus but including other
subcellular structures.
A molecular process that can be carried out by the action of a single macromolecular machine,
usually via direct physical interactions with other molecular entities. Function in this sense
denotes an action, or activity, that a gene product (or a complex) performs. These actions are
described from two distinct but related perspectives: (1) biochemical activity, and (2) role as a
component in a larger system/process.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways
within a cell or an organism.

binding
intracellular organelle
lumen
positive regulation of
macrophage proliferation
intracellular organelle
lumen
chondroitin sulphate
proteoglycan binding

MF

Red

protein binding

0.0004

GO:0035373
GO:0005737

GO:0003674

GO:0120041
GO:0005515

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
Interacting selectively and non-covalently with any protein or protein complex (a complex of two
or more proteins that may include other nonprotein molecules).

1.89E-08

2.09E-06
3.43E-06
9.16E-05

0.000537
4.37E-10
6.00E-08

2.40E-07
3.43E-06
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GO:0043412

The covalent alteration of one or more monomeric units in a polypeptide, polynucleotide,
polysaccharide, or other biological macromolecules, resulting in a change in its properties.

BP

Red

GO:0120041

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.

BP

Turquoise

GO:0070013

An organelle lumen is part of an intracellular organelle.
A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and
replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar
chromosomes and is the site of RNA synthesis and processing. In some species of specialized cell
types, RNA metabolism or DNA replication may be absent.
A molecular process that can be carried out by the action of a single macromolecular machine,
usually via direct physical interactions with other molecular entities. Function in this sense
denotes an action, or activity, that a gene product (or a complex) performs. These actions are
described from two distinct but related perspectives: (1) biochemical activity, and (2) role as a
component in a larger system/process.

CC

Turquoise

macromolecule
modification
positive regulation of
macrophage proliferation
intracellular organelle
lumen

CC

Turquoise

nucleus

5.73E-11

MF

Yellow

6.12E-08

BP

Yellow

molecular function
positive regulation of
macrophage proliferation

CC

Yellow

membrane-bounded
organelle

GO:0005634

GO:0003674
GO:0120041

GO:0043227

Any process that activates or increases the frequency, rate, or extent of macrophage proliferation.
Organized structure of distinctive morphology and function, bounded by a single or double lipid
bilayer membrane. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes
the plasma membrane.

0.000479
3.42E-25
2.23E-12

2.55E-07

9.65E-07

89

Table 3.13: Gene Ontologies for the most enriched ontologies in Stage Five using anRichment
GOID
GO:0120041

GO:0071726

GO:0071870
GO:0120041
GO:0005488
GO:0044237
GO:0120041
GO:0098809

GO:0043226
GO:0120041

GO:0071726
GO:0070052
GO:0120041
GO:0019866
GO:0031966
GO:0120041

DEFINITION
Any process that activates or increases the frequency, rate, or extent of macrophage
proliferation.
Any process that results in a change in state or activity of a cell (in terms of
movement, secretion, enzyme production, gene expression, etc.) as a result of a
diacylated bacterial lipopeptide stimulus.
Any process that results in a change in state or activity of a cell (in terms of
movement, secretion, enzyme production, gene expression, etc.) as a result of a
catecholamine stimulus. A catecholamine is any of a group of biogenic amines that
includes 4-(2-aminoethyl) pyrocatechol [4-(2-aminoethyl) benzene-1,2-diol] and
derivatives formed by substitution.
Any process that activates or increases the frequency, rate, or extent of macrophage
proliferation.
The selective, non-covalent, often stoichiometric, interaction of a molecule with one
or more specific sites on another molecule.
The chemical reactions and pathways by which individual cells transform chemical
substances.
Any process that activates or increases the frequency, rate, or extent of macrophage
proliferation.
Catalysis of the reaction: nitrite + acceptor = product(s) of nitrate reduction + reduced
acceptor.
Organized structure of distinctive morphology and function. Includes the nucleus,
mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton, and
prokaryotic structures such as anammoxosomes and pirellulosomes. Excludes the
plasma membrane.
Any process that activates or increases the frequency, rate or extent of macrophage
proliferation.
Any process that results in a change in state or activity of a cell (in terms of
movement, secretion, enzyme production, gene expression, etc.) as a result of a
diacylated bacterial lipopeptide stimulus.
Interacting selectively and non-covalently with a type V collagen trimer.
Any process that activates or increases the frequency, rate, or extent of macrophage
proliferation.
The inner, i.e. lumen-facing, the lipid bilayer of an organelle envelope; usually highly
selective to most ions and metabolites.
Either of the lipid bilayers surrounds the mitochondrion and form the mitochondrial
envelope.
Any process that activates or increases the frequency, rate or extent of macrophage
proliferation.

ONTOLOGY

Module
Black

GO Process/ Term
positive regulation of macrophage
proliferation

BP

FDR
2.43E-38

BP

Black

cellular response to diacyl bacterial
lipopeptide

3.66E-14

BP

Black

BP

Brown

cellular response to catecholamine
stimulus
positive regulation of macrophage
proliferation

MF

Brown

binding

1.07E-09

BP

Brown

9.83E-09

BP

Green

cellular metabolic process
positive regulation of macrophage
proliferation

MF

Green

nitrite reductase activity

1.04E-05

CC

Green

1.33E-05

BP

Greenyellow

organelle
positive regulation of macrophage
proliferation

BP
MF

Greenyellow
Greenyellow

BP

3.49E-13
1.14E-11

5.52E-06

1.22E-34

Pink

cellular response to diacyl bacterial
lipopeptide
collagen V binding
positive regulation of macrophage
proliferation

0.000262

CC

Pink

organelle inner membrane

0.000645

CC

Pink

0.001661

BP

Red

mitochondrial membrane
positive regulation of macrophage
proliferation

3.08E-18
7.65E-15

1.84E-07
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GO:0005515
GO:0070013

Interacting selectively and non-covalently with any protein or protein complex (a
complex of two or more proteins that may include other nonprotein molecules).
An organelle lumen is part of an intracellular organelle.

MF
CC

Red
Red

protein binding
intracellular organelle lumen

1.43E-05
3.82E-05
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4.0 Discussion
Schizophrenia is a chronic and disabling disorder that affects 1% of the general
population whose causes remain unclear even with much research into disease aetiology
(4). Schizophrenia is a neurodevelopmental disorder, therefore, constructing and
exploring networks of genes, previously identified as associated with schizophrenia,
over key developmental stages could aid our understanding of schizophrenia’s aetiology
and identify novel therapeutic targets of disease.
Although schizophrenia is researched extensively from many angles its mechanisms
remain elusive. It is difficult to predict who will develop schizophrenia because of the
complex interactions between genetic and environmental factors. Schizophrenia is
classed as a neurodevelopmental disorder but as it doesn’t manifest until adolescence it’s
very important to study it at multiple clinical stages (13,53,162). Insults to brain
development in utero can have an impact on the severity of schizophrenia’s symptoms
later in life. Changes in gene expression throughout schizophrenia have been observed,
the study performed by Ota et al. looked at participants blood and compared expression
levels of schizophrenia genes in clinically high-risk patients through to chronic
schizophrenia. They observed changes in gene expression profiles at different clinical
stages (13). Studies like these highlight the importance of looking at schizophrenia at
multiple stages to captures its heterogeneity.
In this study, genes previously identified in a large-scale schizophrenia GWAS as being
significantly associated with schizophrenia were used to filter ABA’s BrainSpan resource
to include gene expression data for these genes across 16 brain areas and five
developmental stages. To find underlying patterns in the gene expression data K-means
analysis was utilised. A systems biology approach (WGCNA) was used to describe the
pairwise relationship between genes at each development stage and to create networks
(i.e., modules) of schizophrenia-associated genes which were co-expressed in each
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Developmental Stage. Next, GO enrichment analysis was applied to each of the modules
using anRichment to aid biological interpretation of the identified networks in each
developmental stage.

4.1 K-means analysis on the schizophrenia-associated genes
K-means clustering was performed on each Developmental Stage. Each schizophreniaassociated gene was assigned to the closest centre (k). Developmental Stage One to Five
can be seen in Figure 3.3.2 to 3.3.7 and a comparison of the five stages in 3.3.7.
If a cluster is filled with genes that are very similar the within-cluster sum of squares of
the cluster will be small and when the cluster is visualised it will appear small and
compact. Each of the clusters in this analysis had a large within-cluster sum of squares,
this means there is variance within the cluster. The total within variance measures the
deviation from the mean. The total within variance in this dataset is low which means
that the dataset is very similar. Usually, only a small amount of the total variance is
explained by the within-cluster sum of squares but in this case, the total variance is low
and the within the sum of squares is high. This tells us the schizophrenia-associated
genes expression profile in the brain are similar to each other. From the k-means results,
it is clear that these genes do not cluster well together, if you increase the number of
clusters for each of the Developmental Stages the sum of squares with each cluster
decreases and the total variance increases but this would mean ignoring the optimal
cluster number for each stage previously calculated.

4.2 Weighted Gene Correlations Network Analysis on schizophreniaassociated genes
WGCNA is a systems biology method that uses gene transcripts to describe pairwise
relationships between the genes. WGCNA was used to calculate modules of
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schizophrenia-associated genes which were co-expressed for each developmental stage.
WGCNA identified three modules in developmental stage One and Five, four in
developmental stages Two and two in developmental Stages Three and Four. The ME of
each cluster was identified and the gene most like the ME is classed as the HG. Each
HG can be seen in Table 9. WGCNA relies strongly on the assumption that gene coexpression networks follow a scale-free topology where highly connected genes are
essential for a functioning system (163). It assumes that gene products associated with
the same phenotype usually participate in the same module (163). When WGCNA was
applied to the expression profiles of the 316 schizophrenia-associated genes in the brain,
each gene was assigned to a module and each module was given a colour. A hierarchical
clustering graph of initial and final (after minimum module size of 10) module
assignments for each Developmental Stage can be seen in Figure 3.4.2. After module
construction, each genes module membership and weight were calculated for
downstream visualisation using Cytoscape.
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4.3 Visualisation of modules using data from WGCNA.
First, genes were assigned to modules. Using each gene’s MM the ME and thus HG was
identified, and the weight calculated. This information was collated into csv files, which
were uploaded to Cytoscape so the modules could be visualised. Cytoscape allows for the
important attributes to be highlighted in the network graph. In each graph node size is
shown by the module membership, edge width signifies weight and node colour displays pvalue as calculated by Pardiñas et al. These p-values range from 2.12x10-44 – 4.88x10-08
the lower the value the greater the association. Each Cytoscape network can be seen in
Figure 3.6.1 to 3.6.27. Only the edges width of 0.8 and over were included to capture the
most important edges.

4.3.1 Developmental Stage One - Prenatal
BrainSpan’s Developmental Stage One includes gene expression for healthy prenatal brains.
Figure 3.6.1 shows the Black module which contains 47 genes. The HG for this module is
SOX5. This gene encodes a transcription factor that mediates DNA binding and nuclear
trafficking (114). SOX5 modulates the timing of important processes during corticofugal
neuron production so consequently neocortical neuron diversity and sub-type specific
differentiation (164). SOX5 has been linked to Lamb Shaffer syndrome which is a
developmental disorder that involves ID, language, and motor deficits and serves various roles
in multiple cancer types (165,166). Figure 3.6.2 shows the blue module and contains 74 genes,
two of which have split into a small module. The HG for this module is FHIT, this genes
inactivation, deletion and decreased expression is seen in most cancers (116). It can induce cell
apoptosis, stunt the cell growth cycle which can impede tumour proliferation (167). Figure
3.6.3 displays the Brown module which contains 32 genes and whose HG is SLC12A4 codes
for KCC1. KCC1 is a protein that facilitates the symport of chlorine and potassium through
cells surfaces and is involved in cancer growth, bone turnover and sickle cell formation (117).
Na-K-Cl and K-Cl co-transporters regulate Cl levels, shifts in chloride electrochemical
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gradients can affect GABAergic transmission which is seen to be impaired in schizophrenia
especially in ANPs (168,169). Figure 3.6.4 shows the pink module with 20 genes, the HG
OTOL1 which is essential for hearing and vestibular function (119,120). It is not known what
function OTOL1 has in the brain. Figure 3.6.5 shows the large turquoise module which contains
101 genes. The HG for the Turquoise module is TMEM194A also known as NEMP1. This gene
is poorly understood but the NEMP1 protein has been linked to eye development from the
gastrula through to the neurula stage (123).
Stage One is the prenatal stage, SOX5 being associated with a neurodevelopmental disorder and
NEMP1 being linked to eye development are interesting. There are several physiological and
structural impairments in the eye associated with schizophrenia. The retina and the brain
develop from the same tissue the neuroectoderm and it has been proposed that retinal changes
can be a marker for progressive brain tissue loss and function (170). This may mean that retinal
structure changes could parallel the brain (171). Performing a longitudinal study observing
retinal changes and linking them to schizophrenia symptoms could potentially map the
progression of schizophrenia.

4.3.2 Developmental Stage Two – Infant (0-2 years)
BrainSpan’s Developmental Stage Two includes gene expression for a healthy infant’s brain
from 0-2 years old. 3.6.6 shows the blue module which has 43 genes, the HG is KCNV1, this
gene is involved in another neurodevelopmental disorder autism spectrum disorder (ASD)
(124). It codes for a subunit that regulates potassium channels which regulates
neurotransmission release, neuronal excitability, and epithelial electrolyte transport controlled
by BK channels (125). The BK channels have been linked to schizophrenia (172). Figure 3.6.7
displays the brown module with 31 genes and whose HG is NDRG4 which is involved in cell
proliferation, differentiation, and development (127). NDRG4 deficient mice are at a greater
risk of cerebral ischemia and exhibit poor spatial learning (127,173). Knockout of NDRG4
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induces glioblastoma cell apoptosis which contributes to neurological damage (127). Figure
3.6.8 shows the green module and has 26 genes, two of the genes in the modules have split into
their submodule. The HG for the module is GPR52 which is a G protein-coupled receptor, it is
thought that it could regulate dopaminergic and glutamatergic transmission which is
responsible for cognitive function and is affected in schizophrenia (128). Figure 3.6.9 displays
the turquoise module; this module has six sub-modules and contains 147 genes in total. The HG
for the module is STAG1 is needed for cohesion at telomeres and DNA replication (131).
STAG1 deletions and point mutations can attribute to syndromic unspecific ID (132).

4.3.3 Developmental Stage Three – Child (3- 11 years)
Developmental Stage Three contains gene expression across the brains of children between the
ages of 3 and 11 years. Figure 3.6.10 displays the blue module and contains one connected
component and contains 33 genes. The HG for the module is SATB2, which is involved in
transcription regulation and chromatin remodelling (133). SATB2 is a transcription factor that
regulates neocortical circuitry and organisation (133). SATB2 has been shown to cause SATB2associated syndrome and developmental delays (133,134). Figure 3.6.11 shows the brown
module which contains 14 genes and whose HG is INA. It is found in developing neuroblasts
and in cerebellar granule in the adult CNS (135,174). INA maintains the morphogenesis of
neurons (135). Figure 3.6.12 shows the turquoise module and has 144 genes and whose HG is
TRANK1. TRANK1 encodes a protein in the brain with unknown function (175). Decreased
expression of TRANK1 affected the expression of several genes which are involved in neural
development (175). Low levels of TRANK1 mRNA expression is a BP risk factor (175,176).
The yellow module is shown in Figure 3.6.13 and has16 genes in the module. The HG is
ANKRD63 but not much is known about the function of this gene.
There is not a clear link between the HGs in Developmental Stage Three. SATB2-syndrome is a
neurodevelopmental disorder that leads to developmental delays, it also regulates chromatin
remodelling. Defects in chromatin remodelling are often seen in neurodevelopmental disorders,
97

these defects can compound over time and impair brain circuit establishment (177). These
impairments in neurodevelopmental disorders can lead to decreased cognitive function.
Although not much is known about the exact function of TRANK1 it has been linked to BP,
schizophrenia and BP share some symptomatology and significant genetic overlap with a
genetic correlation from common risks estimated to be 0.6-0.7, and 114 loci contributing to
both (178).

4.3.4 Developmental Stage Four – Adolescent (12-18 years)
Developmental Stage Four captures gene expression in the brain for adolescents. Typically
schizophrenia manifests its symptoms during this time frame (179). Figure 3.6.14 illustrates the
blue Module with 38 genes. The HG for this module is MEF2C, this gene regulates expression
across development in processes such as synapse formation and development, neuronal
differentiation (140). It has also been shown to be involved in numerous neurodevelopmental
disorders including ASD (180). Figure 3.6.15 displays the brown module with 25 genes. This
module’s HG is SMG6, although there is not much known about this gene’s exact function.
Still, it has been linked to pancreatic adenosquamous carcinoma and lissencephaly (181).
SMG6 hyperfunction has been shown in epileptic seizures (182). Figure 3.6.16 displays the
green module with 17 genes, this module has very few edges and is filled with genes with very
low p-values showing a statistically strong link to schizophrenia. The HG for this module is
TAOK2 which regulates neurodevelopment, synapse formation and the development of
synapses through modulation of the cytoskeleton which can be linked to schizophrenia (141).
TAOK2 has also been seen to regulate apoptosis by activating T cells and is a
neurodevelopmental risk gene (141). Figure 3.6.17 shows the magenta module which contains
only 12 genes. OPCML is the HG for this module and has been connected to the lung, brain,
and cervical cancers (143,145). This gene regulates synaptogenesis and synaptic plasticity.
Figure 3.6.18 shows the purple module with 32 genes. The HG is GPR52 which is a G proteincoupled receptor, it may regulate dopaminergic and glutamatergic transmission which is
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responsible for cognitive function (129). Figure 3.6.19 displays the red module which is a
small module with 14 genes. The HG of this module is WHSC1L1/NSD3. This gene has been
linked to numerous cancers, cell cycle progression and promotes antiviral innate immunity
(146,147). Figure 3.6.20 presents the turquoise module with 58 genes. The HG is CA8 which is
a member of the carbonic anhydrase family, it is expressed in Purkinje cells in the cerebellum.
It is a IP3R1 inhibitor that regulates calcium levels which help key cellular processes (150,183).
Figure 3.6.21 shows the yellow module with 21 genes. The HG is ALMS1 which is involved in
the maintenance of centromere cohesion, transcription and actin organisation and endosomal
trafficking. Mutations in ALMS1 can cause Alström syndrome which can sometimes include
ID and can cause psychotic like symptoms in adults which is also when psychotic symptoms
appear in schizophrenia (184).
MEF2C and TAOK2 are both involved in synapse formation and development. Dysregulated
synaptic development has been hypothesised as underlying altered neuronal function in
schizophrenia (185). Synaptic pruning occurs during adolescence Developmental Stage Four
(12 – 18 years old) 30% of synapses which are formed during adolescence in the dorsolateral
prefrontal cortex are lost but in people with schizophrenia it is closer to 60% (186). The
synaptic pruning roughly ends at the time of schizophrenia onset leading to the hypothesis that
altered synaptic pruning may be a part of the pathophysiology of schizophrenia (185).

4.3.5 Developmental Stage Five – Adult (>19 years)
Figure 3.6.22 shows the Black module which has 104 genes that have formed their
submodule. The HG for this module is C16orf86 which is associated with insulin
sensitivity in human skeletal muscles, insulin sensitivity in a subgroup of patients with
schizophrenia who are anti-psychotic resistant (155). Figure 3.6.23 displays the brown
module with 36 modules. The modules HG is RFTN2 is implicated in glass syndrome
which is characterised by developmental delay, speech development and ID. Glass
syndrome has some symptom similarities to schizophrenia which would suggest some
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shared underlying pathways. Figure 3.6.24 shows the green module with 19 genes. Its HG
is NFATC3, a member of the calcineurin nuclear factor of activation of T cells who play an
essential role in the immune system (187). It is a transcription factor that is involved in the
development and progression of tumours and is important for brain tissue homeostasis
(158) and is a prompter of neural progenitor cell differentiation into neurons and astrocytes
(188). Figure 3.6.25 shows the Greenyellow which houses 77 genes. The modules HG is
SATB2 which encodes a protein that is involved in transcription regulation and chromatin
remodelling (133). SATB2 is a transcription factor that regulates neocortical circuitry and
organisation (133). SATB2 has been shown to cause SATB2-associated syndrome and
developmental delays (133,134). Figure 3.6.26 displays that the pink module houses only
12 genes. CHRNA5 is the HG for this module which is a nicotinic acetylcholine receptor,
three other members of the family are in this module, altered cholinergic neural
transmission has been shown to increase susceptibility to cognitive deficits, and in the
Chinese Han population, it has been linked to early-onset and more severe symptoms of
schizophrenia (160,189). Figure 3.6.27 shows the red module and has 19 genes. INA is the
HG in this module which is found in developing neuroblasts and in cerebellar granule in
the adult CNS and INA maintains the morphogenesis of neurons (135). It is a prognostic
marker for poor survival rates in colorectal cancer patients(190).
RFTN2 and SATB2 are both involved in glass syndrome that is also known as SATB2syndrome, which is characterised by ID, craniofacial abnormalities, dental abnormalities,
and behavioural problems. CHRNA5 has been shown to increase cognitive deficits, these
and the genes involved in the SATB2 syndrome are linked to the cognitive and negative
symptoms of schizophrenia.

4.3.6 Recurring Hub Genes Across Developmental Stages
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Of the 316 schizophrenia-associated genes 27 modules were formed and three genes repeated
over two modules, GPR52, INA and SATB2.
GPR52 is an orphan G- protein-coupled receptor (GPCR) which is selectively expressed in
the striatum and regulates various brain functions including homeostasis, immune function,
neurotransmission and metabolism (191,192). It is expressed in the striatum and nucleus
accumbens which have been linked with psychiatric disorders. GPCR’s are mediators of
signal transduction in the CNS and have been actively investigated for their role in the
development of mood disorders (193). GPCR’s are the most common targets of antipsychotics
and play crucial roles in controlling brain function by regulating numerous downstream
signalling pathways (192). GPR52 has been highlighted as a potential therapeutic target for
schizophrenia, it is thought that GPR52 signalling via 5’-cyclic adenosine monophosphate
(cAMP) could oppose D2 signalling activity in the striatum while stimulating D1/NMDA
function in the frontal cortex (194,195). The role of GPR52 in the dopaminergic system may
aggravate the symptoms of schizophrenia (193).
SATB2 is a transcription factor that regulates neocortical organisation and circuitry (133).
SATB2 is required for the projection of upper-layer neurons and it can regulate other genes by
mediating chromatin loop formation and can modify higher-order chromatin structure (133).
It can control the expression of genes that are involved in pluripotency and self-renewal (196).
During CNS development the SATB2 protein is expressed in the superficial cortical layers
and determines neuron projection. In adult CNS it is expressed in pyramidal neurons of all
cortical layers and regulates long-term memory and synaptic plasticity which is linked to
cognition (197). SATB2 facilitates callosal projection by repressing the BCL11B gene whose
protein is required for subcortical projection neuron identity and postnatal development of the
hippocampus (133). This can lead to altered cognition which is seen in schizophrenia. Loss of
BCL11B leads to weakened hippocampal memory and learning (133). De novo structural or
single-nucleotide variants in SATB2 is linked to SATB2-associated syndrome which is
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characterised by intellectual disability, developmental delays, abnormal craniofacial features
and behavioural issues (133,197).
INA (α-Internexin) codes a class IV neuronal intermediate filament protein which
maintains neuronal morphogenesis and provides strength to the cell (135). This protein is
a structural component of the cytoskeleton and is involved in neurogenesis (136). INA
regulates the expression of other neurofilaments during brain development (198). It is
widely accepted that INA is involved in neuronal development, but its function remains
unknown. INA is the main component of neuronal IF inclusion disease which causes rare
frontal dementia and behavioural and personality changes and has been linked to brain
tumours (135). The INA protein is believed to be involved in tumour initiation and
progression and is one of the most overexpressed proteins in gliomas (174,190).
INA and SATB2 are repeated in Developmental Stage Three and Developmental Stage
Five and GPR52 is repeated in Developmental Stage Two and Four. GPR52 is thought to
aggravate schizophrenia’s positive symptoms, and SATB2 and INA mutations can cause
symptoms that look like schizophrenia’s negative and cognitive symptoms. Our results
suggest that INA, SATB2 and GPR52 represent candidate genes for future evaluation of
their potential as a therapeutic target for schizophrenia.
Pardiñas et al. study applied Summary-data-based Mendelian Randomisation (SMR)
analysis to the schizophrenia-associated gene with dorsal prefrontal cortex expression
quantitative trait locus (eQTL) using CommonMind Consortium. This analysis aimed to
uncover variants that could be causally linked to expression changes in specific genes.
They applied a threshold of 0.05 which highlighted colocalised signals due to a single
casual variant. From this, they discovered 22 candidate variants at 19 loci with an FDR P
<0.05. ALMS1 the HG in the green Module in Developmental Stage Two and TRANK1
the HG in the brown Module of Developmental Stage Three identified in our study were
also identified in the SMR analysis. Thus our results suggesting these genes are HGs adds
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further evidence that they would be good candidates for further research as they may
regulate several schizophrenia-related genes in their respective modules.

4.4 Gene Ontologies
On each of the modules calculated by WGCNA, anRichment was run. anRichment is run
to biologically interpret the modules. P-values were calculated and GO’s which were lower
than the threshold of 0.05 after Bonferroni correction was applied were retained. As
anRichment produced many significant GO’s, GO parent terms were excluded to focus on
more specific pathways. The complete ontologies calculated from anRichment in R
including the genes involved can be found in the appendix from Table 3 to Table 27.

Across the developmental stages, anRichment has highlighted the immune system and
inflammation,

specifically

concerning

macrophage

proliferation

(GO:00120041).

Inflammation in the CNS is facilitated by astrocytes, microglial cells, proinflammatory
cytokines, invading immune cells which includes macrophages, monocytes, and T or B
lymphocytes. For appropriate function, a well-regulated inflammatory response is
essential, but uncontrolled inflammation caused by infectious agents, genetics or physical
trauma can be detrimental (199). The macrophages of the brain are called microglia and
they play a crucial role in the innate immunity of the CNS and represent up to 10% of total
brain cells, but their cell density depends on the area of the brain (200,201). Microglial
cells are derived from the yolk sac progenitors during embryogenesis and migrate
throughout the CNS, they are maintained through adulthood by self-renewal and rapid cell
turnover (201,202). Microglia are involved in the synaptic organisation, phagocytosis of
apoptotic cells during development, maintenance of neuronal excitability, trophic neuronal
support in the developing brain and brain protection and repair (202). In post-mortem
cortical tissue of patients with schizophrenia, the synapse density is reduced. This
excessive pruning reflects abnormalities in synaptic structures and microglia like cells
103

(203). A lot of this synaptic pruning occurs during adolescence, this is when schizophrenia
symptoms occur (203). In utero MIA is a risk factor for neurodevelopmental disorders like
schizophrenia. O’Loughlin et al. administered lipopolysaccharide to mice on embryonic
day 12 to induce MIA. This induced a pro-inflammatory cytokine profile which continued
in the amygdala to early adulthood. These alterations in the foetal brain elicited by MIA
can lead to alterations to microglia (54). Pre and perinatal activation of the immune system
can increase the immune system’s sensitivity throughout life (18). Diverse immune
alteration has been observed in those with schizophrenia and autoimmune disorders and
severe infections are linked to schizophrenia risk (21,204).
Cellular response to diacyl lipopeptide stimulus (GO:0071726) showed up in the top three
gene ontologies in at least one module per Developmental Stage apart from Developmental
Stage Four.
Cellular response to catecholamine stimulus was highlighted by anRichment in at least one
module

per

Developmental

Stage

(GO:0071870).

Catecholamines,

which

are

neurotransmitters in the CNS and peripheral nervous system, include dopamine,
norepinephrine

and

mesocorticolimbic

adrenaline

system

and

(127).
affects

Catecholamine
executive

signalling

function

and

underlies
cognition

the
(206).

Catecholamine signalling pathways are pharmacological therapy targets for patients with
neuropsychiatric disorders because of their relationship with affective, executive and
cognitive functions (206). Catecholamines have versatile functions as slow-acting
neurotransmitters in synaptic neurotransmission and controlling the effects of fast-acting
neurotransmitters (205). Dopamine has been linked with schizophrenia for many years and
dopamine receptor antagonists continue to be the leading therapy for schizophrenia (5).
Dopamine neurotransmission is altered in many neural pathways in schizophrenia (207),
these alterations include hyperactive dopaminergic transmission in the striatum,
hippocampus and mesolimbic areas and hypoactive transmission in the PFC of patients
which schizophrenia (207). Dopamine displays regulatory effects on an immune response
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which depends on dopamine concentration, sub-type of receptors, time of exposure, type of
immune cell and immune cell activation (31). This has been shown to affect cognitive
functions (207). Immune cells in particular T-cells, microglial and peripheral monocytes
collaborate with the CNS and have cognitive and behavioural function which are seen to be
altered in schizophrenia (31,207). Dopamine has been seen to influence the activity of these
immune cells since they express dopamine receptors (207). Changes in dopamine
concentration and/or receptors in T cells are thought to be the cause of abnormal immune
functions in people with schizophrenia and Parkinson’s (208). Low levels of dopamine
neurotransmission, as well as serotonin and glutamatergic neurotransmission, are seen in
people with schizophrenia. These are connected to low levels of neuroinflammation, which
has been hypothesised to be the reason for CNS volume loss and low levels of microglial
activation in schizophrenia patients in neuroimaging studies (18). Renalase is thought to
metabolise dopamine. In a study conducted by Catak et al. which used thirty-three
schizophrenia patients it was found that the levels of renalase in these patients was
significantly lower than the control group. This could be a potential biomarker for
schizophrenia (209).
Regulation of neurotransmitter secretion (GO:0046928) was enriched in Developmental Stage
One and Three and Neurotransmitter receptor activity (GO:0030594) in Developmental Stage
Four. Multiple neurotransmitters have been implicated in being involved in schizophrenia
including Dopamine, Serotonin, GABA and NMDA (37).
In Developmental Stage One, oestrogen 16-alpha-hydroxylase activity (GO:0101020) was
highlighted as being enriched in the turquoise module. Oestrogen is produced in the brain in
areas including the hippocampus, cortex, amygdala, hypothalamus and cerebellum (210).
Because oestrogen can have a powerful effect on numerous areas of the brain it can affect
mood, cognition and behaviour (211). It plays a critical role in influencing dopamine,
serotonin, glutamate and GABA neurotransmitters which are key in schizophrenia (210).
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Although oestrogen is involved in brain development the exact role of oestrogen 16-alphahydroxylase activity in schizophrenia is less obvious.
The immune system, inflammation, catecholamines and neurotransmitter dysfunctions have
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been identified as being important for each developmental stage. One of the important findings
from the study performed by Pardinas et al. was the significance of the SNP which was found
in the major histocompatibility complex (xMHC) region which is linked to the adaptive
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immune system. Although SNPs associated with the MHC region was included in the gene list
which was provided by Pardinas’s study, ABA’s BrainSpan resource did not include gene
expression data for it and thus were not included in our downstream analysis. Our findings
support the role of the immune system in Schizophrenia over each of the Developmental
Stages.

4.5 Limitations of the study
There were several limitations of this study. Firstly, ABA’s BrainSpan resource developed in
2014 uses healthy brains for each developmental stage. ABA’s BrainSpan contains gene
expression data across 16 brain regions from 8 post-conception to 40 years, covering the
complete development process (79). The atlas contains next-generation RNA sequencing data
which has collected 579 tissue samples from thirty neurologically unremarkable brains over
five developmental stages (80). A limitation to the BrainSpan resource is that the brain is
divided into just 16 regions and that the brain sample size is small. In addition, ~80% of
participants had transcriptomes missing from at least one brain region which means you’re not
getting complete pictures of the brain (79). ABA uses only neurotypical brains, we applied
similar methods which had proven to be successful in studies performed by McCarthy et al. and
Negi et al. (82,83). An additional gene expression database is the genotype tissue expression
(GTEx) project. This database was created to enable the study of human gene regulation and
variation of gene expression in multiple tissues (212). The GTEx consortium collected 14,787
transcriptomes from 948 patients including 13 brain regions (79). The largest limitation of
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using GTEx is that it does not have developing brain data which is why ABA was used in this
study.
Brain tissue is comprised of diverse basic cell types, if the expression at tissue levels changes it
may be due to alterations in the proportion of basic cell types (213). Single-cell sequencing
(scRNASeq) allows for the dissection of gene expression at single-cell resolution, using
scRNASeq can lead to findings in cell expression alterations and dynamics (214). This
revolutionary tool if applied to schizophrenia could uncover the uniqueness of each brain cell at
microscopic resolution (215). PsychENCODE is a resource that was built to elucidate the
underlying molecular mechanisms of psychiatric disorders. The resource includes the
integration of data from ENCODE, GTEx, Roadmap and relevant single-cell studies.
PsychENCODE’s main success has been the multi-omics approach of non-coding elements and
transcriptome in neurotypical developing brains and adults with psychiatric disorders (213).
Unfortunately, PsychENCODE does not have a developmental database and thus was not used
in this current study.
The schizophrenia-associated gene set which was used in this study was taken from a study
performed by Pardiñas et al. (66). Pardiñas et al. used these results as a training set to create
risk profile scores to identify SNPs at high confidence (66). This study is the largest
schizophrenia GWAS to date with 40,675 cases. The study size could be larger and could
produce more reproducible SNP’s. The SNPs identified were mapped to the closest loci and if
there were no overlapping genes it was mapped to the closest gene within a 500 KB distance
(66). As with all GWAS, the best way to discover more and yield more accurate results is to
increase the sample size of the study. The Pardiñas study mapped to 479 genes, of these genes
only 316 genes were available on ABA’s BrainSpan transcriptome atlas. Missing a large
portion of the Pardiñas gene set is a limitation of the current study and some SNPs did not map
to any genes available in ABA.
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K-means as a method has several limitations, firstly because the user has to decide on the
number of clusters k before beginning the analysis. Secondly, k-means has a bias of creating
modules of a similar size which may not accurately represent the group (90). Lastly, k-means
centroids are immensely affected by outliers and can give the outliers disproportionate
importance (89,90). K-means was used in this analysis to look for underlying patterns within
the genetic data per stage. When the Pardiñas gene set was put through k-means the intercluster
variation explained most of the total variance in the data which is not typical for good
clustering.
An additional limitation of this study is that there was no clinical data that could be applied to
the WGCNA data. Calculating gene trait significance also allows for the gene expression to be
linked to biologically relevant traits. Studies which had clinical data were able to determine the
GS threshold by combining it with module membership. Those with the highest GS can be
considered HG for a module. In this study, MM was calculated by determining the node
distance from the central ME. The MM calculated measured by Pearson correlation between
ME and gene expression should only contain genes with the highest correlation but one study
concluded that 25% be a better fit in other modules (216). Usually, WGCNA analysis uses
much more data, more genes could mean more than one HG for a module and can give a better
insight into the critical underlying pathways within a module.

4.6 Future Directions
To get a more comprehensive understanding of the brain changes which result in severe
psychiatric diseases it is important to have a clear understanding of mechanisms that occur in
normal brain development. When there is a comprehensive understanding of normal brain
development it will be easier to observe the changes that occur in neuropsychiatric conditions
like schizophrenia. At present, it is difficult to obtain full affected brains at any stage and as
there are no biomarkers it is difficult to predict who will develop schizophrenia until it
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eventually manifests. This would mean prenatal, child and early adolescence brains which are
obtained could not be confirmed that they would develop schizophrenia. In schizophrenia, it is
important to understand the brains mechanisms and what goes awry in the early stages. To
create a developmental resource researcher would have to use brains from people who are
high risk (perhaps based on the polygenic risk scores for schizophrenia) or those who have
close relatives with schizophrenia.
To combat these limitations a longitudinal study where participants who are more high risk to
develop schizophrenia than the general population could be studied from birth to adulthood.
This type of analysis would use blood samples and MRIs but a limitation for this kind of
study is the inability to study arguably the most important stage during development in utero,
where crucial decisions involving cell fate and distinctive development of the brain occur.
Thus, the incorporation of genetic, epigenome and gene expression data and machine learning
approaches will allow for a better understanding of abnormal brain development.
Gene Ontology databases are ever-growing with continual studies uncovering molecular
functions, cellular locations, and biological processes. With more studies utilising WGS there
will be a more absolute understanding of the genome and what it does and continuously
expand the scope of GO. Using GO enrichment analysis like in this study could identify
biological differences between controls and schizophrenia patients which could provide
pharmaceutical companies with novel therapeutic targets.
Functional work on the HG’s of interest at each of the stages could be performed, looking at
risk variants. These genes could be studied in knock out mice. It would be particularly
interesting to study ALMS1 and TRANK1 which were highlighted as being interesting in this
study and Pardiñas et al. Clustered regularly interspaced short palindromic repeat (CRISPRCas9) is a genome-editing tool that can induce double-strand breaks at target regions and can
alleviate a gene's function (217,218). As ALMS1 and TRANK1 were highlighted as being
important in both this study and Pardiñas study these would be great candidate genes for
further downstream analysing including CRISPR-Cas9.
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In the future, a method similar to this could be applied to other neuropsychiatric disorders
including ASD, MD and BPD. Studying conditions like these over time could assist in more
accurate prediction of whom will develop, how severe the symptoms could be, and which
treatments could be effective as well as identify candidate genes for downstream analysis.
This type of analysis could be easily adapted when newer GWAS produce more
comprehensive gene lists.

4.7 Conclusion
Schizophrenia is still a long way from being fully understood. From the schizophreniaassociated genes which were highlighted by Pardiñas and available in ABA’s BrainSpan
resource, 316 genes were available. Once GO enrichment was applied to the modules
produced by WGCNA, it was clear that macrophage proliferation and catecholamine
dysfunction were important mechanisms underlying schizophrenia in each developmental
stage. The importance of the immune system and catecholamine’s most notably dopamine has
been highlighted in multiple previous studies. There is an interaction between the immune
system and dopamine and evidence for this is co-morbidities of schizophrenia and
autoimmune diseases. Researching them together may give additional insight into their
interdependency.
To more accurately pinpoint central ontologies for each stage a study like this must be done
comparing controls and patients with schizophrenia. Studying them and looking at immune
and catecholamine processes specifically throughout development could produce novel
therapeutics with better efficacy and less severe side effects.

110

5.0 Bibliography
1.

2.
3.

4.
5.

6.
7.
8.
9.
10.
11.
12.
13.

14.
15.
16.
17.

18.
19.
20.
21.

22.

Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological Insights From
108 Schizophrenia-Associated Genetic Loci. Nature. 2014;511(7510):421–7. Available from:
http://www.nature.com/authors/editorial_policies/license.html#terms
Stilo SA, Murray RM. Non-Genetic Factors in Schizophrenia. Curr Psychiatry Rep. 2019;21(100).
Pugliese V, Bruni A, Carbone EA, Calabrò G, Cerminara G, Sampogna G, et al. Maternal stress,
prenatal medical illnesses and obstetric complications: Risk factors for schizophrenia spectrum
disorder, bipolar disorder and major depressive disorder. Psychiatry Res. 2019;271:23–30.
Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding
schizophrenia. F1000Prime Rep. 2014;6(57):1–11.
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles and
CUC. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging
pharmacological entities Amanda. CNS Spectr. 2019;24:41–68.
Carbon M, Correll CU. Thinking and acting beyond the positive: The role of the cognitive and
negative symptoms in schizophrenia. CNS Spectr. 2014;19(S1):35–53.
Gobira PH, Ropke J, Aguiar DC, Crippa JAS, Moreira FA. Animal models for predicting the efficacy
and side effects of antipsychotic drugs. Rev Bras Psiquiatr. 2013;35:132–9.
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97.
Avramopoulos D. Recent Advances in the Genetics of Schizophrenia. Mol Neuropsychiatry
[Internet]. 2018 [cited 2019 Sep 3];4:35–51. Available from: www.karger.com/mnp
Insel TR. Rethinking schizophrenia. Nature. 2010. p. 187–93.
Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules.
2018;23(2087).
Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: A
comprehensive model updated and revisited. J Autoimmun. 2006;27:71–80.
Ota VK, Moretti PN, Santoro ML, Talarico F, Spindola LM, Xavier G, et al. Gene expression over
the course of schizophrenia: from clinical high-risk for psychosis to chronic stages. npj Schizophr.
2019;5(5).
Gejman P V., Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr
Clin North Am. 2010;33(1):35–66.
Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: A review. Br Med Bull.
2015;114:169–79.
Muller N, J. Schwarz M. The Role of Immune System in Schizophrenia. Curr Immunol Rev.
2010;6(3):213–20.
Van Kesteren CFMG, Gremmels H, De Witte LD, Hol EM, Van Gool AR, Falkai PG, et al. Immune
involvement in the pathogenesis of schizophrenia: A meta-analysis on postmortem brain studies.
Transl Psychiatry. 2017;7(3). Available from: http://dx.doi.org/10.1038/tp.2017.4
Müller N. Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations.
Schizophr Bull. 2018;44(5):973–82.
Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Frontiers
in Neuroscience. 2015.
Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry.
2014;75(4):316–23. Available from: http://dx.doi.org/10.1016/j.biopsych.2013.06.010
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune
diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register
study. Am J Psychiatry. 2011;168(12):1303–10.
Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity
in schizophrenia: Implications for pathophysiology and treatment. The Lancet Psychiatry.
2015;2(3):258–70.
111

23.

24.
25.
26.

27.
28.
29.
30.
31.
32.
33.
34.

35.
36.

37.
38.

39.
40.
41.

42.
43.

44.

45.

Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B, Brian J. Miller, Peter Buckley, Wesley
Seabolt, Andrew Mellor and BK. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical
Status and Antipsychotic Effects Brian. Biol Psychiatry. 2011;70(7):663–71.
Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The Interaction of Nuclear Factor-Kappa B and
Cytokines Is Associated with Schizophrenia. Biol Psychiatry. 2009;65:481–8.
Dinan TG, Borre YE, Cryan JF. Genomics of schizophrenia: Time to consider the gut microbiome?
Mol Psychiatry. 2014;19:1252–7.
Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with
schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors
in mice. Sci Adv. 2019;5.
Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG. The role of the gut microbiome in the
development of schizophrenia. Schizophr Res. 2020;
Magdalon J, Mansur F, Teles e Silva AL, de Goes VA, Reiner O, Sertié AL. Complement System in
Brain Architecture and Neurodevelopmental Disorders. Front Neurosci. 2020;14(23).
Owen MJ, O’donovan MC. Schizophrenia and the neurodevelopmental continuum:evidence from
genomics. World Psychiatry. 2017;16:227–35.
Gupta S, Kulhara P. What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or
a combination of both A critical analysis. Indian J Psychiatry. 2010;52(1):21–7.
S.M Matt P. G. Where is Dopamine and How Do Immune Cells See It?: Dopamine-Mediated
Immune Cell Function in Health and Disease. J Neuroimmune Pharmacol. 2020;15(1):114–64.
Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: An update for the 21st
century. J Psychopharmacol. 2015;29(2):97–115.
Kesby JP, Eyles DW, McGrath JJ, Scott JG. Dopamine, psychosis and schizophrenia: The widening
gap between basic and clinical neuroscience. Transl Psychiatry. 2018;8(30).
Murray RM, Bhavsar V, Tripoli G, Howes O. 30 Years on: How the Neurodevelopmental
Hypothesis of Schizophrenia Morphed into the Developmental Risk Factor Model of Psychosis.
Schizophr Bull. 2017;43(6):1190–6.
Frank TVM and MJ. An Integrative Perspective on the Role of Dopamine in Schizophrenia. Biol
Psychiatry. 2017;176(1):52–66.
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment
resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.
Biol Psychiatry. 2014;75(5).
Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J
Mol Sci. 2017;18(1689).
Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al. The role of dopamine in
schizophrenia from a neurobiological and evolutionary perspective: Old fashioned, but still in vogue.
Front Psychiatry. 2014;5(47).
Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204–
15.
Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis:
Dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187–91.
Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, et al. Increased glutamine in patients
undergoing long-term treatment for schizophrenia: A proton magnetic resonance spectroscopy study
at 3 T. JAMA Psychiatry. 2014;71(3):265–72.
Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate
mechanisms. In: Brain Research Reviews. 2000. p. 302–12.
Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J. The cannabinoid receptor 1 associates with
NMDA receptors to produce glutamatergic hypofunction: Implications in psychosis and
schizophrenia. Front Pharmacol. 2014;4(169).
Marsman A, Van Den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate
in schizophrenia: A focused review and meta-analysis of 1H-MRS studies. Schizophr Bull.
2013;39(1):120–9.
Egerton A, Modinos G, Ferrera D, McGuire P. Neuroimaging studies of GABA in schizophrenia: A
112

46.

47.
48.
49.
50.
51.
52.
53.

54.

55.

56.
57.

58.

59.
60.

61.

62.

63.
64.
65.
66.

systematic review with meta-analysis. Transl Psychiatry. 2017;7:1–10.
Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on
GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res. 2015;167(1–3):98–
107.
Glausier JR, Lewis DA. GABA and schizophrenia: Where we stand and where we need to go.
Schizophr Res. 2017;181:2–3.
Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia.
Nat Rev Neurosci. 2017;18:727–40.
Quednow BB, Geyer MA, Halberstadt AL. Serotonin and Schizophrenia. In: Handbook of
Behavioral Neuroscience. 2010. p. 585–620.
Abi-Dargham A. Alterations of Serotonin Transmission in Schizophrenia. Int Rev Neurobiol.
2007;78:133–64.
Sumiyoshi T, Kunugi H, Nakagome K. Serotonin and dopamine receptors in motivational and
cognitive disturbances of schizophrenia. Front Neurosci. 2014;8(395).
Van Os J, Kenis G, Rutten BPF. The environment and schizophrenia. Nature. 2010;468(7321):203–
12. Available from: http://dx.doi.org/10.1038/nature09563
Janoutová J, Janáčková P, Šerý O, Zeman T, Ambroz P, Kovalová M, et al. Epidemiology and risk
factors of schizophrenia. Neuroendocrine Letters. 2016;37(1):26994378–370116. Available from:
www.nel.edu
O’Loughlin E, Pakan JMP, Yilmazer-Hanke D, McDermott KW. Acute in utero exposure to
lipopolysaccharide induces inflammation in the pre- and postnatal brain and alters the glial
cytoarchitecture in the developing amygdala. J Neuroinflammation. 2017;14(1):1–12.
Hollins SL, Cairns MJ. MicroRNA: Small RNA mediators of the brains genomic response to
environmental stress. Prog Neurobiology. 2016;143:61–81. Available from:
http://dx.doi.org/10.1016/j.pneurobio.2016.06.005
Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93(1):23–58.
Shenton ME, Dickey CC, Frumin M, Mccarley RW. A review of MRI findings in schizophrenia.
Schizophr Res . 2001;49(1):1–52. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812015/
Dietsche B, Kircher T, Falkenberg I. Structural brain changes in schizophrenia at different stages of
the illness: A selective review of longitudinal magnetic resonance imaging studies. Aust N Z J
Psychiatry. 2017;1–9.
Haijma S V., Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain volumes
in schizophrenia: A meta-analysis in over 18 000 subjects. Schizophr Bull. 2013;39(5):1129–38.
Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain
changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI
studies. Neurosci Biobehav Rev. 2013;37(8):1680–91.
Scheepers FE, De Wied CCG, Pol HEH, Van De Flier W, Van Der Linden JA, Kahn RS. The effect
of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical
antipsychotics. Neuropsychopharmacology. 2001;24(1):47–54.
Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of
Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. Biol
Psychiatry. 2018;83(6):492–8. Available from: http://dx.doi.org/10.1016/j.biopsych.2017.08.017
Schwab SG, Wildenauer DB. Genetics of psychiatric disorders in the GWAS era: An update on
schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263:147–54.
Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: Overview of methods, findings
and limitations. Front Hum Neurosci. 2017;11(322).
Duncan EL, Brown MA. Genome-Wide Association Studies. In: Genetics of Bone Biology and
Skeletal Disease: Second Edition. 2017.
Antonio F. Pardiñas1, Peter Holmans1, Andrew J. Pocklington1, Valentina Escott- Price1, Stephan
Ripke2, 3, Noa Carrera1, Sophie E. Legge1, Sophie Bishop1, Darren Cameron1, Marian L.
Hamshere1, Jun Han1, Leon Hubbard1, Amy Lynham1, Kiran Mantripragada1 ER. Common
schizophrenia alleles are enriched in mutation intolerant genes and in region under strong
113

67.
68.
69.
70.

71.
72.

73.
74.

75.

76.
77.
78.
79.

80.

81.
82.

83.

84.
85.
86.
87.

background selection. Nature Genetics. 2018;50(3):381–9. Available from: file:///C:/Users/Carla
Carolina/Desktop/Artigos para acrescentar na qualificação/The impact of birth weight on
cardiovascular disease risk in the.pdf
Skene NG, Bryois J, Bakken TE, Breen G, James J, Gaspar HA, et al. Genetic identification of brain
cell types underlying schizophrenia. 2019;50(6):825–33.
Bush WS, Moore JH. Chapter 11: Genome-Wide Association Studies. PLoS Comput Biol.
2012;8(12):1–10.
Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS
Discovery: Biology, Function, and Translation. American Journal of Human Genetics. 2017. p. 5–22.
van Mierlo HC, Schot A, Boks MPM, de Witte LD. The association between schizophrenia and the
immune system: Review of the evidence from unbiased ‘omic-studies.’ Schizophrenia Research.
2020;217:114–23. Available from: https://doi.org/10.1016/j.schres.2019.05.028
Aguet F, Brown AA, Castel SE, Davis JR, He Y, Jo B, et al. Genetic effects on gene expression
across human tissues. Nature. 2017;550(7675):204–13.
Mantione KJ, Kream RM, Kuzelova H, Ptacek R, Raboch J, Samuel JM, et al. Comparing
bioinformatic gene expression profiling methods: microarray and RNA-Seq. Med Sci Monit Basic
Res. 2014;20:138–41.
Ball S, Gilbert TL, Overly CC. The Human Brain Online: An Open Resource for Advancing Brain
Research. PLoS Biol. 2012;10(12).
Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically
comprehensive atlas of the adult human brain transcriptome. Nature. 2012 Sep 20;489(7416):391–9.
Available from: http://www.nature.com/articles/nature11405
Sunkin SM, Ng L, Lau C, Dolbeare T, Gilbert TL, Thompson CL, et al. Allen Brain Atlas: An
integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res.
2013;41(database issue).
Arnatkevic̆iūtė A, Fulcher BD, Fornito A. A practical guide to linking brain-wide gene expression
and neuroimaging data. Neuroimage. 2019;189:353–67.
Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A, et al. Transcriptional landscape of the
prenatal human brain. Nature. 2014;508:199–206.
Vasung L, Abaci Turk E, Ferradal SL, Sutin J, Stout JN, Ahtam B, et al. Exploring early human brain
development with structural and physiological neuroimaging. Neuroimage. 2019;187:226–54.
Pei G, Wang YY, Simon LM, Dai Y, Zhao Z, Jia P. Gene expression imputation and cell-type
deconvolution in human brain with spatiotemporal precision and its implications for brain-related
disorders. Genome Res. 2021;1(1):146–58.
Mahfouz A, Ziats MN, Rennert OM, Lelieveldt BPF, Reinders MJT. Shared Pathways Among
Autism Candidate Genes Determined by Co-expression Network Analysis of the Developing Human
Brain Transcriptome. J Mol Neurosci. 2015;57:580–94.
Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically
comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391–9.
Negi SK, Guda C. Global gene expression profiling of healthy human brain and its application in
studying neurological disorders OPEN. Nat Reports. 2017 Dec 18 ;7(897):1–12. Available from:
www.nature.com/scientificreports/
Mccarthy MJ, Liang S, Spadoni AD, Kelsoe JR, Simmons AN. Whole Brain Expression of Bipolar
Disorder Associated Genes: Structural and Genetic Analyses. PLoS One . 2014 ;9(6):1–13. Available
from: www.plosone.org
Rodriguez MZ, Comin CH, Casanova D, Bruno OM, Amancio DR, Costa L da F, et al. Clustering
algorithms: A comparative approach. PLoS One. 2019;14(1).
Jayanthi K, Mahesh C. A Study on machine learning methods and applications in genetics and
genomics. Int J Eng Technol. 2018;7(1.7):201–4.
Saelens W, Cannoodt R, Saeys Y. A comprehensive evaluation of module detection methods for
gene expression data. Nat Commun. 2018;9(1090):1–12.
Gibbons FD, Roth FP. Judging the quality of gene expression-based clustering methods using gene
annotation. Genome Res. 2002;12:1574–81.
114

88.
89.

90.
91.
92.
93.
94.
95.
96.

97.

98.
99.
100.

101.
102.
103.
104.
105.

106.
107.
108.
109.
110.
111.
112.
113.

Jain AK. Data clustering: 50 years beyond K-means. Pattern Recognit Lett. 2010;31:651–66.
Shi N, Liu X, Guan Y. Research on k-means clustering algorithm: An improved k-means clustering
algorithm. In: 3rd International Symposium on Intelligent Information Technology and Security
Informatics, IITSI 2010. IEEE; 2010. p. 63–7.
Morissette L, Chartier S. The k-means clustering technique: General considerations and
implementation in Mathematica. Tutor Quant Methods Psychol. 2013;9(1):15–24.
Charrad M, Ghazzali N, Boiteau V, Niknafs A. Nbclust: An R package for determining the relevant
number of clusters in a data set. J Stat Softw. 2014;61(6):1–36.
Kassambara A, Mundt F. Factoextra: extract and visualize the results of multivariate data analyses
[Computer sofware, package]. R package version. 2017.
van Dam S, Võsa U, van der Graaf A, Franke L, de Magalhães JP. Gene co-expression analysis for
functional classification and gene-disease predictions. Brief Bioinform. 2018;19(4):575–92.
Li J, Zhou D, Qiu W, Shi Y, Yang JJ, Chen S, et al. Application of Weighted Gene Co-expression
Network Analysis for Data from Paired Design. Sci Rep. 2018;8(622).
Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC
Bioinformatics. 2008;9(559).
Liu Y, Gu HY, Zhu J, Niu YM, Zhang C, Guo GL. Identification of Hub Genes and Key Pathways
Associated With Bipolar Disorder Based on Weighted Gene Co-expression Network Analysis. Front
Physiol. 2019;10:1–9.
Costantini G, Epskamp S, Borsboom D, Perugini M, Mõttus R, Waldorp LJ, et al. State of the aRt
personality research: A tutorial on network analysis of personality data in R. J Res Pers. 2015;54:13–
29.
Yu D, Kim M, Xiao G, Hwang TH. Review of Biological Network Data and Its Applications.
Genomics Inform. 2013;11(4):200–10.
Sun K, Gonçalves JP, Larminie C, Pržulj N. Predicting disease associations via biological network
analysis. BMC Bioinformatics. 2014;15(304):1–13.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software
Environment for integrated models of biomolecular interaction networks. Genome Res.
2003;13:2498–504.
Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological
networks and gene expression data using cytoscape. Nat Protoc. 2007;2(10):2336–82.
Gang Su1, John H. Morris2, Barry Demchak3 and GDB. BIOLOGICAL NETWORK
EXPLORATION WITH CYTOSCAPE 3. Curr Protoc Bioinforma. 2014;74(8).
Assenov Y, Ramírez F, Schelhorn SESE, Lengauer T, Albrecht M. Computing topological
parameters of biological networks. Bioinformatics. 2008;24(2):282–4.
Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological
networks. Methods Mol Biol. 2011;
Carbon S, Dietze H, Lewis SE, Mungall CJ, Munoz-Torres MC, Basu S, et al. Expansion of the gene
ontology knowledgebase and resources: The gene ontology consortium. Nucleic Acids Res.
2017;45(Database issue):331-D338.
Blake JA, Christie KR, Dolan ME, Drabkin HJ, Hill DP, Ni L, et al. Gene ontology consortium:
Going forward. Nucleic Acids Res. 2015;43(D1):1049–56.
Langfelder P. anRichment: Collections and annotation data for use with anRichmentMethods. 2020.
Carlson M. org.Hs.eg.db: Genome wide annotation for Human. 2019.
Kassambara A, Mundt F, Kassambara, A.; Mundt F. Factoextra: extract and visualize the results of
multivariate data analyses. URL http//www.sthda.com/english/rpkgs/factoextra BugReports. 2017;
Barabási AL, Oltvai ZN. Network biology: Understanding the cell’s functional organization. Nat Rev
Genet. 2004;5:101–13.
Pavlopoulos GA, Secrier M, Moschopoulos CN, Soldatos TG, Kossida S, Aerts J, et al. Using graph
theory to analyze biological networks. BioData Min. 2011;4(10).
Jacob R, Harikrishnan KP, Misra R, Ambika G. Measure for degree heterogeneity in complex
networks and its application to recurrence network analysis. R Soc Open Sci. 2017;4(1).
Dong J, Horvath S. Understanding network concepts in modules. BMC Syst Biol. 2007;1(24).
115

114. Zawerton, Ash; Mignot, Cyril; Sigafoos, Ashley; Blackburn, Patrick R.; Haseeb, Abdul; McWalter,
Kirsty; Ichikawa, Shoji; Nava, Caroline; Keren, Boris; Charles, Perrine; Marey, Isabelle; Tabet,
Anne-Claude; Levy, Jonathan; Perrin, Laurence; Hartmann, Andre C. Widening of the genetic and
clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5
haploinsufficiency. Genet Med. 2019;0(0).
115. Manfred Schartl1, 2, 3, Susanne Schories1, Yuko Wakamatsu1, Yusuke Nagao4, Hisashi
Hashimoto4, Chloé Bertin5, Brigitte Mourot5, Cornelia Schmidt1, Dagmar Wilhelm6, Lazaro
Centanin7 YG and AH. Sox5 is involved in germ-cell regulation and sex determination in medaka
following co-option of nested transposable elements. BMC Biol. 2018;16(16).
116. Tae-Gul Lee1, 2 , Eun-Hui Jeong1, Seo Yun Kim1, Hye-Ryoun Kim1 HK, Kim C-H. Fhit, a tumor
suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells. Oncotarget.
2017;8(19):31923–37.
117. Garneau AP, Slimani S, Tremblay LE, Fiola MJ, Marcoux AA, Isenring P. K+-Cl− cotransporter 1
(KCC1): a housekeeping membrane protein that plays key supplemental roles in hematopoietic and
cancer cells. J Hematol Oncol [Internet]. 2019 Dec 11;12(1):74. Available from:
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0766-x
118. Fiona C. Brown, 1 Ashlee J. Conway, 1 Loretta Cerruti, 1 Janelle E. Collinge, 2 Catriona McLean, 3
James S. Wiley, 4 Ben T. Kile, 2 Stephen M. Jane, 1, 3, 5,* and David J. Curtis1iona C. Brown, 1
Ashlee J. Conway, 1 Loretta Cerruti, 1 Janelle E. Collinge, and DJC. Activation of the erythroid KCl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model. Blood.
2015;126(26):2863–70.
119. Kourosh Parham, M.D., Ph.D.1, George A. Kuchel, M.D.2, Janet E. McElhaney, M.D.4, and Laura
Haynes PD. A relationship between blood levels of otolin-1 and vitamin D. Otol Neurotol.
2018;39(4):269–73.
120. Murat Doğan , Mustafa Şahin YK. Otolin-1, as a Potential Marker for Inner Ear Trauma after
Mastoidectomy. J Int Adv Otol. 2019;15(2):200–3.
121. Yanyan Liu1 2 · Chuang Tong2 · Jun Cao2 · Maoming Xiong1. NEMP1 Promotes Tamoxifen
Resistance in Breast Cancer Cells. Biochem Genet. 2019;57(6):813–26.
122. Yonit Tsatskis1*, Robyn Rosenfeld1, 2*, Joel D. Pearson1*, Curtis Boswell2, 3*, Yi Qu1, Kyunga
Kim1, 4, Lacramioara Fabian5, Ariz Mohammad6, Xian Wang7, 8, Michael I. Robson9, Karen
Krchma10, Jun Wu10, João Gonçalves1, Didier Hodzic11, Shu Wu1, Daniel Pot HM. The NEMP
family supports metazoan fertility and nuclear envelope stiffness. Sci Adv Genet. 2020;6.
123. Hiroshi Mamada, Noriyuki Takahashi MT. Involvement of an inner nuclear membrane protein,
Nemp1, in Xenopus neural development through an interaction with the chromatin protein BAF. Dev
Biol. 2009;327:497–507.
124. Marta Codina-Solà, Benjamín Rodríguez-Santiago, Aïda Homs, Javier Santoyo, Maria Rigau,
Gemma Aznar-Laín, Miguel del Campo, Blanca Gener, Elisabeth Gabau, María Pilar Botella,
Armand Gutiérrez-Arumí1, Guillermo Antiñolo, Luis Alberto Pérez-Jurado and IC. Integrated
analysis of whole-exome sequencing and transcriptome profiling in males with autism spectrum
disorders. Mol Autism. 2015;6(21).
125. Mitsuru Ebihara, Hisako Ohba, Mika Kikuchi TY. Structural characterization and promoter analysis
of human potassium channel Kv8.1 (KCNV1) gene. Gene. 2004;325:89–96.
126. Takashi Hashimoto 1, Shohei Maekawa SM. IgLON cell adhesion mol- ecules regulate
synaptogenesis in hippocampal neurons. Cell Biochem Functopm. 2009;7:496–8.
127. Lan Wen a, Lei Liu b, Linyan Tong a, Jinfang Li a, Keming Zhang a, Qinbin Zhang a CL a. NDRG4
prevents cerebral ischemia/reperfusion injury by inhibiting neuronal apoptosis. Genes Dis.
2019;6:448–54.
128. Mitsuo Wada, Kayo Yukawa, Hiroyuki Ogasawara, ..., Takeshi Ohta, Eunyoung Lee TM. GPR52
accelerates fatty acid biosynthesis in a ligand-dependent manner in hepatocytes and in response to
excessive fat intake in mice. iScience. 2021;24(102260).
129. Hidetoshi Komatsu1*., Minoru Maruyama2., Shuuhei Yao3, Tokuyuki Shinohara4, Kensuke
Sakuma2, Sachiko Imaichi4, Tomoko Chikatsu2, Kanako Kuniyeda5, Foo Kok Siu6, Lam Sock
Peng6, Katherine Zhuo7, Lay Sock Mun7, Tan Min Han7, Yoshio Matsumoto3, Tadatoshi Has MM.
116

130.

131.

132.

133.

134.
135.

136.

137.
138.

139.

140.

141.

142.
143.

144.

Anatomical Transcriptome of G Protein-Coupled Receptors Leads to the Identification of a Novel
Therapeutic Candidate GPR52 for Psychiatric Disorders. PLoS One. 2014;9(2).
Lorena Benedetti1, 2 , Matteo Cereda1, 2 , LeeAnn Monteverde1, 2 , Nikita Desai1 2 and, Ciccarelli
FD. Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1.
Oncotarget. 2017;8(23):37619–32.
Petra van derPetra van der Lelij1,* , Joseph A Newman2,*, Simone Lieb3,*, Julian Jude1,*, Vittorio
Katis2, Thomas Hoffmann1, Matthias Hinterndorfer1, Gerd Bader3, Norbert Kraut3, Mark A
Pearson3, Jan-Michael Peters1, 4, Johannes Zuber1, 4, Opher Gileadi2, MP. STAG1 vulnerabilities
for exploiting cohesin synthetic lethality in STAG2-deficient cancers. Life Sci Alliance. 2020;3(7).
Daphné Lehalle, 1, 2 Anne-Laure Mosca-Boidron, 3, 4 Amber Begtrup, 5 Odile Boute-Benejean, 6
Perrine Charles, 7 Megan T Cho, 5 Amanda Clarkson, 8 Orrin Devinsky, 9 Yannis Duffourd, 4
Laurence Duplomb-Jego, 3, 4 Bénédicte Gérard, 10 Aurélia Jacquette, 7 Pa 4 Laurence Faivre1.
STAG1 mutations cause a novel cohesinopathy characterised by unspecific syndromic intellectual
disability. BMJ. 2017;54(7):479–88.
Whitton L, Apostolova G, Rieder D, Dechant G, Rea S, Donohoe G, et al. Genes regulated by
SATB2 during neurodevelopment contribute to schizophrenia and educational attainment. PLoS
Genet. 2018;14(7).
Qian Y, Liu J, Yang Y, Chen M, Jin C, Chen P, et al. Paternal low-level mosaicism-caused SATB2associated syndrome. Front Genet. 2019;
Schult, D., Ho¨lsken MB, Schlaffer, S.-M. Siegel, S. Buslei, I. Kreitschmann-Andermahr , R.
Fahlbusch R. Expression pattern of neuronal intermediate filament a-internexin in anterior pituitary
gland and related tumors. Pituitary. 2015;18:465–473.
Yingjie Li, Liangliang Bai, Huichuan Yu, Du Cai, Xiaolin Wang, Baoyuan Huang, Shaoyong Peng,
Meijin Huang, Guangwen Cao, Andrew M. Kaz, William M. Grady, Jianping Wang, and Yingjie Li,
Liangliang Bai1, Huichuan Yu, Du and YLL. Epigenetic Inactivation of α-Internexin Accelerates
Microtubule Polymerization in Colorectal Cancer. Cancer Res. 2020;80(23):5203–15.
Whelan R, Clair DS, Mustard CJ, Hallford P, Wei J. Study of novel autoantibodies in schizophrenia.
Schizophr Bull. 2018;44(6):1341–9.
Xiaoyu Xu1, 2,† Zhao Zeng1,† Li Huo1,† Hong Liu1, 3 Yan Yu1 Ling Zhang1 Jiannong Cen1
Huiying Qiu1, 3 Xiaowen Tang1, 3 Chengcheng Fu1, 3 Yue Han1, 2, 3 Miao Miao1, 3 Zhengming
Jin1, 3 Changgeng Ruan1, 2, 3 Depei Wu1, 2, 3 Suning Chen1, 2, 3 Qinrong Wang1 3, Lingzhi Yan1
3. High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid
leukaemia with normal karyotype. BJH Corresp. 2019;189(1):23–7.
Adam J Harrington 1, Catherine M Bridges 2, Stefano Berto 3, Kayla Blankenship 1, Jennifer Y Cho
2, Ahlem Assali 1, Benjamin M Siemsen 4, Hannah W Moore 5, Evgeny Tsvetkov 1, Acadia
Thielking 1, Genevieve Konopka 3, David B Everman 5, Michael D Scofield 4 CWC 6. MEF2C
Hypofunction in Neuronal and Neuroimmune Populations Produces MEF2C Haploinsufficiency
Syndrome-like Behaviors in Mic. Biol Psychiatry. 2020;15(88):488–99.
Adam J Harrington1 2†, , Aram Raissi2† , Kacey Rajkovich3 SB, Jaswinder Kumar2 4, Molinaro3
G, Raduazzo2 J, Guo2 Y, et al. MEF2C regulates cortical inhibitory and excitatory synapses and
behaviors relevant to neurodevelopmental disorders. Elife. 2016;5.
Melanie Richter1, Nadeem Murtaza2, 3 Robin Scharrenberg1 Sean H. White2, 3 Ole Johanns1 Susan
Walker4, 5 , Ryan K. C. Yuen 4, 5 Birgit Schwanke1 Bianca Bedürftig1 Melad Henis1, 6 Sarah
Scharf7 Vanessa Kraus7 , Ronja Dörk7 Jakob Hellmann7 Zsuzsa Lindenmaie 3 Froylan Calderon de
Anda. Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive
abnormalities through RhoA signaling. Mol Psychiatry. 2019;24:1329–50.
Chih-Yeu Fang 1, Tsung-Ching Lai 2, 3, Michael Hsiao 1, 4 and Y-CC. The Diverse Roles of TAO
Kinases in Health and Diseases. J Mol Sci. 2020;27(7463).
Yang Shao1, 2, Jing Kong1† HX, , Xiaoli Wu1, YuePeng Cao1 , Weijian Li 1 , Jing Han4 , Dake Li
1 KX and JW. OPCML Methylation and the Risk of Ovarian Cancer: A Meta and Bioinformatics
Analysis. Front Cell Dev Biol. 2021;9(570908).
Zhengrong Zhang, Maoqing Ye, Qiongwei Li, Rena Li, Jun Li DZ. The Schizophrenia Susceptibility
Gene OPCML Regulates Spine Maturation and Cognitive Behaviors through Eph-Cofilin Signaling.
117

Cell Rep. 2019;29:49–61.
145. Jane Antony1, 2, 3, Elisa Zanini1 , Zoe Kelly1, Tuan Zea Tan2, Evdoxia Karali1, Mohammad
Alomary1, Youngrock Jung1, Katherine Nixon1, Paula Cunnea1, Christina Fotopoulou1, Andrew
Paterson1, Sushmita Roy-Nawathe1, Gordon B Mills4, Ruby Yun-Ju Huang2, 5, Je & CR. The
tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian
cancer. EMBO J. 2081;19(e45670).
146. Vougiouklakis1 T, Ryuji Hamamoto1 Y, Vassiliki N&, Saloura* 1. The NSD family of protein
methyltransferases in human cancer. Epigenomics. 2015;7(5).
147. Li LYLYQLC. Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via
ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells. Onco Targets Ther.
2019;12:3933–43.
148. Chunmei Wang, 1, 2 Qinlan Wang, 3 Xiaoqing Xu, 1 Bin Xie, 3 Yong Zhao, 4 Nan Li, 2 and Xuetao
Cao1, 2 3. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine
methylation of IRF3. J Exp Med. 2017;214(12):3597–610.
149. Vassiliki Saloura1 , Theodore Vougiouklakis1, Makda Zewde1, Kiyotani1 Kazuma, Jae-Hyun Park1,
Guimin Gao2, Theodore Karrison2, Mark Lingen3 , Yusuke Nakamura1, 4 RH. WHSC1L1 drives
cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell
carcinoma of the head and neck. Oncotarget. 2016;7(27):42527–38.
150. Paternoster L, Soblet J, Aeby A, De Tiège X, Goldman S, Yue WW, et al. Novel homozygous
variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental
retardation, and disequilibrium syndrome subtype 3. Am J Med Genet Part A. 2020;97(3):516–20.
151. Ma HL, Yu SJ, Chen J, Ding XF, Chen G, Liang Y, et al. CA8 promotes RCC proliferation and
migration though its expression level is lower in tumor compared to adjacent normal tissue. Biomed
Pharmacother. 2020;121(109578).
152. Zhuang GZ, Keeler B, Grant J, Bianchi L, Fu ES, Zhang YP, et al. Carbonic anhydrase-8 regulates
inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway. PLoS One. 2015;10(3).
153. Tom Hearn. ALMS1 and Alström syndrome: a recessive form of metabolic, neurosensory and
cardiac deficits. J Mol Med. 2019;97:1–17.
154. Shao-Yan Zhang, Chao Xuan, Yi Wang, Shao-Qiang Zhang, Hui Li, Guo-Wei He and Q-WT.
Association between ALMS 1 variants and early-onset coronary artery disease: a case–control study
in Chinese population. Biosci Rep. 2020;40(BSR20193637).
155. Hemang M. Parikh1 2*, , Targ Elgzyri2, Amra Alibegovic3, Natalie Hiscock4, Ola Ekström2, KarlFredrik Eriksson2, Allan Vaag3, Leif C. Groop2, 5, Kristoffer Ström2 6† and Ola Hansson.
Relationship between insulin sensitivity and gene expression in human skeletal muscle. BMC Endocr
Disord. 2021;21(32).
156. Jakub Tomasik, PhD1; Santiago G. Lago, PhD1; Javier Vázquez-Bourgon, MD P. Association of
Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic
Treatment. JAMA Psychiatry. 2019;76(8).
157. Zaoa X, *, Jin Chengb *, Congle Shena , Guiwen Guana, Xiaoyu Fenga, Jun Zoua, Jing Zhanga TL,
Huiling Zhenga, Ting Zhanga, Jie Wanga, Jia Liua, Deyao Lia, Fengmin Lu, Fuping You and XC.
NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-Imediated interferon transcription. Oncoimmunology. 2021;10(1).
158. Katia Urso, Andrés Fernández, Patricia Velasco, Javier Cotrina, Belén de Andrés, Pilar SánchezGómez , Aurelio Hernández-Laín, Sonsoles Hortelano JMR& EC. NFATc3 controls tumour growth
by regulating proliferation and migration of human astroglioma cells. Nat Sci Reports. 2019;9(9361).
159. Sridevi Venkatesan EKL. Chrna5 is essential for a rapid and protected response to optogenetic
release of endogenous acetylcholine in prefrontal cortex. bioXriv. 2020;40(38):7255–68.
160. Thaka’a K. Al-Omoush1, Karem H. Alzoubi, Omar F. Khabour, Fawzi M. Alsheyab, Ahmed Abusiniyeh, Nour A. Al-Sawalha, Fadia A. Mayyas, Caroline O. Cobb TE. The CHRNA5 Polymorphism
(rs16969968) and its Association with Waterpipe Smoking Addiction among Jordanians. Arab J
Basix Appl Sci. 2020;27(1):450–5.
161. Myriam Srour, Noriaki Shimokawa, Fadi F. Hamdan, Christina Nassif, Chantal Poulin, Lihadh Al
Gazali, Jill A. Rosenfeld, Noriyuki Koibuchi, Guy A. Rouleau, Aisha Al Shamsi and JLM.
118

162.

163.

164.
165.
166.
167.
168.
169.
170.
171.
172.
173.

174.

175.

176.

177.

178.
179.
180.

181.

Dysfunction of the Cerebral Glucose Transporter SLC45A1 in Individuals with Intellectual Disability
and Epilepsy. CellPress. 2017;100(5):824–30.
Thyme SB, Pieper LM, Li EH, Pandey S, Wang Y, Morris NS, et al. Phenotypic Landscape of
Schizophrenia-Associated Genes Defines Candidates and Their Shared Functions. Cell [Internet].
2019;177(2):478–91. Available from: https://doi.org/10.1016/j.cell.2019.01.048
Sant’Anna Feltrin A, Tahira AC, Simões SN, Brentani H, Martins DC. Assessment of
complementarity of WGCNA and NERI results for identification of modules associated to
schizophrenia spectrum disorders. PLoS One [Internet]. 2019 [cited 2019 Jul 3];14(1):1–22.
Available from: https://doi.org/10.1371/journal.pone.0210431
Lai T, Jabaudon D, Molyneaux BJ, Azim E, Arlotta P, Menezes JRL, et al. SOX5 Controls the
Sequential Generation of Distinct Corticofugal Neuron Subtypes. Neuron. 2008;57:232–47.
Sun C, Ban Y, Wang KAI, Sun Y, Zhao Z. SOX5 promotes breast cancer proliferation and invasion
by transactivation of EZH2. Oncol Lett. 2019;17(3):1–9.
You J, Zhao Q, Fan X, Wang J. SOX5 promotes cell invasion and metastasis via activation of twistmediated epithelial– mesenchymal transition in gastric cancer. Onco Targets Ther. 2019;12:2465–76.
Fu Y, Shan X, Song W, Xu K, Jiao C, Zhang Q. Correlations of breast cancer FHIT gene with the
incidence and prognosis of breast cancer. JBUON. 2019;24(9):40–7.
Sullivan CR, Funk AJ, Shan D, Haroutunian V, McCullumsmith RE. Decreased chloride channel
expression in the dorsolateral prefrontal cortex in schizophrenia. PLoS One. 2015;10(3).
Lewis DA, Narendran R. In Vivo Measurement of GABA Transmission in Healthy Subjects and
Schizophrenia Patients W. Am J Psychiatry. 2016;172(11):1148–59.
Silverstein SM, Rosen R. Cognition Schizophrenia and the eye. Schizophr Res. 2015;2(Cognition
2):46–55.
Almonte MT, Capellàn P, Yap TE, Cordeiro MF. Retinal correlates of psychiatric disorders. Ther
Adv Chronic Dis. 2020;11:1–21.
Zhang L, Li X, Zhou R, Xing G. Possible role of potassium channel , big K in etiology of
Schizophrenia. Med Hypotheses. 2006;67:41–3.
Yamamoto H, Kokame K, Okuda T, Nakajo Y, Yanamoto H, Miyata T. NDRG4 Protein-deficient
Mice Exhibit Spatial Learning Deficits and Vulnerabilities to Cerebral Ischemia * □. J Biol Chem.
2011;286(29):26158–65.
F. Ducray, MD E. Crinie`re, MSc A. Idbaih, MD, PhD K. Mokhtari, MD Y. Marie, MSc S. Paris,
MSc S. Navarro, MD F. Laigle-Donadey, MD C. Dehais, MD J. Thillet, PhD K. Hoang-Xuan, MD,
PhD, J.-Y. Delattre, MD M. Sanson, MD P. alpha-Internexin expression identifies 1p19q codeleted
gliomas. Neurology. 2009;72(2):156–61.
Jiang X, Detera-Wadleigh SD, Akula N, Mallon BS, Hou L, Xiao T, et al. Sodium valproate rescues
expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with
serious mental illness. Mol Psychiatry [Internet]. 2019;24(4):613–24. Available from:
http://dx.doi.org/10.1038/s41380-018-0207-1
Li W, Cai X, Li HJ, Song M, Zhang CY, Yang Y, et al. Independent replications and integrative
analyses confirm TRANK1 as a susceptibility gene for bipolar disorder. Neuropsychopharmacology.
2020;0:1–10.
Mossink B, Negwer M, Schubert D, Nadif Kasri N. The emerging role of chromatin remodelers in
neurodevelopmental disorders: a developmental perspective [Internet]. Vol. 78, Cellular and
Molecular Life Sciences. Springer International Publishing; 2021. 2517–2563 p. Available from:
https://doi.org/10.1007/s00018-020-03714-5
Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW, et al. Genomic dissection
of bipolar disorder and schizophrenia including 28 subphenotypes. bioRxiv. 2017;173(7):1705–15.
Laskaris LE, Di Biase MA, Everall I, Chana G, Christopoulos A, Skafidas E, et al. Microglial
activation and progressive brain changes in schizophrenia. Br J Pharmacol. 2016;173(4):666–80.
Li M, Santpere G, Kawasawa YI, Evgrafov O V., Gulden FO, Pochareddy S, et al. Integrative
functional genomic analysis of human brain development and neuropsychiatric risks. Science (80- ).
2018;362(6420).
Tangliang Li1, Yue Shi2, Pei Wang1, Luis Miguel Guachalla3, Baofa Sun2, Tjard Joerss1, Yu-Sheng
119

182.

183.

184.
185.
186.
187.
188.

189.

190.

191.

192.
193.
194.

195.

196.
197.
198.

199.
200.

Chen2, Marco Groth1, Anja Krueger1, Matthias Platzer1, Yun-Gui Yang2, Karl Lenhard Rudolph1,
3 & Zhao-Qi Wang1 4, Abstract. Smg6Est1 licenses embryonic stem cell differentiation via
nonsense‐mediated mRNA decay. Embo J. 2015;34(12).
Tao H, Zhou X, Xie Q, Ma Z, Sun F, Cui L, et al. SRR intronic variation inhibits expression of its
neighbouring SMG6 gene and protects against temporal lobe epilepsy. J Cell Mol Med.
2018;22(3):1883–93.
Chi TH, Hsieh BY, Liang PS, Han TH, Hsieh M. Expression and Functional Study of Single
Mutations of Carbonic Anhydrase 8 in Neuronal Cells. Cell Mol Neurobiol [Internet].
2020;(0123456789). Available from: https://doi.org/10.1007/s10571-020-00907-1
Citton V, Favaro A, Bettini V, Gabrieli J, Milan G, Greggio NA, et al. Brain involvement in Alström
syndrome. Ophanet J Rare Dis. 2013;8(24).
Wang X, Christian KM, Song H, Ming G. Synaptic dysfunction in complex psychiatric disorders :
from genetics to mechanisms. Genome Med. 2018;10(9):9–11.
Bennett MR. Synapse formation and regression in the cortex during adolescence and in
schizophrenia. Med J Aust. 2009;190(4):4–6.
Minami T. Calcineurin-NFAT activation and DSCR-1 auto-inhibitory loop : how is homoeostasis
regulated ? J Biochem. 2014;155(4):217–26.
Kipanyula MJ, Kimaro WH, Etet PFS. The Emerging Roles of the Calcineurin-Nuclear Factor of
Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases. J Aging Res.
2016;5081021.
Wei Han, Tianxiao Zhang, Tong Ni, Li Zhu, Dan Liu, Gang Chen, Huali Lin, Teng Chen FG.
Relationship of common variants in CHRNA5 with early-onset schizophrenia and executive
function. Schizophr Res. 2019;206:407–12.
Yuhong Wang, Yuanjia Chen, Xiaoxing Li, Wanming Hu, Yu Zhang, Luohai Chen MC and JC. Loss
of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine
neoplasm. BMC Cancer. 2018;18(691).
Xi Lin, Mingyue Li, Niandong Wang, Yiran Wu, Zhipu Luo, Shimeng Guo, Gye-Won Han, Shaobai
Li, Yang Yue1, Xiaohu Wei Xin Xie, Yong Chen, Suwen Zhao, Jian Wu ML& FX. Structural basis
of ligand recognition and self-activation of orphan GPR52. Nature. 2020;579(7797):152–7.
Hidetoshi Komatsu MF and YH. Potential Utility of Biased GPCR Signaling for Treatment of
Psychiatric Disorders. Int J Mol Sci. 2019;20(3207).
Orlandi C, Watkins LR. Orphan g protein coupled receptors in affective disorders. Genes (Basel).
2020;11(6):1–32.
Pingyuan Wang, Daniel E. Felsing, Haiying Chen, Sonja J. Stutz, Ryan E. Murphy, Kathryn A.
Cunningham JAA and J. Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses
Psychostimulant Behavior. J Med Chem. 2020;22:13951–13972.
Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, et al. FTBMT, a novel and
selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents,
revealing a potential therapeutic agent for schizophrenia. J Pharmacol Exp Ther. 2017;363(2):253–
64.
Roy SK, Shrivastava A, Srivastav S, Shankar S, Srivastava RK. SATB2 is a novel biomarker and
therapeutic target for cancer. J Cell Mol Med. 2020;24(19):11064–9.
Gary Donohoe DWMICLW, Georg Dechant GA. Genes encoding SATB2-interacting proteins in
adult cerebral cortex contribute to human cognitive ability. PLoS Genet. 2019;15(2).
Lu X, Chen X, Huang L, Zhu C, Gu Y, Ye S. Anti- a -Internexin Autoantibody from
Neuropsychiatric Lupus Induce Cognitive Damage via Inhibiting Axonal Elongation and Promote
Neuron Apoptosis. PLoS One. 2010;5(6).
Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front
Neurosci. 2015;9(372).
Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, et al. Neuroinflammation in
schizophrenia especially focused on the role of microglia. Prog Neuro-Psychopharmacology Biol
Psychiatry [Internet]. 2013;42:115–21. Available from:
http://dx.doi.org/10.1016/j.pnpbp.2011.12.002
120

201. Pepe G, De Maglie M, Minoli L, Villa A, Maggi A, Vegeto E. Selective proliferative response of
microglia to alternative polarization signals. J Neuroinflammation. 2017;14(236).
202. Bachiller S, Jiménez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, et al. Microglia in
neurological diseases: A road map to brain-disease dependent-inflammatory response. Front Cell
Neurosci. 2018;12(488).
203. Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse
elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci
[Internet]. 2019;22(3):374–85. Available from: http://dx.doi.org/10.1038/s41593-018-0334-7
204. Miller BJ, Goldsmith DR. Towards an Immunophenotype of Schizophrenia: Progress, Potential
Mechanisms, and Future Directions. Neuropsychopharmacology. 2017;42:299–317.
205. Nagatsu T. The catecholamine system in health and disease - Relation to tyrosine 3-monooxygenase
and other catecholamine-synthesizing enzymes. Proc Japan Acad Ser B Phys Biol Sci. 2006;82:388–
415.
206. Fujita H, Carlson ES. Catecholamine signaling that modulates cerebellar operations in cognition.
Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology. 2021.
207. Vidal PM, Pacheco R. The Cross-Talk Between the Dopaminergic and the Immune System Involved
in Schizophrenia. Front Pharmacol. 2020;11(394).
208. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine:
An update. Brain Behav Immun [Internet]. 2010;24(4):525–8. Available from:
http://dx.doi.org/10.1016/j.bbi.2009.10.015
209. Catak Z, Kocdemir E, Ugur K, Yardim M, Sahin I, Kaya H, et al. A novel biomarker renalase and its
relationship with its substrates in schizophrenia. J Med Biochem. 2019;38(3):299–305.
210. Crider A, Pillai A. Estrogen signaling as a therapeutic target in neurodevelopmental disorders. J
Pharmacol Exp Ther. 2017;360(1):48–58.
211. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. A Role for Estrogen in Schizophrenia:
Clinical and Preclinical Findings. Int J Endocrinol. 2015;2015(615356).
212. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression
(GTEx) project. Nat Genet. 2013;45(6):580–5.
213. Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP, et al. Comprehensive functional genomic
resource and integrative model for the human brain. Science (80- ). 2018;362(6420).
214. Chen G, Ning B, Shi T. Single-cell RNA-seq technologies and related computational data analysis.
Front Genet. 2019;10(317).
215. Hedlund E, Deng Q. Single-cell RNA sequencing : Technical advancements and biological
applications. Mol Aspects Med [Internet]. 2018;59:36–46. Available from:
https://doi.org/10.1016/j.mam.2017.07.003
216. Botía JA, Vandrovcova J, Forabosco P, Guelfi S, D’Sa K, Hardy J, et al. An additional k-means
clustering step improves the biological features of WGCNA gene co-expression networks. BMC Syst
Biol. 2017;
217. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat
Biotechnol. 2016;34(9):933–41.
218. Chen CH, Xiao T, Xu H, Jiang P, Meyer CA, Li W, et al. Improved design and analysis of CRISPR
knockout screens. Bioinformatics. 2018;34(23):4095–101.

121

6.0 Appendix

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Table 6.1: Schizophrenia-associated gene set from the 145 loci identified by Pardiñas et al. which are available in ABA’s BrainSpan resource.

ABCB9
ACD
ACTR5
ADAMTSL3
AIG1
AKAP6
AKT3
ALDOA
ALMS1
ALPK3
AMBRA1
ANKRD44
ANKRD63
ANP32E
AP3B2
ARHGAP1
ARL6IP4
AS3MT
ASH2L
ASPG
ASPHD1
ATG13
ATP2A2
ATPAF2
ATXN7
B3GAT1
BAG4

BTBD18
BTG1
C10orf32
C11orf31
C12orf65
C14orf2
C16orf86
C16orf92
C2orf47
C2orf82
C3orf49
C4orf27
CA14
CA8
CACNA1C
CACNA1D
CACNA1I
CACNB2
CALB2
CDK2AP1
CENPM
CENPT
CHRM3
CHRNA2
CHRNA3
CHRNA5
CHRNB4

CNOT1
CNTN4
COQ10B
CPEB1
CPNE8
CREB3L1
CSMD1
CTNND1
CTRL
CUL3
CYP17A1
DDHD2
DDX28
DFNA5
DGKI
DGKZ
DMTF1
DNAJC19
DOC2A
DOPEY1
DPEP2
DPEP3
DPYD
DRD2
EDC4
EFHD1
EHBP1L1

ERCC4
ESAM
ESRP2
ETF1
F2
FAM109B
FAM57B
FANCL
FGFR1
FHIT
FOXP1
FSHB
FXR1
GABBR2
GATAD2A
GDPD3
GFOD2
GIGYF2
GPM6A
GPR135
GPR52
GRIN2A
GRM3
HAPLN4
HARBI1
HCN1
HIRIP3

IGSF9B
IMMP2L
INA
INO80E
INPP4B
IREB2
JKAMP
KAT5
KCNJ13
KCNK7
KCNV1
KCTD13
KDM4A
KIAA1324L
L3MBTL2
LCAT
LETM2
LRP1
LRRC48
LSM1
MAD1L1
MAP3K11
MAPK3
MARS2
MAU2
MED19
MEF2C

MPPED2
MSL2
MSRA
NAB2
NAGA
NCAN
NCK1
NDFIP2
NDRG4
NDUFA4L2
NDUFA6
NEK1
NFATC3
NGEF
NLGN4X
NMB
NRGN
NRN1L
NT5C2
NUTF2
NXPH4
OGFOD2
OPCML
OTOL1
OTUD7B
PAK6
PARD6A

PITPNM2
PLA2G15
PLCB2
PLCH2
PLCL1
PLCL2
PLEKHO1
PPAPDC1B
PPP1R13B
PPP2R2A
PPP2R3A
PPP4C
PRKCB
PRKD1
PRMT1
PSD3
PSMA4
PSMB10
PSMD6
PTK2B
PTN
PTPRF
PTPRK
R3HDM2
RABGAP1L
RAI1
RALGAPA2

RELA
RERE
RFT1
RFTN2
RGS6
RILPL2
RIMS1
RLTPR
RPS19BP1
RPTOR
RRAS
RWDD2A
SATB2
SBNO1
SCAF1
SDCCAG8
SEC11A
SEMA6D
Sep-03
SERPINC1
SERPING1
SETD6
SETD8
SEZ6L2
SF3B1
SFMBT1
SFXN5

SLC39A8
SLC45A1
SLC7A6
SMG6
SNAP91
SNX19
SOX5
SPATS2L
SREBF1
SREBF2
SRPK2
SRR
STAC3
STAG1
STAR
STAT6
SUGP1
TAB1
TAOK2
TBC1D5
TBX6
TCF20
TCF4
TDRD9
THAP11
THOC7
TLE3

TNFRSF13C
TOM1L2
TRANK1
TSNARE1
TSNAXIP1
TSR1
TYW5
VPS13C
VPS45
VRK2
VSIG2
WBP2NL
WDR73
WHSC1L1
XRCC3
YPEL3
YPEL4
ZBTB37
ZC3H7B
ZDHHC5
ZEB2
ZFYVE21
ZNF408
ZNF536
ZNF592
ZNF804A
ZNF823
148

BANK1
BCL11B
BCL2L12
BNIP3L

CKAP5
CLCN3
CLP1
CLU

EMB
EMX1
EP300
EPHX2

HS3ST5
HSPA9
HSPD1
HSPE1

MGAT3
MMP16
MOB4
MPHOSPH9

PCCB
PCGF6
PCNXL3
PDE4B

RANBP10
RANGAP1
RBFOX1
RBM26

SHMT2
SIPA1
SLC12A4
SLC32A1

BOLL

CNNM2

EPN2

HYDIN

MPP6

PGM3

RC3H1

SLC38A7

TM6SF2
TMEM194A
TMEM219
TMX2
TMX2CTNND1

ZSCAN2

149

Table 6.2: Cluster assignments for each schizophrenia-associated gene over the five stages using the kmeans function available in R.
Gene Name

ABCB1
ABCB9
ABCD2
ACO2
ACP2
ACTR1A
ACTR5
ADAMTSL3
ADAMTSL4
AIG1
AKAP6
AKT3
ALAS1
ALDOA
ALMS1
ANAPC7
ANKRD44
ANKRD45
ANKRD63
APOPT1
ARL5B
ARTN
AS3MT
ATF4
ATP13A1
ATPAF2
ATXN7

Developmental Stage One

Developmental Stage Two

3
1
2
3
3
2
3
2
3
3
3
2
2
3
3
3
2
2
3
3
2
3
3
1
1
3
2

2
2
1
2
2
1
2
2
2
2
1
1
1
1
2
2
2
1
2
1
1
2
2
1
2
2
2

Developmental Stage
Three

2
1
2
2
1
1
1
2
1
1
2
2
1
2
1
1
1
1
1
2
2
1
1
1
1
1
1

Developmental Stage
Four

2
2
2
2
2
2
2
2
2
2
1
1
2
2
2
2
2
2
2
1
1
2
2
1
2
2
2

Developmental Stage Five

2
1
2
2
1
1
2
2
2
2
1
1
2
1
2
2
2
2
2
2
1
2
2
2
1
2
1
150

B9D1
BAG4
BANK1
BCL11B
BCL2L12
BNIP3L
BRD8
BTBD18
C2orf47
C2orf82
CA8
CACNA1C
CACNA1D
CACNA1I
CACNB2
CALB2
CENPM
CENPT
CEP170
CHRNA2
CHRNA3
CLCN3
CLDN23
CNOT1
CNTN4
CSMD1
CUL3
DFNA5
DGKI
DNAJC19
DOPEY1

3
2
3
2
3
2
3
1
3
1
3
1
2
1
1
3
3
1
2
3
3
3
2
3
3
2
2
2
1
3
2

1
1
2
2
2
1
2
2
1
1
2
2
2
1
1
2
2
2
1
2
2
2
2
2
2
1
1
2
2
1
2

2
2
1
1
1
2
1
1
2
2
1
1
1
2
2
1
1
1
1
1
1
2
2
1
1
2
2
2
1
2
1

2
1
2
2
2
1
2
2
1
1
2
2
1
1
1
2
2
2
2
2
2
2
2
2
2
1
1
1
2
1
2

2
1
2
2
2
1
1
1
2
2
2
1
1
1
1
2
2
2
1
2
2
1
2
1
2
1
1
1
1
2
1
151

DPYD
DRD2
EMB
EMX1
ESAM
FANCL
FHIT
FOXP1
FTSJ2
GABBR2
GPM6A
GRIA1
GRIN2A
GRM3
HCN1
IGSF9B
IL20RB
IMMP2L
INHBC
INPP4B
ME1
MGAT3
MMP16
NDFIP2
NLGN4X
OPCML
PDE4B
PSD3
PTPRK
RBFOX1
RERE

1
3
3
1
3
1
3
3
3
1
2
1
1
1
1
3
3
3
3
3
3
1
2
2
3
2
3
1
1
2
2

1
2
2
1
2
1
2
1
1
1
1
2
1
2
1
2
2
1
2
2
2
2
2
1
2
1
2
1
1
1
2

2
1
1
2
2
1
1
2
2
1
2
1
2
2
2
1
1
2
1
1
2
1
2
2
1
1
2
1
2
2
1

2
2
2
1
2
2
2
1
1
1
1
2
1
2
1
2
2
2
2
2
1
2
1
1
2
1
2
2
1
1
2

2
2
1
1
2
2
2
1
1
1
2
2
1
2
1
1
2
2
2
2
2
1
1
1
2
1
2
1
1
1
1
152

RGS6
RIMS1
RPTOR
SATB2
SEMA6D
SNX19
SPATS2L
TBC1D5
TCF4
TRANK1
TSNARE1
ZEB2
ZNF440
ZNF536
ZNF804A

1
3
1
2
3
2
3
3
1
3
1
2
2
3
3

1
2
2
1
2
2
1
2
2
2
2
2
2
2
2

2
1
2
2
2
2
2
2
2
1
2
1
1
1
1

1
2
1
1
2
2
1
2
2
2
1
2
2
2
2

1
2
1
1
1
2
1
1
1
1
1
2
2
2
1

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Table 6.3: Gene Ontologies identified for the Black module in developmental stage One using the anRichment function as part of WGCNA in R using the default
settings.

GOID

DEFINITION

GO:012
0041

Any process that activates or
increases the frequency, rate or
extent of macrophage
proliferation.

GO:004
3231

The selective, non-covalent,
often stoichiometric, interaction
of a molecule with one or more
specific sites on another
molecule.
Organised structure of
distinctive morphology and
function, bounded by a single or
double lipid bilayer membrane
and occurring within the cell.
Includes the nucleus,
mitochondria, plastids,
vacuoles, and vesicles. Excludes
the plasma membrane.

GO:000
5488

ONTOL
OGY

Module

GO Process

FDR

BP

Black

positive
regulation of
macrophage
proliferation

2.92E
-15

MF

Black

binding

1.88E
-10

CC

Black

intracellular
membranebounded organelle

GO:000
5737

All of the contents of a cell
excluding the plasma membrane
and nucleus but including other
subcellular structures.

CC

Black

cytoplasm

5.00E
-09

GO:001
6020

A lipid bilayer along with all the
proteins and protein complexes
embedded in it an attached to it.

CC

Black

membrane

2.01E
-08

6.74E
-10

Genes
ARHGAP1, CYP17A1, FSHB, GRM3, HSPE1, KCNJ13, MMP16,
NRGN, STAT6, FXR1, AP3B2, CUL3, INPP4B, DGKI, GPR52,
KDM4A, PSMD6, RABGAP1L, MPHOSPH9, TAB1, SDCCAG8,
SMG6, SATB2, PSD3, ABCB9, KCNV1, FOXP1, B3GAT1,
TMX2, MSL2, NDUFA4L2, AS3MT, SUGP1, DPEP2, CPEB1,
MAIP1, EFHD1, YPEL3, IMMP2L, C12orf65, OTOL1, LETM2,
PHETA2, YPEL4, STAC3
ARHGAP1, MPPED2, CYP17A1, FSHB, HSPE1, MMP16,
NRGN, STAT6, FXR1, CUL3, INPP4B, DGKI, KDM4A, PSMD6,
RABGAP1L, TAB1, SDCCAG8, SMG6, SATB2, PSD3, ABCB9,
FOXP1, B3GAT1, BANK1, MSL2, SUGP1, DPEP2, CPEB1,
MAIP1, EFHD1, YPEL3, C12orf65, OTOL1, LETM2, PHETA2,
YPEL4, STAC3

CYP17A1, HSPE1, MMP16, NRGN, STAT6, FXR1, AP3B2,
CUL3, DGKI, KDM4A, PSMD6, RABGAP1L, MPHOSPH9,
TAB1, SMG6, SATB2, ABCB9, FOXP1, B3GAT1, MSL2,
NDUFA4L2, SUGP1, CPEB1, MAIP1, EFHD1, YPEL3, IMMP2L,
C12orf65, LETM2, PHETA2, YPEL4, STAC3
ARHGAP1, CYP17A1, FSHB, HSPE1, MMP16, NRGN, STAT6,
FXR1, AP3B2, CUL3, INPP4B, DGKI, KDM4A, PSMD6,
RABGAP1L, MPHOSPH9, TAB1, SDCCAG8, SMG6, ABCB9,
B3GAT1, NDUFA4L2, AS3MT, CPEB1, MAIP1, EFHD1,
IMMP2L, C12orf65, LETM2, PHETA2, STAC3
ARHGAP1, CYP17A1, GRM3, HSPE1, KCNJ13, MMP16,
NRGN, STAT6, FXR1, AP3B2, CUL3, DGKI, GPR52,
MPHOSPH9, TAB1, PSD3, ABCB9, KCNV1, B3GAT1, TMX2,
NDUFA4L2, DPEP2, CPEB1, MAIP1, EFHD1, IMMP2L,
180

GO:007
0013

An organelle lumen that is part
of an intracellular organelle.

CC

Black

intracellular
organelle lumen

9.92E
-08

LETM2, STAC3
ARHGAP1, CYP17A1, FSHB, GRM3, HSPE1, KCNJ13, MMP16,
NRGN, STAT6, FXR1, CUL3, INPP4B, DGKI, GPR52, KDM4A,
PSMD6, RABGAP1L, TAB1, SDCCAG8, SMG6, SATB2, PSD3,
KCNV1, FOXP1, TMX2, BANK1, CPEB1, MAIP1, EFHD1,
YPEL3, STAC3

181

Table 6.4: Gene Ontologies for the Blue module in developmental stage One using the anRichment function of WGCNA on the schizophrenia-associated genes.
GOID

GO:0071870

DEFINITION
Any process that activates or
increases the frequency, rate or extent
of macrophage proliferation.
An organelle lumen that is part of an
intracellular organelle.
Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a catecholamine stimulus.
A catecholamine is any of a group of
biogenic amines that includes 4-(2aminoethyl) pyrocatechol [4-(2aminoethyl) benzene-1,2-diol] and
derivatives formed by substitution.

GO:0005737

All the contents of a cell excluding
the plasma membrane and nucleus
but including other subcellular
structures.

GO:0120041
GO:0070013

GO:0071726

GO:0016020

Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.)
because of a diacylated bacterial
lipopeptide stimulus.
A lipid bilayer along with all the
proteins and protein complexes
embedded in it an attached to it.

ONTOLOGY

Module

BP

Blue

CC

Blue

GO Process
positive regulation
of macrophage
proliferation
intracellular
organelle lumen

FDR

Genes

1.75E-29

More than 50 overlapping genes

2.74E-14

More than 50 overlapping genes

BP

Blue

cellular response to
catecholamine
stimulus

CC

Blue

cytoplasm

1.15E-11

BP

Blue

cellular response to
diacyl bacterial
lipopeptide

1.70E-11

CC

Blue

membrane

2.79E-11

4.03E-13

CLCN3, DRD2, EP300, EPHX2, ETF1, PTK2B,
GPM6A, LRP1, NEK1, PPP2R2A, PRKCB, RELA,
SIPA1, TCF4, HIRIP3, ASH2L, INA, AKAP6,
BAG4, SNAP91, AKT3, CLP1, SF3B1, VPS13C,
SRR, BCL11B, ACD, SETD6, PCGF6, WDR73,
ATPAF2, DNAJC19, RILPL2, KCTD13, INO80E,
HCN1, BTBD18
SERPING1, CALB2, CLCN3, DRD2, EP300,
EPHX2, ETF1, PTK2B, LRP1, MAP3K11, NEK1,
PCCB, PGM3, PLCL1, PPP2R2A, PRKCB,
PSMB10, RANGAP1, RELA, SIPA1, STAR, VRK2,
DGKZ, INA, AKAP6, BAG4, ATP5MPL, SNAP91,
AKT3, RAI1, CLP1, DOP1A, VPS13C, SRR, BOLL,
SETD6, DRC3, TLCD3B, WDR73, ATPAF2,
SFXN5, BORCS7, DNAJC19, RILPL2, HS3ST5
SERPING1, DRD2, EP300, EPHX2, ETF1, PTK2B,
LRP1, MAP3K11, NEK1, PCCB, PGM3, PLCL1,
PPP2R2A, PRKCB, PSMB10, RANGAP1, RELA,
RRAS, STAR, TCF4, VRK2, DGKZ, ASH2L,
BAG4, AKT3, RAI1, CLP1, ZC3H7B, SF3B1, AIG1,
ADAMTSL3, ALPK3, SCAF1, SRR, BCL11B,
ACD, BOLL, ZNF408, SETD6, TLCD3B, PCGF6,
MED19, HS3ST5, KCTD13, INO80E, BTBD18
CALB2, CLCN3, DRD2, PTK2B, GPM6A, LRP1,
MAP3K11, PLCL1, PRKCB, RANGAP1, RRAS,
SIPA1, STAR, VRK2, DGKZ, INA, AKAP6, BAG4,
182

ATP5MPL, SNAP91, AKT3, DOP1A, SEZ6L2,
SLC45A1, AIG1, CNNM2, VPS13C, SLC38A7,
SRR, TLCD3B, WDR73, SFXN5, BORCS7,
TMEM219, RFTN2, DNAJC19, CPNE8, C16orf92,
RILPL2, HS3ST5, HCN1

GO:0097178

GO:0048519

GO:0005634
GO:0006996

The aggregation, arrangement and
bonding together of a set of
components to form a ruffle, a
projection at the leading edge of a
crawling cell; the protrusions are
supported by a microfilament
meshwork. The formation of ruffles
(also called membrane ruffling) is
thought to be controlled by a group
of enzymes known as Rho GTPases,
specifically RhoA, Rac1 and cdc42.
Any process that stops, prevents, or
reduces the frequency, rate or extent
of a biological process. Biological
processes are regulated by many
means; examples include the control
of gene expression, protein
modification or interaction with a
protein or substrate molecule.
A membrane-bounded organelle of
eukaryotic cells in which
chromosomes are housed and
replicated. In most cells, the nucleus
contains all of the cell's
chromosomes except the organellar
chromosomes and is the site of RNA
synthesis and processing. In some
species, or in specialized cell types,
RNA metabolism or DNA replication
may be absent.
A process that is carried out at the
cellular level which results in the

BP

BP

Blue

Blue

CC

Blue

BP

Blue

ruffle assembly

negative regulation
of biological
process

nucleus
organelle
organization

1.53E-10

CLCN3, DRD2, EP300, ETF1, PTK2B, LRP1,
MAP3K11, NEK1, PCCB, PRKCB, RANGAP1,
RELA, RRAS, STAR, TCF4, VRK2, DGKZ, BAG4,
AKT3, CLP1, ZC3H7B, SF3B1, CNNM2, ALPK3,
SCAF1, SRR, BCL11B, ACD, BOLL, ZNF408,
PCGF6, HS3ST5, HCN1

1.73E-10

SERPING1, DRD2, EP300, ETF1, PTK2B, LRP1,
PLCL1, PPP2R2A, PRKCB, PSMB10, RANGAP1,
RELA, RRAS, SIPA1, STAR, AKAP6, BAG4,
AKT3, RAI1, CLP1, ZC3H7B, VPS13C, BCL11B,
ACD, BOLL, SETD6, TLCD3B, PCGF6, WDR73,
HS3ST5, KCTD13, BTBD18

5.27E-10
6.74E-10

CALB2, EP300, PTK2B, LRP1, NEK1, PPP2R2A,
PRKCB, PSMB10, RANGAP1, RELA, SIPA1,
TCF4, VRK2, HIRIP3, DGKZ, ASH2L, INA,
AKAP6, BAG4, AKT3, RAI1, CLP1, ZC3H7B,
SF3B1, ALPK3, SCAF1, BCL11B, ACD, ZNF408,
SETD6, PCGF6, ATPAF2, MED19, KCTD13,
INO80E, BTBD18
CLCN3, EP300, EPHX2, PTK2B, LRP1, NEK1,
PPP2R2A, PRKCB, RELA, SIPA1, HIRIP3, ASH2L,
183

GO:0060255

GO:1901561

GO:0080154

GO:0043168

assembly, arrangement of constituent
parts, or disassembly of an organelle
within a cell. An organelle is an
organized structure of distinctive
morphology and function. Includes
the nucleus, mitochondria, plastids,
vacuoles, vesicles, ribosomes and the
cytoskeleton. Excludes the plasma
membrane.
Any process that modulates the
frequency, rate or extent of the
chemical reactions and pathways
involving macromolecules, any
molecule of high relative molecular
mass, the structure of which
essentially comprises the multiple
repetition of units derived, actually or
conceptually, from molecules of low
relative molecular mass.
Any process that results in a change
in state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
benomyl stimulus.
Any process that modulates the rate,
frequency or extent of fertilization.
Fertilization is the union of gametes
of opposite sexes during the process
of sexual reproduction to form a
zygote. It involves the fusion of the
gametic nuclei (karyogamy) and
cytoplasm (plasmogamy).
Interacting selectively and noncovalently with anions, charged
atoms or groups of atoms with a net
negative charge.

INA, BAG4, SNAP91, AKT3, VPS13C, ACD,
SETD6, PCGF6, WDR73, DNAJC19, RILPL2,
KCTD13, INO80E, BTBD18

BP

Blue

regulation of
macromolecule
metabolic process

BP

Blue

response to
benomyl

1.47E-09

3.08E-09

BP

Blue

regulation of
fertilization

1.07E-08

MF

Blue

anion binding

1.45E-08

SERPING1, DRD2, EP300, EPHX2, ETF1, PTK2B,
LRP1, MAP3K11, NEK1, PLCL1, PPP2R2A,
PRKCB, PSMB10, RELA, RRAS, STAR, TCF4,
VRK2, ASH2L, BAG4, RAI1, CLP1, ZC3H7B,
SF3B1, BCL11B, ACD, BOLL, ZNF408, SETD6,
PCGF6, MED19, KCTD13, BTBD18
CLCN3, EP300, ETF1, PTK2B, LRP1, MAP3K11,
NEK1, PCCB, PRKCB, RANGAP1, RELA, RRAS,
TCF4, VRK2, DGKZ, BAG4, AKT3, CLP1,
ZC3H7B, SF3B1, CNNM2, ALPK3, SCAF1, SRR,
BCL11B, ACD, BOLL, ZNF408, PCGF6, HS3ST5,
HCN1

SERPING1, DRD2, EP300, EPHX2, ETF1, PTK2B,
LRP1, MAP3K11, NEK1, PLCL1, PPP2R2A,
PRKCB, PSMB10, RELA, RRAS, STAR, TCF4,
VRK2, DGKZ, ASH2L, BAG4, RAI1, BCL11B,
ACD, BOLL, ZNF408, SETD6, PCGF6, MED19,
BTBD18
CLCN3, PTK2B, LRP1, MAP3K11, NEK1, PCCB,
PLCL1, PRKCB, RELA, RRAS, VRK2, DGKZ,
SNAP91, AKT3, CLP1, CNNM2, ALPK3, SRR,
CPNE8, HS3ST5, HCN1
184

GO:0006464

The covalent alteration of one or
more amino acids occurring in
proteins, peptides and nascent
polypeptides (co-translational, posttranslational modifications) occurring
at the level of an individual cell.
Includes the modification of charged
tRNAs that are destined to occur in a
protein (pre-translation
modification).

GO:0032502

Any process that activates or
increases the frequency, rate or extent
of NAD+ ADP-ribosyltransferase
activity.
A biological process whose specific
outcome is the progression of an
integrated living unit: an anatomical
structure (which may be a subcellular
structure, cell, tissue, or organ), or
organism over time from an initial
condition to a later condition.

GO:1901679

The directed movement of nucleotide
across a membrane.

GO:1901666

GO:0044249

GO:0006950

The chemical reactions and pathways
resulting in the formation of
substances, carried out by individual
cells.
Any process that results in a change
in state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene

BP

BP

Blue

cellular protein
modification
process

1.59E-08

Blue

positive regulation
of NAD+ ADPribosyltransferase
activity

2.84E-08

Blue

developmental
process

5.31E-08

Blue

nucleotide
transmembrane
transport

6.96E-08

BP

Blue

cellular
biosynthetic
process

2.45E-07

BP

Blue

response to stress

2.85E-07

BP

BP

DRD2, EP300, ETF1, PTK2B, LRP1, MAP3K11,
NEK1, PGM3, PLCL1, PPP2R2A, PRKCB,
PSMB10, RANGAP1, RELA, RRAS, VRK2,
ASH2L, BAG4, AKT3, ALPK3, SETD6, PCGF6,
HS3ST5, KCTD13, INO80E
SERPING1, DRD2, EP300, ETF1, PTK2B, LRP1,
MAP3K11, NEK1, PCCB, PGM3, PLCL1,
PPP2R2A, PRKCB, PSMB10, RANGAP1, RELA,
RRAS, VRK2, ASH2L, BAG4, AKT3, ADAMTSL3,
ALPK3, SRR, BOLL, SETD6, TLCD3B, PCGF6,
HS3ST5, KCTD13, INO80E
SERPING1, CLCN3, DRD2, EP300, PTK2B,
GPM6A, LRP1, PGM3, PRKCB, PSMB10, RELA,
RRAS, STAR, TCF4, ASH2L, INA, AKAP6, AKT3,
RAI1, CLP1, ALPK3, SRR, BCL11B, BOLL,
SETD6, TLCD3B, DNAJC19, RILPL2, HCN1,
BTBD18
DRD2, EP300, EPHX2, ETF1, PTK2B, PGM3,
PLCL1, PRKCB, PSMB10, RELA, STAR, TCF4,
DGKZ, ASH2L, RAI1, CLP1, SCAF1, SRR,
BCL11B, ACD, BOLL, ZNF408, SETD6, TLCD3B,
PCGF6, MED19, HS3ST5, KCTD13, BTBD18
DRD2, EP300, EPHX2, ETF1, PTK2B, PGM3,
PRKCB, PSMB10, RELA, STAR, TCF4, DGKZ,
ASH2L, RAI1, CLP1, SCAF1, SRR, BCL11B, ACD,
BOLL, ZNF408, SETD6, TLCD3B, PCGF6, MED19,
HS3ST5, KCTD13, BTBD18
SERPING1, DRD2, EP300, EPHX2, PTK2B, LRP1,
MAP3K11, NEK1, PRKCB, PSMB10, RANGAP1,
RELA, SIPA1, STAR, VRK2, DGKZ, ASH2L,
BAG4, AKT3, VPS13C, ACD, SETD6, INO80E
185

GO:0031325

GO:0070016

GO:0032559

expression, etc.) as a result of a
disturbance in organismal or cellular
homeostasis, usually, but not
necessarily, exogenous (e.g.,
temperature, humidity, ionizing
radiation).
Any process that activates or
increases the frequency, rate or extent
of the chemical reactions and
pathways by which individual cells
transform chemical substances.
Interacting selectively and noncovalently with the armadillo repeat
domain of a protein, an
approximately 40 amino acid long
tandemly repeated sequence motif
first identified in the Drosophila
segment polarity protein armadillo.
Arm-repeat proteins are involved in
various processes, including
intracellular signalling and
cytoskeletal regulation.
Interacting selectively and noncovalently with an adenyl
ribonucleotide, any compound
consisting of adenosine esterified
with (ortho)phosphate or an
oligophosphate at any hydroxyl
group on the ribose moiety.

BP

MF

MF

Blue

positive regulation
of cellular
metabolic process

Blue

armadillo repeat
domain binding

Blue

adenyl
ribonucleotide
binding

2.96E-07

DRD2, EP300, PTK2B, LRP1, MAP3K11, NEK1,
PRKCB, RELA, STAR, TCF4, DGKZ, ASH2L,
BAG4, RAI1, VPS13C, BCL11B, ACD, BOLL,
MED19, KCTD13, BTBD18

2.96E-07

SERPING1, CALB2, CLCN3, DRD2, EP300,
EPHX2, PTK2B, GPM6A, LRP1, PLCL1, PRKCB,
PSMB10, RANGAP1, STAR, DGKZ, AKAP6,
BAG4, AKT3, CNNM2, VPS13C, ACD, BOLL,
HCN1

3.98E-07

CLCN3, PTK2B, MAP3K11, NEK1, PCCB, PRKCB,
VRK2, DGKZ, AKT3, CLP1, CNNM2, ALPK3,
SRR, HS3ST5, HCN1
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Table 6.5: Gene Ontology Brown Module for developmental stage One using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0005488

GO:0070013

GO:0043231

DEFINITION

Any process that
activates or increases
the frequency, rate or
extent of macrophage
proliferation.
The selective, noncovalent, often
stoichiometric,
interaction of a
molecule with one or
more specific sites on
another molecule.

An organelle lumen
that is part of an
intracellular organelle.
Organised structure of
distinctive
morphology and
function, bounded by
a single or double
lipid bilayer
membrane and
occurring within the
cell. Includes the
nucleus,
mitochondria,
plastids, vacuoles, and
vesicles. Excludes the
plasma membrane.

ONTOLOGY

BP

Module

GO Process

FDR

Brown

positive regulation
of macrophage
proliferation

2.10E-15

Genes
SERPINC1, ATP2A2, CACNB2, CHRM3, CHRNA2,
CTRL, IREB2, NAB2, NAGA, NDUFA6, SREBF2,
SRPK2, DOC2A, CACNA1I, GABBR2, ZNF536,
R3HDM2, IGSF9B, DDHD2, MOB4, PARD6A,
SFMBT1, ZSCAN2, SBNO1, ZNF823, RPTOR, RBM26,
COQ10B, GFOD2, L3MBTL2, CREB3L1, WBP2NL,
KIAA1324L, EHBP1L1, KMT5A, SNX19

MF

Brown

binding

3.36E-10

CC

Brown

intracellular
organelle lumen

4.32E-09

SERPINC1, ATP2A2, CACNB2, CHRM3, CHRNA2,
IREB2, NAB2, NAGA, SREBF2, SRPK2, DOC2A,
CACNA1I, GABBR2, ZNF536, R3HDM2, IGSF9B,
DDHD2, MOB4, PARD6A, SFMBT1, ZSCAN2,
ZNF823, RPTOR, RBM26, COQ10B, L3MBTL2,
CREB3L1, WBP2NL, KMT5A, SNX19
SERPINC1, ATP2A2, CACNB2, CHRM3, CHRNA2,
IREB2, NAB2, SREBF2, SRPK2, DOC2A, CACNA1I,
GABBR2, ZNF536, IGSF9B, DDHD2, PARD6A,
SFMBT1, ZSCAN2, SBNO1, ZNF823, RPTOR, RBM26,
L3MBTL2, CREB3L1, WBP2NL, KMT5A, SNX19

2.02E-08

SERPINC1, ATP2A2, IREB2, NAB2, NAGA, NDUFA6,
SREBF2, SRPK2, DOC2A, ZNF536, R3HDM2, DDHD2,
MOB4, PARD6A, SFMBT1, ZSCAN2, SBNO1, ZNF823,
RPTOR, RBM26, COQ10B, L3MBTL2, CREB3L1,
WBP2NL, KMT5A

CC

Brown

intracellular
membrane-bounded
organelle
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Table 6.6: Gene Ontology for Pink Module in Developmental Stage One using the anRichment function as part of WGCNA in R using the default settings

GOID

DEFINITION

ONTO
LOGY

Module

GO:0005515

Interacting selectively and non-covalently
with any protein or protein complex (a
complex of two or more proteins that may
include other nonprotein molecules).

MF

Pink

GO:0008152

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
The chemical reactions and pathways,
including anabolism and catabolism, by
which living organisms transform
chemical substances. Metabolic processes
typically transform small molecules, but
also include macromolecular processes
such as DNA repair and replication, and
protein synthesis and degradation.

GO:0070013

An organelle lumen that is part of an
intracellular organelle.

GO:0120041

BP

BP

CC

Pink

GO
Process

protein
binding
positive
regulation
of
macrophag
e
proliferatio
n

FDR

1.61E-08

Genes
ERCC4, HSPA9, PPP2R3A, PPP4C,
SHMT2, XRCC3, TBC1D5, NUTF2,
STAG1, KAT5, LSM1, HPF1, PAK6,
OTUD7B, SEMA6D, THOC7, TYW5,
TOM1L2, TSNARE1

2.30E-07

ERCC4, HSPA9, PPP4C, SHMT2,
XRCC3, PLCH2, TBC1D5, NUTF2,
STAG1, KAT5, LSM1, HPF1, TSR1,
PAK6, OTUD7B, SEMA6D, THOC7,
RFT1, TYW5, TOM1L2, TSNARE1

Pink

metabolic
process

6.41E-07

Pink

intracellula
r organelle
lumen

8.50E-07

ERCC4, HSPA9, PPP2R3A, PPP4C,
SHMT2, XRCC3, PLCH2, TBC1D5,
NUTF2, STAG1, KAT5, LSM1, HPF1,
TSR1, PAK6, OTUD7B, THOC7, TYW5
ERCC4, HSPA9, PPP2R3A, PPP4C,
SHMT2, XRCC3, PLCH2, TBC1D5,
NUTF2, STAG1, KAT5, LSM1, HPF1,
PAK6, OTUD7B, SEMA6D, RFT1,
TOM1L2
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Table 6.7: Gene Ontologies for Turquoise Module in Developmental Stage One using the anRichment function as part of WGCNA in R using the default settings

GOID

Ontolo
gy

Module

BP

GO:0070016

Definition
Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme production,
gene expression, etc.) as a result of a
diacylated bacterial lipopeptide stimulus.
Interacting selectively and non-covalently
with the armadillo repeat domain of a
protein, an approximately 40 amino acid
long tandemly repeated sequence motif
first identified in the Drosophila segment
polarity protein armadillo. Arm-repeat
proteins are involved in various processes,
including intracellular signalling and
cytoskeletal regulation.

GO:0071870

Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme production,
gene expression, etc.) as a result of a
catecholamine stimulus. A catecholamine
is any of a group of biogenic amines that
includes 4-(2-aminoethyl) pyrocatechol [4(2-aminoethyl)benzene-1,2-diol] and
derivatives formed by substitution.

BP

Turquoise

cellular response to
catecholamine
stimulus

GO:0005829

The part of the cytoplasm that does not
contain organelles, but which does contain
other particulate matter, such as protein
complexes.

CC

Turquoise

cytosol

GO:0120041

GO:0071726

Turquoise

GO Process
positive regulation of
macrophage
proliferation

FDR

Genes

9.49E-49

More than 50 overlapping genes

BP

Turquoise

cellular response to
diacyl bacterial
lipopeptide

1.07E-17

MF

Turquoise

armadillo repeat
domain binding

4.10E-17

1.97E-14

8.03E-14

More than 50 overlapping genes
BNIP3L, CACNA1C, CACNA1D, CHRNA3,
CHRNA5, CHRNB4, CLU, CTNND1, DPYD,
EMX1, F2, FGFR1, GRIN2A, PRMT1,
MEF2C, NMB, PDE4B, PRKD1, PSMA4,
PTN, SLC12A4, SREBF1, TLE3, ALMS1,
TAOK2, KCNK7, VPS45, RIMS1, PLCL2,
PPP1R13B, NGEF, GIGYF2, PLEKHO1,
TM6SF2, NLGN4X, SLC39A8, CSMD1,
ZNF804A, TNFRSF13C, CARMIL2, CNTN4
RERE, BNIP3L, BTG1, CHRNA3, CHRNB4,
CLU, NCAN, CTNND1, EMX1, F2, FGFR1,
PRMT1, MEF2C, PRKD1, PTN, PTPRK,
ATXN7, SLC12A4, SREBF1, TLE3, ALMS1,
TAOK2, ATG13, CKAP5, ZEB2, EPN2,
RIMS1, CNOT1, PPP1R13B, MAU2, NGEF,
PLEKHO1, HYDIN, NSD3, AMBRA1,
NLGN4X, NDRG4, CENPM, ACTR5, CENPT,
ANP32E, ESAM, ZNF804A, TDRD9, EMB,
CARMIL2, CNTN4
BNIP3L, CLU, CTNND1, GSDME, DPYD,
FGFR1, FHIT, PRMT1, MSRA, NFATC3,
PDE4B, PRKD1, PSMA4, ATXN7, SREBF1,
ALMS1, TAOK2, RGS6, ATG13, CKAP5,
ZEB2, DMTF1, EPN2, NT5C2, RIMS1,
CNOT1, PPP1R13B, EDC4, NGEF, SPATS2L,
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GO:0048523

Any process that stops, prevents, or
reduces the frequency, rate or extent of a
cellular process, any of those that are
carried out at the cellular level, but are not
necessarily restricted to a single cell. For
example, cell communication occurs
among more than one cell, but occurs at
the cellular level.

BP

Turquoise

negative regulation of
cellular process

2.03E-13

GO:0080154

Any process that modulates the rate,
frequency or extent of fertilization.
Fertilization is the union of gametes of
opposite sexes during the process of
sexual reproduction to form a zygote. It
involves the fusion of the gametic nuclei
(karyogamy) and cytoplasm
(plasmogamy).

BP

Turquoise

regulation of
fertilization

8.45E-13

GO:0071986

A eukaryotically conserved protein
complex; in humans, it is comprised of
LAMTOR1, LAMTOR2, LAMTOR3,
LAMTOR4, and LAMTOR5. The
complex is anchored to lipid rafts in late
endosome membranes via LAMTOR1,
constitutes a guanine nucleotide exchange
factor (GEF) for the Rag GTPases.

CC

Turquoise

Ragulator complex

4.49E-12

Turquoise

positive regulation of
NAD+ ADPribosyltransferase
activity

7.48E-12

GO:1901666

NA

BP

GIGYF2, AMBRA1, RALGAPA2, PITPNM2,
RANBP10, NDRG4, CENPM, CENPT,
RPS19BP1, HARBI1, ASPG
RERE, BNIP3L, BTG1, CACNA1C, CLU,
CTNND1, GSDME, F2, FGFR1, FHIT,
PRMT1, MEF2C, MGAT3, NFATC3, NMB,
PRKD1, PSMA4, PTN, PTPRK, SOX5,
SREBF1, TLE3, TAOK2, RGS6, ZEB2, EPN2,
CNOT1, PLCL2, PPP1R13B, NGEF, GIGYF2,
GATAD2A, AMBRA1, THAP11, NLGN4X,
NDRG4, BCL2L12, TDRD9, CARMIL2,
CNTN4
RERE, BTG1, CHRNA3, CLU, GSDME,
EMX1, F2, FGFR1, FHIT, GRIN2A, PRMT1,
MEF2C, MGAT3, NFATC3, PRKD1, PSMA4,
PTN, PTPRK, SOX5, SREBF1, TLE3, TAOK2,
ZNF592, ATG13, ZEB2, DMTF1, CNOT1,
PLCL2, GIGYF2, TM6SF2, NDFIP2,
RBFOX1, GATAD2A, NSD3, AMBRA1,
THAP11, NDRG4, ACTR5, ESRP2, CENPT,
BCL2L12, ZBTB37, TNFRSF13C
CACNA1C, CACNA1D, CHRNA3, CHRNA5,
CHRNB4, CLU, CTNND1, GSDME, F2,
FGFR1, FHIT, GRIN2A, OPCML, PDE4B,
PRKD1, PTN, PTPRK, SLC12A4, RGS6,
CKAP5, KCNK7, RIMS1, PPP1R13B, VSIG2,
CA14, ZDHHC5, PLEKHO1, RALGAPA2,
NLGN4X, SLC39A8, GPR135, NDRG4,
PLPP5, ESAM, ZNF804A, TNFRSF13C, EMB,
CARMIL2, CNTN4, HARBI1, SNORC
BNIP3L, BTG1, CHRNA3, CLU, NCAN,
GSDME, DPYD, F2, FGFR1, FHIT, GRIN2A,
PRMT1, MEF2C, MGAT3, MSRA, PDE4B,
PRKD1, PSMA4, PTN, PTPRK, ATXN7,
SREBF1, TAOK2, ATG13, ZEB2, NT5C2,
CNOT1, PLCL2, SEC11A, PLA2G15,
ZDHHC5, GIGYF2, JKAMP, NDFIP2, NSD3,
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Turquoise

positive regulation of
stomach fundus
smooth muscle
contraction

3.89E-11

CC

Turquoise

plasma membrane

5.94E-11

CC

Turquoise

integral component of
membrane

2.67E-10

CC

Turquoise

intracellular nonmembrane-bounded
organelle

3.17E-10

BP

Turquoise

regulation of gastric
emptying

4.35E-10

GO:0120069

Any process that increases the frequency,
rate or extent of any stomach fundus
smooth muscle contraction.

BP

GO:0005886

The membrane surrounding a cell that
separates the cell from its external
environment. It consists of a phospholipid
bilayer and associated proteins.

GO:0016021

The component of a membrane consisting
of the gene products and protein
complexes having at least some part of
their peptide sequence embedded in the
hydrophobic region of the membrane.

GO:0043232

GO:0120060

Organised structure of distinctive
morphology and function, not bounded by
a lipid bilayer membrane and occurring
within the cell. Includes ribosomes, the
cytoskeleton and chromosomes.
Any process that modulates the frequency,
rate or extent of any gastric emptying
process, the process in which the liquid
and liquid-suspended solid contents of the

FANCL, NDRG4, GDPD3, ACTR5, BCL2L12,
MARS2, TNFRSF13C, ASPHD1, ASPG
RERE, CHRNA3, EMX1, FGFR1, PRMT1,
MEF2C, PRKD1, PTN, PTPRK, ALMS1,
TAOK2, CKAP5, ZEB2, RIMS1, NGEF,
PLEKHO1, HYDIN, NDRG4, ZNF804A,
EMB, CARMIL2, CNTN4
CACNA1C, CACNA1D, CHRNA3, CHRNA5,
CHRNB4, CTNND1, GSDME, F2, FGFR1,
FHIT, GRIN2A, OPCML, PDE4B, PRKD1,
PTN, PTPRK, SLC12A4, RGS6, CKAP5,
KCNK7, RIMS1, PPP1R13B, VSIG2, CA14,
ZDHHC5, PLEKHO1, RALGAPA2, NLGN4X,
SLC39A8, GPR135, NDRG4, PLPP5, ESAM,
ZNF804A, TNFRSF13C, EMB, CARMIL2,
CNTN4, HARBI1
BNIP3L, CACNA1C, CACNA1D, CHRNA3,
CHRNA5, CHRNB4, FGFR1, GRIN2A,
MGAT3, PDE4B, PTPRK, SLC12A4, SREBF1,
TAOK2, KCNK7, VPS45, NEMP1, SEC11A,
VSIG2, CA14, ZDHHC5, GIGYF2, JKAMP,
TM6SF2, NDFIP2, NLGN4X, SLC39A8,
CSMD1, GPR135, GDPD3, PLPP5, ESAM,
TNFRSF13C, EMB, ASPHD1, SNORC,
PCNX3
CACNA1C, CACNA1D, CLU, EMX1, FGFR1,
FHIT, MEF2C, MSRA, PDE4B, PSMA4,
ATXN7, ALMS1, TAOK2, CKAP5, ZEB2,
RIMS1, CNOT1, MAU2, EDC4, SPATS2L,
GIGYF2, ARL6IP4, HYDIN, GATAD2A,
NSD3, AMBRA1, CENPM, ACTR5, CENPT,
ANP32E, RPS19BP1, ZNF804A, TDRD9,
CARMIL2, HARBI1
CACNA1C, CHRNA3, CHRNA5, CHRNB4,
CLU, CTNND1, GRIN2A, NMB, PDE4B,
PTPRK, ALMS1, TAOK2, NGEF, ZDHHC5,
GIGYF2, PLEKHO1, HYDIN, AMBRA1,
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stomach exit through the pylorus into the
duodenum.

GO:0070052

GO:0044267

GO:0010468

GO:0031175

Interacting selectively and non-covalently
with a type V collagen trimer.

The chemical reactions and pathways
involving a specific protein, rather than of
proteins in general, occurring at the level
of an individual cell. Includes cellular
protein modification.
Any process that modulates the frequency,
rate or extent of gene expression. Gene
expression is the process in which a gene's
coding sequence is converted into a
mature gene product or products (proteins
or RNA). This includes the production of
an RNA transcript as well as any
processing to produce a mature RNA
product or an mRNA or circRNA (for
protein-coding genes) and the translation
of that mRNA or circRNA into protein.
Protein maturation is included when
required to form an active form of a
product from an inactive precursor form.
The process whose specific outcome is the
progression of a neuron projection over
time, from its formation to the mature
structure. A neuron projection is any
process extending from a neural cell, such

MF

Turquoise

collagen V binding

4.49E-10

BP

Turquoise

cellular protein
metabolic process

8.60E-10

NLGN4X, NDRG4, ZNF804A, EMB,
CARMIL2, CNTN4
RERE, BNIP3L, BTG1, CLU, NCAN, EMX1,
F2, FGFR1, FHIT, PRMT1, MEF2C, MSRA,
NFATC3, PSMA4, ATXN7, SREBF1, TLE3,
TAOK2, CKAP5, ZEB2, DMTF1, PPP1R13B,
MAU2, EDC4, PLA2G15, SPATS2L,
ARL6IP4, GATAD2A, NSD3, FANCL,
THAP11, CENPM, ACTR5, ESRP2, CENPT,
ANP32E, RPS19BP1, MARS2
BNIP3L, BTG1, CHRNA3, CLU, GSDME, F2,
FGFR1, FHIT, GRIN2A, PRMT1, MEF2C,
MGAT3, MSRA, PRKD1, PSMA4, PTN,
PTPRK, ATXN7, SREBF1, TAOK2, ATG13,
ZEB2, CNOT1, PLCL2, SEC11A, ZDHHC5,
GIGYF2, JKAMP, NDFIP2, NSD3, FANCL,
NDRG4, ACTR5, BCL2L12, MARS2,
ASPHD1

9.68E-10

RERE, BTG1, CLU, EMX1, F2, FGFR1,
PRMT1, MEF2C, NFATC3, PDE4B, PRKD1,
PSMA4, PTPRK, SOX5, SREBF1, TLE3,
ZNF592, ZEB2, DMTF1, RIMS1, CNOT1,
EDC4, GIGYF2, NDFIP2, RBFOX1,
GATAD2A, NSD3, THAP11, ACTR5, ESRP2,
CENPT, BCL2L12, ZBTB37, ZNF804A,
TNFRSF13C, TDRD9

2.13E-09

RERE, CHRNA3, EMX1, FGFR1, PRMT1,
MEF2C, PRKD1, PTN, PTPRK, TAOK2,
ZEB2, RIMS1, NGEF, NDRG4, ZNF804A,
EMB, CNTN4

BP

BP

Turquoise

Turquoise

regulation of gene
expression

neuron projection
development
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as axons or dendrites (collectively called
neurites).

GO:1901555

Any process that results in a change in
state or activity of a cell or an organism (in
terms of movement, secretion, enzyme
production, gene expression, etc.) as a
result of a paclitaxel stimulus.

BP

Turquoise

response to paclitaxel

5.31E-09

GO:0009653

The process in which anatomical
structures are generated and organized.
Morphogenesis pertains to the creation of
form.

BP

Turquoise

anatomical structure
morphogenesis

1.15E-08

GO:1901679

The directed movement of nucleotide
across a membrane.

BP

Turquoise

nucleotide
transmembrane
transport

1.22E-08

CC

Turquoise

neuron projection

1.83E-08

GO:0043005

GO:0035556

GO:0007417

A prolongation or process extending from
a nerve cell, e.g. an axon or dendrite.
The process in which a signal is passed on
to downstream components within the cell,
which become activated themselves to
further propagate the signal and finally
trigger a change in the function or state of
the cell.
The process whose specific outcome is the
progression of the central nervous system
over time, from its formation to the mature
structure. The central nervous system is

BP

Turquoise

intracellular signal
transduction

2.69E-08

BP

Turquoise

central nervous
system development

2.88E-08

RERE, BTG1, CLU, DPYD, EMX1, FGFR1,
FHIT, GRIN2A, PRMT1, MEF2C, NFATC3,
PDE4B, PRKD1, PSMA4, PTPRK, SOX5,
SREBF1, TLE3, ZNF592, ZEB2, DMTF1,
NT5C2, CNOT1, EDC4, GIGYF2, ARL6IP4,
RBFOX1, GATAD2A, NSD3, FANCL,
THAP11, ACTR5, ESRP2, CENPT, BCL2L12,
ZBTB37, MARS2, TDRD9, HARBI1
RERE, BTG1, CACNA1C, CHRNA3, CLU,
EMX1, F2, FGFR1, MEF2C, PRKD1, PSMA4,
PTN, TLE3, TAOK2, ZEB2, EPN2, RIMS1,
NGEF, PLEKHO1, NDRG4, ESRP2,
TNFRSF13C, EMB, CARMIL2, CNTN4
RERE, BTG1, CLU, NCAN, DPYD, EMX1,
FGFR1, PRMT1, MEF2C, MGAT3, NFATC3,
PDE4B, PRKD1, PSMA4, PTPRK, SOX5,
SREBF1, TLE3, ZNF592, ZEB2, DMTF1,
NT5C2, CNOT1, PLCL2, ZDHHC5, GIGYF2,
GATAD2A, NSD3, THAP11, PITPNM2,
ACTR5, CENPT, BCL2L12, ZBTB37,
MARS2, TNFRSF13C, ASPG
CACNA1C, CHRNA3, CHRNA5, CHRNB4,
CLU, CTNND1, GRIN2A, NMB, PDE4B,
PTPRK, TAOK2, NGEF, ZDHHC5, GIGYF2,
NLGN4X, ZNF804A, EMB, CNTN4
CA8, CACNA1C, CLU, GSDME, F2, FGFR1,
FHIT, GRIN2A, PRMT1, MEF2C, NFATC3,
PRKD1, PSMA4, TAOK2, RGS6, ZEB2,
CNOT1, PLCL2, PPP1R13B, NGEF, NDFIP2,
RALGAPA2, PITPNM2, NDRG4, BCL2L12
RERE, CLU, NCAN, CTNND1, EMX1, F2,
FGFR1, GRIN2A, PTN, ZEB2, GIGYF2,
HYDIN, NLGN4X, NDRG4, CNTN4,
HAPLN4
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the core nervous system that serves an
integrating and coordinating function. In
vertebrates it consists of the brain and
spinal cord. In those invertebrates with a
central nervous system it typically consists
of a brain, cerebral ganglia and a nerve
cord.

GO:0050793

The chemical reactions and pathways
resulting in the formation of substances,
carried out by individual cells.
Any process that modulates the frequency,
rate or extent of development, the
biological process whose specific outcome
is the progression of a multicellular
organism over time from an initial
condition (e.g. a zygote, or a young adult)
to a later condition (e.g. a multicellular
animal or an aged adult).

GO:0051252

Any process that modulates the frequency,
rate or extent of the chemical reactions and
pathways involving RNA.

GO:0044249

GO:0005654
GO:0010604

That part of the nuclear content other than
the chromosomes or the nucleolus.
Any process that increases the frequency,
rate or extent of the chemical reactions and

BP

Turquoise

cellular biosynthetic
process

BP

Turquoise

regulation of
developmental
process

BP

Turquoise

regulation of RNA
metabolic process

CC

Turquoise

BP

Turquoise

nucleoplasm
positive regulation of
macromolecule

3.33E-08

4.70E-08

5.30E-08

6.26E-08
6.68E-08

RERE, BTG1, CLU, NCAN, DPYD, EMX1,
FGFR1, PRMT1, MEF2C, MGAT3, NFATC3,
PDE4B, PRKD1, PSMA4, PTPRK, SOX5,
SREBF1, TLE3, ZNF592, ZEB2, DMTF1,
NT5C2, CNOT1, ZDHHC5, GIGYF2,
GATAD2A, NSD3, THAP11, PITPNM2,
ACTR5, CENPT, BCL2L12, ZBTB37,
MARS2, TNFRSF13C, ASPG

BTG1, CHRNA3, EMX1, F2, FGFR1, PRMT1,
MEF2C, NFATC3, PRKD1, PSMA4, PTN,
SOX5, TAOK2, ZEB2, EPN2, RIMS1, CNOT1,
NGEF, PLEKHO1, NDRG4, BCL2L12,
ZNF804A, TNFRSF13C, CNTN4
RERE, BTG1, CLU, EMX1, FGFR1, PRMT1,
MEF2C, NFATC3, PRKD1, PSMA4, PTPRK,
SOX5, SREBF1, TLE3, ZNF592, ZEB2,
DMTF1, CNOT1, GIGYF2, RBFOX1,
GATAD2A, NSD3, THAP11, ACTR5, ESRP2,
CENPT, BCL2L12, ZBTB37
RERE, BNIP3L, BTG1, PRMT1, MEF2C,
MSRA, NFATC3, PSMA4, ATXN7, SREBF1,
TLE3, DMTF1, PPP1R13B, MAU2, EDC4,
PLA2G15, ARL6IP4, GATAD2A, NSD3,
FANCL, THAP11, CENPM, ACTR5, ESRP2,
CENPT, ANP32E, RPS19BP1
RERE, CHRNA3, CLU, GSDME, F2, FGFR1,
GRIN2A, PRMT1, MEF2C, NFATC3, PDE4B,
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GO:0033554

pathways involving macromolecules, any
molecule of high relative molecular mass,
the structure of which essentially
comprises the multiple repetition of units
derived, actually or conceptually, from
molecules of low relative molecular mass.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme production,
gene expression, etc.) as a result of a
stimulus indicating the organism is under
stress. The stress is usually, but not
necessarily, exogenous (e.g. temperature,
humidity, ionizing radiation).

GO:0090317

Any process that decreases the frequency,
rate or extent of the directed movement of
proteins within cells.

GO:0031325

GO:0051128

GO:0006811

Any process that activates or increases the
frequency, rate or extent of the chemical
reactions and pathways by which
individual cells transform chemical
substances.
Any process that modulates the frequency,
rate or extent of a process involved in the
formation, arrangement of constituent
parts, or disassembly of cell structures,
including the plasma membrane and any
external encapsulating structures such as
the cell wall and cell envelope.
The directed movement of charged atoms
or small charged molecules into, out of or
within a cell, or between cells, by means

metabolic process

BP

BP

BP

PRKD1, SOX5, SREBF1, TAOK2, ATG13,
ZEB2, DMTF1, RIMS1, CNOT1, GIGYF2,
NDFIP2, NSD3, NDRG4, BCL2L12,
ZNF804A, TNFRSF13C

Turquoise

cellular response to
stress

7.77E-08

Turquoise

negative regulation of
intracellular protein
transport

8.52E-08

Turquoise

positive regulation of
cellular metabolic
process

9.84E-08

BP

Turquoise

regulation of cellular
component
organization

BP

Turquoise

ion transport

1.16E-07

1.49E-07

BNIP3L, CLU, PRMT1, MEF2C, MGAT3,
MSRA, PRKD1, PSMA4, PTN, PTPRK,
SREBF1, TAOK2, ATG13, ZEB2, CNOT1,
GIGYF2, JKAMP, FANCL, AMBRA1,
ACTR5, BCL2L12
RERE, BTG1, CLU, EMX1, FGFR1, PRMT1,
MEF2C, NFATC3, PRKD1, PSMA4, PTPRK,
SOX5, SREBF1, TLE3, ZNF592, ZEB2,
DMTF1, CNOT1, EDC4, GIGYF2, ARL6IP4,
RBFOX1, GATAD2A, NSD3, FANCL,
THAP11, ACTR5, ESRP2, CENPT, BCL2L12,
ZBTB37, MARS2, TDRD9, HARBI1
RERE, BNIP3L, CHRNA3, CLU, GSDME, F2,
FGFR1, GRIN2A, PRMT1, MEF2C, NFATC3,
PRKD1, SOX5, SREBF1, TAOK2, ATG13,
ZEB2, DMTF1, CNOT1, GIGYF2, NDFIP2,
NSD3, AMBRA1, NDRG4, BCL2L12,
TNFRSF13C

BNIP3L, BTG1, CHRNA3, CLU, F2, FGFR1,
MEF2C, PRKD1, PTN, SREBF1, ALMS1,
TAOK2, ATG13, ZEB2, RIMS1, CNOT1,
PPP1R13B, NGEF, NSD3, NDRG4, ZNF804A,
CARMIL2
CACNA1C, CACNA1D, CHRNA3, CHRNA5,
CHRNB4, F2, FGFR1, GRIN2A, MEF2C,
NMB, PDE4B, SLC12A4, KCNK7, RIMS1,
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of some agent such as a transporter or
pore.

GO:0009966

Any process that modulates the frequency,
rate or extent of signal transduction.

CA14, NDFIP2, PITPNM2, SLC39A8, EMB

BP

Turquoise

regulation of signal
transduction

1.94E-07

Turquoise

movement of cell or
subcellular
component

2.51E-07

CLU, CTNND1, GSDME, F2, FGFR1,
GRIN2A, PRMT1, MEF2C, PRKD1, PSMA4,
TLE3, TAOK2, RGS6, ZEB2, EPN2, RIMS1,
CNOT1, PLCL2, PPP1R13B, NGEF, NDFIP2,
RALGAPA2, NLGN4X, NDRG4, BCL2L12
RERE, BTG1, CACNA1C, CACNA1D, F2,
FGFR1, MEF2C, MGAT3, PDE4B, PRKD1,
PTN, PTPRK, TAOK2, ZEB2, PLEKHO1,
HYDIN, NDRG4, ESAM, EMB, CARMIL2,
CNTN4

BP

Turquoise

GO:0099192

The directed, self-propelled movement of
a cell or subcellular component without
the involvement of an external agent such
as a transporter or a pore.
Any process that modulates the frequency
or amplitude of synaptic transmission, the
process of communication from a neuron
to a target (neuron, muscle, or secretory
cell) across a synapse. Amplitude, in this
case, refers to the change in postsynaptic
membrane potential due to a single
instance of synaptic transmission.
A synapse formed by a cerebellar Golgi
cell synapsing on to a cerebellar granule
cell.

CC

Turquoise

modulation of
chemical synaptic
transmission
cerebellar Golgi cell
to granule cell
synapse

GO:0043412

The covalent alteration of one or more
monomeric units in a polypeptide,
polynucleotide, polysaccharide, or other
biological macromolecule, resulting in a
change in its properties.

BP

Turquoise

macromolecule
modification

3.04E-07

MF

Turquoise

carbon monoxide
binding

3.11E-07

CACNA1D, CHRNA3, CHRNA5, CHRNB4,
GRIN2A, MEF2C, PTN, RIMS1, PLCL2,
NLGN4X, CNTN4
CACNA1D, CHRNA3, CHRNA5, CHRNB4,
GRIN2A, MEF2C, PTN, RIMS1, PLCL2,
NLGN4X, CNTN4
BTG1, CHRNA3, CLU, GSDME, F2, FGFR1,
PRMT1, MEF2C, MGAT3, MSRA, PRKD1,
PSMA4, PTN, PTPRK, ATXN7, SREBF1,
TAOK2, ATG13, ZEB2, PLCL2, ZDHHC5,
NDFIP2, GATAD2A, NSD3, FANCL, NDRG4,
ACTR5, TDRD9, ASPHD1
CACNA1C, CACNA1D, CHRNA3, CLU, F2,
FGFR1, GRIN2A, MEF2C, PDE4B, PRKD1,
PTN, TAOK2, RGS6, ATG13, ZEB2, RIMS1,
PLCL2, MAU2, NGEF, NDFIP2, AMBRA1,
RALGAPA2, ANP32E, BCL2L12

BP

Turquoise

excitatory
postsynaptic potential

3.77E-07

CHRNA3, CHRNA5, CHRNB4, GRIN2A,
MEF2C, RIMS1, NLGN4X

GO:0006928

GO:0050804

GO:0070025

GO:0060079

Interacting selectively and non-covalently
with carbon monoxide (CO).
A process that leads to a temporary
increase in postsynaptic potential due to
the flow of positively charged ions into the

BP

2.71E-07

2.76E-07
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GO:0009059

postsynaptic cell. The flow of ions that
causes an EPSP is an excitatory
postsynaptic current (EPSC) and makes it
easier for the neuron to fire an action
potential.
The chemical reactions and pathways
resulting in the formation of a
macromolecule, any molecule of high
relative molecular mass, the structure of
which essentially comprises the multiple
repetition of units derived, actually or
conceptually, from molecules of low
relative molecular mass.

BP

Turquoise

macromolecule
biosynthetic process

4.21E-07

RERE, BTG1, CLU, NCAN, EMX1, FGFR1,
PRMT1, MEF2C, MGAT3, NFATC3, PRKD1,
PSMA4, PTPRK, SOX5, SREBF1, TLE3,
ZNF592, ZEB2, DMTF1, CNOT1, ZDHHC5,
GIGYF2, GATAD2A, NSD3, THAP11,
ACTR5, CENPT, BCL2L12, ZBTB37,
MARS2, TNFRSF13C
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Table 6.8: Gene Ontologies for Blue Module in Developmental Stage Two using the anRichment function as part of WGCNA in R using the default settings

GOID

GO:0120041

GO:0043231

GO:0005737

GO:0044237

GO:0044238

Definition

Any process that activates or
increases the frequency, rate
or extent of macrophage
proliferation.
Organised structure of
distinctive morphology and
function, bounded by a single
or double lipid bilayer
membrane and occurring
within the cell. Includes the
nucleus, mitochondria,
plastids, vacuoles, and
vesicles. Excludes the plasma
membrane.
All of the contents of a cell
excluding the plasma
membrane and nucleus but
including other subcellular
structures.
The chemical reactions and
pathways by which
individual cells transform
chemical substances.
The chemical reactions and
pathways involving those
compounds which are
formed as a part of the
normal anabolic and
catabolic processes. These

Ontology

BP

CC

CC

BP

BP

Module

GO Process

FD
R

Blue

positive regulation
of macrophage
proliferation

9.38
E19

Genes
CLU, NCAN, CTNND1, CYP17A1, EPHX2, FGFR1, GRM3, HSPD1,
HSPE1, MMP16, NAGA, NDUFA6, OPCML, PCCB, STAT6, TBX6,
TLE3, INPP4B, DGKI, GABBR2, KDM4A, MPHOSPH9, VPS45,
SATB2, PSD3, ZDHHC5, FOXP1, B3GAT1, LSM1, RBFOX1,
RALGAPA2, SUGP1, NDRG4, ZFYVE21, GDPD3, COQ10B, DRC3,
YPEL3, L3MBTL2, PLPP5, C12orf65, RPS19BP1, TNFRSF13C,
RFTN2, LETM2, C16orf92, WBP2NL, RILPL2, YPEL4, MED19

intracellular
membrane-bounded
organelle

2.90
E12

Blue

cytoplasm

1.74
E10

Blue

cellular metabolic
process

6.66
E09

CLU, NCAN, CTNND1, CYP17A1, EPHX2, FGFR1, HSPD1, HSPE1,
MMP16, NAGA, NDUFA6, PCCB, STAT6, TBX6, TLE3, DGKI,
KDM4A, MPHOSPH9, VPS45, SATB2, FOXP1, B3GAT1, LSM1,
RBFOX1, RALGAPA2, SUGP1, NDRG4, COQ10B, YPEL3,
L3MBTL2, C12orf65, RPS19BP1, LETM2, WBP2NL, YPEL4,
MED19
CLU, NCAN, CTNND1, CYP17A1, EPHX2, FGFR1, HSPD1, HSPE1,
MMP16, NAGA, NDUFA6, PCCB, STAT6, INPP4B, DGKI,
GABBR2, KDM4A, MPHOSPH9, VPS45, B3GAT1, LSM1, RBFOX1,
RALGAPA2, NDRG4, ZFYVE21, GDPD3, COQ10B, DRC3, PLPP5,
C12orf65, RPS19BP1, LETM2, WBP2NL, RILPL2
CLU, NCAN, CYP17A1, EPHX2, FGFR1, HSPD1, HSPE1, NAGA,
NDUFA6, PCCB, STAT6, TBX6, TLE3, INPP4B, DGKI, KDM4A,
SATB2, ZDHHC5, FOXP1, B3GAT1, LSM1, RBFOX1, SUGP1,
NDRG4, GDPD3, COQ10B, L3MBTL2, PLPP5, C12orf65,
TNFRSF13C, WBP2NL, MED19

2.27
E08

CLU, NCAN, CYP17A1, EPHX2, FGFR1, HSPD1, HSPE1, MMP16,
NAGA, PCCB, STAT6, TBX6, TLE3, INPP4B, DGKI, KDM4A,
SATB2, ZDHHC5, FOXP1, B3GAT1, LSM1, RBFOX1, SUGP1,
NDRG4, GDPD3, L3MBTL2, PLPP5, C12orf65, TNFRSF13C,
WBP2NL, MED19

Blue

Blue

primary metabolic
process
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GO:0071726

GO:0016020

GO:0005515

GO:0043233

GO:0070052

processes take place in most,
if not all, cells of the
organism.
Any process that results in a
change in state or activity of
a cell (in terms of movement,
secretion, enzyme
production, gene expression,
etc.) as a result of a
diacylated bacterial
lipopeptide stimulus.
A lipid bilayer along with all
the proteins and protein
complexes embedded in it an
attached to it.
Interacting selectively and
non-covalently with any
protein or protein complex (a
complex of two or more
proteins that may include
other nonprotein molecules).
The internal volume enclosed
by the membranes of a
particular organelle; includes
the volume enclosed by a
single organelle membrane,
e.g. endoplasmic reticulum
lumen, or the volume
enclosed by the innermost of
the two lipid bilayers of an
organelle envelope, e.g.
nuclear lumen.
Interacting selectively and
non-covalently with a type V
collagen trimer.

BP

CC

MF

Blue

Blue

Blue

cellular response to
diacyl bacterial
lipopeptide

3.35
E08

membrane

1.24
E07

CLU, NCAN, CYP17A1, EPHX2, FGFR1, HSPD1, HSPE1, MMP16,
NAGA, PCCB, STAT6, TBX6, TLE3, INPP4B, DGKI, KDM4A,
SATB2, ZDHHC5, FOXP1, B3GAT1, LSM1, RBFOX1, SUGP1,
NDRG4, GDPD3, COQ10B, L3MBTL2, PLPP5, C12orf65,
TNFRSF13C, WBP2NL, MED19
CLU, CTNND1, CYP17A1, FGFR1, GRM3, HSPD1, HSPE1, MMP16,
NDUFA6, OPCML, STAT6, DGKI, GABBR2, MPHOSPH9, VPS45,
PSD3, ZDHHC5, B3GAT1, RALGAPA2, NDRG4, GDPD3, COQ10B,
PLPP5, TNFRSF13C, RFTN2, LETM2, C16orf92, RILPL2

1.24
E07

MPPED2, CLU, CTNND1, EPHX2, FGFR1, HSPD1, HSPE1, NAGA,
PCCB, STAT6, TBX6, TLE3, INPP4B, DGKI, GABBR2, KDM4A,
VPS45, SATB2, PSD3, FOXP1, LSM1, RBFOX1, RALGAPA2,
SUGP1, NDRG4, ZFYVE21, L3MBTL2, RPS19BP1, WBP2NL,
RILPL2, MED19

2.00
E07
2.00
E07

CLU, NCAN, EPHX2, FGFR1, HSPD1, HSPE1, MMP16, PCCB,
STAT6, TBX6, TLE3, DGKI, KDM4A, SATB2, FOXP1, SUGP1,
YPEL3, L3MBTL2, C12orf65, RPS19BP1, YPEL4, MED19
CLU, NCAN, EPHX2, FGFR1, HSPD1, HSPE1, MMP16, PCCB,
STAT6, TBX6, TLE3, DGKI, KDM4A, SATB2, FOXP1, SUGP1,
YPEL3, L3MBTL2, C12orf65, RPS19BP1, YPEL4, MED19

protein binding

CC

Blue

organelle lumen

MF

Blue

collagen V binding
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Table 6.9: Gene Ontologies for Brown Module in Developmental Stage Two using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

GO:0120041

Any process that activates or
increases the frequency, rate or extent
of macrophage proliferation.

GO:0070013

An organelle lumen that is part of an
intracellular organelle.

GO:0005737

GO:0005515

GO:0016043

GO:0071870

All of the contents of a cell excluding
the plasma membrane and nucleus
but including other subcellular
structures.
Interacting selectively and noncovalently with any protein or protein
complex (a complex of two or more
proteins that may include other
nonprotein molecules).
A process that results in the
assembly, arrangement of constituent
parts, or disassembly of a cellular
component.
Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a catecholamine stimulus.
A catecholamine is any of a group of
biogenic amines that includes 4-(2aminoethyl) pyrocatechol [4-(2-

Ontology

Module

GO Process

FDR

Brown

positive
regulation of
macrophage
proliferation

7.94E15

CC

Brown

intracellular
organelle
lumen

2.07E09

CC

Brown

cytoplasm

9.37E09

MF

Brown

protein
binding

2.41E08

Brown

cellular
component
organization

4.64E08

Genes
BTG1, CACNA1C, CHRNA5, ETF1, F2, PTK2B,
KCNJ13, NEK1, NRGN, MAPK3, TCF4, FXR1,
ATP5MPL, KCNK7, NXPH4, IGSF9B, SMG6,
PPP1R13B, MAU2, NGEF, AMBRA1, TSNAXIP1,
NDUFA4L2, ADAMTSL3, AS3MT, SRR, DPEP3,
BOLL, ZNF408, SETD6, CENPT, EFHD1, WDR73,
CREB3L1, TMEM219, SNORC, PCNX3
BTG1, CACNA1C, CHRNA5, ETF1, F2, PTK2B,
KCNJ13, NEK1, NRGN, MAPK3, TCF4, FXR1,
KCNK7, NXPH4, IGSF9B, SMG6, PPP1R13B, MAU2,
NGEF, AMBRA1, BOLL, ZNF408, SETD6, CENPT,
EFHD1, WDR73, CREB3L1, TMEM219
BTG1, CACNA1C, ETF1, F2, PTK2B, NEK1, NRGN,
MAPK3, FXR1, ATP5MPL, SMG6, PPP1R13B,
NGEF, AMBRA1, TSNAXIP1, NDUFA4L2, AS3MT,
SRR, DPEP3, BOLL, SETD6, CENPT, EFHD1,
WDR73, CREB3L1, SNORC
BTG1, CACNA1C, CHRNA5, ETF1, F2, PTK2B,
NEK1, NRGN, MAPK3, TCF4, FXR1, NXPH4,
IGSF9B, SMG6, PPP1R13B, MAU2, NGEF,
AMBRA1, ADAMTSL3, SRR, BOLL, ZNF408,
SETD6, CENPT, CREB3L1, TMEM219
BTG1, ETF1, F2, PTK2B, NEK1, MAPK3, TCF4,
IGSF9B, SMG6, PPP1R13B, MAU2, NGEF,
AMBRA1, SRR, DPEP3, SETD6, CENPT, EFHD1,
WDR73, CREB3L1

Brown

cellular
response to
catecholamine
stimulus

7.59E08

BTG1, ETF1, F2, PTK2B, NEK1, MAPK3, TCF4,
IGSF9B, SMG6, PPP1R13B, MAU2, NGEF,
AMBRA1, SRR, DPEP3, SETD6, CENPT, EFHD1,
WDR73, CREB3L1

BP

BP

BP
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aminoethyl)benzene-1,2-diol] and
derivatives formed by substitution.

GO:0016020

A lipid bilayer along with all the
proteins and protein complexes
embedded in it an attached to it.

CC

Brown

membrane

1.22E07

CACNA1C, CHRNA5, F2, PTK2B, KCNJ13, NRGN,
MAPK3, FXR1, ATP5MPL, KCNK7, IGSF9B,
PPP1R13B, NGEF, AMBRA1, NDUFA4L2, SRR,
DPEP3, EFHD1, WDR73, CREB3L1, TMEM219,
SNORC, PCNX3
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Table 6.10: Gene Ontology for Green Module Stage Two using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0003674

Definition
A molecular process that can be carried out
by the action of a single macromolecular
machine, usually via direct physical
interactions with other molecular entities.
Function in this sense denotes an action, or
activity, that a gene product (or a complex)
performs. These actions are described from
two distinct but related perspectives: (1)
biochemical activity, and (2) role as a
component in a larger system/process.

GO:0120041

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.

GO:1902644

GO:0032991

GO:0043170
GO:0044237

NA
A stable assembly of two or more
macromolecules, i.e. proteins, nucleic
acids, carbohydrates or lipids, in which at
least one component is a protein and the
constituent parts function together.
The chemical reactions and pathways
involving macromolecules, any molecule of
high relative molecular mass, the structure
of which essentially comprises the multiple
repetition of units derived, actually or
conceptually, from molecules of low
relative molecular mass.
The chemical reactions and pathways by

Ontology

MF

BP

BP

CC

BP
BP

Module

Green

Green

Green

Green
Green

Green

GO Process

molecular
function

positive
regulation of
macrophage
proliferation
tertiary
alcohol
metabolic
process

proteincontaining
complex

macromolec
ule
metabolic
process
cellular

FDR

2.31E12

7.16E10

Genes

BNIP3L, CACNB2, CLCN3,
ERCC4, PRMT1, HSPA9, NCK1,
PPP2R3A, PPP4C, PTPRK,
PSMD6, NUTF2, KAT5, CLP1,
NEMP1, SF3B1, SEC11A,
ZSCAN2, TSR1, ACTR5, THOC7,
IMMP2L, RFT1, TYW5,
TSNARE1, ASPHD1, HAPLN4
BNIP3L, CACNB2, CLCN3,
ERCC4, PRMT1, HSPA9, NCK1,
PPP4C, PTPRK, PSMD6, NUTF2,
KAT5, CLP1, NEMP1, SF3B1,
SEC11A, ZSCAN2, TSR1, ACTR5,
THOC7, IMMP2L, RFT1, TYW5,
TSNARE1, ASPHD1, HAPLN4

7.70E09

ERCC4, PRMT1, NCK1,
PPP2R3A, PPP4C, PSMD6, KAT5,
CLP1, SF3B1, SEC11A, ACTR5
CACNB2, ERCC4, PRMT1,
NCK1, PPP2R3A, PPP4C, PSMD6,
NUTF2, KAT5, CLP1, SF3B1,
SEC11A, TSR1, ACTR5, THOC7,
IMMP2L, TSNARE1

4.82E08
1.56E-

BNIP3L, ERCC4, PRMT1, NCK1,
PPP2R3A, PPP4C, PTPRK,
PSMD6, NUTF2, KAT5, CLP1,
SF3B1, SEC11A, ZSCAN2, TSR1,
ACTR5, THOC7, IMMP2L,
TYW5, ASPHD1
BNIP3L, ERCC4, PRMT1, HSPA9,

2.55E09
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which individual cells transform chemical
substances.

GO:0043227

Any process that results in a change in state
or activity of a cell (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a stimulus
indicating the organism is under stress. The
stress is usually, but not necessarily,
exogenous (e.g. temperature, humidity,
ionizing radiation).
Organised structure of distinctive
morphology and function, bounded by a
single or double lipid bilayer membrane.
Includes the nucleus, mitochondria,
plastids, vacuoles, and vesicles. Excludes
the plasma membrane.

GO:0005622

The living contents of a cell; the matter
contained within (but not including) the
plasma membrane, usually taken to exclude
large vacuoles and masses of secretory or
ingested material. In eukaryotes it includes
the nucleus and cytoplasm.

GO:0033554

metabolic
process

07

Green

cellular
response to
stress

1.69E07

CC

Green

membranebounded
organelle

1.88E07

CC

Green

intracellular

2.20E07

BP

NCK1, PPP2R3A, PPP4C, PTPRK,
PSMD6, KAT5, CLP1, SF3B1,
SEC11A, ZSCAN2, TSR1, ACTR5,
THOC7, IMMP2L, TYW5,
ASPHD1

BNIP3L, ERCC4, PRMT1, HSPA9,
NCK1, PPP4C, PTPRK, PSMD6,
KAT5, ACTR5, IMMP2L
BNIP3L, CLCN3, ERCC4,
PRMT1, HSPA9, NCK1, PPP4C,
PTPRK, PSMD6, NUTF2, KAT5,
CLP1, NEMP1, SF3B1, SEC11A,
ZSCAN2, TSR1, ACTR5, THOC7,
IMMP2L, RFT1
BNIP3L, CLCN3, ERCC4,
PRMT1, HSPA9, NCK1,
PPP2R3A, PPP4C, PTPRK,
PSMD6, NUTF2, KAT5, CLP1,
NEMP1, SF3B1, ZSCAN2, TSR1,
ACTR5, THOC7, IMMP2L,
TYW5, TSNARE1
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Table 6.11: Gene Ontology for Turquoise Module Stage Two using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0070016

GO:0071726

GO:0071870
GO:0005829

Definition
Any process that activates or
increases the frequency, rate or
extent of macrophage
proliferation.
Interacting selectively and noncovalently with the armadillo
repeat domain of a protein, an
approximately 40 amino acid long
tandemly repeated sequence motif
first identified in the Drosophila
segment polarity protein
armadillo. Arm-repeat proteins are
involved in various processes,
including intracellular signalling
and cytoskeletal regulation.
Any process that results in a
change in state or activity of a cell
(in terms of movement, secretion,
enzyme production, gene
expression, etc.) as a result of a
diacylated bacterial lipopeptide
stimulus.
Any process that results in a
change in state or activity of a cell
(in terms of movement, secretion,
enzyme production, gene
expression, etc.) as a result of a
catecholamine stimulus. A
catecholamine is any of a group of
biogenic amines that includes 4(2-aminoethyl) pyrocatechol [4-(2aminoethyl) benzene-1,2-diol] and
derivatives formed by substitution.
The part of the cytoplasm that

Ontology

Module

GO Process

FDR

Genes

BP

Turquoise

positive regulation of
macrophage proliferation

1.10E-69

More than 50 overlapping genes

MF

Turquoise

armadillo repeat domain
binding

3.94E-28

More than 50 overlapping genes

BP

Turquoise

cellular response to diacyl
bacterial lipopeptide

4.57E-25

More than 50 overlapping genes

BP
CC

Turquoise
Turquoise

cellular response to
catecholamine stimulus
cytosol

8.10E-24
1.76E-20

More than 50 overlapping genes
More than 50 overlapping genes
204

GO:0080154
GO:1901679

GO:1901666

GO:0070052

GO:0120060

GO:0006996

does not contain organelles, but
which does contain other
particulate matter, such as protein
complexes.
Any process that modulates the
rate, frequency or extent of
fertilization. Fertilization is the
union of gametes of opposite sexes
during the process of sexual
reproduction to form a zygote. It
involves the fusion of the gametic
nuclei (karyogamy) and cytoplasm
(plasmogamy).
The directed movement of
nucleotide across a membrane.
Any process that activates or
increases the frequency, rate or
extent of NAD+ ADPribosyltransferase activity.
Interacting selectively and noncovalently with a type V collagen
trimer.

Any process that modulates the
frequency, rate or extent of any
gastric emptying process, the
process in which the liquid and
liquid-suspended solid contents of
the stomach exit through the
pylorus into the duodenum.
A process that is carried out at the
cellular level which results in the
assembly, arrangement of
constituent parts, or disassembly

BP

Turquoise

BP

Turquoise

regulation of fertilization
nucleotide transmembrane
transport

5.50E-19

More than 50 overlapping genes

1.48E-16

More than 50 overlapping genes

Turquoise

positive regulation of NAD+
ADP-ribosyltransferase
activity

BP

1.48E-16

More than 50 overlapping genes

MF

Turquoise

collagen V binding

3.74E-15

More than 50 overlapping genes

BP

Turquoise

regulation of gastric
emptying

5.54E-15

BP

Turquoise

organelle organization

6.90E-15
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ATP2A2, CALB2, CHRM3, CHRNA3,
CHRNB4, DRD2, GPM6A, GRIN2A, LRP1,
NMB, PDE4B, PRKCB, PTPRF, RANGAP1,
STAR, ALMS1, AP3B2, DOC2A, CUL3,
TAOK2, SDCCAG8, GIGYF2, PARD6A,
PLEKHO1, HYDIN, NLGN4X, RPTOR,
CPEB1, BCL11B, ZNF804A, EMB,
SLC32A1, CARMIL2, CNTN4, HCN1
ALDOA, RERE, ATP2A2, EP300, LRP1,
MEF2C, PPP2R2A, PRKCB, PRKD1, RELA,
ATXN7, SIPA1, SREBF1, SREBF2, SRPK2,
ALMS1, MAD1L1, CUL3, HIRIP3, ASH2L,
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GO:1901555

GO:0099551

GO:0046872
GO:0097178

of an organelle within a cell. An
organelle is an organized structure
of distinctive morphology and
function. Includes the nucleus,
mitochondria, plastids, vacuoles,
vesicles, ribosomes and the
cytoskeleton. Excludes the plasma
membrane.
Any process that results in a
change in state or activity of a cell
or an organism (in terms of
movement, secretion, enzyme
production, gene expression, etc.)
as a result of a paclitaxel stimulus.
Cell-cell signalling between
presynapse and postsynapse, via
the vesicular release and reception
of neuropeptide molecules, that
modulates the synaptic
transmission properties of the
synapse.

Interacting selectively and noncovalently with any metal ion.
The aggregation, arrangement and

INA, TAOK2, BAG4, CKAP5, ZEB2, AKT3,
STAG1, SDCCAG8, CNOT1, DDHD2,
PARD6A, SFMBT1, HYDIN, VPS13C,
NSD3, MSL2, PAK6, CENPM, MAIP1,
ANP32E, PCGF6, DNAJC19, CARMIL2,
TOM1L2, SNX19, BTBD18

BP

BP

MF
BP

Turquoise

Turquoise

Turquoise

response to paclitaxel

trans-synaptic signalling by
neuropeptide, modulating
synaptic transmission

metal ion binding
ruffle assembly

1.74E-14

More than 50 overlapping genes

8.65E-14

ATP2A2, CACNA1D, CALB2, CHRM3,
CHRNA3, CHRNB4, DRD2, GRIN2A,
MEF2C, PLCL1, PRKCB, PTN, RELA,
SLC12A4, STAR, DOC2A, RIMS1, PLCL2,
NLGN4X, SLC32A1, CNTN4, STAC3

9.32E-14
1.29E-13

RERE, ATP2A2, CA8, CACNA1D, CALB2,
DPYD, EP300, GRIN2A, IREB2, LRP1,
PDE4B, PLCB2, PRKCB, PRKD1, SHMT2,
SRPK2, DOC2A, ASH2L, ZNF592, PLCH2,
ZNF536, ZEB2, RAI1, NT5C2, RIMS1,
DDHD2, ZC3H7B, CA14, MOB4,
GATAD2A, NSD3, MSL2, ZNF823,
OTUD7B, THAP11, PITPNM2, RBM26,
DPEP2, CPEB1, BCL11B, PCGF6, ZBTB37,
ZNF804A, OTOL1, STAC3, HARBI1
More than 50 overlapping genes
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bonding together of a set of
components to form a ruffle, a
projection at the leading edge of a
crawling cell; the protrusions are
supported by a microfilament
meshwork. The formation of
ruffles (also called membrane
ruffling) is thought to be
controlled by a group of enzymes
known as Rho GTPases,
specifically RhoA, Rac1 and
cdc42.

GO:0098935

The directed movement of
organelles or molecules along
microtubules in dendrites.

GO:0099552

Cell-cell signalling between
presynapse and postsynapse, via
the release and reception of lipid
molecules, that modulates the
synaptic transmission properties of
the synapse.

GO:0070025
GO:2000225

Interacting selectively and noncovalently with carbon monoxide
(CO).
Any process that stops, prevents,
or reduces the frequency, rate or

Turquoise

BP

BP

Turquoise

Turquoise

dendritic transport

trans-synaptic signalling by
lipid, modulating synaptic
transmission

4.88E-13

6.04E-13

Turquoise
MF
BP

carbon monoxide binding
negative regulation of
testosterone biosynthetic

7.03E-13
1.12E-12

ATP2A2, CACNA1D, CALB2, CHRM3,
CHRNA3, CHRNB4, DRD2, GRIN2A,
MEF2C, PLCL1, PRKCB, PTN, SLC12A4,
STAR, DOC2A, RIMS1, PLCL2, NLGN4X,
SLC32A1, CNTN4, STAC3

ATP2A2, CACNA1D, CALB2, CHRM3,
CHRNA3, CHRNB4, DRD2, GRIN2A,
MEF2C, PLCL1, PRKCB, PTN, SLC12A4,
STAR, DOC2A, RIMS1, PLCL2, NLGN4X,
SLC32A1, CNTN4, STAC3
ARHGAP1, SERPINC1, SERPING1,
CACNA1D, CHRNA3, DRD2, EP300, FSHB,
GRIN2A, LRP1, MEF2C, NAB2, PDE4B,
PLCB2, PLCL1, PPP2R2A, PRKCB, PRKD1,
PTN, PTPRF, RANGAP1, RELA, SIPA1,
TAOK2, BAG4, RGS6, TBC1D5, ZEB2,
RABGAP1L, TAB1, RIMS1, PLCL2, PAK6,
RPTOR, RBM26, ANP32E, DNAJC19,
STAC3
RERE, DRD2, EMX1, EP300, FSHB, IREB2,
MEF2C, NAB2, NFATC3, PRKCB, PRKD1,
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extent of testosterone biosynthetic
process.

process

PSMA4, PSMB10, RELA, SHMT2, SOX5,
SREBF1, SREBF2, CUL3, ASH2L, ZNF592,
ZNF536, ZEB2, DMTF1, STAG1, TAB1,
RAI1, CNOT1, GIGYF2, SFMBT1,
GATAD2A, NSD3, BANK1, ZNF823, PAK6,
OTUD7B, THAP11, RPTOR, CPEB1,
BCL11B, PCGF6, ZBTB37, BTBD18

Turquoise

GO:1901561

GO:0005886

GO:0005654

GO:0035556

Any process that results in a
change in state or activity of a cell
or an organism (in terms of
movement, secretion, enzyme
production, gene expression, etc.)
as a result of a benomyl stimulus.
The membrane surrounding a cell
that separates the cell from its
external environment. It consists
of a phospholipid bilayer and
associated proteins.

That part of the nuclear content
other than the chromosomes or the
nucleolus.
The process in which a signal is
passed on to downstream
components within the cell, which
become activated themselves to
further propagate the signal and
finally trigger a change in the

BP

Turquoise

response to benomyl

1.16E-12

More than 50 overlapping genes

CC

Turquoise

plasma membrane

2.53E-12

More than 50 overlapping genes

CC

BP

Turquoise

nucleoplasm

3.26E-12

intracellular signal
transduction

5.12E-12

RERE, ATP2A2, EP300, MEF2C, MSRA,
NFATC3, PPP2R2A, PRKCB, PSMA4,
PSMB10, RANGAP1, RELA, ATXN7,
SREBF1, SREBF2, SRPK2, CDK2AP1,
CUL3, ASH2L, INA, DMTF1, STAG1,
TAB1, RAI1, EDC4, PLA2G15, ARL6IP4,
SFMBT1, GATAD2A, NSD3, MSL2,
THAP11, RPTOR, CPEB1, CENPM, ESRP2,
ANP32E, PCGF6, ATPAF2, STAC3
ARHGAP1, ATP2A2, CA8, GSDME, DRD2,
EP300, FHIT, GRIN2A, LRP1, MEF2C,
NFATC3, PLCB2, PLCL1, PRKCB, PRKD1,
PSMA4, PSMB10, RELA, SIPA1, SRPK2,
CUL3, TAOK2, BAG4, RGS6, PLCH2,
ZEB2, AKT3, TAB1, CNOT1, PLCL2,
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function or state of the cell.

BANK1, PAK6, OTUD7B, RPTOR,
PITPNM2, STAC3
Turquoise

GO:0071986

A eukaryotically conserved
protein complex; in humans, it is
comprised of LAMTOR1,
LAMTOR2, LAMTOR3,
LAMTOR4, and LAMTOR5. The
complex is anchored to lipid rafts
in late endosome membranes via
LAMTOR1, constitutes a guanine
nucleotide exchange factor (GEF)
for the Rag GTPases.

CC

GO:1901558

Any process that results in a
change in state or activity of a cell
or an organism (in terms of
movement, secretion, enzyme
production, gene expression, etc.)
as a result of a metformin
stimulus.

BP

GO:0043232

Organised structure of distinctive
morphology and function, not
bounded by a lipid bilayer
membrane and occurring within
the cell. Includes ribosomes, the
cytoskeleton and chromosomes.

CC

Turquoise

Ragulator complex

5.36E-12

Turquoise

response to metformin

6.72E-12

Turquoise

intracellular non-membranebounded organelle

8.10E-12

More than 50 overlapping genes

ALDOA, RERE, DRD2, EMX1, EP300,
FSHB, IREB2, MEF2C, NAB2, NFATC3,
PDE4B, PRKCB, PRKD1, PSMA4, PSMB10,
RELA, SOX5, SREBF1, SREBF2, STAR,
CUL3, ASH2L, ZNF592, ZNF536, ZEB2,
DMTF1, STAG1, TAB1, RAI1, NT5C2,
CNOT1, SFMBT1, GATAD2A, NSD3,
ZNF823, PAK6, OTUD7B, THAP11, RPTOR,
SCAF1, BCL11B, PCGF6, ZBTB37, BTBD18
ALDOA, CACNA1D, CALB2, EMX1,
EP300, FHIT, MEF2C, MSRA, PDE4B,
PSMA4, RANGAP1, RELA, ATXN7,
SHMT2, SRPK2, ALMS1, MAD1L1,
DOC2A, CUL3, HIRIP3, ASH2L, INA,
TAOK2, CKAP5, ZEB2, STAG1, SDCCAG8,
RIMS1, CNOT1, DDHD2, EDC4, SPATS2L,
GIGYF2, PARD6A, ARL6IP4, HYDIN,
GATAD2A, NSD3, PAK6, RPTOR, CPEB1,
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CENPM, ANP32E, ZNF804A, CARMIL2,
HARBI1

GO:0120069

GO:0090317

GO:0097707

Any process that increases the
frequency, rate or extent of any
stomach fundus smooth muscle
contraction.

Any process that decreases the
frequency, rate or extent of the
directed movement of proteins
within cells.
A programmed cell death
characterized morphologically by
the presence of smaller than
normal mitochondria with
condensed mitochondrial
membrane densities, reduction or
vanishing of mitochondria crista,
and outer mitochondrial
membrane rupture. Activation of
mitochondrial voltage-dependent
anion channels and mitogenactivated protein kinases,

BP

BP

Turquoise

Turquoise

positive regulation of
stomach fundus smooth
muscle contraction

negative regulation of
intracellular protein
transport

2.94E-11

RERE, CHRNA3, DRD2, EMX1, EP300,
GPM6A, LRP1, MEF2C, PRKD1, PTN,
PTPRF, ALMS1, TAOK2, BAG4, CKAP5,
ZEB2, SDCCAG8, RIMS1, PLEKHO1,
HYDIN, BCL11B, SEMA6D, ZNF804A,
EMB, CARMIL2, CNTN4

3.44E-11

RERE, DRD2, EMX1, EP300, FSHB,
MEF2C, NAB2, NFATC3, PPP2R2A,
PRKCB, PRKD1, PSMA4, PSMB10, RELA,
SOX5, SREBF1, SREBF2, SRPK2, CUL3,
ASH2L, ZNF592, ZNF536, ZEB2, DMTF1,
STAG1, TAB1, RAI1, CNOT1, ZC3H7B,
EDC4, GIGYF2, ARL6IP4, SFMBT1,
GATAD2A, NSD3, ZNF823, PAK6,
OTUD7B, THAP11, RPTOR, SCAF1,
RBM26, CPEB1, BCL11B, ESRP2, PCGF6,
ZBTB37, HARBI1, BTBD18

4.67E-11

RERE, DRD2, EMX1, EP300, FSHB,
MEF2C, NAB2, NFATC3, PRKCB, PRKD1,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
ZEB2, DMTF1, STAG1, TAB1, RAI1,
CNOT1, SFMBT1, GATAD2A, NSD3,
ZNF823, PAK6, OTUD7B, THAP11, RPTOR,
SCAF1, BCL11B, PCGF6, ZBTB37, BTBD18

Turquoise

BP

ferroptosis
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upregulation of endoplasmic
reticulum stress, and inhibition of
cystine/glutamate antiporter are
involved in the induction of
ferroptosis. This process is
characterized by the accumulation
of lipid peroxidation products and
lethal reactive oxygen species
(ROS) derived from iron
metabolism. Glutathione
peroxidase 4 (GPX4), heat shock
protein beta-1, and nuclear factor
erythroid 2-related factor 2
function as negative regulators of
ferroptosis by limiting ROS
production and reducing cellular
iron uptake, respectively. In
contrast, NADPH oxidase and p53
act as positive regulators of
ferroptosis by promotion of ROS
production and inhibition of
expression of SLC7A11 (a specific
light-chain subunit of the
cystine/glutamate antiporter),
respectively. Misregulated
ferroptosis has been implicated in
multiple physiological and
pathological processes.

GO:0099192

A synapse formed by a cerebellar
Golgi cell synapsing on to a
cerebellar granule cell.

CC

GO:1903593

Any process that modulates the
frequency, rate or extent of
histamine secretion by mast cell.

BP

Turquoise

cerebellar Golgi cell to
granule cell synapse

4.68E-11

regulation of histamine
secretion by mast cell

6.09E-11

ATP2A2, CACNA1D, CALB2, CHRNA3,
CHRNB4, DRD2, GRIN2A, MEF2C, PLCL1,
PRKCB, PTN, STAR, RIMS1, PLCL2,
NLGN4X, CNTN4
RERE, DRD2, EMX1, EP300, FSHB,
MEF2C, NAB2, NFATC3, PRKCB, PRKD1,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
ZEB2, DMTF1, STAG1, TAB1, RAI1,
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CNOT1, SFMBT1, GATAD2A, NSD3,
ZNF823, PAK6, OTUD7B, THAP11, RPTOR,
BCL11B, PCGF6, ZBTB37, BTBD18

Turquoise

GO:2001234

GO:0030054

GO:0033554

Any process that stops, prevents,
or reduces the frequency, rate or
extent of apoptotic signalling
pathway.
A cellular component that forms a
specialized region of connection
between two or more cells or
between a cell and the
extracellular matrix. At a cell
junction, anchoring proteins
extend through the plasma
membrane to link cytoskeletal
proteins in one cell to cytoskeletal
proteins in neighbouring cells or to
proteins in the extracellular
matrix.
Any process that results in a
change in state or activity of a cell
(in terms of movement, secretion,
enzyme production, gene
expression, etc.) as a result of a
stimulus indicating the organism is

BP

CC

BP

Turquoise

Turquoise

negative regulation of
apoptotic signalling pathway

6.32E-11

cell junction

8.62E-11

cellular response to stress

1.64E-10

RERE, DRD2, EMX1, EP300, FSHB,
MEF2C, NAB2, NFATC3, PRKCB, PRKD1,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
ZEB2, DMTF1, STAG1, TAB1, RAI1,
CNOT1, SFMBT1, GATAD2A, NSD3,
ZNF823, PAK6, OTUD7B, THAP11, RPTOR,
BCL11B, PCGF6, ZBTB37, BTBD18

ATP2A2, CACNA1D, CALB2, CHRM3,
CHRNA3, CHRNB4, DRD2, GPM6A,
GRIN2A, LRP1, MEF2C, PDE4B, PPP2R2A,
PRKCB, PTN, RELA, DOC2A, INA,
SDCCAG8, RIMS1, PARD6A, PAK6,
NLGN4X, CPEB1, ESAM, ZNF804A, EMB,
SLC32A1
ATP2A2, EP300, LRP1, MEF2C, MGAT3,
MSRA, PRKD1, PSMA4, PSMB10, PTN,
PTPRF, RELA, SIPA1, SREBF1, SREBF2,
CUL3, ASH2L, TAOK2, BAG4, ZEB2,
AKT3, TAB1, CNOT1, GIGYF2, JKAMP,
VPS13C, PAK6, RPTOR, CPEB1
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under stress. The stress is usually,
but not necessarily, exogenous
(e.g. temperature, humidity,
ionizing radiation).

GO:0006357

GO:0051172

GO:0030425
GO:0097473

Any process that modulates the
frequency, rate or extent of
transcription mediated by RNA
polymerase II.

Any process that stops, prevents,
or reduces the frequency, rate or
extent of the chemical reactions
and pathways involving nitrogen
or nitrogenous compounds.
A neuron projection that has a
short, tapering, morphology.
Dendrites receive and integrate
signals from other neurons or from
sensory stimuli, and conduct nerve
impulses towards the axon or the
cell body. In most neurons, the
impulse is conveyed from
dendrites to axon via the cell body,
but in some types of unipolar
neuron, the impulse does not travel
via the cell body.
Any apoptotic process in a retinal

Turquoise

BP

BP

Turquoise

Turquoise

regulation of transcription
by RNA polymerase II

negative regulation of
nitrogen compound
metabolic process

2.45E-10

RERE, DRD2, EMX1, EP300, FSHB,
MEF2C, NFATC3, PRKCB, PRKD1,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
ZEB2, DMTF1, STAG1, RAI1, CNOT1,
GATAD2A, ZNF823, OTUD7B, THAP11,
BCL11B, PCGF6, ZBTB37, BTBD18

3.20E-10

SERPINC1, RERE, SERPING1, DRD2,
EP300, FHIT, GRIN2A, IREB2, MEF2C,
MGAT3, NAB2, NFATC3, PTN, RELA,
SOX5, SREBF1, SREBF2, CUL3, ZNF536,
ZEB2, CNOT1, GIGYF2, PARD6A,
SFMBT1, GATAD2A, BANK1, OTUD7B,
THAP11, RPTOR, CPEB1, PCGF6

3.31E-10
3.48E-10

CALB2, CHRM3, CHRNA3, DRD2, GPM6A,
GRIN2A, LRP1, PDE4B, RANGAP1,
TAOK2, GIGYF2, NLGN4X, RPTOR,
CPEB1, ZNF804A, SLC32A1, HCN1
CALB2, CHRM3, CHRNA3, DRD2, GPM6A,

Turquoise

CC
BP

dendrite
retinal rod cell apoptotic

213

rod cell, one of the two
photoreceptor cell types of the
vertebrate retina.

process

GRIN2A, LRP1, PDE4B, RANGAP1,
TAOK2, GIGYF2, NLGN4X, RPTOR,
CPEB1, ZNF804A, SLC32A1, HCN1

Turquoise

GO:0071516

The initial formation of a stable
single-strand DNA lesion that
triggers programmed gene
conversion at the mating-type
locus, thereby restricting matingtype interconversion to one of the
two sister chromatids during DNA
replication.

BP

Turquoise

establishment of imprinting
at mating-type locus

6.63E-10

GO:0019899

Interacting selectively and noncovalently with any enzyme.

MF

Turquoise

enzyme binding

8.13E-10

GO:0070901

The posttranscriptional addition of
methyl groups to specific residues
in a mitochondrial tRNA
molecule.

BP

Turquoise

mitochondrial tRNA
methylation

1.75E-09

GO:2000134

Any cell cycle regulatory process
that prevents the commitment of a
cell from G1 to S phase of the
mitotic cell cycle.

negative regulation of G1/S
transition of mitotic cell
cycle

2.39E-09

BP

CHRM3, CHRNA3, DRD2, EP300, FSHB,
LRP1, MEF2C, PDE4B, PRKCB, PTN,
RANGAP1, RELA, SHMT2, SOX5, SREBF1,
STAR, BAG4, TAB1, CNOT1, PARD6A,
RPTOR, CPEB1, ESRP2, HCN1

ARHGAP1, SERPINC1, ATP2A2, FHIT,
LRP1, MEF2C, PPP2R2A, PRKCB, PTN,
RANGAP1, RELA, SLC12A4, SREBF1,
CDK2AP1, CUL3, TAOK2, BAG4, TBC1D5,
RABGAP1L, TAB1, RIMS1, PARD6A,
JKAMP, BANK1, PAK6, RPTOR, PITPNM2,
SCAF1, TOM1L2
ATP2A2, CHRM3, CHRNA3, GSDME,
DRD2, EP300, FSHB, LRP1, MEF2C,
MGAT3, MSRA, PDE4B, PRKCB, PRKD1,
PSMA4, PSMB10, PTN, RANGAP1, RELA,
SHMT2, SIPA1, SOX5, SREBF1, STAR,
CUL3, INA, BAG4, TAB1, CNOT1,
PARD6A, RPTOR, CPEB1, ESRP2, CPNE8,
HCN1
CHRNA3, DRD2, EMX1, EP300, FSHB,
LRP1, MEF2C, NFATC3, PRKCB, PRKD1,
PSMA4, PSMB10, PTN, PTPRF, RELA,
SOX5, STAR, ASH2L, ZNF536, ZEB2,
AKT3, RIMS1, PARD6A, SFMBT1,
BCL11B, SEMA6D, ZNF804A, CNTN4
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Turquoise

GO:0016477

GO:0016021

GO:0050767

GO:0071727
GO:0031175

The controlled self-propelled
movement of a cell from one site
to a destination guided by
molecular cues. Cell migration is a
central process in the development
and maintenance of multicellular
organisms.

The component of a membrane
consisting of the gene products
and protein complexes having at
least some part of their peptide
sequence embedded in the
hydrophobic region of the
membrane.
Any process that modulates the
frequency, rate or extent of
neurogenesis, the generation of
cells in the nervous system.
Any process that results in a
change in state or activity of a cell
(in terms of movement, secretion,
enzyme production, gene
expression, etc.) as a result of a
triacylated bacterial lipopeptide
stimulus.
The process whose specific
outcome is the progression of a

BP

CC

BP

BP
BP

Turquoise

Turquoise

Turquoise
Turquoise

cell migration

integral component of
membrane

regulation of neurogenesis

cellular response to triacyl
bacterial lipopeptide
neuron projection
development

4.23E-09

RERE, DRD2, FSHB, GPM6A, LRP1,
MEF2C, MGAT3, PDE4B, PRKD1, PTN,
PTPRF, CUL3, SLC7A6, TAOK2, BAG4,
ZEB2, AKT3, SDCCAG8, PLEKHO1, PAK6,
BCL11B, SEMA6D, ESAM, CARMIL2

4.24E-09

ATP2A2, CACNA1D, CHRM3, CHRNA3,
CHRNB4, DRD2, GPM6A, GRIN2A, LRP1,
MGAT3, PDE4B, PTPRF, SLC12A4,
SREBF1, SREBF2, CACNA1I, SLC7A6,
GPR52, TAOK2, ABCB9, VSIG2, CA14,
GIGYF2, SEZ6L2, SLC45A1, TMX2, AIG1,
JKAMP, TM6SF2, CNNM2, NLGN4X,
SLC39A8, CSMD1, GPR135, SEMA6D,
TLCD3B, ESAM, SFXN5, DNAJC19, EMB,
SLC32A1, KIAA1324L, STAC3, HCN1

5.08E-09

7.84E-09
9.95E-09

CHRNA3, DRD2, EMX1, EP300, LRP1,
MEF2C, PRKD1, PTN, PTPRF, RELA,
STAR, ZNF536, ZEB2, RIMS1, BCL11B,
SEMA6D, ZNF804A, CNTN4
ARHGAP1, CACNA1D, CHRNA3, DRD2,
LRP1, PRKCB, RANGAP1, SREBF1,
SREBF2, AP3B2, SLC7A6, TAOK2, BAG4,
TBC1D5, CKAP5, RABGAP1L, RIMS1,
DOP1A, ABCB9, PARD6A, VPS13C,
BANK1, RBM26, MAIP1, SFXN5,
DNAJC19, SLC32A1, TOM1L2, SNX19
RERE, CHRNA3, DRD2, EMX1, EP300,
GPM6A, LRP1, MEF2C, PRKD1, PTN,
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neuron projection over time, from
its formation to the mature
structure. A neuron projection is
any process extending from a
neural cell, such as axons or
dendrites (collectively called
neurites).

GO:1901890

Any process that activates or
increases the frequency, rate or
extent of cell junction assembly.

GO:0051254

Any process that activates or
increases the frequency, rate or
extent of the chemical reactions
and pathways involving RNA.

GO:0101020

GO:0070852

GO:0098631

Catalysis of the reaction:
oestrogen + donor-H2 + O2 = 16alpha-hydroxyestrogen + H2O.
A neuron projection that is found
in unipolar neurons and
corresponds to the region between
the cell body and the point at
which the single projection
branches.
The binding by a cell-adhesion
protein on the cell surface to an
extracellular matrix component, to
mediate adhesion of the cell to the
external substrate or to another
cell.

PTPRF, TAOK2, ZEB2, RIMS1, BCL11B,
SEMA6D, ZNF804A, EMB, CNTN4

Turquoise

BP

BP

MF

Turquoise

Turquoise

Turquoise
Turquoise

positive regulation of cell
junction assembly

positive regulation of RNA
metabolic process

oestrogen 16-alphahydroxylase activity

1.58E-08

CHRM3, CHRNA3, DRD2, GRIN2A, LRP1,
MEF2C, PDE4B, PPP2R2A, PRKCB, PTN,
RANGAP1, RELA, SHMT2, SREBF1,
SREBF2, STAR, JKAMP, RPTOR, CPEB1,
HCN1

1.58E-08

RERE, DRD2, EP300, FSHB, MEF2C,
NFATC3, PRKCB, PRKD1, RELA, SOX5,
SREBF1, SREBF2, ASH2L, ZEB2, DMTF1,
STAG1, RAI1, CNOT1, GIGYF2, NSD3,
RPTOR, CPEB1, BCL11B, BTBD18

1.71E-08

ATP2A2, CACNA1D, CHRNA3, CHRNB4,
DRD2, MEF2C, PRKCB, DOC2A, RIMS1,
SLC32A1

CC

cell body fibre

2.40E-08

MF

cell adhesion mediator
activity

2.43E-08

ATP2A2, CACNA1D, DRD2, GPM6A,
GRIN2A, PDE4B, PLCB2, PRKCB,
CACNA1I, PLCH2, CNNM2, SLC39A8,
MAIP1, STAC3
ARHGAP1, ATP2A2, CHRNB4, DRD2,
LRP1, MGAT3, PRKD1, SLC12A4, SREBF1,
SREBF2, AP3B2, DOC2A, CUL3, TBC1D5,
TAB1, DOP1A, ABCB9, MOB4, TM6SF2,
VPS13C, RPTOR, GPR135, TLCD3B,
BORCS7, SLC32A1, SNX19
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Turquoise

GO:0071329

GO:0072528

Any process that results in a
change in state or activity of a cell
(in terms of movement, secretion,
enzyme production, gene
expression, etc.) as a result of a
sucrose stimulus.
The chemical reactions and
pathways resulting in the
formation of a pyrimidinecontaining compound, i.e. any
compound that contains
pyrimidine or a formal derivative
thereof.

BP

BP

GO:0098808

The chemical reactions and
pathways resulting in the
breakdown of substances, carried
out by individual cells.
Interacting selectively and noncovalently with a 7methylguanosine (m7G) group or
derivative located at the 5' end of
an mRNA molecule.

MF

GO:0006468

The process of introducing a
phosphate group on to a protein.

BP

GO:0044248

BP

Turquoise

cellular response to sucrose
stimulus

Turquoise

pyrimidine-containing
compound biosynthetic
process

Turquoise

Turquoise

cellular catabolic process

2.52E-08

CHRM3, CHRNA3, GSDME, DRD2, EP300,
FSHB, LRP1, MEF2C, PDE4B, PRKCB,
PRKD1, PSMA4, PSMB10, PTN, RANGAP1,
RELA, SHMT2, SOX5, SREBF1, STAR,
CUL3, INA, BAG4, TAB1, CNOT1,
PARD6A, RPTOR, CPEB1, ESRP2, HCN1

2.86E-08

ATP2A2, CACNA1D, DRD2, GPM6A,
GRIN2A, PDE4B, PLCB2, PRKCB,
CACNA1I, PLCH2, CNNM2, SLC39A8,
MAIP1, STAC3

2.95E-08

DPYD, DRD2, EP300, FHIT, LRP1, MGAT3,
PDE4B, PPP2R2A, PRKD1, PSMA4,
PSMB10, SHMT2, SREBF1, SREBF2, CUL3,
TBC1D5, NT5C2, CNOT1, DDHD2, EDC4,
PLA2G15, GIGYF2, AIG1, JKAMP,
VPS13C, OTUD7B, RPTOR

mRNA cap binding

3.23E-08

protein phosphorylation

5.64E-08

CACNA1D, CALB2, CHRM3, DRD2,
GPM6A, GRIN2A, PDE4B, PRKCB, PTN,
DOC2A, RIMS1, NLGN4X, ZNF804A,
SLC32A1
CHRNA3, GSDME, DRD2, LRP1, MEF2C,
NAB2, PLCL1, PRKCB, PRKD1, PSMA4,
PSMB10, SRPK2, CDK2AP1, CUL3,
TAOK2, BAG4, ZEB2, AKT3, TAB1,
PLCL2, PARD6A, BANK1, PAK6, RPTOR,
ALPK3
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Turquoise

GO:0007420

GO:1901678

GO:0031399

GO:0140244
GO:0010558

The process whose specific
outcome is the progression of the
brain over time, from its formation
to the mature structure. Brain
development begins with
patterning events in the neural
tube and ends with the mature
structure that is the centre of
thought and emotion. The brain is
responsible for the coordination
and control of bodily activities and
the interpretation of information
from the senses (sight, hearing,
smell, etc.).

The directed movement of an iron
coordination entity into, out of or
within a cell, or between cells, by
means of some agent such as a
transporter or pore.
Any process that modulates the
frequency, rate or extent of the
covalent alteration of one or more
amino acid residues within a
protein.

Any process that regulates
translation occurring at the
presynapse.
Any process that decreases the

BP

BP

Turquoise

Turquoise
Turquoise

BP

BP
BP

Turquoise

brain development

6.79E-08

RERE, DRD2, EMX1, GRIN2A, LRP1, PTN,
STAR, INA, ZEB2, AKT3, HYDIN,
NLGN4X, BCL11B, SEMA6D, SLC32A1,
CNTN4

iron coordination entity
transport

6.97E-08

regulation of protein
modification process

8.87E-08

ALDOA, CTRL, DPYD, FHIT, GRIN2A,
LRP1, MGAT3, PDE4B, PLCB2, PPP2R2A,
PSMA4, PSMB10, RELA, SHMT2, CUL3,
PLCH2, NT5C2, CNOT1, DDHD2, EDC4,
PLA2G15, GIGYF2, AIG1, JKAMP,
OTUD7B, ASPG
CHRNA3, GSDME, DRD2, EP300, LRP1,
NAB2, PLCL1, PPP2R2A, PRKD1, PTN,
RELA, SREBF1, CDK2AP1, CUL3, TAOK2,
BAG4, ZEB2, TAB1, PLCL2, PARD6A,
NSD3, BANK1, PAK6, RPTOR

1.07E-07
1.21E-07

RERE, EMX1, EP300, MEF2C, NAB2,
NFATC3, PRKCB, RELA, SOX5, SREBF1,
SREBF2, ZNF592, ZNF536, ZEB2, DMTF1,
STAG1, RAI1, SFMBT1, GATAD2A, NSD3,
ZNF823, THAP11, BCL11B, PCGF6,
ZBTB37
RERE, EP300, IREB2, MEF2C, NAB2,

regulation of translation at
presynapse
negative regulation of
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rate, frequency or extent of the
chemical reactions and pathways
resulting in the formation of a
macromolecule, any molecule of
high relative molecular mass, the
structure of which essentially
comprises the multiple repetition
of units derived, actually or
conceptually, from molecules of
low relative molecular mass.

GO:0043168

GO:0055065

GO:0004620

GO:0010647

Interacting selectively and noncovalently with anions, charged
atoms or groups of atoms with a
net negative charge.
Any process involved in the
maintenance of an internal steady
state of metal ions within an
organism or cell.
Catalysis of the hydrolysis of a
glycerophospholipid.
Any process that increases the
frequency, rate or extent of cell
communication. Cell
communication is the process that
mediates interactions between a
cell and its surroundings.
Encompasses interactions such as
signalling or attachment between
one cell and another cell, between
a cell and an extracellular matrix,
or between a cell and any other

macromolecule biosynthetic
process

NFATC3, RELA, SOX5, SREBF1, SREBF2,
CUL3, ZNF536, ZEB2, CNOT1, GIGYF2,
SFMBT1, GATAD2A, BANK1, OTUD7B,
THAP11, CPEB1, PCGF6

Turquoise

MF

Turquoise

anion binding

1.21E-07

metal ion homeostasis

1.27E-07

SERPINC1, ATP2A2, GSDME, DPYD,
LRP1, PDE4B, PLCL1, PRKCB, PRKD1,
PTN, PTPRF, RELA, SHMT2, SRPK2,
DOC2A, TAOK2, AKT3, PLCL2, ABCB9,
PLA2G15, CNNM2, PAK6, NLGN4X,
ALPK3, PITPNM2, CPNE8, CARMIL2,
HCN1, SNX19
ATP2A2, CACNA1D, CALB2, DRD2,
GRIN2A, IREB2, LRP1, NMB, PLCB2,
PRKCB, SLC12A4, PLCH2, CNNM2,
SLC39A8, MAIP1

phospholipase activity

1.37E-07

CHRM3, PLCB2, PLCL1, PLCH2, PLCL2,
DDHD2, PLA2G15, ASPG

1.41E-07

ARHGAP1, CACNA1D, CALB2, CHRNB4,
GSDME, DRD2, EP300, GRIN2A, LRP1,
NMB, PRKCB, PRKD1, PSMA4, PSMB10,
PTN, RELA, TAOK2, BAG4, ZEB2, AKT3,
TAB1, RIMS1, BANK1, RPTOR

Turquoise
BP

MF

BP

Turquoise

positive regulation of cell
communication
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aspect of its environment.

GO:0120071

Any process that modulates the
frequency, rate or extent of any
pyloric antrum smooth muscle
contraction.

GO:0023056

Any process that activates,
maintains or increases the
frequency, rate or extent of a
signalling process.

GO:0048858

GO:0046928

GO:0010628

The process in which the
anatomical structures of a cell
projection are generated and
organized.
Any process that modulates the
frequency, rate or extent of the
regulated release of a
neurotransmitter from a cell.
Any process that increases the
frequency, rate or extent of gene
expression. Gene expression is the
process in which a gene's coding
sequence is converted into a
mature gene product or products
(proteins or RNA). This includes
the production of an RNA
transcript as well as any
processing to produce a mature
RNA product or an mRNA or
circRNA (for protein-coding
genes) and the translation of that
mRNA or circRNA into protein.
Protein maturation is included

Turquoise

BP

BP

BP

Turquoise

Turquoise

Turquoise

Turquoise
BP

BP

1.44E-07

RERE, CHRNA3, DRD2, EMX1, GPM6A,
LRP1, PTN, TAOK2, ZEB2, RIMS1,
PLEKHO1, BCL11B, SEMA6D, EMB,
CNTN4

1.51E-07

ARHGAP1, CACNA1D, CALB2, CHRNB4,
GSDME, DRD2, EP300, GRIN2A, LRP1,
NMB, PRKCB, PRKD1, PSMA4, PSMB10,
PTN, RELA, TAOK2, BAG4, ZEB2, AKT3,
TAB1, RIMS1, BANK1, RPTOR

cell projection
morphogenesis

1.55E-07

RERE, CHRNA3, DRD2, EMX1, GPM6A,
LRP1, PTN, TAOK2, ZEB2, RIMS1,
PLEKHO1, BCL11B, SEMA6D, EMB,
CNTN4

regulation of
neurotransmitter secretion

1.56E-07

ATP2A2, CACNA1D, CHRNA3, CHRNB4,
DRD2, MEF2C, PRKCB, RIMS1

1.73E-07

DRD2, EP300, FSHB, LRP1, MEF2C,
NFATC3, PDE4B, PRKD1, RELA, SOX5,
SREBF1, SREBF2, SRPK2, STAR, ASH2L,
ZEB2, DMTF1, STAG1, RAI1, RIMS1,
NSD3, RPTOR, CPEB1, BCL11B, ZNF804A,
BTBD18

regulation of pyloric antrum
smooth muscle contraction

positive regulation of
signalling

positive regulation of gene
expression
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when required to form an active
form of a product from an inactive
precursor form.

GO:2000226

Any process that modulates the
frequency, rate or extent of
pancreatic A cell differentiation.

GO:0007166

A specialised 9+0 non-motile
cilium found in photoreceptor
cells. A ciliary transition zone
called 'photoreceptor connecting
cilium' links the photoreceptor
outer segment to the inner
segment.
A series of molecular signals
initiated by activation of a receptor
on the surface of a cell. The
pathway begins with binding of an
extracellular ligand to a cell
surface receptor, or for receptors
that signal in the absence of a
ligand, by ligand-withdrawal or
the activity of a constitutively
active receptor. The pathway ends
with regulation of a downstream
cellular process, e.g. transcription.

GO:1901894

Any process that modulates the
frequency, rate or extent of an
ATPase-coupled calcium
transmembrane transporter activity

GO:0097733

Turquoise

BP

CC

Turquoise

Turquoise

regulation of pancreatic A
cell differentiation

photoreceptor cell cilium

2.32E-07

EP300, IREB2, MEF2C, NAB2, NFATC3,
RELA, SOX5, SREBF1, SREBF2, CUL3,
ZNF536, ZEB2, CNOT1, GIGYF2, SFMBT1,
GATAD2A, BANK1, OTUD7B, THAP11,
CPEB1, PCGF6

2.32E-07

ALDOA, ARHGAP1, SERPING1, CHRNB4,
DRD2, GRIN2A, LRP1, PDE4B, SIPA1,
SREBF1, SREBF2, AP3B2, DOC2A,
TAOK2, TBC1D5, RABGAP1L, TAB1,
DOP1A, DDHD2, GIGYF2, GPR135,
ANP32E, SLC32A1, CARMIL2, EHBP1L1,
SNX19

2.76E-07

CHRNA3, CHRNB4, DRD2, EP300, FSHB,
GRIN2A, LRP1, MEF2C, NFATC3, PDE4B,
PLCB2, PRKCB, PRKD1, PSMA4, PSMB10,
PTN, PTPRF, RELA, SREBF1, CUL3, BAG4,
ZEB2, TAB1, RIMS1, PLCL2, GIGYF2,
PARD6A, NLGN4X, ESRP2, SEMA6D

3.17E-07

CHRM3, CHRNA3, DRD2, LRP1, MEF2C,
PDE4B, PRKCB, RANGAP1, RELA,
SHMT2, SREBF1, STAR, RPTOR, CPEB1,
HCN1

Turquoise

cell surface receptor
signalling pathway
regulation of calciumtransporting ATPase activity

BP

BP

Turquoise
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Table 6.12: Gene Ontologies for Blue Module Stage Three using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0043231

GO:0044238

GO:0070013

GO:0071726

Definition

Any process that activates or
increases the frequency, rate or
extent of macrophage
proliferation.
Organized structure of
distinctive morphology and
function, bounded by a single or
double lipid bilayer membrane
and occurring within the cell.
Includes the nucleus,
mitochondria, plastids, vacuoles,
and vesicles. Excludes the
plasma membrane.
The chemical reactions and
pathways involving those
compounds which are formed as
a part of the normal anabolic and
catabolic processes. These
processes take place in most, if
not all, cells of the organism.

An organelle lumen that is part
of an intracellular organelle.
Any process that results in a
change in state or activity of a
cell (in terms of movement,
secretion, enzyme production,
gene expression, etc.) as a result
of a diacylated bacterial
lipopeptide stimulus.

Ontology

BP

CC

BP

CC

BP

Module

GO Process

FDR

Blue

positive
regulation of
macrophage
proliferation

2.37E-12

Genes
BNIP3L, CLU, GRM3, HSPD1, HSPE1, MAP3K11,
MMP16, NAGA, PCCB, PRKCB, STAR, STAT6, TBX6,
FXR1, DGKI, GABBR2, VPS45, SATB2, FOXP1,
TM6SF2, RBFOX1, ZSCAN2, TSR1, NDUFA4L2,
PAK6, RALGAPA2, BCL11B, NDRG4, ZFYVE21,
GDPD3, DRC3, YPEL3, C16orf92, MED19

Blue

intracellular
membranebounded
organelle

1.70E-10

BNIP3L, CLU, HSPD1, HSPE1, MMP16, NAGA, PCCB,
PRKCB, STAR, STAT6, TBX6, FXR1, DGKI, VPS45,
SATB2, FOXP1, TM6SF2, RBFOX1, ZSCAN2, TSR1,
NDUFA4L2, PAK6, RALGAPA2, BCL11B, NDRG4,
YPEL3, MED19

Blue

primary
metabolic
process

1.03E-09

Blue

intracellular
organelle
lumen

3.05E-09

BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, MMP16,
NAGA, PCCB, PPP2R3A, PRKCB, STAR, STAT6,
TBX6, FXR1, DGKI, SATB2, FOXP1, TM6SF2,
RBFOX1, ZSCAN2, TSR1, PAK6, BCL11B, NDRG4,
GDPD3, MED19
BNIP3L, CLU, GRM3, HSPD1, HSPE1, MAP3K11,
MMP16, PPP2R3A, PRKCB, STAR, STAT6, TBX6,
FXR1, DGKI, GABBR2, VPS45, SATB2, FOXP1,
TM6SF2, RBFOX1, ZSCAN2, PAK6, RALGAPA2,
BCL11B, NDRG4, YPEL3, MED19

Blue

cellular
response to
diacyl
bacterial
lipopeptide

6.83E-09

BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, MMP16,
NAGA, PCCB, PPP2R3A, PRKCB, STAR, STAT6,
TBX6, FXR1, DGKI, SATB2, FOXP1, TM6SF2,
RBFOX1, ZSCAN2, TSR1, PAK6, BCL11B, NDRG4,
GDPD3, MED19
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GO:0005737

GO:0005515

GO:0080154

GO:0031325

GO:0070052

GO:0006807

All of the contents of a cell
excluding the plasma membrane
and nucleus but including other
subcellular structures.
Interacting selectively and noncovalently with any protein or
protein complex (a complex of
two or more proteins that may
include other nonprotein
molecules).
Any process that modulates the
rate, frequency or extent of
fertilization. Fertilization is the
union of gametes of opposite
sexes during the process of
sexual reproduction to form a
zygote. It involves the fusion of
the gametic nuclei (karyogamy)
and cytoplasm (plasmogamy).
Any process that activates or
increases the frequency, rate or
extent of the chemical reactions
and pathways by which
individual cells transform
chemical substances.
Interacting selectively and noncovalently with a type V
collagen trimer.
The chemical reactions and
pathways involving organic or
inorganic compounds that
contain nitrogen.

CC

MF

Blue

Blue

cytoplasm

protein
binding

Blue

regulation of
fertilization

BP

Blue

positive
regulation of
cellular
metabolic
process

MF

Blue

BP

Blue

BP

collagen V
binding
nitrogen
compound
metabolic
process

1.69E-08

BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, MMP16,
NAGA, PCCB, PRKCB, STAR, STAT6, FXR1, DGKI,
GABBR2, VPS45, TM6SF2, RBFOX1, TSR1,
NDUFA4L2, PAK6, RALGAPA2, NDRG4, ZFYVE21,
GDPD3, DRC3

4.22E-08

BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, NAGA,
PCCB, PPP2R3A, PRKCB, STAR, STAT6, TBX6,
FXR1, DGKI, GABBR2, VPS45, SATB2, FOXP1,
RBFOX1, PAK6, RALGAPA2, BCL11B, NDRG4,
ZFYVE21, MED19

6.19E-08

CLU, HSPD1, HSPE1, MAP3K11, PPP2R3A, PRKCB,
STAR, STAT6, TBX6, FXR1, SATB2, FOXP1,
TM6SF2, RBFOX1, ZSCAN2, PAK6, BCL11B, NDRG4,
MED19

8.68E-08

2.27E-07

2.46E-07

BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, PRKCB,
STAR, STAT6, TBX6, FXR1, SATB2, PAK6, BCL11B,
NDRG4, MED19
BNIP3L, CLU, HSPD1, HSPE1, MMP16, PCCB,
PRKCB, STAR, STAT6, TBX6, FXR1, DGKI, SATB2,
FOXP1, TSR1, PAK6, YPEL3, MED19
BNIP3L, CLU, HSPD1, HSPE1, MAP3K11, MMP16,
NAGA, PCCB, PPP2R3A, PRKCB, STAT6, TBX6,
FXR1, SATB2, FOXP1, RBFOX1, ZSCAN2, TSR1,
PAK6, BCL11B, NDRG4, GDPD3, MED19
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Table 6.13: Gene Ontologies for Brown Module Stage Three using the anRichment function as part of WGCNA in R using the default settings

GOID

GO:0120041

GO:0070013

GO:0099582

GO:0005515

GO:0060078

Definition

Any process that activates or increases
the frequency, rate or extent of
macrophage proliferation.

An organelle lumen that is part of an
intracellular organelle.
Any neurotransmitter receptor activity
that is involved in regulating the
concentration of calcium in the
presynaptic cytosol.
Interacting selectively and non-covalently
with any protein or protein complex (a
complex of two or more proteins that may
include other nonprotein molecules).
Any process that modulates the potential
difference across a post-synaptic
membrane.

Ontolog
y

Module

GO Process

FDR

BP

Brown

positive regulation of macrophage
proliferation

4.06E-08

CC

Brown

intracellular organelle lumen

8.00E-06

MF

Brown

neurotransmitter receptor activity
involved in regulation of presynaptic
cytosolic calcium ion concentration

1.25E-05

MF

Brown

protein binding

2.88E-05

CHRNA2, CHRNA5, PTK2B,
IGSF9B
CHRNA5, ETF1, PTK2B, TCF4,
PSMD6, IGSF9B, SMG6, MAU2,
NGEF, AMBRA1, BOLL,
ZNF408, SETD6, THOC7,
TMEM219

BP

Brown

regulation of postsynaptic membrane
potential

3.17E-05

CHRNA2, CHRNA5, PTK2B,
IGSF9B

Genes
CHRNA2, CHRNA5, ETF1,
PTK2B, TCF4, ATP5MPL,
PSMD6, KCNK7, IGSF9B,
SMG6, MAU2, NGEF,
AMBRA1, AS3MT, BOLL,
ZNF408, SETD6, THOC7,
TMEM219, ASPHD1
CHRNA2, CHRNA5, ETF1,
PTK2B, TCF4, PSMD6, KCNK7,
IGSF9B, SMG6, MAU2, NGEF,
AMBRA1, BOLL, ZNF408,
SETD6, TMEM219
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Table 6.14: Gene Ontology for Turquoise Stage Three using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0071870

GO:0071726

GO:0070016

GO:0005829

Definition
Any process that activates or increases
the frequency, rate or extent of
macrophage proliferation.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme
production, gene expression, etc.) as a
result of a catecholamine stimulus. A
catecholamine is any of a group of
biogenic amines that includes 4-(2aminoethyl) pyrocatechol [4-(2aminoethyl)benzene-1,2-diol] and
derivatives formed by substitution.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme
production, gene expression, etc.) as a
result of a diacylated bacterial
lipopeptide stimulus.
Interacting selectively and noncovalently with the armadillo repeat
domain of a protein, an approximately
40 amino acid long tandemly repeated
sequence motif first identified in the
Drosophila segment polarity protein
armadillo. Arm-repeat proteins are
involved in various processes,
including intracellular signalling and
cytoskeletal regulation.
The part of the cytoplasm that does not
contain organelles, but which does
contain other particulate matter, such
as protein complexes.

Ontology

Module

GO Process

FDR

Genes

BP

Turquoise

positive regulation of
macrophage proliferation

5.64E77

More than 50 overlapping genes

BP

Turquoise

cellular response to
catecholamine stimulus

4.05E29

More than 50 overlapping genes

BP

Turquoise

cellular response to diacyl
bacterial lipopeptide

1.01E23

More than 50 overlapping genes

MF

Turquoise

armadillo repeat domain
binding

2.25E18

More than 50 overlapping genes

CC

Turquoise

cytosol

7.69E18

More than 50 overlapping genes
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GO:0070052

GO:0033554

GO:0043232

GO:0097178
GO:1901666

Interacting selectively and noncovalently with a type V collagen
trimer.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme
production, gene expression, etc.) as a
result of a stimulus indicating the
organism is under stress. The stress is
usually, but not necessarily, exogenous
(e.g. temperature, humidity, ionizing
radiation).

Organised structure of distinctive
morphology and function, not bounded
by a lipid bilayer membrane and
occurring within the cell. Includes
ribosomes, the cytoskeleton and
chromosomes.
The aggregation, arrangement and
bonding together of a set of
components to form a ruffle, a
projection at the leading edge of a
crawling cell; the protrusions are
supported by a microfilament
meshwork. The formation of ruffles
(also called membrane ruffling) is
thought to be controlled by a group of
enzymes known as Rho GTPases,
specifically RhoA, Rac1 and cdc42.
Any process that activates or increases
the frequency, rate or extent of NAD+

MF

Turquoise

collagen V binding

1.91E15

BP

Turquoise

cellular response to stress

4.35E14

CC

Turquoise

intracellular non-membranebounded organelle

5.38E14

BP

Turquoise

BP

Turquoise

ruffle assembly
positive regulation of NAD+
ADP-ribosyltransferase

7.53E14
1.35E13

More than 50 overlapping genes

ATP2A2, EP300, LRP1, MEF2C, MSRA,
NEK1, MAPK3, PSMA4, PSMB10, PTN,
PTPRF, RELA, SIPA1, SREBF1, SREBF2,
XRCC3, CUL3, ASH2L, TAOK2, BAG4,
ATG13, AKT3, TAB1, CNOT1, B3GAT1,
VPS13C, FANCL, RPTOR, CPEB1, ACD,
ACTR5, IMMP2L, CREB3L1, INO80E
CACNA1C, EMX1, EP300, FGFR1, MEF2C,
MSRA, NEK1, MAPK3, PSMA4, RELA,
SHMT2, SRPK2, XRCC3, ALMS1,
MAD1L1, DOC2A, CUL3, HIRIP3, ASH2L,
INA, TAOK2, MPHOSPH9, STAG1,
SDCCAG8, RIMS1, CNOT1, DDHD2,
SPATS2L, LSM1, ARL6IP4, HYDIN,
GATAD2A, NSD3, DDX28, RPTOR,
CPEB1, ACD, CENPM, ACTR5, CREB3L1,
C12orf65, RPS19BP1, ZNF804A, TDRD9,
CARMIL2, WBP2NL, RILPL2, YPEL4,
HARBI1, INO80E

More than 50 overlapping genes
Formatted: Font: (Default) Times New Roman, Font color:
Black, Pattern: Clear

More than 50 overlapping genes
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GO:1901679

GO:1901561

GO:1901555

GO:0005654

GO:0080154

GO:0010604

ADP-ribosyltransferase activity.
The directed movement of nucleotide
across a membrane.
Any process that results in a change in
state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
benomyl stimulus.
Any process that results in a change in
state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
paclitaxel stimulus.

That part of the nuclear content other
than the chromosomes or the
nucleolus.
Any process that modulates the rate,
frequency or extent of fertilization.
Fertilization is the union of gametes of
opposite sexes during the process of
sexual reproduction to form a zygote.
It involves the fusion of the gametic
nuclei (karyogamy) and cytoplasm
(plasmogamy).
Any process that increases the
frequency, rate or extent of the
chemical reactions and pathways
involving macromolecules, any

BP

Turquoise

activity
nucleotide transmembrane
transport

BP

Turquoise

response to benomyl

1.71E13

BP

Turquoise

response to paclitaxel

1.71E13

CC

Turquoise

nucleoplasm

2.85E13

BP

Turquoise

regulation of fertilization

1.39E12

Turquoise

positive regulation of
macromolecule metabolic
process

1.59E12

BP

1.45E13

More than 50 overlapping genes

More than 50 overlapping genes

More than 50 overlapping genes
RERE, ATP2A2, EP300, MEF2C, MSRA,
NFATC3, PPP2R2A, MAPK3, PSMA4,
PSMB10, RELA, SREBF1, SREBF2, SRPK2,
XRCC3, CUL3, ASH2L, INA, DMTF1,
NUTF2, STAG1, TAB1, RAI1, CLP1,
PPP1R13B, PLA2G15, ARL6IP4,
GATAD2A, NSD3, FANCL, MSL2,
THAP11, RPTOR, SUGP1, CPEB1, ACD,
CENPM, ACTR5, RPS19BP1, ATPAF2,
STAC3, INO80E

More than 50 overlapping genes
RERE, GSDME, DRD2, EP300, F2, FGFR1,
FSHB, GRIN2A, LRP1, MEF2C, NAB2,
NEK1, NFATC3, MAPK3, RELA, SOX5,
SREBF1, SREBF2, SRPK2, CUL3, ASH2L,
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molecule of high relative molecular
mass, the structure of which essentially
comprises the multiple repetition of
units derived, actually or conceptually,
from molecules of low relative
molecular mass.

GO:0003824

GO:0120060

GO:0048513

Catalysis of a biochemical reaction at
physiological temperatures. In
biologically catalysed reactions, the
reactants are known as substrates, and
the catalysts are naturally occurring
macromolecular substances known as
enzymes. Enzymes possess specific
binding sites for substrates, and are
usually composed wholly or largely of
protein, but RNA that has catalytic
activity (ribozyme) is often also
regarded as enzymatic.

Any process that modulates the
frequency, rate or extent of any gastric
emptying process, the process in which
the liquid and liquid-suspended solid
contents of the stomach exit through
the pylorus into the duodenum.
Development of a tissue or tissues that
work together to perform a specific
function or functions. Development
pertains to the process whose specific
outcome is the progression of a
structure over time, from its formation
to the mature structure. Organs are
commonly observed as visibly distinct
structures but may also exist as loosely
associated clusters of cells that work

TAOK2, BAG4, ATG13, TBC1D5, DMTF1,
STAG1, TAB1, RAI1, RIMS1, CNOT1,
NDFIP2, NSD3, RPTOR, CPEB1, ACD,
CREB3L1, ZNF804A, TNFRSF13C,
WBP2NL, BTBD18

MF

Turquoise

catalytic activity

1.69E12

regulation of gastric emptying

2.44E12

More than 50 overlapping genes
ATP2A2, CACNA1C, CHRNB4, DRD2,
GPM6A, GRIN2A, LRP1, NMB, NRGN,
MAPK3, PTPRF, ALMS1, AP3B2, DOC2A,
CUL3, TAOK2, SDCCAG8, PSD3,
ZDHHC5, LSM1, PLEKHO1, HYDIN,
RPTOR, CPEB1, ZNF804A, EMB,
SLC32A1, CARMIL2, CNTN4, WBP2NL,
RILPL2, HCN1

2.56E12

SERPINC1, RERE, CACNA1C, GSDME,
DRD2, EMX1, EP300, FGFR1, FSHB,
GPM6A, GRIN2A, IREB2, LRP1, MEF2C,
NAB2, NRGN, PGM3, MAPK3, PSMA4,
PSMB10, PTN, RELA, SOX5, SREBF1,
MAD1L1, CUL3, ASH2L, INA, AKAP6,
AKT3, TAB1, CLP1, HYDIN, ALPK3,
IMMP2L, DNAJC19, SLC32A1, CNTN4,
STAC3, HCN1, SNORC

Turquoise
BP

BP

Turquoise

animal organ development
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GO:0090317

together to perform a specific function
or functions.
Any process that decreases the
frequency, rate or extent of the
directed movement of proteins within
cells.

BP

Turquoise

negative regulation of
intracellular protein transport

5.06E12

GO:0031325

Any process that activates or increases
the frequency, rate or extent of the
chemical reactions and pathways by
which individual cells transform
chemical substances.

BP

Turquoise

positive regulation of cellular
metabolic process

5.77E12

GO:0051173

Any process that activates or increases
the frequency, rate or extent of the
chemical reactions and pathways
involving nitrogen or nitrogenous
compounds.

BP

Turquoise

positive regulation of
nitrogen compound metabolic
process

3.82E11

CC

Turquoise

Ragulator complex

4.75E11

Turquoise

intracellular signal
transduction

5.12E11

GO:0071986

GO:0035556

A eukaryotically conserved protein
complex; in humans, it is comprised of
LAMTOR1, LAMTOR2, LAMTOR3,
LAMTOR4, and LAMTOR5. The
complex is anchored to lipid rafts in
late endosome membranes via
LAMTOR1, constitutes a guanine
nucleotide exchange factor (GEF) for
the Rag GTPases.
The process in which a signal is passed
on to downstream components within
the cell, which become activated
themselves to further propagate the

BP

More than 50 overlapping genes
RERE, GSDME, DRD2, EP300, F2, FGFR1,
FSHB, GRIN2A, LRP1, MEF2C, NAB2,
NEK1, NFATC3, MAPK3, RELA, SOX5,
SREBF1, SREBF2, CUL3, ASH2L, TAOK2,
BAG4, ATG13, TBC1D5, DMTF1, STAG1,
TAB1, RAI1, CNOT1, NDFIP2, VPS13C,
NSD3, RPTOR, CPEB1, ACD, CREB3L1,
TNFRSF13C, WBP2NL, BTBD18
RERE, GSDME, DRD2, EP300, F2, FGFR1,
FSHB, GRIN2A, LRP1, MEF2C, NAB2,
NEK1, NFATC3, MAPK3, RELA, SOX5,
SREBF1, SREBF2, CUL3, ASH2L, TAOK2,
BAG4, ATG13, DMTF1, STAG1, TAB1,
RAI1, CNOT1, NDFIP2, NSD3, RPTOR,
CPEB1, ACD, CREB3L1, TNFRSF13C,
WBP2NL, BTBD18
SERPINC1, ATP2A2, CACNA1C, CHRNB4,
CLCN3, GSDME, DRD2, F2, FGFR1,
GPM6A, GRIN2A, LRP1, NRGN, MAPK3,
PTN, PTPRF, CACNA1I, SLC7A6, GPR52,
AKAP6, BAG4, RGS6, PLCH2, TBC1D5,
SNAP91, RIMS1, PSD3, PPP1R13B, VSIG2,
CA14, ZDHHC5, SEZ6L2, PLEKHO1,
MPP6, SLC39A8, DPEP3, CPEB1, GPR135,
ESAM, ZNF804A, TNFRSF13C, EMB,
SLC32A1, CPNE8, CARMIL2, CNTN4,
STAC3, HARBI1, HCN1, SNORC
ATP2A2, CA8, CACNA1C, GSDME, DRD2,
EP300, F2, FGFR1, GRIN2A, LRP1,
MEF2C, NEK1, NFATC3, MAPK3, PSMA4,
PSMB10, RELA, SIPA1, SRPK2, CUL3,
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signal and finally trigger a change in
the function or state of the cell.

GO:0046872

Interacting selectively and noncovalently with any metal ion.

MF

Turquoise

metal ion binding

7.72E11

GO:0005886

The membrane surrounding a cell that
separates the cell from its external
environment. It consists of a
phospholipid bilayer and associated
proteins.

CC

Turquoise

plasma membrane

8.47E11

BP

Turquoise

response to metformin

2.46E10

BP

Turquoise

cellular protein modification
process

2.46E10

GO:1901558

GO:0006464

Any process that results in a change in
state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
metformin stimulus.
The covalent alteration of one or more
amino acids occurring in proteins,
peptides and nascent polypeptides (cotranslational, post-translational

TAOK2, AKAP6, BAG4, RGS6, PLCH2,
AKT3, TAB1, CNOT1, PSD3, PPP1R13B,
NDFIP2, OTUD7B, RPTOR, CREB3L1,
STAC3
RERE, ATP2A2, CA8, CACNA1C, DPYD,
EP300, F2, GRIN2A, IREB2, LRP1, NEK1,
PGM3, SHMT2, SRPK2, DOC2A, ASH2L,
ZNF592, PLCH2, ZNF536, RAI1, NT5C2,
RIMS1, DDHD2, ZC3H7B, CA14, MOB4,
B3GAT1, GATAD2A, NSD3, FANCL,
MSL2, ZNF823, OTUD7B, THAP11,
DPEP2, DPEP3, CPEB1, ZBTB37,
ZNF804A, YPEL4, STAC3, HARBI1
SERPINC1, ATP2A2, CACNA1C, CHRNB4,
CLCN3, GSDME, DRD2, F2, FGFR1,
GPM6A, GRIN2A, LRP1, NRGN, MAPK3,
PTN, PTPRF, CACNA1I, SLC7A6, GPR52,
AKAP6, BAG4, RGS6, PLCH2, TBC1D5,
SNAP91, RIMS1, PSD3, PPP1R13B, VSIG2,
CA14, ZDHHC5, SEZ6L2, PLEKHO1,
MPP6, SLC39A8, DPEP3, CPEB1, GPR135,
ESAM, ZNF804A, TNFRSF13C, EMB,
SLC32A1, CPNE8, CARMIL2, CNTN4,
STAC3, HARBI1, HCN1
RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, IREB2, MEF2C, NAB2, NFATC3,
PGM3, MAPK3, PSMA4, PSMB10, RELA,
SOX5, SREBF1, SREBF2, CUL3, ASH2L,
ZNF592, ZNF536, DMTF1, STAG1, TAB1,
RAI1, CLP1, NT5C2, CNOT1, GATAD2A,
NSD3, ZNF823, OTUD7B, THAP11,
RPTOR, SCAF1, ACD, ACTR5, ZBTB37,
CREB3L1, WBP2NL, BTBD18
SERPINC1, GSDME, DRD2, EP300, F2,
FGFR1, LRP1, MEF2C, MSRA, NAB2,
NEK1, PGM3, PPP2R2A, MAPK3, PSMA4,
PSMB10, PTN, PTPRF, RELA, SHMT2,
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modifications) occurring at the level of
an individual cell. Includes the
modification of charged tRNAs that
are destined to occur in a protein (pretranslation modification).

GO:0050793

GO:0098631

GO:0097707

Any process that modulates the
frequency, rate or extent of
development, the biological process
whose specific outcome is the
progression of a multicellular
organism over time from an initial
condition (e.g. a zygote, or a young
adult) to a later condition (e.g. a
multicellular animal or an aged adult).

The binding by a cell-adhesion protein
on the cell surface to an extracellular
matrix component, to mediate
adhesion of the cell to the external
substrate or to another cell.
A programmed cell death
characterized morphologically by the
presence of smaller than normal
mitochondria with condensed
mitochondrial membrane densities,
reduction or vanishing of mitochondria
crista, and outer mitochondrial
membrane rupture. Activation of
mitochondrial voltage-dependent anion
channels and mitogen-activated
protein kinases, upregulation of
endoplasmic reticulum stress, and
inhibition of cystine/glutamate
antiporter are involved in the induction
of ferroptosis. This process is

SREBF1, SRPK2, CUL3, ASH2L, TAOK2,
BAG4, ATG13, AKT3, TAB1, ZDHHC5,
B3GAT1, NDFIP2, NSD3, FANCL, MSL2,
OTUD7B, RPTOR, ALPK3, ACTR5,
HS3ST5, INO80E

BP

Turquoise

regulation of developmental
process

2.46E10

MF

Turquoise

cell adhesion mediator
activity

2.85E10

DRD2, EMX1, EP300, F2, FGFR1, FSHB,
LRP1, MEF2C, NAB2, NFATC3, PSMA4,
PSMB10, PTN, PTPRF, RELA, SOX5,
ASH2L, TAOK2, AKAP6, ZNF536, AKT3,
RAI1, EPN2, RIMS1, CNOT1, DDHD2,
LSM1, PLEKHO1, TLCD3B, CREB3L1,
ZNF804A, TNFRSF13C, CNTN4
ATP2A2, CHRNB4, CLCN3, DRD2, LRP1,
NRGN, SREBF1, SREBF2, AP3B2, DOC2A,
CUL3, AKAP6, TBC1D5, MPHOSPH9,
NUTF2, TAB1, EPN2, DOP1A, ABCB9,
MOB4, B3GAT1, NDFIP2, VPS13C,
RPTOR, GPR135, TLCD3B, BORCS7,
SLC32A1, HS3ST5

4.03E10

RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, MEF2C, NAB2, NFATC3, MAPK3,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
DMTF1, STAG1, TAB1, RAI1, CLP1,
CNOT1, GATAD2A, NSD3, ZNF823,
OTUD7B, THAP11, RPTOR, SCAF1,
ACTR5, ZBTB37, CREB3L1, WBP2NL,
BTBD18

Turquoise
BP

ferroptosis
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characterized by the accumulation of
lipid peroxidation products and lethal
reactive oxygen species (ROS) derived
from iron metabolism. Glutathione
peroxidase 4 (GPX4), heat shock
protein beta-1, and nuclear factor
erythroid 2-related factor 2 function as
negative regulators of ferroptosis by
limiting ROS production and reducing
cellular iron uptake, respectively. In
contrast, NADPH oxidase and p53 act
as positive regulators of ferroptosis by
promotion of ROS production and
inhibition of expression of SLC7A11
(a specific light-chain subunit of the
cystine/glutamate antiporter),
respectively. Misregulated ferroptosis
has been implicated in multiple
physiological and pathological
processes.

GO:0003676

Interacting selectively and noncovalently with any nucleic acid.

MF

Turquoise

nucleic acid binding

5.31E10

negative regulation of
testosterone biosynthetic
process

7.81E10

Turquoise

GO:2000225

Any process that stops, prevents, or
reduces the frequency, rate or extent of
testosterone biosynthetic process.

BP

RERE, EMX1, EP300, IREB2, LRP1,
MEF2C, NFATC3, RELA, SOX5, SREBF1,
SREBF2, SRPK2, XRCC3, BAG4, ZNF592,
ZNF536, DMTF1, R3HDM2, RIMS1,
CNOT1, ZC3H7B, SPATS2L, LSM1,
ARL6IP4, GATAD2A, ZNF823, DDX28,
OTUD7B, THAP11, SUGP1, SCAF1,
CPEB1, ACD, ZBTB37, CREB3L1,
C12orf65, RPS19BP1, ZNF804A, TDRD9,
WBP2NL, SELENOH
RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, IREB2, MEF2C, NAB2, NFATC3,
MAPK3, PSMA4, PSMB10, RELA, SHMT2,
SOX5, SREBF1, SREBF2, CUL3, ASH2L,
ZNF592, ZNF536, DMTF1, STAG1, TAB1,
RAI1, CNOT1, GATAD2A, NSD3, ZNF823,
OTUD7B, THAP11, RPTOR, CPEB1, ACD,
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ACTR5, ZBTB37, CREB3L1, BTBD18

GO:0051130

Any process that activates or increases
the frequency, rate or extent of a
process involved in the formation,
arrangement of constituent parts, or
disassembly of cell structures,
including the plasma membrane and
any external encapsulating structures
such as the cell wall and cell envelope.

GO:0120069

Any process that increases the
frequency, rate or extent of any
stomach fundus smooth muscle
contraction.

GO:1903593

Any process that modulates the
frequency, rate or extent of histamine
secretion by mast cell.

GO:0016021
GO:2001234

The component of a membrane
consisting of the gene products and
protein complexes having at least
some part of their peptide sequence
embedded in the hydrophobic region
of the membrane.
Any process that stops, prevents or
reduces the frequency, rate or extent of

Turquoise

positive regulation of cellular
component organization

1.03E09

BP

Turquoise

positive regulation of
stomach fundus smooth
muscle contraction

2.08E09

BP

Turquoise

regulation of histamine
secretion by mast cell

2.25E09

integral component of
membrane
negative regulation of
apoptotic signalling pathway

2.25E09
2.32E09

BP

Turquoise
CC
BP

DRD2, EP300, FGFR1, GPM6A, LRP1,
MAPK3, PTN, SREBF1, SREBF2, CUL3,
BAG4, ATG13, TBC1D5, RIMS1, CNOT1,
DDHD2, PPP1R13B, VPS13C, NSD3, ACD,
ZNF804A, CARMIL2
RERE, DRD2, EMX1, EP300, FGFR1,
GPM6A, LRP1, MEF2C, NEK1, MAPK3,
PTN, PTPRF, ALMS1, TAOK2, BAG4,
SDCCAG8, RIMS1, PLEKHO1, HYDIN,
ZNF804A, EMB, CARMIL2, CNTN4,
RILPL2
RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, MEF2C, NAB2, NFATC3, MAPK3,
PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
DMTF1, STAG1, TAB1, RAI1, CNOT1,
GATAD2A, NSD3, ZNF823, OTUD7B,
THAP11, RPTOR, ACTR5, ZBTB37,
CREB3L1, WBP2NL, BTBD18
ATP2A2, CACNA1C, CHRNB4, CLCN3,
DRD2, FGFR1, GPM6A, GRIN2A, LRP1,
PTPRF, SREBF1, SREBF2, CACNA1I,
SLC7A6, GPR52, TAOK2, AKAP6, ABCB9,
VSIG2, CA14, ZDHHC5, SEZ6L2, B3GAT1,
SLC45A1, TMX2, AIG1, NDFIP2,
SLC39A8, GPR135, TLCD3B, IMMP2L,
ESAM, CREB3L1, SFXN5, TNFRSF13C,
DNAJC19, EMB, SLC32A1, TSNARE1,
KIAA1324L, HS3ST5, STAC3, HCN1,
SNORC, PCNX3
RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, MEF2C, NAB2, NFATC3, MAPK3,
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apoptotic signalling pathway.

Turquoise

GO:0071727

GO:0048699

GO:0033043

GO:0007049

GO:0030054

Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme
production, gene expression, etc.)
because of a triacylated bacterial
lipopeptide stimulus.
The process in which nerve cells are
generated. This includes the
production of neuroblasts and their
differentiation into neurons.
Any process that modulates the
frequency, rate or extent of a process
involved in the formation, arrangement
of constituent parts, or disassembly of
an organelle.
The progression of biochemical and
morphological phases and events that
occur in a cell during successive cell
replication or nuclear replication
events. Canonically, the cell cycle
comprises the replication and
segregation of genetic material
followed by the division of the cell,
but in endocycles or syncytial cells
nuclear replication or nuclear division
may not be followed by cell division.
A cellular component that forms a
specialized region of connection
between two or more cells or between

BP

Turquoise

cellular response to triacyl
bacterial lipopeptide

2.75E09

BP

Turquoise

generation of neurons

2.92E09

BP

Turquoise

regulation of organelle
organization

3.22E09

BP

CC

Turquoise

cell cycle

4.58E09

cell junction

4.95E09

PSMA4, PSMB10, RELA, SOX5, SREBF1,
SREBF2, CUL3, ASH2L, ZNF592, ZNF536,
DMTF1, STAG1, TAB1, RAI1, CNOT1,
GATAD2A, NSD3, ZNF823, OTUD7B,
THAP11, RPTOR, ACTR5, ZBTB37,
CREB3L1, WBP2NL, BTBD18
CACNA1C, DRD2, LRP1, MAPK3,
SREBF1, SREBF2, AP3B2, SLC7A6,
TAOK2, AKAP6, BAG4, ATG13, TBC1D5,
SNAP91, NUTF2, RIMS1, DOP1A,
PPP1R13B, ABCB9, NDFIP2, VPS13C,
ACD, MAIP1, IMMP2L, SFXN5, DNAJC19,
SLC32A1, TOM1L2, RILPL2, TSNARE1
RERE, GSDME, DRD2, EMX1, EP300, F2,
FGFR1, GPM6A, LRP1, MEF2C, MAPK3,
PTN, PTPRF, RELA, SOX5, TAOK2,
ZNF536, SDCCAG8, RIMS1, LSM1,
ZNF804A, EMB, CNTN4, HCN1
LRP1, MEF2C, MAPK3, SREBF1, SREBF2,
XRCC3, ALMS1, MAD1L1, CUL3, TAOK2,
BAG4, ATG13, STAG1, SDCCAG8,
CNOT1, DDHD2, PPP1R13B, VPS13C,
NSD3, ACD, CARMIL2, TOM1L2

DRD2, EP300, FGFR1, NEK1, PPP2R2A,
MAPK3, PSMA4, PSMB10, SIPA1, SRPK2,
XRCC3, ALMS1, MAD1L1, CUL3, TAOK2,
DMTF1, STAG1, SDCCAG8, CNOT1,
PPP1R13B, RPTOR, DPEP3, TDRD9,
TOM1L2, WBP2NL, BTBD18
ATP2A2, CACNA1C, CHRNB4, CLCN3,
DRD2, GPM6A, GRIN2A, LRP1, MEF2C,
NRGN, PPP2R2A, MAPK3, PTN, RELA,
234

a cell and the extracellular matrix. At a
cell junction, anchoring proteins
extend through the plasma membrane
to link cytoskeletal proteins in one cell
to cytoskeletal proteins in
neighbouring cells or to proteins in the
extracellular matrix.

DOC2A, INA, AKAP6, SNAP91,
SDCCAG8, RIMS1, PSD3, CPEB1, ESAM,
ZNF804A, EMB, SLC32A1

Turquoise

GO:0045202

The process whose specific outcome is
the progression of the cell over time,
from its formation to the mature
structure. Cell development does not
include the steps involved in
committing a cell to a specific fate.
The junction between a nerve fibre of
one neuron and another neuron,
muscle fibre or glial cell. As the nerve
fibre approaches the synapse it
enlarges into a specialized structure,
the presynaptic nerve ending, which
contains mitochondria and synaptic
vesicles. At the tip of the nerve ending
is the presynaptic membrane; facing it
and separated from it by a minute cleft
(the synaptic cleft) is a specialized area
of membrane on the receiving cell,
known as the postsynaptic membrane.
In response to the arrival of nerve
impulses, the presynaptic nerve ending
secretes molecules of
neurotransmitters into the synaptic
cleft. These diffuse across the cleft and
transmit the signal to the postsynaptic
membrane.

CC

synapse

6.10E09

GO:0034220

A process in which an ion is
transported across a membrane.

BP

ion transmembrane transport

7.66E09

GO:0048468

BP

Turquoise

cell development

5.13E09

Turquoise

RERE, ATP2A2, DRD2, EMX1, EP300, F2,
FGFR1, GPM6A, LRP1, MEF2C, MAPK3,
PTN, PTPRF, RELA, CUL3, TAOK2,
AKAP6, ZNF536, RIMS1, LSM1, HYDIN,
ALPK3, ZNF804A, EMB, CNTN4, RILPL2,
STAC3, HCN1

ATP2A2, CACNA1C, CHRNB4, CLCN3,
DRD2, GPM6A, GRIN2A, MEF2C, NRGN,
PPP2R2A, PTN, RELA, DOC2A, INA,
SNAP91, RIMS1, PSD3, CPEB1, ZNF804A,
EMB, SLC32A1
ATP2A2, CACNA1C, CHRNB4, CLCN3,
DRD2, F2, GPM6A, GRIN2A, MEF2C,
CACNA1I, SLC7A6, AKAP6, PLCH2,
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Turquoise

GO:0006357

Any process that modulates the
frequency, rate or extent of
transcription mediated by RNA
polymerase II.

GO:0060322

Interacting selectively and noncovalently with anions, charged atoms
or groups of atoms with a net negative
charge.
The biological process whose specific
outcome is the progression of a head
from an initial condition to its mature
state. The head is the anterior-most
division of the body.

GO:0019899

Interacting selectively and noncovalently with any enzyme.

GO:0043168

GO:0006928

GO:0010647

The directed, self-propelled movement
of a cell or subcellular component
without the involvement of an external
agent such as a transporter or a pore.
Any process that increases the
frequency, rate or extent of cell
communication. Cell communication
is the process that mediates

BP

Turquoise

regulation of transcription by
RNA polymerase II

1.01E08

MF

Turquoise

anion binding

1.03E08

BP

Turquoise

head development

2.76E08

MF

Turquoise

enzyme binding

3.58E08

BP

movement of cell or
subcellular component

3.63E08

BP

positive regulation of cell
communication

4.57E08

Turquoise

ABCB9, SLC39A8, MAIP1, SFXN5, EMB,
SLC32A1, STAC3, HCN1
RERE, DRD2, EMX1, EP300, FGFR1,
FSHB, MEF2C, NFATC3, MAPK3, PSMA4,
PSMB10, RELA, SOX5, SREBF1, SREBF2,
CUL3, ASH2L, ZNF592, ZNF536, DMTF1,
STAG1, RAI1, CNOT1, GATAD2A,
ZNF823, OTUD7B, THAP11, ZBTB37,
CREB3L1, BTBD18
SERPINC1, ATP2A2, CLCN3, GSDME,
DPYD, F2, FGFR1, LRP1, NEK1, NRGN,
MAPK3, PTN, PTPRF, RELA, SHMT2,
SRPK2, XRCC3, DOC2A, TAOK2, SNAP91,
AKT3, CLP1, ABCB9, PLA2G15, DDX28,
ALPK3, TDRD9, CPNE8, CARMIL2,
HS3ST5, HCN1
RERE, DRD2, EMX1, EP300, FGFR1,
GRIN2A, LRP1, NRGN, MAPK3, PTN, INA,
AKT3, CLP1, HYDIN, IMMP2L, SLC32A1,
CNTN4
SERPINC1, ATP2A2, LRP1, MEF2C,
PPP2R2A, MAPK3, PTN, RELA, SREBF1,
CUL3, TAOK2, AKAP6, BAG4, ATG13,
TBC1D5, SNAP91, NUTF2, TAB1, RIMS1,
PSD3, FANCL, RPTOR, SCAF1, ACD,
RPS19BP1, TOM1L2, RILPL2
RERE, ATP2A2, CACNA1C, DRD2, F2,
FGFR1, FSHB, GPM6A, LRP1, MEF2C,
MAPK3, PTN, PTPRF, AP3B2, CUL3,
CACNA1I, SLC7A6, TAOK2, BAG4, AKT3,
SDCCAG8, PLEKHO1, HYDIN, ESAM,
EMB, CARMIL2, CNTN4
CHRNB4, GSDME, DRD2, EP300, F2,
FGFR1, GRIN2A, LRP1, NMB, NRGN,
MAPK3, PSMA4, PSMB10, PTN, RELA,
TAOK2, AKAP6, BAG4, AKT3, TAB1,
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interactions between a cell and its
surroundings. Encompasses
interactions such as signalling or
attachment between one cell and
another cell, between a cell and an
extracellular matrix, or between a cell
and any other aspect of its
environment.

EPN2, RIMS1, PPP1R13B, NDFIP2, RPTOR

Turquoise

GO:0070762

A subcomplex of the nuclear pore
complex (NPC) that spans the nuclear
membrane and anchors the NPC to the
nuclear envelope. In S. cerevisiae, the
transmembrane ring is composed of
Pom152p, Pom34p, and Ndc1p. In
vertebrates, it is composed of Gp210,
Ndc1, and Pom121. Components are
arranged in 8-fold symmetrical
'spokes' around the central transport
channel. A single 'spoke', can be
isolated and is sometime referred to as
the Ndc1 complex.

CC

Turquoise

nuclear pore transmembrane
ring

4.65E08

GO:0042592

Any biological process involved in the
maintenance of an internal steady
state.

BP

Turquoise

homeostatic process

4.67E08

GO:0023056

Any process that activates, maintains
or increases the frequency, rate or
extent of a signalling process.

BP

positive regulation of
signalling

4.85E08

GO:0070025

Interacting selectively and noncovalently with carbon monoxide
(CO).

MF

carbon monoxide binding

6.02E08

Turquoise

F2, GRIN2A, LRP1, PTN, SREBF1,
SREBF2, AP3B2, TAOK2, AKAP6, BAG4,
ATG13, TBC1D5, NUTF2, RIMS1,
PPP1R13B, VPS13C, OTUD7B, ACD,
MAIP1, IMMP2L, DNAJC19, TOM1L2,
RILPL2, TSNARE1, STAC3
ATP2A2, CACNA1C, CLCN3, DRD2,
EMX1, F2, FSHB, GRIN2A, IREB2, LCAT,
LRP1, MEF2C, NMB, MAPK3, SREBF2,
XRCC3, ALMS1, AKAP6, PLCH2, AKT3,
TMX2, SLC39A8, ACD, MAIP1,
TNFRSF13C
CHRNB4, GSDME, DRD2, EP300, F2,
FGFR1, GRIN2A, LRP1, NMB, NRGN,
MAPK3, PSMA4, PSMB10, PTN, RELA,
TAOK2, AKAP6, BAG4, AKT3, TAB1,
EPN2, RIMS1, PPP1R13B, NDFIP2, RPTOR
SERPINC1, CACNA1C, DRD2, EP300, F2,
FGFR1, FSHB, GRIN2A, LRP1, MEF2C,
NAB2, NEK1, PPP2R2A, MAPK3, PTN,
PTPRF, RELA, SIPA1, TAOK2, AKAP6,
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Turquoise

BP

Turquoise

locomotion

6.02E08

GO:0097733

Self-propelled movement of a cell or
organism from one location to another.
A specialised 9+0 non-motile cilium
found in photoreceptor cells. A ciliary
transition zone called 'photoreceptor
connecting cilium' links the
photoreceptor outer segment to the
inner segment.

CC

Turquoise

photoreceptor cell cilium

8.68E08

Turquoise

GO:0006796

The chemical reactions and pathways
involving the phosphate group, the
anion or salt of any phosphoric acid.

BP

phosphate-containing
compound metabolic process

1.35E07

mitochondrial tRNA
methylation

2.13E07

CC

coated vesicle

2.27E07

BP

catabolic process

2.37E07

GO:0040011

GO:0070901

GO:0030135

GO:0009056

The posttranscriptional addition of
methyl groups to specific residues in a
mitochondrial tRNA molecule.
Small membrane-bounded organelle
formed by pinching off of a coated
region of membrane. Some coats are
made of clathrin, whereas others are
made from other proteins.
The chemical reactions and pathways
resulting in the breakdown of
substances, including the breakdown

BP

Turquoise

Turquoise

BAG4, RGS6, ATG13, TBC1D5, TAB1,
RIMS1, NDFIP2, RPTOR, ACD, DNAJC19,
STAC3
RERE, DRD2, EP300, F2, FGFR1, FSHB,
GPM6A, GRIN2A, LRP1, MEF2C, MAPK3,
PTN, PTPRF, CUL3, CACNA1I, SLC7A6,
TAOK2, BAG4, AKT3, SDCCAG8,
PLEKHO1, ESAM, EMB, CARMIL2,
CNTN4
CHRNB4, CLCN3, DRD2, FGFR1, GRIN2A,
LRP1, NRGN, MAPK3, SIPA1, SREBF1,
SREBF2, AP3B2, DOC2A, TAOK2,
TBC1D5, SNAP91, TAB1, EPN2, DOP1A,
DDHD2, NDFIP2, DPEP3, GPR135,
SLC32A1, CARMIL2, PHETA2, EHBP1L1
GSDME, DRD2, F2, FGFR1, LCAT, LRP1,
MEF2C, NAB2, NEK1, PGM3, PPP2R2A,
MAPK3, PSMA4, PSMB10, PTN, PTPRF,
SHMT2, SRPK2, CUL3, INPP4B, TAOK2,
BAG4, PLCH2, ATG13, AKT3, TAB1,
CLP1, NT5C2, DDHD2, PLA2G15, RPTOR,
ALPK3
ATP2A2, GSDME, DRD2, EP300, FGFR1,
FSHB, LRP1, MEF2C, MSRA, MAPK3,
PSMA4, PSMB10, PTN, RELA, SHMT2,
SIPA1, SOX5, SREBF1, CUL3, INA,
AKAP6, BAG4, TAB1, EPN2, CNOT1,
B3GAT1, RPTOR, CPEB1, CREB3L1,
TNFRSF13C, CPNE8, HCN1

LRP1, NRGN, SREBF1, SREBF2, AP3B2,
TBC1D5, SNAP91, EPN2, DDHD2,
SLC32A1, PHETA2
CTRL, DPYD, DRD2, EP300, GRIN2A,
LRP1, PPP2R2A, MAPK3, PSMA4,
PSMB10, RELA, SHMT2, SREBF1,
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of carbon compounds with the
liberation of energy for use by the cell
or organism.

SREBF2, CUL3, PLCH2, ATG13, TBC1D5,
NT5C2, CNOT1, DDHD2, PLA2G15, LSM1,
AIG1, NDFIP2, VPS13C, OTUD7B, RPTOR
Turquoise

GO:0000902

The developmental process in which
the size or shape of a cell is generated
and organized.

BP

Turquoise

cell morphogenesis

2.46E07

RERE, DRD2, EMX1, EP300, F2, GPM6A,
LRP1, MEF2C, MAPK3, PSMB10, PTN,
CUL3, TAOK2, RIMS1, PLEKHO1, EMB,
CNTN4, RILPL2
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Table 6.15: Gene Ontology for Yellow Module Stage Three using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0005488

Definition
The selective, non-covalent, often
stoichiometric, interaction of a molecule
with one or more specific sites on another
molecule.

GO:0120041

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.

GO:0044237

GO:0043227

The chemical reactions and pathways by
which individual cells transform chemical
substances.
Organized structure of distinctive
morphology and function, bounded by a
single or double lipid bilayer membrane.
Includes the nucleus, mitochondria,
plastids, vacuoles, and vesicles. Excludes
the plasma membrane.

Ontology

Module

GO Process

FDR

MF

Yellow

binding

3.20E-07

BP

Yellow

positive
regulation of
macrophage
proliferation

3.44E-07

BP

Yellow

cellular metabolic
process

1.60E-06

Genes
BTG1, CHRM3, CYP17A1, PRMT1,
HSPA9, NCK1, PLCL1, PPP4C, TLE3,
RABGAP1L, KAT5, SF3B1, GIGYF2,
JKAMP, CNNM2, TYW5, LETM2
BTG1, CHRM3, CYP17A1, PRMT1,
HSPA9, NCK1, PLCL1, PPP4C, TLE3,
RABGAP1L, KAT5, SF3B1, SEC11A,
GIGYF2, JKAMP, CNNM2, TYW5,
LETM2
BTG1, CHRM3, CYP17A1, PRMT1,
HSPA9, NCK1, PLCL1, PPP4C, TLE3,
KAT5, SF3B1, SEC11A, GIGYF2, JKAMP,
TYW5

1.00E-05

BTG1, CYP17A1, PRMT1, HSPA9, NCK1,
PPP4C, TLE3, RABGAP1L, KAT5, SF3B1,
SEC11A, GIGYF2, JKAMP, CNNM2,
LETM2

CC

Yellow

membranebounded organelle
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Table 6.16: Gene Ontology for Blue Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0005737

GO:0005488

GO:0043231

Definition

Any process that activates or
increases the frequency, rate
or extent of macrophage
proliferation.
All of the contents of a cell
excluding the plasma
membrane and nucleus but
including other subcellular
structures.
The selective, non-covalent,
often stoichiometric,
interaction of a molecule with
one or more specific sites on
another molecule.
Organized structure of
distinctive morphology and
function, bounded by a single
or double lipid bilayer
membrane and occurring
within the cell. Includes the
nucleus, mitochondria,
plastids, vacuoles, and
vesicles. Excludes the plasma
membrane.

Ontology

Module

Go Process

FDR

BP

Blue

positive
regulation of
macrophage
proliferation

1.70E-10

CC

Blue

cytoplasm

4.22E-09

MF

Blue

binding

4.46E-08

Genes
CHRM3, CYP17A1, GRM3, HSPD1, HSPE1, MMP16,
NDUFA6, PCCB, STAR, STAT6, DGKI, VPS45, SATB2,
VSIG2, MOB4, FOXP1, LSM1, RBFOX1, TSR1, PAK6,
RALGAPA2, NDRG4, ZFYVE21, GDPD3, MAIP1, COQ10B,
DRC3, YPEL3, C12orf65, RPS19BP1, RILPL2, YPEL4,
EHBP1L1, ASPG
CYP17A1, HSPD1, HSPE1, MMP16, NDUFA6, PCCB, STAR,
STAT6, DGKI, VPS45, MOB4, LSM1, RBFOX1, TSR1,
PAK6, RALGAPA2, NDRG4, ZFYVE21, GDPD3, MAIP1,
COQ10B, DRC3, C12orf65, RPS19BP1, RILPL2, EHBP1L1,
ASPG
MPPED2, CHRM3, CYP17A1, HSPD1, HSPE1, MMP16,
PCCB, STAR, STAT6, DGKI, VPS45, SATB2, MOB4,
FOXP1, LSM1, RBFOX1, TSR1, PAK6, RALGAPA2,
NDRG4, ZFYVE21, GDPD3, MAIP1, COQ10B, YPEL3,
C12orf65, RPS19BP1, RILPL2, YPEL4

Blue

intracellular
membranebounded
organelle

1.57E-07

CYP17A1, HSPD1, HSPE1, MMP16, NDUFA6, PCCB, STAR,
STAT6, DGKI, VPS45, SATB2, MOB4, FOXP1, LSM1,
RBFOX1, TSR1, PAK6, RALGAPA2, NDRG4, MAIP1,
COQ10B, YPEL3, C12orf65, RPS19BP1, YPEL4

CC
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Table 6.17: Gene Ontology for Brown Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

GO:0120041

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.

GO:0005488

The selective, non-covalent, often
stoichiometric, interaction of a molecule
with one or more specific sites on another
molecule.

GO:0070013

An organelle lumen that is part of an
intracellular organelle.

Ontology

Module

Go Process

FDR

BP

Brown

positive regulation
of macrophage
proliferation

1.89E-08

MF

Brown

binding

4.85E-07

Genes
BNIP3L, CA8, ERCC4, ETF1, FGFR1, SIPA1,
SREBF1, ATP5MPL, GABBR2, TAB1,
IGSF9B, ABCB9, HYDIN, CNNM2,
GATAD2A, ZSCAN2, AMBRA1, NLGN4X,
RANBP10, SETD6, CENPT, TLCD3B,
ZNF804A, SFXN5, STAC3
BNIP3L, CA8, ERCC4, ETF1, FGFR1, SIPA1,
SREBF1, GABBR2, TAB1, IGSF9B, ABCB9,
CNNM2, GATAD2A, ZSCAN2, AMBRA1,
NLGN4X, RANBP10, SETD6, CENPT,
ANKRD44, ZNF804A, STAC3

2.09E-06

BNIP3L, CA8, ERCC4, ETF1, FGFR1, SIPA1,
SREBF1, GABBR2, TAB1, IGSF9B, CNNM2,
GATAD2A, ZSCAN2, AMBRA1, NLGN4X,
SETD6, CENPT, TLCD3B, ZNF804A, STAC3

CC

Brown

intracellular
organelle lumen
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Table 6.18: Gene Ontology for Green Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

Ontology

Module

GO:0120041

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.

BP

Green

GO:0070013

GO:0035373

GO:0050896

An organelle lumen that is part of an
intracellular organelle.
Interacting selectively and non-covalently with
a chondroitin sulphate proteoglycan, any
proteoglycan containing chondroitin sulphate
as the glycosaminoglycan carbohydrate unit.
Any process that results in a change in state or
activity of a cell or an organism (in terms of
movement, secretion, enzyme production,
gene expression, etc.) as a result of a stimulus.
The process begins with detection of the
stimulus and ends with a change in state or
activity or the cell or organism.

Go Process
positive
regulation of
macrophage
proliferation

CC

Green

MF

Green

intracellular
organelle
lumen
chondroitin
sulphate
proteoglycan
binding

Green

response to
stimulus

BP

FDR

9.16E-05

Genes
CACNA1C, FSHB, MAP3K11, PTN,
PTPRF, GPR52, TBC1D5, RAI1, NXPH4,
EPN2, DOP1A, CA14, THAP11, ACTR5,
CARMIL2, TOM1L2, PCNX3
CACNA1C, FSHB, MAP3K11, PTN,
PTPRF, GPR52, TBC1D5, RAI1, NXPH4,
EPN2, THAP11, ACTR5, CARMIL2,
TOM1L2

0.000174

PTN, PTPRF

0.000336

CACNA1C, FSHB, MAP3K11, PTN,
PTPRF, GPR52, TBC1D5, NXPH4, EPN2,
ACTR5, CARMIL2, TOM1L2

3.43E-06
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Table 6.19: Gene Ontology for Magenta Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

Ontology

Module

Go Process

FDR

Genes

7.51E-05

BTG1, PLCB2, ALMS1,
FXR1, CDK2AP1,
TAOK2, CLP1, TM6SF2,
PLPP5, LETM2, WBP2NL

GO:0003674

All of the contents of a cell excluding the plasma
membrane and nucleus but including other
subcellular structures.
A molecular process that can be carried out by the
action of a single macromolecular machine,
usually via direct physical interactions with other
molecular entities. Function in this sense denotes
an action, or activity, that a gene product (or a
complex) performs. These actions are described
from two distinct but related perspectives: (1)
biochemical activity, and (2) role as a component
in a larger system/process.

MF

Magenta

molecular function

0.000264

GO:0019222

Any process that modulates the frequency, rate or
extent of the chemical reactions and pathways
within a cell or an organism.

BP

Magenta

regulation of metabolic process

0.000537

BP

Magenta

positive regulation of macrophage
proliferation

0.000585

BP

Magenta

primary metabolic process

0.000978

BP

Magenta

cellular response to diacyl
bacterial lipopeptide

0.001976

GO:0005737

GO:0120041

GO:0044238

GO:0071726

Any process that activates or increases the
frequency, rate, or extent of macrophage
proliferation.
The chemical reactions and pathways involving
those compounds which are formed as a part of
the normal anabolic and catabolic processes.
These processes take place in most, if not all,
cells of the organism.
Any process that results in a change in state or
activity of a cell (in terms of movement,
secretion, enzyme production, gene expression,
etc.) as a result of a diacylated bacterial
lipopeptide stimulus.

CC

Magenta

cytoplasm

BTG1, PLCB2, ALMS1,
FXR1, CDK2AP1,
TAOK2, CLP1, TM6SF2,
BCL2L12, PLPP5,
LETM2, WBP2NL
BTG1, ALMS1, FXR1,
CDK2AP1, TAOK2,
CLP1, TM6SF2,
BCL2L12, WBP2NL
BTG1, PLCB2, ALMS1,
FXR1, CDK2AP1,
TAOK2, CLP1, TM6SF2,
BCL2L12, PLPP5,
LETM2, WBP2NL
BTG1, PLCB2, FXR1,
CDK2AP1, TAOK2,
CLP1, TM6SF2,
BCL2L12, PLPP5,
WBP2NL
BTG1, PLCB2, FXR1,
CDK2AP1, TAOK2,
CLP1, TM6SF2,
BCL2L12, PLPP5,
WBP2NL
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Table 6.20: Gene Ontology for Purple Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

GO:0120041

Any process that activates or
increases the frequency, rate,
or extent of macrophage
proliferation.

GO:0070013

GO:1901666

GO:0044267

GO:0005515

An organelle lumen that is
part of an intracellular
organelle.
Any process that activates or
increases the frequency, rate
or extent of NAD+ ADPribosyltransferase activity.
The chemical reactions and
pathways involving a
specific protein, rather than
of proteins in general,
occurring at the level of an
individual cell. Includes
cellular protein modification.
Interacting selectively and
non-covalently with any
protein or protein complex (a
complex of two or more
proteins that may include
other nonprotein molecules).

Ontology

Module

Go Process

FDR

BP

Purple

positive regulation of
macrophage
proliferation

4.37E-10

CC

Purple

BP

Purple

BP

MF

Purple

Purple

intracellular organelle
lumen
positive regulation of
NAD+ ADPribosyltransferase
activity

cellular protein
metabolic process

protein binding

2.40E-07

Genes
CHRNA2, CHRNA3, CLU, FHIT, GRIN2A,
HSPA9, NCK1, PPP4C, SLC12A4, VRK2, AP3B2,
AKAP6, CKAP5, PSMD6, KAT5, PLCL2,
SEC11A, B3GAT1, FANCL, SBNO1, OTUD7B,
RBM26, SEMA6D, THOC7, WDR73, RFT1,
TNFRSF13C, BORCS7, TYW5, ASPHD1,
HAPLN4
CHRNA2, CHRNA3, CLU, FHIT, GRIN2A,
HSPA9, NCK1, PPP2R3A, PPP4C, SLC12A4,
VRK2, AKAP6, CKAP5, PSMD6, KAT5, PLCL2,
BANK1, FANCL, SBNO1, OTUD7B, RBM26,
SEMA6D, WDR73, RFT1, TNFRSF13C
CHRNA3, CLU, FHIT, GRIN2A, NCK1,
PPP2R3A, PPP4C, VRK2, PSMD6, KAT5, PLCL2,
SEC11A, B3GAT1, BANK1, FANCL, OTUD7B,
TNFRSF13C, TYW5, ASPHD1

4.22E-07

CHRNA3, CLU, FHIT, GRIN2A, NCK1,
PPP2R3A, PPP4C, VRK2, PSMD6, KAT5, PLCL2,
SEC11A, B3GAT1, BANK1, FANCL, OTUD7B,
ASPHD1

7.41E-07

CHRNA3, CLU, FHIT, GRIN2A, HSPA9, NCK1,
PPP2R3A, PPP4C, SLC12A4, VRK2, AKAP6,
CKAP5, PSMD6, KAT5, PLCL2, BANK1,
FANCL, OTUD7B, RBM26, SEMA6D, THOC7,
BORCS7, TYW5

6.00E-08
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Table 6.21: Gene Ontology for Red Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0005515

GO:0043412

GO:0099080

Definition
Any process that activates or
increases the frequency, rate or
extent of macrophage
proliferation.
Interacting selectively and noncovalently with any protein or
protein complex (a complex of
two or more proteins that may
include other nonprotein
molecules).
The covalent alteration of one or
more monomeric units in a
polypeptide, polynucleotide,
polysaccharide, or other
biological macromolecule,
resulting in a change in its
properties.
A cellular component that
consists of an indeterminate
number of proteins or
macromolecular complexes,
organized into a regular, higherorder structure such as a
polymer, sheet, network, or a
fibre.

Ontology

Module

BP

Red

Go Process
positive
regulation of
macrophage
proliferation

FDR

3.43E-06

Genes
CACNA1D, DRD2, GPM6A, NAGA, PGM3, PLCL1,
PSMB10, HIRIP3, ATG13, ZDHHC5, NDFIP2,
SLC38A7, PITPNM2, CPEB1, GFOD2, TDRD9,
HS3ST5

CACNA1D, DRD2, GPM6A, NAGA, PLCL1, PSMB10,
HIRIP3, ATG13, NDFIP2, SLC38A7, PITPNM2,
CPEB1, HS3ST5

MF

Red

protein binding

0.0004

BP

Red

macromolecule
modification

0.000479

DRD2, PGM3, PLCL1, PSMB10, ATG13, ZDHHC5,
NDFIP2, TDRD9, HS3ST5

CC

Red

supramolecular
complex

0.00068

CACNA1D, DRD2, GPM6A
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Table 6.22: Gene Ontology for Turquoise Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

Ontology

Module

GO:0120041

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.

BP

CC

GO:0005634

An organelle lumen that is part of an
intracellular organelle.
A membrane-bounded organelle of eukaryotic
cells in which chromosomes are housed and
replicated. In most cells, the nucleus contains
all of the cell's chromosomes except the
organellar chromosomes and is the site of RNA
synthesis and processing. In some species, or in
specialized cell types, RNA metabolism or
DNA replication may be absent.

GO:2000225

Any process that stops, prevents, or reduces the
frequency, rate or extent of testosterone
biosynthetic process.

GO:0071726
GO:0016020

Any process that results in a change in state or
activity of a cell (in terms of movement,
secretion, enzyme production, gene expression,
etc.) as a result of a diacylated bacterial
lipopeptide stimulus.
A lipid bilayer along with all the proteins and

GO:0070013

Turquoise

Go Process
positive
regulation of
macrophage
proliferation

3.42E25

Turquoise

intracellular
organelle lumen

2.23E12

CC

Turquoise

BP

Turquoise

nucleus
negative
regulation of
testosterone
biosynthetic
process

Turquoise
Turquoise

cellular response
to diacyl bacterial
lipopeptide
membrane

BP
CC

FDR

5.73E11

3.29E09

3.32E09
5.76E-

Genes

More than 50 overlapping genes
SERPINC1, RERE, ATP2A2, GSDME, EMX1,
IREB2, LRP1, NAB2, NEK1, NFATC3, NMB,
MAPK3, PSMA4, RELA, SHMT2, SOX5,
SREBF2, MAD1L1, CUL3, INPP4B, CACNA1I,
RGS6, ZNF592, PLCH2, ZNF536, DMTF1,
AKT3, SDCCAG8, CNOT1, DDHD2, VPS13C,
NSD3, ZNF823, SLC39A8, BCL11B, ZBTB37,
CREB3L1, SLC32A1, CNTN4, MED19, HCN1,
BTBD18
RERE, ATP2A2, EMX1, LRP1, NAB2, NEK1,
NFATC3, MAPK3, PSMA4, RELA, SHMT2,
SOX5, SREBF2, MAD1L1, CUL3, RGS6,
ZNF592, ZNF536, DMTF1, AKT3, R3HDM2,
CNOT1, PLA2G15, SPATS2L, NSD3, ZNF823,
BCL11B, CENPM, ZBTB37, CREB3L1, MED19,
HARBI1, BTBD18
RERE, EMX1, IREB2, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SHMT2, SOX5, SREBF2, CUL3,
ZNF592, ZNF536, DMTF1, CNOT1, NSD3,
ZNF823, BCL11B, ZBTB37, CREB3L1, MED19,
BTBD18
SERPINC1, RERE, GSDME, EMX1, IREB2,
LRP1, NAB2, NEK1, NFATC3, MAPK3, PSMA4,
RELA, SHMT2, SOX5, SREBF2, CUL3, INPP4B,
SLC7A6, ZNF592, PLCH2, ZNF536, DMTF1,
AKT3, CNOT1, DDHD2, PLA2G15, AIG1,
NSD3, ZNF823, ADAMTSL3, DPEP2, BCL11B,
ZBTB37, CREB3L1, MED19, HARBI1, BTBD18
SERPINC1, ATP2A2, GSDME, LRP1, MAPK3,
247

protein complexes embedded in it an attached
to it.

09

GO:0080154

Any process that modulates the rate, frequency
or extent of fertilization. Fertilization is the
union of gametes of opposite sexes during the
process of sexual reproduction to form a
zygote. It involves the fusion of the gametic
nuclei (karyogamy) and cytoplasm
(plasmogamy).

BP

Turquoise

GO:0006357

Any process that modulates the frequency, rate
or extent of transcription mediated by RNA
polymerase II.

BP

Turquoise

GO:0005515

Interacting selectively and non-covalently with
any protein or protein complex (a complex of
two or more proteins that may include other
nonprotein molecules).

MF

Turquoise

GO:1903593

Any process that modulates the frequency, rate
or extent of histamine secretion by mast cell.

BP

Turquoise

GO:2001234

Any process that stops, prevents or reduces the
frequency, rate or extent of apoptotic signalling
pathway.

GO:0016043

A process that results in the assembly,
arrangement of constituent parts, or
disassembly of a cellular component.

BP

BP

regulation of
fertilization
regulation of
transcription by
RNA polymerase
II

Turquoise

protein binding
regulation of
histamine
secretion by mast
cell
negative
regulation of
apoptotic
signalling
pathway

Turquoise

cellular
component
organization

7.34E09

1.03E08

1.04E08

1.95E08

1.96E08

2.04E08

SHMT2, SREBF2, CUL3, CACNA1I, SLC7A6,
RGS6, PLCH2, AKT3, MPHOSPH9, CNOT1,
DDHD2, PLA2G15, SEZ6L2, SLC45A1, AIG1,
MPP6, VPS13C, SLC39A8, DPEP2, ESAM,
CREB3L1, EMB, SLC32A1, CPNE8, CNTN4,
KIAA1324L, HARBI1, HCN1

SERPINC1, RERE, GSDME, EMX1, IREB2,
LRP1, NAB2, NEK1, NFATC3, MAPK3, PSMA4,
RELA, SHMT2, SOX5, SREBF2, CUL3, ZNF592,
ZNF536, DMTF1, CNOT1, NSD3, ZNF823,
BCL11B, ZBTB37, CREB3L1, MED19, BTBD18
RERE, EMX1, NFATC3, MAPK3, PSMA4,
RELA, SOX5, SREBF2, CUL3, ZNF592, ZNF536,
DMTF1, CNOT1, ZNF823, BCL11B, ZBTB37,
CREB3L1, MED19, BTBD18
SERPINC1, RERE, ATP2A2, EMX1, IREB2,
LRP1, NAB2, NEK1, NFATC3, NMB, MAPK3,
PSMA4, RELA, SHMT2, SOX5, SREBF2,
MAD1L1, CUL3, INPP4B, CACNA1I, RGS6,
ZNF592, AKT3, SDCCAG8, CNOT1, AIG1,
MPP6, NSD3, ADAMTSL3, BCL11B, ESAM,
CREB3L1, EMB, CNTN4, MED19, HCN1
RERE, EMX1, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SOX5, SREBF2, CUL3, ZNF592,
ZNF536, DMTF1, CNOT1, NSD3, ZNF823,
BCL11B, ZBTB37, CREB3L1, MED19, BTBD18
RERE, EMX1, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SOX5, SREBF2, CUL3, ZNF592,
ZNF536, DMTF1, CNOT1, NSD3, ZNF823,
BCL11B, ZBTB37, CREB3L1, MED19, BTBD18
RERE, ATP2A2, EMX1, LRP1, NEK1, MAPK3,
RELA, SHMT2, SREBF2, MAD1L1, CUL3,
SLC7A6, AKT3, SDCCAG8, CNOT1, DDHD2,
MPP6, VPS13C, NSD3, BCL11B, CENPM,
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ESAM, CREB3L1, EMB, CNTN4, HCN1,
BTBD18

GO:0071870

GO:0097707

Any process that results in a change in state or
activity of a cell (in terms of movement,
secretion, enzyme production, gene expression,
etc.) as a result of a catecholamine stimulus. A
catecholamine is any of a group of biogenic
amines that includes 4-(2-aminoethyl)
pyrocatechol [4-(2-aminoethyl)benzene-1,2diol] and derivatives formed by substitution.
A programmed cell death characterized
morphologically by the presence of smaller
than normal mitochondria with condensed
mitochondrial membrane densities, reduction or
vanishing of mitochondria crista, and outer
mitochondrial membrane rupture. Activation of
mitochondrial voltage-dependent anion
channels and mitogen-activated protein kinases,
upregulation of endoplasmic reticulum stress,
and inhibition of cystine/glutamate antiporter
are involved in the induction of ferroptosis.
This process is characterized by the
accumulation of lipid peroxidation products
and lethal reactive oxygen species (ROS)
derived from iron metabolism. Glutathione
peroxidase 4 (GPX4), heat shock protein beta1, and nuclear factor erythroid 2-related factor
2 function as negative regulators of ferroptosis
by limiting ROS production and reducing
cellular iron uptake, respectively. In contrast,
NADPH oxidase and p53 act as positive
regulators of ferroptosis by promotion of ROS
production and inhibition of expression of
SLC7A11 (a specific light-chain subunit of the
cystine/glutamate antiporter), respectively.
Misregulated ferroptosis has been implicated in
multiple physiological and pathological

BP

BP

Turquoise

Turquoise

cellular response
to catecholamine
stimulus

ferroptosis

3.49E08

RERE, ATP2A2, EMX1, LRP1, NEK1, MAPK3,
RELA, SHMT2, SREBF2, MAD1L1, CUL3,
SLC7A6, AKT3, SDCCAG8, CNOT1, DDHD2,
MPP6, VPS13C, NSD3, BCL11B, CENPM,
ESAM, CREB3L1, EMB, CNTN4, HCN1,
BTBD18

3.52E08

RERE, EMX1, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SOX5, SREBF2, CUL3, ZNF592,
ZNF536, DMTF1, CNOT1, NSD3, ZNF823,
BCL11B, ZBTB37, CREB3L1, MED19, BTBD18
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processes.

GO:1901679

GO:1901558

GO:0140244

GO:0031325

The directed movement of nucleotide across a
membrane.
Any process that results in a change in state or
activity of a cell or an organism (in terms of
movement, secretion, enzyme production, gene
expression, etc.) as a result of a metformin
stimulus.
Any process that regulates translation occurring
at the presynapse.
Any process that activates or increases the
frequency, rate or extent of the chemical
reactions and pathways by which individual
cells transform chemical substances.

BP

Turquoise

BP

Turquoise

BP

Turquoise

BP

Turquoise

nucleotide
transmembrane
transport

response to
metformin
regulation of
translation at
presynapse
positive
regulation of
cellular metabolic
process

4.74E08

8.94E08
1.50E07

2.81E07

RERE, EMX1, IREB2, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SHMT2, SOX5, SREBF2, CUL3,
INPP4B, ZNF592, PLCH2, ZNF536, DMTF1,
CNOT1, DDHD2, NSD3, ZNF823, BCL11B,
ZBTB37, CREB3L1, MED19, BTBD18
RERE, EMX1, IREB2, NAB2, NFATC3, MAPK3,
PSMA4, RELA, SOX5, SREBF2, CUL3, ZNF592,
ZNF536, DMTF1, CNOT1, NSD3, ZNF823,
BCL11B, ZBTB37, CREB3L1, MED19, BTBD18
RERE, EMX1, NAB2, NFATC3, RELA, SOX5,
SREBF2, ZNF592, ZNF536, DMTF1, NSD3,
ZNF823, BCL11B, ZBTB37, CREB3L1, MED19
RERE, GSDME, LRP1, NAB2, NEK1, NFATC3,
MAPK3, RELA, SOX5, SREBF2, CUL3, DMTF1,
CNOT1, VPS13C, NSD3, BCL11B, CREB3L1,
MED19, BTBD18
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Table 6.23: Gene Ontology for Yellow Module Stage 4 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0003674

GO:0120041

GO:0043227

GO:0043229

GO:0008152

Definition
A molecular process that can be carried out by the
action of a single macromolecular machine, usually
via direct physical interactions with other molecular
entities. Function in this sense denotes an action, or
activity, that a gene product (or a complex)
performs. These actions are described from two
distinct but related perspectives: (1) biochemical
activity, and (2) role as a component in a larger
system/process.

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
Organized structure of distinctive morphology and
function, bounded by a single or double lipid bilayer
membrane. Includes the nucleus, mitochondria,
plastids, vacuoles, and vesicles. Excludes the
plasma membrane.
Organized structure of distinctive morphology and
function, occurring within the cell. Includes the
nucleus, mitochondria, plastids, vacuoles, vesicles,
ribosomes, and the cytoskeleton. Excludes the
plasma membrane.
The chemical reactions and pathways, including
anabolism and catabolism, by which living
organisms transform chemical substances.
Metabolic processes typically transform small
molecules, but also include macromolecular
processes such as DNA repair and replication, and
protein synthesis and degradation.

Ontology

Module

Go Process

FDR

Genes

Yellow

molecular function

6.12E-08

BP

Yellow

positive regulation of
macrophage
proliferation

2.55E-07

CC

Yellow

membrane-bounded
organelle

9.65E-07

CC

Yellow

intracellular organelle

1.06E-06

CALB2, DPYD, EP300, LCAT,
MGAT3, MSRA, PPP2R2A, PRKCB,
PRKD1, TBX6, DOC2A, NT5C2,
RIMS1, ZC3H7B, PLEKHO1,
ARL6IP4, NDUFA4L2, RPTOR,
ALPK3, DPEP3, DNAJC19, KMT5A
CALB2, DPYD, EP300, LCAT,
MGAT3, MSRA, PPP2R2A, PRKCB,
PRKD1, TBX6, DOC2A, NT5C2,
RIMS1, ZC3H7B, PLEKHO1,
ARL6IP4, NDUFA4L2, RPTOR,
ALPK3, DPEP3, DNAJC19, KMT5A
CALB2, EP300, LCAT, MGAT3,
MSRA, PPP2R2A, PRKCB, PRKD1,
TBX6, DOC2A, ZC3H7B, PLEKHO1,
ARL6IP4, NDUFA4L2, RPTOR,
ALPK3, DPEP3, DNAJC19, KMT5A
CALB2, EP300, MGAT3, MSRA,
PPP2R2A, PRKCB, PRKD1, TBX6,
DOC2A, RIMS1, ZC3H7B,
PLEKHO1, ARL6IP4, NDUFA4L2,
RPTOR, ALPK3, DPEP3, DNAJC19,
KMT5A

5.41E-06

DPYD, EP300, LCAT, MGAT3,
MSRA, PPP2R2A, PRKCB, PRKD1,
TBX6, NT5C2, RIMS1, ZC3H7B,
ARL6IP4, NDUFA4L2, RPTOR,
ALPK3, DPEP3, KMT5A

MF

BP

Yellow

metabolic process
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Table 6.24: Gene Ontology for Black Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

GO:0071870

Any process that activates or
increases the frequency, rate or
extent of macrophage proliferation.
Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a diacylated bacterial
lipopeptide stimulus.
Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a catecholamine stimulus.
A catecholamine is any of a group of
biogenic amines that includes 4-(2aminoethyl) pyrocatechol [4-(2aminoethyl)benzene-1,2-diol] and
derivatives formed by substitution.

GO:1901679

The directed movement of
nucleotide across a membrane.

GO:2000225

Any process that stops, prevents, or
reduces the frequency, rate or extent
of testosterone biosynthetic process.

GO:0120041

GO:0071726

Ontology

Module

Go Process

FDR

Genes

BP

Black

positive regulation of
macrophage proliferation

2.43E38

More than 50 overlapping genes

BP

Black

cellular response to diacyl
bacterial lipopeptide

3.66E14

More than 50 overlapping genes

BP

Black

cellular response to
catecholamine stimulus

3.49E13

BP

Black

nucleotide transmembrane
transport

1.02E12

Black

negative regulation of
testosterone biosynthetic
process

1.86E12

BP

RERE, ATP2A2, CACNB2, CHRNA3, EMX1,
EP300, FGFR1, GPM6A, LRP1, PRKCB,
MAPK3, PTPRF, RELA, SHMT2, SIPA1,
SREBF1, SREBF2, MAD1L1, CUL3, SLC7A6,
AKAP6, CKAP5, AKT3, SDCCAG8, EPN2,
CNOT1, DDHD2, MAU2, MPP6, HYDIN,
VPS13C, NSD3, BCL11B, CENPM, CENPT,
IMMP2L, ESAM, CREB3L1, EMB, CARMIL2,
CNTN4, TSNARE1, HCN1, BTBD18
RERE, DPYD, EMX1, EP300, FGFR1, IREB2,
NAB2, NFATC3, PDE4B, PRKCB, MAPK3,
PSMA4, RELA, SHMT2, SOX5, SREBF1,
SREBF2, CUL3, INPP4B, ZNF592, PLCH2,
ZNF536, PSMD6, DMTF1, TAB1, RAI1,
NT5C2, CNOT1, DDHD2, GATAD2A, NSD3,
BANK1, ZNF823, CPEB1, BCL11B, CENPT,
BCL2L12, ZBTB37, CREB3L1, MARS2,
TNFRSF13C, BTBD18
RERE, EMX1, EP300, FGFR1, IREB2, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SHMT2, SOX5, SREBF1, SREBF2, CUL3,
ZNF592, ZNF536, PSMD6, DMTF1, TAB1,
RAI1, CNOT1, GATAD2A, NSD3, BANK1,
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ZNF823, CPEB1, BCL11B, CENPT, BCL2L12,
ZBTB37, CREB3L1, BTBD18

GO:0070016

Interacting selectively and noncovalently with the armadillo repeat
domain of a protein, an
approximately 40 amino acid long
tandemly repeated sequence motif
first identified in the Drosophila
segment polarity protein armadillo.
Arm-repeat proteins are involved in
various processes, including
intracellular signalling and
cytoskeletal regulation.

MF

Black

armadillo repeat domain
binding

4.04E12

GO:0080154

Any process that modulates the rate,
frequency or extent of fertilization.
Fertilization is the union of gametes
of opposite sexes during the process
of sexual reproduction to form a
zygote. It involves the fusion of the
gametic nuclei (karyogamy) and
cytoplasm (plasmogamy).

BP

Black

regulation of fertilization

1.59E11

GO:1901561

Any process that results in a change
in state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
benomyl stimulus.

BP

Black

response to benomyl

2.72E11

GO:0006357

Any process that modulates the
frequency, rate or extent of
transcription mediated by RNA
polymerase II.

BP

Black

regulation of transcription
by RNA polymerase II

3.13E11

SERPINC1, ATP2A2, CACNA1C, CACNB2,
CHRNA3, DPYD, EMX1, EP300, FGFR1,
GPM6A, IREB2, LRP1, NMB, PDE4B,
PRKCB, MAPK3, PSMA4, SHMT2, SREBF1,
SREBF2, CUL3, CACNA1I, AKAP6, PLCH2,
PSMD6, AKT3, TMX2, VPS13C, SLC39A8,
TNFRSF13C, SLC32A1, CARMIL2, CNTN4,
HCN1
SERPINC1, RERE, CHRNA3, GSDME,
EMX1, EP300, FGFR1, IREB2, LRP1, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SHMT2, SOX5, SREBF1, SREBF2, CUL3,
ZNF592, ZNF536, PSMD6, DMTF1, TAB1,
RAI1, CNOT1, RBFOX1, GATAD2A, NSD3,
BANK1, ZNF823, CPEB1, BCL11B, CENPT,
BCL2L12, ZBTB37, CREB3L1, TNFRSF13C,
BTBD18
RERE, ATP2A2, MPPED2, DPYD, EMX1,
EP300, FGFR1, IREB2, LRP1, NFATC3,
PDE4B, PRKCB, MAPK3, RELA, SHMT2,
SOX5, SREBF1, SREBF2, ZNF592, ZNF536,
DMTF1, AKT3, R3HDM2, NT5C2, CNOT1,
MAU2, ABCB9, SPATS2L, ARL6IP4,
RBFOX1, GATAD2A, ZNF823, ALPK3,
CPEB1, BCL11B, CENPT, ZBTB37,
CREB3L1, MARS2, HCN1
RERE, EMX1, EP300, FGFR1, NFATC3,
PRKCB, MAPK3, PSMA4, RELA, SOX5,
SREBF1, SREBF2, CUL3, ZNF592, ZNF536,
PSMD6, DMTF1, RAI1, CNOT1, GATAD2A,
ZNF823, BCL11B, CENPT, BCL2L12,
ZBTB37, CREB3L1, BTBD18
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GO:0048513

GO:0097178

GO:1901555

GO:0005829

Development of a tissue or tissues
that work together to perform a
specific function or functions.
Development pertains to the process
whose specific outcome is the
progression of a structure over time,
from its formation to the mature
structure. Organs are commonly
observed as visibly distinct
structures but may also exist as
loosely associated clusters of cells
that work together to perform a
specific function or functions.
The aggregation, arrangement and
bonding together of a set of
components to form a ruffle, a
projection at the leading edge of a
crawling cell; the protrusions are
supported by a microfilament
meshwork. The formation of ruffles
(also called membrane ruffling) is
thought to be controlled by a group
of enzymes known as Rho GTPases,
specifically RhoA, Rac1 and cdc42.

Any process that results in a change
in state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
paclitaxel stimulus.
The part of the cytoplasm that does
not contain organelles, but which
does contain other particulate matter,
such as protein complexes.

BP

BP

Black

Black

animal organ development

ruffle assembly

3.43E11

4.10E11

BP

Black

response to paclitaxel

4.48E11

CC

Black

cytosol

6.13E11

SERPINC1, RERE, CACNA1C, GSDME,
EMX1, EP300, FGFR1, GPM6A, IREB2,
LRP1, NAB2, PRKCB, MAPK3, PSMA4,
RELA, SOX5, SREBF1, MAD1L1, CUL3,
AKAP6, PSMD6, AKT3, TAB1, HYDIN,
ALPK3, BCL11B, IMMP2L, SLC32A1,
CNTN4, STAC3, HCN1

RERE, ATP2A2, MPPED2, DPYD, EMX1,
EP300, FGFR1, IREB2, LRP1, NFATC3,
PDE4B, PRKCB, MAPK3, RELA, SHMT2,
SOX5, SREBF1, SREBF2, ZNF592, ZNF536,
DMTF1, AKT3, R3HDM2, NT5C2, CNOT1,
MAU2, ABCB9, SPATS2L, ARL6IP4,
RBFOX1, GATAD2A, ZNF823, ALPK3,
CPEB1, BCL11B, CENPT, ZBTB37,
CREB3L1, MARS2, HCN1
RERE, DPYD, EMX1, EP300, FGFR1, IREB2,
NAB2, NFATC3, PDE4B, PRKCB, MAPK3,
PSMA4, RELA, SHMT2, SOX5, SREBF1,
SREBF2, CUL3, ZNF592, ZNF536, PSMD6,
DMTF1, TAB1, RAI1, NT5C2, CNOT1,
ARL6IP4, RBFOX1, GATAD2A, NSD3,
FANCL, ZNF823, CPEB1, BCL11B, CENPT,
BCL2L12, ZBTB37, CREB3L1, MARS2,
HARBI1, BTBD18
GSDME, DPYD, EP300, FGFR1, IREB2,
NFATC3, PDE4B, PRKCB, MAPK3, PSMA4,
RELA, SIPA1, SREBF1, SREBF2, MAD1L1,
CUL3, INPP4B, RGS6, CKAP5, PSMD6,
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GO:0009653

The process in which anatomical
structures are generated and
organized. Morphogenesis pertains
to the creation of form.

BP

Black

anatomical structure
morphogenesis

9.42E11

GO:1903593

Any process that modulates the
frequency, rate, or extent of
histamine secretion by mast cell.

BP

Black

regulation of histamine
secretion by mast cell

1.07E10

GO:2001234

Any process that stops, prevents, or
reduces the frequency, rate or extent
of apoptotic signalling pathway.

BP

Black

negative regulation of
apoptotic signalling pathway

1.10E10

BP

Black

response to metformin

1.33E10

BP

Black

ferroptosis

2.84E10

GO:1901558

GO:0097707

Any process that results in a change
in state or activity of a cell or an
organism (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
metformin stimulus.
A programmed cell death
characterized morphologically by
the presence of smaller than normal
mitochondria with condensed
mitochondrial membrane densities,
reduction or vanishing of

DMTF1, TAB1, SDCCAG8, EPN2, NT5C2,
CNOT1, DDHD2, SPATS2L, VPS13C,
RALGAPA2, RANBP10, CPEB1, CENPM,
CENPT, STAC3, HARBI1
RERE, CACNA1C, CHRNA3, EMX1, EP300,
FGFR1, GPM6A, LRP1, NAB2, PRKCB,
MAPK3, PSMA4, RELA, CUL3, PSMD6,
AKT3, TAB1, SDCCAG8, EPN2, DDHD2,
BCL11B, CREB3L1, TNFRSF13C, EMB,
CARMIL2, CNTN4, HCN1
RERE, EMX1, EP300, FGFR1, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SOX5, SREBF1, SREBF2, CUL3, ZNF592,
ZNF536, PSMD6, DMTF1, TAB1, RAI1,
CNOT1, GATAD2A, NSD3, ZNF823,
BCL11B, CENPT, BCL2L12, ZBTB37,
CREB3L1, BTBD18
RERE, EMX1, EP300, FGFR1, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SOX5, SREBF1, SREBF2, CUL3, ZNF592,
ZNF536, PSMD6, DMTF1, TAB1, RAI1,
CNOT1, GATAD2A, NSD3, ZNF823,
BCL11B, CENPT, BCL2L12, ZBTB37,
CREB3L1, BTBD18
RERE, EMX1, EP300, FGFR1, IREB2, NAB2,
NFATC3, PDE4B, PRKCB, MAPK3, PSMA4,
RELA, SOX5, SREBF1, SREBF2, CUL3,
ZNF592, ZNF536, PSMD6, DMTF1, TAB1,
RAI1, NT5C2, CNOT1, GATAD2A, NSD3,
ZNF823, BCL11B, CENPT, BCL2L12,
ZBTB37, CREB3L1, BTBD18
RERE, EMX1, EP300, FGFR1, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SOX5, SREBF1, SREBF2, CUL3, ZNF592,
ZNF536, PSMD6, DMTF1, TAB1, RAI1,
CNOT1, GATAD2A, NSD3, ZNF823,
BCL11B, CENPT, BCL2L12, ZBTB37,
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mitochondria crista, and outer
mitochondrial membrane rupture.
Activation of mitochondrial voltagedependent anion channels and
mitogen-activated protein kinases,
upregulation of endoplasmic
reticulum stress, and inhibition of
cystine/glutamate antiporter are
involved in the induction of
ferroptosis. This process is
characterized by the accumulation of
lipid peroxidation products and
lethal reactive oxygen species (ROS)
derived from iron metabolism.
Glutathione peroxidase 4 (GPX4),
heat shock protein beta-1, and
nuclear factor erythroid 2-related
factor 2 function as negative
regulators of ferroptosis by limiting
ROS production and reducing
cellular iron uptake, respectively. In
contrast, NADPH oxidase and p53
act as positive regulators of
ferroptosis by promotion of ROS
production and inhibition of
expression of SLC7A11 (a specific
light-chain subunit of the
cystine/glutamate antiporter),
respectively. Misregulated
ferroptosis has been implicated in
multiple physiological and
pathological processes.

GO:0090317

Any process that decreases the
frequency, rate or extent of the
directed movement of proteins
within cells.

CREB3L1, BTBD18

BP

Black

negative regulation of
intracellular protein
transport

9.81E10

RERE, EMX1, EP300, FGFR1, NAB2,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SOX5, SREBF1, SREBF2, CUL3, ZNF592,
ZNF536, PSMD6, DMTF1, TAB1, RAI1,
CNOT1, ARL6IP4, RBFOX1, GATAD2A,
256

NSD3, FANCL, ZNF823, CPEB1, BCL11B,
CENPT, BCL2L12, ZBTB37, CREB3L1,
MARS2, HARBI1, BTBD18

GO:0035556

GO:0005886

GO:0033554

GO:0120060

GO:0071986

The process in which a signal is
passed on to downstream
components within the cell, which
become activated themselves to
further propagate the signal and
finally trigger a change in the
function or state of the cell.

The membrane surrounding a cell
that separates the cell from its
external environment. It consists of a
phospholipid bilayer and associated
proteins.
Any process that results in a change
in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a stimulus indicating the
organism is under stress. The stress
is usually, but not necessarily,
exogenous (e.g. temperature,
humidity, ionizing radiation).
Any process that modulates the
frequency, rate or extent of any
gastric emptying process, the
process in which the liquid and
liquid-suspended solid contents of
the stomach exit through the pylorus
into the duodenum.
A eukaryotically conserved protein
complex; in humans, it is comprised
of LAMTOR1, LAMTOR2,

BP

Black

intracellular signal
transduction

1.56E09

CC

Black

plasma membrane

4.80E09

ATP2A2, CA8, CACNA1C, GSDME, EP300,
FGFR1, LRP1, NFATC3, PRKCB, MAPK3,
PSMA4, RELA, SIPA1, CUL3, AKAP6, RGS6,
PLCH2, PSMD6, AKT3, TAB1, CNOT1,
BANK1, RALGAPA2, BCL2L12, CREB3L1,
STAC3
SERPINC1, ATP2A2, CACNA1C, CACNB2,
CHRNA3, GSDME, FGFR1, GPM6A, LRP1,
PDE4B, PRKCB, MAPK3, PTPRF, CACNA1I,
SLC7A6, AKAP6, GABBR2, RGS6, PLCH2,
CKAP5, SEZ6L2, MPP6, RALGAPA2,
SLC39A8, CPEB1, ESAM, TNFRSF13C, EMB,
SLC32A1, CPNE8, CARMIL2, CNTN4,
STAC3, HARBI1, HCN1

4.92E09

ATP2A2, EP300, LRP1, MAPK3, PSMA4,
PTPRF, RELA, SIPA1, SREBF1, SREBF2,
CUL3, PSMD6, AKT3, TAB1, CNOT1,
JKAMP, VPS13C, FANCL, CPEB1, BCL2L12,
IMMP2L, CREB3L1

BP

Black

cellular response to stress

BP

Black

regulation of gastric
emptying

6.68E09

CC

Black

Ragulator complex

8.46E09

ATP2A2, CACNA1C, CHRNA3, GPM6A,
LRP1, NMB, PDE4B, PRKCB, MAPK3,
PTPRF, AP3B2, CUL3, GABBR2, SDCCAG8,
HYDIN, CPEB1, BCL11B, EMB, SLC32A1,
CARMIL2, CNTN4, HCN1
SERPINC1, ATP2A2, CACNA1C, CACNB2,
CHRNA3, GSDME, FGFR1, GPM6A, LRP1,
PDE4B, PRKCB, MAPK3, PTPRF, CACNA1I,
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GO:0006928

LAMTOR3, LAMTOR4, and
LAMTOR5. The complex is
anchored to lipid rafts in late
endosome membranes via
LAMTOR1, constitutes a guanine
nucleotide exchange factor (GEF)
for the Rag GTPases.
The directed, self-propelled
movement of a cell or subcellular
component without the involvement
of an external agent such as a
transporter or a pore.

SLC7A6, AKAP6, GABBR2, RGS6, PLCH2,
CKAP5, SEZ6L2, MPP6, RALGAPA2,
SLC39A8, CPEB1, ESAM, TNFRSF13C, EMB,
SLC32A1, CPNE8, CARMIL2, CNTN4,
STAC3, HARBI1, HCN1

BP

Black

movement of cell or
subcellular component

1.74E08

GO:0140244

Any process that regulates
translation occurring at the
presynapse.

BP

Black

regulation of translation at
presynapse

2.89E08

GO:1901666

Any process that activates or
increases the frequency, rate or
extent of NAD+ ADPribosyltransferase activity.

BP

Black

positive regulation of NAD+
ADP-ribosyltransferase
activity

3.59E08

GO:0070901

The posttranscriptional addition of
methyl groups to specific residues in
a mitochondrial tRNA molecule.

BP

Black

mitochondrial tRNA
methylation

4.16E08

GO:0031981

The volume enclosed by the nuclear
inner membrane.

CC

Black

nuclear lumen

6.21E08

RERE, ATP2A2, CACNA1C, CACNB2,
FGFR1, GPM6A, LRP1, PDE4B, MAPK3,
PTPRF, AP3B2, CUL3, CACNA1I, SLC7A6,
AKT3, SDCCAG8, HYDIN, BCL11B, ESAM,
EMB, CARMIL2, CNTN4
RERE, EMX1, EP300, NAB2, NFATC3,
PRKCB, RELA, SOX5, SREBF1, SREBF2,
ZNF592, ZNF536, DMTF1, RAI1, GATAD2A,
NSD3, ZNF823, BCL11B, CENPT, ZBTB37,
CREB3L1
SERPINC1, CHRNA3, GSDME, DPYD,
EP300, FGFR1, IREB2, LRP1, NAB2, PDE4B,
PRKCB, MAPK3, PSMA4, PTPRF, RELA,
SHMT2, SREBF1, CUL3, SLC7A6, PSMD6,
AKT3, TAB1, NT5C2, CNOT1, PLA2G15,
JKAMP, NSD3, BANK1, FANCL,
ADAMTSL3, ALPK3, DPEP2, CPEB1,
BCL2L12, IMMP2L, MARS2, TNFRSF13C
ATP2A2, CHRNA3, GSDME, EP300, FGFR1,
LRP1, PDE4B, PRKCB, MAPK3, PSMA4,
RELA, SHMT2, SIPA1, SOX5, SREBF1,
CUL3, AKAP6, PSMD6, TAB1, EPN2,
CNOT1, CPEB1, CREB3L1, TNFRSF13C,
CPNE8, HCN1
RERE, ATP2A2, EMX1, EP300, FGFR1,
NFATC3, PRKCB, MAPK3, PSMA4, RELA,
SREBF1, SREBF2, CUL3, CKAP5, PSMD6,
DMTF1, TAB1, RAI1, MAU2, PLA2G15,
SPATS2L, ARL6IP4, GATAD2A, NSD3,
FANCL, CPEB1, CENPM, CENPT, CREB3L1,
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8.25E08

STAC3
RERE, CHRNA3, GSDME, EMX1, EP300,
FGFR1, GPM6A, LRP1, MAPK3, PTPRF,
RELA, SOX5, ZNF536, SDCCAG8, BCL11B,
EMB, CNTN4, HCN1

8.25E08

RERE, ATP2A2, CHRNA3, EMX1, EP300,
FGFR1, GPM6A, LRP1, MAPK3, PTPRF,
RELA, CUL3, AKAP6, ZNF536, HYDIN,
ALPK3, BCL11B, EMB, CNTN4, STAC3,
HCN1

GO:0003824

The process in which nerve cells are
generated. This includes the
production of neuroblasts and their
differentiation into neurons.
The process whose specific outcome
is the progression of the cell over
time, from its formation to the
mature structure. Cell development
does not include the steps involved
in committing a cell to a specific
fate.
Catalysis of a biochemical reaction
at physiological temperatures. In
biologically catalysed reactions, the
reactants are known as substrates,
and the catalysts are naturally
occurring macromolecular
substances known as enzymes.
Enzymes possess specific binding
sites for substrates, and are usually
composed wholly or largely of
protein, but RNA that has catalytic
activity (ribozyme) is often also
regarded as enzymatic.

MF

Black

catalytic activity

1.04E07

GO:0070052

Interacting selectively and noncovalently with a type V collagen
trimer.

MF

Black

collagen V binding

1.39E07

GO:0034220
GO:0071329

A process in which an ion is
transported across a membrane.
Any process that results in a change

BP

Black

ion transmembrane transport
cellular response to sucrose

1.41E07
1.50E-

GO:0048699

GO:0048468

BP

BP

Black

Black

generation of neurons

cell development

MPPED2, CA8, DPYD, EP300, FGFR1,
IREB2, PDE4B, PRKCB, MAPK3, PSMA4,
PTPRF, SHMT2, CUL3, INPP4B, RGS6,
PLCH2, PSMD6, AKT3, TAB1, NT5C2,
CNOT1, DDHD2, ABCB9, PLA2G15, AIG1,
NSD3, FANCL, ADAMTSL3, ALPK3, DPEP2,
IMMP2L, MARS2, HARBI1
SERPINC1, RERE, ATP2A2, EMX1, EP300,
FGFR1, NFATC3, PRKCB, MAPK3, PSMA4,
RELA, SHMT2, SREBF1, SREBF2, CUL3,
CKAP5, PSMD6, DMTF1, TAB1, RAI1,
MAU2, PLA2G15, SPATS2L, ARL6IP4,
GATAD2A, NSD3, FANCL, CPEB1, CENPM,
CENPT, CREB3L1, MARS2, STAC3
ATP2A2, CACNA1C, CACNB2, CHRNA3,
GPM6A, PDE4B, CACNA1I, SLC7A6,
AKAP6, PLCH2, ABCB9, SLC39A8, EMB,
SLC32A1, STAC3, HCN1
CHRNA3, GSDME, EP300, FGFR1, LRP1,
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GO:0006996

GO:0046872

GO:0071516

GO:0003700

in state or activity of a cell (in terms
of movement, secretion, enzyme
production, gene expression, etc.) as
a result of a sucrose stimulus.
A process that is carried out at the
cellular level which results in the
assembly, arrangement of
constituent parts, or disassembly of
an organelle within a cell. An
organelle is an organized structure of
distinctive morphology and function.
Includes the nucleus, mitochondria,
plastids, vacuoles, vesicles,
ribosomes and the cytoskeleton.
Excludes the plasma membrane.

Interacting selectively and noncovalently with any metal ion.
The initial formation of a stable
single-strand DNA lesion that
triggers programmed gene
conversion at the mating-type locus,
thereby restricting mating-type
interconversion to one of the two
sister chromatids during DNA
replication.
A protein or a member of a complex
that interacts selectively and noncovalently with a specific DNA
sequence (sometimes referred to as a
motif) within the regulatory region
of a gene to modulate transcription.
Regulatory regions include
promoters (proximal and distal) and

stimulus

BP

07

Black

PDE4B, PRKCB, MAPK3, PSMA4, RELA,
SHMT2, SOX5, SREBF1, CUL3, AKAP6,
PSMD6, TAB1, EPN2, CNOT1, CPEB1,
CREB3L1, TNFRSF13C, HCN1

BP

Black

organelle organization

1.64E07

MF

Black

metal ion binding

1.69E07

RERE, ATP2A2, EP300, LRP1, PRKCB,
MAPK3, RELA, SIPA1, SREBF1, SREBF2,
MAD1L1, CUL3, CKAP5, AKT3, SDCCAG8,
CNOT1, DDHD2, MAU2, HYDIN, VPS13C,
NSD3, CENPM, CENPT, IMMP2L, CARMIL2,
TSNARE1, BTBD18
RERE, ATP2A2, MPPED2, CA8, CACNA1C,
DPYD, EP300, IREB2, LRP1, PDE4B, PRKCB,
SHMT2, ZNF592, PLCH2, ZNF536, RAI1,
NT5C2, DDHD2, GATAD2A, NSD3, FANCL,
ZNF823, DPEP2, CPEB1, BCL11B, ZBTB37,
STAC3, HARBI1

2.85E07

CHRNA3, EP300, FGFR1, LRP1, PDE4B,
PRKCB, MAPK3, RELA, SHMT2, SOX5,
SREBF1, AKAP6, TAB1, CNOT1, CPEB1,
CREB3L1, HCN1

4.06E07

RERE, EMX1, EP300, NFATC3, RELA, SOX5,
SREBF1, SREBF2, ZNF592, ZNF536, DMTF1,
RAI1, GATAD2A, ZNF823, BCL11B, CENPT,
ZBTB37, CREB3L1

BP

MF

Black

Black

establishment of imprinting
at mating-type locus

DNA-binding transcription
factor activity
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enhancers. Genes are transcriptional
units and include bacterial operons.

GO:0016021

GO:0051254

GO:0070852

The component of a membrane
consisting of the gene products and
protein complexes having at least
some part of their peptide sequence
embedded in the hydrophobic region
of the membrane.
Any process that activates or
increases the frequency, rate or
extent of the chemical reactions and
pathways involving RNA.
A neuron projection that is found in
unipolar neurons and corresponds to
the region between the cell body and
the point at which the single
projection branches.

CC

Black

integral component of
membrane

4.11E07

BP

Black

positive regulation of RNA
metabolic process

4.21E07

ATP2A2, CACNA1C, CACNB2, CHRNA3,
FGFR1, GPM6A, LRP1, PDE4B, PTPRF,
SREBF1, SREBF2, CACNA1I, SLC7A6,
AKAP6, GABBR2, ABCB9, SEZ6L2, TMX2,
AIG1, JKAMP, SLC39A8, IMMP2L, ESAM,
CREB3L1, TNFRSF13C, EMB, SLC32A1,
TSNARE1, KIAA1324L, STAC3, HCN1
RERE, EP300, NFATC3, PRKCB, MAPK3,
RELA, SOX5, SREBF1, SREBF2, DMTF1,
RAI1, CNOT1, NSD3, CPEB1, BCL11B,
BCL2L12, CREB3L1, BTBD18

cell body fibre

4.52E07

ATP2A2, CACNA1C, CACNB2, GPM6A,
PDE4B, PRKCB, CACNA1I, AKAP6, PLCH2,
SLC39A8, STAC3

CC

Black
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Table 6.25: Gene Ontology for Brown Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

Ontology

Module

Go Process

FDR

1.14E-11

GO:0120041

Any process that activates or increases
the frequency, rate or extent of
macrophage proliferation.

BP

Brown

positive regulation
of macrophage
proliferation

GO:0005488

The selective, non-covalent, often
stoichiometric, interaction of a molecule
with one or more specific sites on
another molecule.

MF

Brown

binding

1.07E-09

GO:0044237

The chemical reactions and pathways by
which individual cells transform
chemical substances.

BP

Brown

cellular metabolic
process

9.83E-09

CC

Brown

cytoplasm

1.07E-08

GO:0005737

GO:0044238

GO:0043226

All of the contents of a cell excluding
the plasma membrane and nucleus but
including other subcellular structures.
The chemical reactions and pathways
involving those compounds which are
formed as a part of the normal anabolic
and catabolic processes. These processes
take place in most, if not all, cells of the
organism.
Organized structure of distinctive
morphology and function. Includes the
nucleus, mitochondria, plastids,
vacuoles, vesicles, ribosomes and the
cytoskeleton, and prokaryotic structures

BP

Brown

primary metabolic
process

5.50E-08

CC

Brown

organelle

1.51E-07

Genes
BTG1, CALB2, GRIN2A, HSPA9, NCK1,
PLCB2, PPP4C, PTN, TLE3, VRK2, ALMS1,
ASH2L, GPR52, TAOK2, KAT5, SEC11A,
CA14, B3GAT1, OTUD7B, GDPD3, ACTR5,
SETD6, SEMA6D, THOC7, PLPP5, WDR73,
TYW5, RFTN2, LETM2, WBP2NL, MED19,
HS3ST5, HAPLN4
BTG1, CALB2, GRIN2A, HSPA9, NCK1,
PLCB2, PPP2R3A, PPP4C, PTN, TLE3, VRK2,
ALMS1, ASH2L, TAOK2, KAT5, CA14,
B3GAT1, OTUD7B, GDPD3, ACTR5, SETD6,
SEMA6D, THOC7, TYW5, LETM2, WBP2NL,
MED19, HS3ST5, HAPLN4
BTG1, GRIN2A, HSPA9, NCK1, PLCB2,
PPP2R3A, PPP4C, PTN, TLE3, VRK2, ASH2L,
TAOK2, KAT5, SEC11A, B3GAT1, OTUD7B,
GDPD3, ACTR5, SETD6, THOC7, PLPP5,
TYW5, WBP2NL, MED19, HS3ST5
BTG1, CALB2, GRIN2A, HSPA9, NCK1,
PLCB2, PPP4C, PTN, VRK2, ALMS1, TAOK2,
KAT5, B3GAT1, OTUD7B, GDPD3, ACTR5,
SETD6, SEMA6D, THOC7, PLPP5, WDR73,
TYW5, LETM2, WBP2NL, HS3ST5
BTG1, GRIN2A, NCK1, PLCB2, PPP2R3A,
PPP4C, PTN, TLE3, VRK2, ASH2L, TAOK2,
KAT5, SEC11A, B3GAT1, OTUD7B, GDPD3,
ACTR5, SETD6, THOC7, PLPP5, TYW5,
WBP2NL, MED19, HS3ST5
BTG1, CALB2, GRIN2A, HSPA9, NCK1,
PPP4C, PTN, TLE3, VRK2, ALMS1, ASH2L,
TAOK2, KAT5, SEC11A, B3GAT1, OTUD7B,
GDPD3, ACTR5, SETD6, SEMA6D, THOC7,
WDR73, LETM2, WBP2NL, MED19, HS3ST5
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GO:0071726

such as anammoxosomes and
pirellulosomes. Excludes the plasma
membrane.
Any process that results in a change in
state or activity of a cell (in terms of
movement, secretion, enzyme
production, gene expression, etc.) as a
result of a diacylated bacterial
lipopeptide stimulus.

BP

Brown

cellular response to
diacyl bacterial
lipopeptide

2.99E-07

BTG1, GRIN2A, NCK1, PLCB2, PPP2R3A,
PPP4C, PTN, TLE3, VRK2, ASH2L, TAOK2,
KAT5, SEC11A, B3GAT1, OTUD7B, GDPD3,
ACTR5, SETD6, THOC7, PLPP5, TYW5,
WBP2NL, MED19, HS3ST5
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Table 6.26: Gene Ontology for Green Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0098809

GO:0043226

GO:0005737

GO:0016020

Definition
Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
Catalysis of the reaction: nitrite + acceptor =
product(s) of nitrate reduction + reduced
acceptor.
Organized structure of distinctive
morphology and function. Includes the
nucleus, mitochondria, plastids, vacuoles,
vesicles, ribosomes and the cytoskeleton, and
prokaryotic structures such as
anammoxosomes and pirellulosomes.
Excludes the plasma membrane.
All of the contents of a cell excluding the
plasma membrane and nucleus but including
other subcellular structures.
A lipid bilayer along with all the proteins and
protein complexes embedded in it an attached
to it.

Ontology

Module

Go Process

FDR

BP

Green

positive regulation
of macrophage
proliferation

5.52E-06

Genes
CHRM3, CHRNB4, CYP17A1, GRM3,
MEF2C, MGAT3, PRKD1, ATXN7, INA,
RABGAP1L, MOB4, PARD6A, PLEKHO1,
CNNM2, ANP32E, ZNF804A, ASPHD1, ASPG

MF

Green

nitrite reductase
activity

1.04E-05

CHRM3, CHRNB4, GRM3, MEF2C, INA,
ZNF804A

CC

Green

organelle

1.33E-05

CC

Green

cytoplasm

8.25E-05

CC

Green

membrane

0.000105

CHRM3, CHRNB4, CYP17A1, GRM3,
MEF2C, MGAT3, PRKD1, ATXN7, INA,
RABGAP1L, MOB4, PARD6A, PLEKHO1,
CNNM2, ANP32E, ZNF804A
CHRNB4, CYP17A1, MEF2C, MGAT3,
PRKD1, ATXN7, INA, RABGAP1L, MOB4,
PARD6A, PLEKHO1, ANP32E, ZNF804A,
ASPG
CHRM3, CHRNB4, CYP17A1, GRM3,
MGAT3, PRKD1, INA, MOB4, PARD6A,
PLEKHO1, CNNM2, ZNF804A, ASPHD1
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Table 6.27: Gene Ontology for Greenyellow Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

Definition

GO:0071726

Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
Any process that results in a change in state
or activity of a cell (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a diacylated
bacterial lipopeptide stimulus.

GO:0070052

Interacting selectively and non-covalently
with a type V collagen trimer.

GO:0120041

GO:0016020

GO:0071870

A lipid bilayer along with all the proteins and
protein complexes embedded in it an
attached to it.
Any process that results in a change in state
or activity of a cell (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a
catecholamine stimulus. A catecholamine is
any of a group of biogenic amines that
includes 4-(2-aminoethyl) pyrocatechol [4-

Ontology

Module

Greenyellow

Go Process
positive
regulation of
macrophage
proliferation

BP

1.22E-34

More than 50 overlapping genes

BP

Greenyellow

cellular response
to diacyl bacterial
lipopeptide

3.08E-18

MF

Greenyellow

collagen V
binding

7.65E-15

CC

Greenyellow

membrane

9.83E-12

Greenyellow

cellular response
to catecholamine
stimulus

1.02E-10

More than 50 overlapping genes
BNIP3L, SERPING1, NCAN, ERCC4,
HSPD1, HSPE1, MMP16, PCCB, PSMB10,
STAT6, XRCC3, FXR1, CDK2AP1, HIRIP3,
DGKZ, DGKI, KDM4A, ZEB2, NUTF2,
CLP1, SATB2, SF3B1, FOXP1, MSL2, TSR1,
PAK6, THAP11, RPTOR, SUGP1, ACD,
MAIP1, ESRP2, YPEL3, L3MBTL2,
C12orf65, YPEL4, INO80E, KMT5A
ARHGAP1, BNIP3L, CACNA1D, CLCN3,
HSPD1, HSPE1, KCNJ13, MAP3K11,
MMP16, NDUFA6, OPCML, PLCL1, RRAS,
STAT6, FXR1, DGKZ, DGKI, BAG4, ATG13,
TBC1D5, SNAP91, NUTF2, VPS45, DOP1A,
PSD3, ZDHHC5, GIGYF2, SLC45A1,
NDFIP2, SLC38A7, NLGN4X, RPTOR,
PITPNM2, SRR, DPEP3, NDRG4, MAIP1,
COQ10B, RFT1, BORCS7, RILPL2,
EHBP1L1, SNORC
BNIP3L, CLCN3, NCAN, ERCC4, HSPD1,
MMP16, NDUFA6, XRCC3, HIRIP3, BAG4,
KDM4A, ATG13, TBC1D5, ZEB2, SNAP91,
CLP1, SATB2, SF3B1, MSL2, TSR1, PAK6,
NLGN4X, RPTOR, SRR, DPEP3, NDRG4,
ACD, MAIP1, L3MBTL2, C12orf65, RFT1,
TDRD9, RILPL2, INO80E, KMT5A

BP

FDR

Genes
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(2-aminoethyl)benzene-1,2-diol] and
derivatives formed by substitution.

GO:0031323

GO:0060255

Any process that modulates the frequency,
rate or extent of the chemical reactions and
pathways by which individual cells transform
chemical substances.
Any process that modulates the frequency,
rate or extent of the chemical reactions and
pathways involving macromolecules, any
molecule of high relative molecular mass, the
structure of which essentially comprises the
multiple repetition of units derived, actually
or conceptually, from molecules of low
relative molecular mass.

GO:0080154

Any process that activates or increases the
frequency, rate or extent of NAD+ ADPribosyltransferase activity.
Any process that modulates the rate,
frequency or extent of fertilization.
Fertilization is the union of gametes of
opposite sexes during the process of sexual
reproduction to form a zygote. It involves the
fusion of the gametic nuclei (karyogamy)
and cytoplasm (plasmogamy).

GO:0005654
GO:0005829

That part of the nuclear content other than
the chromosomes or the nucleolus.
The part of the cytoplasm that does not

GO:1901666

Greenyellow

regulation of
cellular metabolic
process

1.36E-10

Greenyellow

regulation of
macromolecule
metabolic process

2.83E-10

BP

Greenyellow

positive
regulation of
NAD+ ADPribosyltransferase
activity

1.20E-09

BP

Greenyellow
Greenyellow

regulation of
fertilization

9.82E-09

nucleoplasm
cytosol

1.24E-08
2.46E-08

BP

BP

CC
CC

Greenyellow

BNIP3L, SERPING1, ERCC4, HSPD1,
HSPE1, MAP3K11, PLCL1, PSMB10, RRAS,
STAT6, FXR1, CDK2AP1, DGKZ, BAG4,
KDM4A, ATG13, TBC1D5, ZEB2, PLCL2,
SATB2, GIGYF2, FOXP1, NDFIP2, HPF1,
ZSCAN2, PAK6, THAP11, RPTOR, RBM26,
NDRG4, ACD, ESRP2, L3MBTL2, KMT5A
SERPING1, ERCC4, HSPD1, HSPE1,
MAP3K11, PLCL1, PSMB10, RRAS, STAT6,
FXR1, CDK2AP1, BAG4, KDM4A, ATG13,
TBC1D5, ZEB2, NUTF2, CLP1, PLCL2,
SATB2, SF3B1, GIGYF2, FOXP1, NDFIP2,
HPF1, ZSCAN2, PAK6, THAP11, RPTOR,
NDRG4, ACD, ESRP2, L3MBTL2, TDRD9,
KMT5A
BNIP3L, SERPING1, NCAN, CTRL, HSPD1,
HSPE1, MAP3K11, MMP16, NAGA, PCCB,
PGM3, PLCL1, PSMB10, RRAS, FXR1,
CDK2AP1, BAG4, KDM4A, ATG13, ZEB2,
PLCL2, ZDHHC5, GIGYF2, NDFIP2, HPF1,
MSL2, PAK6, RPTOR, SRR, DPEP3,
NDRG4, C12orf65, INO80E, KMT5A
SERPING1, ERCC4, HSPD1, HSPE1,
MAP3K11, PLCL1, PSMB10, RRAS, STAT6,
FXR1, CDK2AP1, DGKZ, BAG4, KDM4A,
ATG13, ZEB2, PLCL2, SATB2, GIGYF2,
FOXP1, NDFIP2, HPF1, ZSCAN2, PAK6,
THAP11, RPTOR, NDRG4, ACD, ESRP2,
L3MBTL2, KMT5A
BNIP3L, ERCC4, PSMB10, STAT6, XRCC3,
CDK2AP1, DGKZ, DGKI, KDM4A, NUTF2,
CLP1, SATB2, SF3B1, FOXP1, MSL2, TSR1,
THAP11, RPTOR, SUGP1, ACD, ESRP2,
L3MBTL2, INO80E, KMT5A
ARHGAP1, BNIP3L, HSPD1, PCCB, PGM3,
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contain organelles, but which does contain
other particulate matter, such as protein
complexes.

2.49E-08

PSMB10, STAT6, XRCC3, FXR1, CDK2AP1,
DGKI, BAG4, KDM4A, ATG13, TBC1D5,
ZEB2, NUTF2, CLP1, DOP1A, GIGYF2,
TSR1, RPTOR, PITPNM2, SRR, NDRG4,
BORCS7, RILPL2, KMT5A
SERPING1, ERCC4, HSPD1, HSPE1,
MAP3K11, PLCL1, PSMB10, RRAS, STAT6,
FXR1, CDK2AP1, BAG4, KDM4A, ATG13,
ZEB2, PLCL2, SATB2, GIGYF2, FOXP1,
NDFIP2, HPF1, ZSCAN2, PAK6, THAP11,
RPTOR, NDRG4, ACD, ESRP2, L3MBTL2,
KMT5A

4.37E-08

ARHGAP1, BNIP3L, SERPING1, CACNA1D,
CLCN3, HSPD1, KCNJ13, PSMB10, DGKI,
BAG4, ATG13, TBC1D5, SNAP91, NUTF2,
VPS45, DOP1A, FOXP1, SLC45A1, NDFIP2,
SLC38A7, NLGN4X, PITPNM2, RBM26,
NDRG4, ACD, MAIP1, RFT1, RILPL2

Greenyellow

GO:0051171

GO:0006810

GO:0048523

Any process that modulates the frequency,
rate or extent of the chemical reactions and
pathways involving nitrogen or nitrogenous
compounds.
The directed movement of substances (such
as macromolecules, small molecules, ions) or
cellular components (such as complexes and
organelles) into, out of or within a cell, or
between cells, or within a multicellular
organism by means of some agent such as a
transporter, pore or motor protein.
Any process that stops, prevents, or reduces
the frequency, rate or extent of a cellular
process, any of those that are carried out at
the cellular level, but are not necessarily
restricted to a single cell. For example, cell
communication occurs among more than one
cell, but occurs at the cellular level.

regulation of
nitrogen
compound
metabolic process

BP
Greenyellow

BP

transport
Greenyellow

negative
regulation of
cellular process

BP

7.30E-08

Greenyellow

GO:1901561

GO:0071725

Any process that results in a change in state
or activity of a cell or an organism (in terms
of movement, secretion, enzyme production,
gene expression, etc.) as a result of a
benomyl stimulus.
Any process that results in a change in state
or activity of a cell or an organism (in terms
of movement, secretion, enzyme production,
gene expression, etc.) as a result of a
triacylated bacterial lipopeptide stimulus.

BP

response to
benomyl

7.32E-08

response to triacyl
bacterial
lipopeptide

8.59E-08

Greenyellow

BP

ARHGAP1, BNIP3L, SERPING1, ERCC4,
HSPD1, PSMB10, RRAS, STAT6, XRCC3,
FXR1, DGKI, BAG4, KDM4A, ZEB2,
PLCL2, SATB2, GIGYF2, FOXP1, THAP11,
NLGN4X, RPTOR, RBM26, NDRG4, ACD,
L3MBTL2, TDRD9, KMT5A
CLCN3, ERCC4, HSPD1, HSPE1, MAP3K11,
PCCB, RRAS, STAT6, XRCC3, FXR1,
DGKZ, DGKI, BAG4, ZEB2, CLP1, SATB2,
SF3B1, GIGYF2, FOXP1, ZSCAN2, TSR1,
PAK6, THAP11, SUGP1, SRR, RBM26, ACD,
ESRP2, C12orf65, TDRD9
ARHGAP1, BNIP3L, CACNA1D, HSPD1,
BAG4, ATG13, TBC1D5, SNAP91, NUTF2,
VPS45, DOP1A, FOXP1, SLC45A1, NDFIP2,
SLC38A7, PITPNM2, RBM26, ACD, MAIP1,
RFT1, RILPL2
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GO:0097178

GO:0033554

The aggregation, arrangement and bonding
together of a set of components to form a
ruffle, a projection at the leading edge of a
crawling cell; the protrusions are supported
by a microfilament meshwork. The
formation of ruffles (also called membrane
ruffling) is thought to be controlled by a
group of enzymes known as Rho GTPases,
specifically RhoA, Rac1 and cdc42.
Any process that results in a change in state
or activity of a cell (in terms of movement,
secretion, enzyme production, gene
expression, etc.) as a result of a stimulus
indicating the organism is under stress. The
stress is usually, but not necessarily,
exogenous (e.g. temperature, humidity,
ionizing radiation).

Greenyellow

BP

ruffle assembly

1.01E-07

Greenyellow

BP

cellular response
to stress

1.37E-07

carbon monoxide
binding

1.57E-07

establishment of
localization in cell

2.30E-07

cellular protein
metabolic process

2.60E-07

anion binding

2.82E-07

Greenyellow

GO:0070025

Interacting selectively and non-covalently
with carbon monoxide (CO).

MF
Greenyellow

GO:0051649

Any process, occurring in a cell, that
localizes a substance or cellular component.
This may occur via movement, tethering or
selective degradation.

BP
Greenyellow

GO:0044267

The chemical reactions and pathways
involving a specific protein, rather than of
proteins in general, occurring at the level of
an individual cell. Includes cellular protein
modification.

BP
Greenyellow

GO:0043168

Interacting selectively and non-covalently
with anions, charged atoms or groups of
atoms with a net negative charge.

CLCN3, ERCC4, HSPD1, HSPE1, MAP3K11,
PCCB, RRAS, STAT6, XRCC3, FXR1,
DGKZ, DGKI, BAG4, ZEB2, CLP1, SATB2,
SF3B1, GIGYF2, FOXP1, ZSCAN2, TSR1,
PAK6, THAP11, SUGP1, SRR, RBM26, ACD,
ESRP2, C12orf65, TDRD9

MF

BNIP3L, ERCC4, MAP3K11, PSMB10,
STAT6, XRCC3, BAG4, ATG13, ZEB2,
GIGYF2, FOXP1, HPF1, PAK6, RPTOR,
ACD, YPEL3, INO80E, KMT5A
ARHGAP1, SERPING1, CACNA1D, ERCC4,
HSPD1, HSPE1, MAP3K11, MMP16, PLCL1,
DGKZ, DGKI, BAG4, ATG13, TBC1D5,
ZEB2, PLCL2, NDFIP2, PAK6, RPTOR,
RBM26, ACD
ARHGAP1, BNIP3L, SERPING1, CACNA1D,
CLCN3, HSPD1, DGKI, BAG4, ATG13,
TBC1D5, SNAP91, NUTF2, VPS45, DOP1A,
NLGN4X, RBM26, NDRG4, ACD, MAIP1,
RILPL2
BNIP3L, SERPING1, HSPD1, HSPE1,
MAP3K11, PGM3, PLCL1, PSMB10, RRAS,
FXR1, CDK2AP1, BAG4, KDM4A, ATG13,
ZEB2, PLCL2, ZDHHC5, GIGYF2, NDFIP2,
HPF1, MSL2, PAK6, RPTOR, NDRG4,
C12orf65, INO80E, KMT5A
CLCN3, NCAN, HSPD1, HSPE1, MAP3K11,
PCCB, PLCL1, RRAS, XRCC3, DGKZ,
DGKI, SNAP91, CLP1, PLCL2, TSR1, PAK6,
NLGN4X, PITPNM2, SRR, TDRD9
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Table 6.28: Gene Ontology for Pink Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0019866

GO:0031966

GO:0003674

Definition
Any process that activates or increases the
frequency, rate or extent of macrophage
proliferation.
The inner, i.e. lumen-facing, lipid bilayer of
an organelle envelope; usually highly
selective to most ions and metabolites.
Either of the lipid bilayers that surround the
mitochondrion and form the mitochondrial
envelope.
A molecular process that can be carried out
by the action of a single macromolecular
machine, usually via direct physical
interactions with other molecular entities.
Function in this sense denotes an action, or
activity, that a gene product (or a complex)
performs. These actions are described from
two distinct but related perspectives: (1)
biochemical activity, and (2) role as a
component in a larger system/process.

Ontology

Module

Pink

Go Process
positive regulation
of macrophage
proliferation

BP

0.000262

Genes
EPHX2, ETF1, STAR, TCF4, ATP5MPL,
IGSF9B, SMG6, NEMP1, AMBRA1,
NDUFA4L2, ZNF408, C16orf92

CC

Pink

organelle inner
membrane

0.000645

STAR, ATP5MPL, NEMP1, NDUFA4L2

CC

Pink

mitochondrial
membrane

0.001661

STAR, ATP5MPL, AMBRA1, NDUFA4L2

0.002147

EPHX2, ETF1, STAR, TCF4, ATP5MPL,
IGSF9B, SMG6, NEMP1, AMBRA1,
NDUFA4L2, ZNF408

MF

Pink

molecular function

FDR
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Table 6.29: Gene Ontology for Red Module Stage 5 using the anRichment function as part of WGCNA in R using the default settings
GOID

GO:0120041

GO:0005515

GO:0070013

GO:0005829

Definition
Any process that
activates or increases
the frequency, rate, or
extent of macrophage
proliferation.
Interacting selectively
and non-covalently
with any protein or
protein complex (a
complex of two or
more proteins that
may include other
nonprotein
molecules).
An organelle lumen
that is part of an
intracellular organelle.
The part of the
cytoplasm that does
not contain
organelles, but which
does contain other
particulate matter,
such as protein
complexes.

Ontology

BP

Module

Go Process

Red

positive
regulation of
macrophage
proliferation

MF

Red

CC

Red

protein
binding
intracellular
organelle
lumen

CC

Red

cytosol

FDR

1.84E-07

Genes

ALDOA, CHRNA5, F2, PTK2B, FHIT, MSRA, PPP2R2A,
RANGAP1, KCNK7, STAG1, ZC3H7B, PPP1R13B, NGEF,
TSNAXIP1, BOLL, PCGF6, ATPAF2, TMEM219, PCNX3

3.82E-05

ALDOA, CHRNA5, F2, PTK2B, FHIT, PPP2R2A, RANGAP1,
STAG1, ZC3H7B, PPP1R13B, NGEF, BOLL, PCGF6, ATPAF2,
TMEM219
ALDOA, CHRNA5, F2, PTK2B, FHIT, PPP2R2A, RANGAP1,
KCNK7, STAG1, ZC3H7B, PPP1R13B, NGEF, BOLL, PCGF6,
TMEM219

0.000218

ALDOA, PTK2B, FHIT, MSRA, PPP2R2A, RANGAP1, STAG1,
PPP1R13B, NGEF, ATPAF2

1.43E-05
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